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ABSTRACT 
Over-expression of Epidermal Growth Factor (EGF) and hypoxia are features of 
colorectal cancer (CRC). Such observations have helped develop novel therapies such as 
cetuximab, a recombinant monoclonal EGF receptor antibody antagonist. Recent studies 
uncovered a pro-angiogenic role for EGF but it is unclear whether this is mediated by 
Vascular Endothelial Growth Factor (VEGF) in CRC. Moreover, it is unknown whether 
hypoxia synergises with EGF to accentuate their individual pro-angiogenic effects. The aim 
of the study was to investigate the angiogenic effect promoted by EGF in combination with 
hypoxia in CRC. 
CRC cell lines Colo 201 and Caco-2 were stimulated with EGF and/or exposed to 1% 
O2 or dimethyloxalylglycine (DMOG), a hypoxia-mimetic. Gene and protein expression of 
hypoxia inducible factor (HIF)-1α, HIF-2α and VEGF were assessed. Gene signatures of 
CRC cells following EGF, hypoxia and DMOG stimulations were assessed by angiogenesis 
PCR arrays. The functional significance was assessed by human umbilical vein endothelial 
cell (HUVEC) migration assay co-cultured with Caco-2. 
HIF-1α and VEGF protein were upregulated in Caco-2 with EGF and DMOG 
stimulation. However, Colo 201 demonstrated an increase in VEGF mRNA and protein only 
under hypoxia but not with EGF. The discrepancy in responses to EGF was attributed to 
differences in ERK kinase signalling between the two cell types. PCR angiogenesis arrays 
also identified angiopoietin-like 4 and ephrin A3 as novel genes which were upregulated by 
HIF overexpression, and stabilin-1, a gene specifically downregulated by EGFR-activation. 
Functional relevance was confirmed by HUVEC migration assay, demonstrating similar 
numbers of migrated HUVEC cell numbers in co-cultures with Caco-2 pre-stimulated with 
EGF and DMOG compared to unstimulated controls. 
In conclusion, EGF receptor activation plays a role in CRC angiogenesis by 
increasing VEGF and HIF-1α protein expression, although such effect is dependent upon 
functional ERK MAPK signalling. However, hypoxia and DMOG consistently exerted an 
over-riding stimulus in significantly promoting expression of angiogenic mediators to drive 
endothelial migration and angiogenesis in CRC. 
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Chapter 1 
1 INTRODUCTION 
Colorectal cancer (CRC) has a significant impact on global health, with an estimated 
1,023,000 new diagnoses made, and 528,978 dying from the condition each year (Parkin et al. 
2005). With the condition having a predilection for developing with advancing age, our 
increasing average life expectancy has lead to predictions that CRC will represent a 
significant global challenge as one of the leading causes of death beyond 2030 (WHO 2008). 
CRC is curable by surgical resection with minimal morbidity and mortality, but it currently 
still carries a bleak prognosis as it is commonly diagnosed at an advanced stage, with 
widespread dissemination beyond its tissue of origin. However, recent discoveries have 
facilitated the development of novel therapies which, by diminishing tumour infiltration and 
spread, could channel more patients with advanced disease towards potential curative 
resections. Several of such promising therapies inhibit signalling through the receptor for 
epidermal growth factor (EGF), which is typically constitutively overactivated in CRC, but it 
remains unclear whether their activity in suppressing new blood vessels formation 
(‘angiogenesis’) may be superseded by intratumoural hypoxia, another distinctive feature of 
CRC. The study aimed to explore the response of CRC cells to activation of EGF receptor 
(EGFR) signalling and to hypoxia, focusing particularly on expression of angiogenic signals 
in the context of the tumour microenvironment. The biological responses elicited were tested 
for their functional relevance in inducing angiogenesis using an endothelial migration assay. 
Furthermore, the study uncovered signalling pathways underlying these angiogenic responses, 
and identified unique differences in signalling patterns which could explain for potential 
resistance of CRC to EGFR antagonist treatments. 
1.1 COLORECTAL CANCER 
CRC is the third most common cancer worldwide and in the European Union alone, 
the lifetime estimated risk of developing the disease is 6%. An estimated 27,800 new cases 
will be diagnosed, with 16,100 patients dying each year from the condition in the UK. This 
makes CRC the second leading cause of all cancer related deaths (Statistics 2006). CRCs 
demonstrate significant worldwide variation in incidence, with as much as 30-fold difference 
between industrialised worlds and developing worlds such as in West Africa (Parkin and Muir 
1992). The differences are not solely a result of genetic factors, as the risk of populations 
increases with migration from low- to high-incidence regions. Furthermore there is a link with 
ethnicity, with African-Americans having the highest risk of being diagnosed with, and dying 
from CRC. Among Caucasians, Jews of Eastern European (Ashkenazi) descent have higher 
incidence of CRC, as opposed to migrant Asians or Hispanics who have overall lower risks 
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than Caucasians. The risk of developing the condition also increases with age, with 83% of 
cases arising in people who are 60 years or older. Until the age of 50, men and women in the 
UK have similar rates for CRC. However later in life, males have a greater propensity of 
developing the condition. There is also a variation in the distribution of cancers throughout 
the bowel, with 69% of cancers occurring in the colon and 31% in the rectum and anus. 
Finally, having a previous diagnosis of bowel cancer increases the lifetime risk of developing 
another metachronous tumour by 4-fold compared to an average healthy individual. 
1.1.1 AETIOLOGY 
Aside from demographics, environmental or lifestyle factors and family history are 
often the most crucial in determining an individual’s risk towards developing CRC. Around 
75% of CRCs arise sporadically in people over the age of 50 years and are thought to be 
mainly due to accumulation of multiple genetic mutations, allowing cells to escape the normal 
physiological control mechanisms of cellular proliferation. The chances of developing such 
sporadic mutations may be related to certain lifestyle factors such as consumption of diets 
rich in red meat (Norat et al. 2005), low in fibre content (Bingham et al. 2005; Park et al. 
2005), low in fruit and vegetables (Steinmetz and Potter 1996), and deficient in folate 
(Sanjoaquin et al. 2005), calcium (Cho et al. 2004) and selenium (Jacobs et al. 2004). In the 
context of the initiation-promotion model for colorectal carcinogenesis, fibre confers 
protective effects by binding mutagens which are key players in the initiation of genomic 
mutations. In addition, fibre dilutes the concentration of mutagens and reduces their contact 
with colonic epithelium, alters faecal pH, and reduces colonic transit time. Dietary fats 
promote carcinogenesis by increasing faecal bile acid which promotes generation of reactive 
oxygen metabolites to enhance conversion of unsaturated fatty acids to compounds that 
promote cellular proliferation. Besides diet, there is growing evidence that bowel cancer risk 
is associated with obesity (Bergstrom et al. 2001), lack of physical exercise (Wei et al. 2004), 
excess alcohol (Su and Arab 2004) and tobacco use (Giovannucci et al. 1995), but the risk 
can be reduced by taking easily available drugs such as non-steroidal anti-inflammatories 
(Baron et al. 2003), statins (Poynter et al. 2005), hormone replacement therapy (Csizmadi et 
al. 2004) and oral contraceptives (Fernandez et al. 2001). 
The chronic inflammatory bowel diseases, ulcerative colitis (UC) and Crohn’s 
disease, predispose individuals to developing CRC and account for 1% of all CRCs. Both 
conditions are characterised by chronic inflammation of unknown aetiology, with UC 
afflicting primarily the colon and rectum, and Crohn’s having the potential to affect any 
region of the entire gastrointestinal tract (GIT). The risk of CRC in UC patients is estimated 
to be approximately 7-14% after 25 years of disease (Lennard-Jones et al. 1990), but risk of 
developing rectal carcinoma for a particular individual is increased if adjusted for duration 
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and extent of disease, and with concurrent primary sclerosing cholangitis (Kornfeld et al. 
1997; Bernstein et al. 2001). The propensity of IBD patients to develop CRC is due to 
abnormalities in molecular pathways similar to those described in carcinogenesis of sporadic 
CRC, namely chromosomal instability, microsatellite instability, and hypermethylation. 
However, such abnormalities are commonly present in inflamed colonic mucosa even before 
any histological evidence of dysplasia or cancer exists. The reason for this remains unknown, 
but it is thought that oxidative stress posed by reactive oxygen and nitrogen species produced 
by inflammatory cells can interact with key genes involved in carcinogenic pathways such as 
p53, DNA mismatch repair genes, and even DNA base excision-repair genes (Itzkowitz and 
Yio 2004). The accumulation of such mutations may eventually drive transformed cells to 
cross the threshold to become dysplastic and malignant cells. 
Majority of CRC have no apparent familial association and are thus considered truly 
sporadic. In 25% of CRC however, there is an inherited pattern to a family history of the 
disease. Two major autosomal dominant inherited conditions, Familial Adenomatous 
Polyposis coli (FAP) and Hereditary Non-Polyposis Colon Cancer (HNPCC), have been 
recognised and these account for 1% of all CRC cases. FAP is an inherited condition, caused 
by a mutation in the APC tumour suppressor gene on chromosome 5q21. It is characterised by 
spontaneous formation of hundreds to thousands of adenomatous polyps throughout the colon 
and rectum, typically manifesting by late teens to early 20s. Although an individual polyp has 
a fairly low risk of turning malignant, the cumulative risk from thousands of lesions would 
mean that if left untreated, the progression to CRC is inevitable within 20 years of adenomas 
developing. Patients with a strong family history of colon cancer, namely those who have 
more than one first-degree relative with the disease, and diagnosis for the relative was made 
before 45 years of age, are at a much higher risk of developing CRC. Such patients fit the 
Amsterdam criteria, a set of conditions which are highly predictive for an autosomal 
dominant inherited disorder known as HNPCC which accounts for 5% of new CRC cases per 
year. HNPCC is caused by a fault in the DNA mismatch repair (MMR) genes, particularly 
involving hMSH2 and hMLH1 which are accountable for 95% of mutations. MMR genes 
serve to identify and repair small deletion and insertion errors incurred during DNA 
replication (Kolodner 1995; Umar and Kunkel 1996), therefore loss-of-function mutations 
afflicting DNA MMR would manifest as global genetic instability. The resultant progressive 
accumulation of genetic abnormalities culminates in dysfunctional regulation of cellular 
activity, such as loss of tumour suppressor function mediated by APC, K-ras, p53, 
transforming growth factor (TGF) β receptor II gene (growth controlling pathway), BAX 
(apoptosis) and even the MMR genes (Umar and Kunkel 1996). Patients with HNPCC are 
typically diagnosed young at a mean age of 45 years or below, with tumours developing at the 
proximal portion of the colon with rapid transformation from a benign to malignant 
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phenotype. Since these tumours develop as a consequence of global dysregulation in 
oncogenic and tumour suppressor activity, cancers unrelated to bowel such as cancers of 
endometrium, ovaries, stomach, pancreatico-biliary system and urinary tract could develop 
simultaneously or in isolation. 
1.1.2 MOLECULAR GENETICS 
Transformation of cells towards acquiring malignant phenotype requires 
accumulation of mutations within the genome, ranging from single base-pair mutations to 
portions of chromosomes being deleted or translocated. Such mutations commonly occur 
sporadically, and the resultant aberrant genetic events that controls CRC carcinogenesis have 
been classified into two classical pathways, the chromosomal instability pathway (adenoma-
carcinoma sequence), and microsatellite instability. However, recent developments in 
molecular biology have revealed novel pathways, including the transforming growth factor-
β/SMAD, serrated, and epigenetic pathways, which interact together to form complex 
interlinked networks with multi-levels of cross talk (Takayama et al. 2006). 
The chromosomal instability pathway first proposed by Fearon and Vogelstein 
(Fearon and Vogelstein 1990) describes the sequential transition from healthy colonic 
epithelia, to increasingly dysplastic adenoma and finally to CRC, by progressive 
accumulation of mutations. The theory proposed multiple stepwise allelic losses commencing 
with chromosome 5q, resulting in loss of APC function during the early development of 
polyps. APC has a critical role as a tumour suppressor because 30-70% of sporadic cancers 
demonstrate APC mutations, and furthermore allelic loss results in germline mutations 
responsible for FAP. APC affects Wnt signalling by binding β-catenin to form a complex with 
axin and GSK-3β, which is subsequently rapidly degraded by ubiquitylation. This regulatory 
pathway prevents β-catenin from accumulating and translocating into the nucleus to drive 
transcription of multiple genes implicated in tumour growth and invasion. The next phase in 
the adenoma-carcinoma sequence involves mutation of K-ras, followed by deletions of 
chromosomes 17p and 18q resulting in loss of functions in p53 during the adenomatous stage. 
K-ras mutations are important because their presence in 40 – 65% of CRC have been 
correlated with heightened mitogen activated protein kinase (MAPK) and Phosphoinositide 3 
kinase activities (PI3K), resulting in enhanced tumour growth, evasion from apoptosis, 
enhanced proteolysis and binding of tumour cells to extracellular matrix and promotion of 
tumour angiogenesis. Loss of p53 function classically represents the tipping point of 
malignant cell transformation. It has overriding effects in controlling cell cycle progression by 
inducing G1 cell-cycle arrest, enabling cells to undergo DNA repair or to induce apoptosis. 
The subsequent mutation in chromosome 18q to affect DCC/SMAD4 completes the terminal 
stages of transition to malignancy. 
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Microsatellite instability (MSI) is characterised by expansions or contractions in the 
number of tandem repeat DNA sequences or microsatellites. This pathway bears resemblance 
to that described for HNPCC, as the manifestation of microsatellite mutations is a marker of 
global genetic instability as a consequence of deficient MMR enzyme function (Fishel et al. 
1993; Ionov et al. 1993; Thibodeau et al. 1993). Mutations affecting DNA MMR enzymes, 
including hMSH2, hMLH1, hPMS1, hPMS2, and hMSH6, have been shown to be responsible 
for MSI (Bronner et al. 1994; Nicolaides et al. 1994; Nicolaides et al. 1995). With failure of 
the surveillance system to monitor integrity of the genome, mutations that develop in 
microsatellites of oncogenes and tumour suppressor genes could accelerate malignant 
transformation. MSI affecting regulatory functions of various genes have been reported 
(Souza et al. 1996; Rampino et al. 1997; Guanti et al. 2000), one example being transforming 
growth factor-β (TGF-β) which failed to repress cell cycle activity through the TGF-β/SMAD 
signalling pathway due to CRC MSI (Markowitz et al. 1995). MSI tumours are also more 
prone to develop mutations of the APC, K-ras and p53 genes, and loss of heterozygosity 
(LOH) of chromosomes 5q, 19p, and 18q (Takayama et al. 2006). 
1.1.3 CLINICAL PRESENTATION & HISTOLOGICAL STAGING 
Majority of patients with CRC are symptomatic at point of diagnosis, but the phased 
introduction of NHS Bowel Cancer Screening Programme since 2006 has increased detection 
of cancers in asymptomatic individuals. Symptoms of CRC can vary with the site of the 
tumour, where proximal tumours are more closely correlated with abdominal pain, vomiting, 
palpable mass, or change in bowel habit. In contrast, distal lesions in the rectum and distal 
colon usually cause bleeding, tenesmus and/or altered bowel habits especially constipation 
(Majumdar et al. 1999). Unfortunately, a fifth of patients present during the later stages of 
disease with acute bowel obstruction or peritonitis due to bowel perforation (Koehne et al. 
1999). However, majority of patients present with non-specific symptoms such as weight loss, 
anorexia and iron-deficiency anaemia due to occult blood loss. 
A broad range of diagnostic studies can be employed in the evaluation of suspected 
CRC. Rectosigmoid cancers which account for 36% of all CRC can be simply detected by 
digital rectal examination and rigid sigmoidoscopy, as 40-80% of patients with rectal cancers 
present with palpable masses (Shallow et al. 1955; McSherry et al. 1969). Majority of cancers 
causing rectal bleeding and/or a change in bowel habit without any other significant 
diagnostic factors tend to be sited within 60cm of the anal verge, and are thus amenable to 
examination by flexible sigmoidoscopy. Patients presenting with ‘red flag’ symptoms 
consistent with proximal cancers should be assessed by colonoscopy. Completion 
colonoscopy is important for all patients diagnosed with potentially curable CRC to visualise 
the entire length of colon, as the incidence of synchronous lesions is in the order of 4-5% 
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(Finan et al. 1987; Barillari et al. 1990). 
Figure 1.1  Histopathological staging of CRC with Dukes’ and TNM classification 
Schematic description of the staging systems with respect to depth of invasion, lymph node 
involvement and distance metastasis. TNM staging was developed by International Union Against 
Cancer (UICC) and American Joint Committee on Cancer (AJCC) with reference to Tumor invasion 
(T), Nodal involvement (N), and distant Metastasis (M) (Hutter 1987).  
 
 
Table 1.1 Incidence of CRC in relation to Dukes’ stage and correlation to survival 
Incidence at which patients present at various stages of CRC and their prognosis. 
Dukes’ Stage modified Approximate 
frequency at diagnosis 
5-year survival 
A 11% 83% 
B 35% 64% 
C 26% 38% 
D 29% 3% 
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Diagnosis of CRC is based on histological examination of biopsies taken during 
endoscopic assessments. Newly diagnosed patients would subsequently undergo a process of 
staging as it underpins decisions regarding future management plans, and guide optimal use 
of adjuvant and surgical treatments. Pre-operative staging in the form of computed 
tomography (CT) of the thorax, abdomen and pelvis allows determination of local and distant 
extent of disease. Similarly, pelvic magnetic resonance imaging (MRI) allows assessment of 
local tumour infiltration in rectal cancers, which helps to determine whether curative excision 
with tumour-free margins is feasible. 
Pathologically, 98% of cancers within the large bowel are adenocarcinomas with 
rarer tumours comprising of carcinoid, primary and secondary lymphoma and 
leiomyosarcoma. Macroscopically, the tumours can appear as papilliferous, ulcerating, 
annular circumferential lesions, diffusely infiltrating and colloid tumours producing excess 
mucus. The main purpose of histological examination of CRC is to determine the pathological 
stage, as it is the most accurate predictor of prognosis and survival, and it forms the crux to 
the future management of patients with the condition. The Dukes’ classification of tumours 
founded in 1932 categorised CRC lesions into stages A to C (Figure 1.1) and is still used 
today, but newer more precise clinicopathological staging based on TNM is being phased in. 
Table 1.1 shows the importance of staging CRC because it is the single most accurate 
predictor of survival. Patients presenting with Dukes’ A early cancers are on average just over 
2 times more likely to survive within 5 years of diagnosis compared to those presenting later 
with advanced Dukes’ C cancers. 
1.1.4 MANAGEMENT 
Endoscopic examination of the bowel provides the ideal opportunity to remove 
neoplastic polyps for histological diagnosis, and also acts as treatment by interrupting the 
transition of adenomatous lesions to invasive cancers. Lesions which demonstrate invasion 
through the muscularis mucosa are by definition malignant, and would normally require 
further surgery. However, small pT1 rectal cancers and polyps containing small areas of 
invasive cancer can be safely treated by local excision, provided the resection margin was 
negative for cancer (Whiteway et al. 1985). More recently, local excision of rectal adenomas, 
and well- or moderately-well differentiated pT1 rectal cancers by transanal endoscopic 
microsurgery has been gaining popularity, with published data suggesting that this is at least 
as good as traditional transanal resection (Steele et al. 1996). However, histopathological 
examination of some of these locally excised lesions may identify a proportion of patients 
who will require more radical surgery. Decisions regarding patient management should be 
discussed, and a consensus achieved by a multidisciplinary team comprised of a panel of 
specialists with clinically relevant skills and expertise, in order for all patients to benefit from 
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suitably informed oncological and surgical opinions. The surgical goals in resecting a primary 
CRC are to achieve an en-bloc resection that encompasses an adequate amount of normal 
colon proximal and distal to the tumour, to obtain adequate lateral margins if the tumour is 
adherent to contiguous structures, to remove regional lymph nodes, and to maintain continuity 
of bowel through primary anastamosis. Accomplishment of these goals optimises the chance 
of preventing locoregional recurrence of the disease, and provides better quality of life for 
patients. For colonic lesions, segmental resection of large bowel with its regional lymph 
nodes is the best accepted practice, but recently, there has been a trend towards extended right 
hemicolectomy for tumours of transverse colon and splenic flexure. In rectal cancers, careful 
removal of tumours by total mesorectal excision, either as part of an anterior resection or 
abdomino-perineal excision (APER), should be performed to minimise significant variations 
in reported recurrence rates ranging from 2.6% (Karanjia et al. 1990) to 32% (Hurst et al. 
1982) after curative rectal resections (Heald et al. 1982; Heald and Ryall 1986; Heald 1988). 
Adjuvant therapies in the form of radiotherapy and chemotherapy have increasing 
roles in the management of CRC, and have been major contributing factors to the significant 
improvements in prognosis over the last two decades. Patients with resectable rectal cancers 
who received short course preoperative radiotherapy (SCRT), and postoperative radiotherapy 
have demonstrated significant reduction in local recurrence following surgical resection 
(Kapiteijn et al. 2001), but borderline or no significant survival benefits were achieved. For 
patients with advanced locoregional rectal disease, long course pre-operative radiotherapy 
given in the neo-adjuvant setting to downstage the tumour has been shown to be effective, 
particularly in combination with 5-fluoropyrimidine-based chemotherapy such as fluorouracil 
(5-FU) as combined regime known as chemoradiotherapy (CRT) (Sauer et al. 2004; Bosset et 
al. 2005). CRT therefore offers hope to the large subgroup of patients (up to 55% of all CRC) 
who present late with advanced CRC (Campbell et al. 2001), with potential curative resection 
following adequate downstaging of the tumour. Furthermore, chemotherapy in the form of 
5FU as a single agent, or combined with oxaliplatin, improves disease-free survival and 
overall survival for patients with lymph node positive disease who have undergone surgical 
resection (Wolmark et al. 2000; Andre et al. 2004; NICE 2005). Despite these advances, 
significant challenges are still encountered particularly in managing patients who have 
operable metastatic disease, inoperable disease, recurrence of disease, and those who 
demonstrate resistance to CRT. 
There is clear indication that breakthrough treatments with novel therapeutic targets 
are in demand. The ultimate aim of such agents would be to slow or inhibit tumour growth, 
and ideally cause tumour regression. The quest to develop such treatments led to discovery of 
bevacizumab, a novel monoclonal antibody therapy which inhibits growth and development 
of new tumour vessels (angiogenesis) by inhibiting vascular endothelial growth factor 
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(VEGF). VEGF was selected as the anti-angiogenic target because it is a potent promoter of 
tumour angiogenesis, and its expression is commonly upregulated in numerous solid 
malignancies including primary and metastatic CRC (Ferrara and Davis-Smyth 1997). The 
rationale for targeting tumour vessels stems from knowledge that tumour growth is limited to 
2-3mm3 in the absence of neo-vascularisation, and highlights the importance of tumour 
angiogenesis in potentiating tumour growth and metastasis (Folkman and Shing 1992). Anti-
VEGF monoclonal antibody bevacizumab represents the first of a new class of 
chemotherapeutic agents which affects tumour survival and progression by selectively 
modifying critical biological systems underlying CRC development and growth. New 
therapies currently in development are directed at modulating cell signalling and gene 
expression of cancer cells, or altering the tumour microenvironment that forms the supportive 
framework for sustaining cancers. Modification of the tumour microenvironment is proving 
increasingly attractive since the constituent stromal components are composed of stable and 
non-transformed cells. Transforming the tumour landscape could deprive tumours of nutrients 
and oxygen by suppressing angiogenesis, reduce growth factor and cytokine availability, and 
antagonise invasion and metastasis of cancer cells. Another recently developed novel class of 
agents, one of which is Cetuximab, inhibits ErbB signalling networks which mediate EGF 
signalling. ErbB signalling is commonly overactivated in cancers to promote clonal expansion 
of transformed cells, modulate cellular adhesion, differentiation and apoptosis to enhance 
tumourigenicity and malignant progression (Yarden and Sliwkowski 2001). Cetuximab is a 
chimeric monoclonal anti-EGFR antibody, whereas the newer Panitumumab is the first fully 
human anti-EGFR monoclonal antibody. Human cancers can hyperactivate a range of 
mechanisms involved in ErbB signalling by overproduction of ligands and/ or corresponding 
receptors, or expression of constitutively activated receptors. The critical role of the tumour 
microenvironment in malignancy is further supported by the strong causal relationship 
between chronic inflammatory conditions and cancer, such as exemplified by ulcerative 
colitis. Inflammation is inevitable following tissue injury as it is a vital component for cellular 
regeneration and repair. Persistent inflammation however, could result in cumulative tissue 
injury and DNA damage, and coupled with cytokine-induced cellular proliferation could lead 
to malignant transformation as the end-result. These inflammatory changes are heavily 
influenced by cytokines, which exert critical functions in modulating host immune responses 
to generate antitumour effects by activating immune cells, or to promote a tumourigenic 
environment (Lin and Karin 2007). Thus, modulation of growth factors and inflammatory 
cytokines is recognised as important and promising therapeutic targets, given their pleiotropic 
role in orchestrating complex interactions between cancer cells and its microenvironment. 
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1.2 ROLE OF GROWTH FACTORS AND INFLAMMATORY CYTOKINES 
1.2.1 EPIDERMAL GROWTH FACTOR 
One example of a cytokine with potent tumourigenic properties is EGF. EGF is a 
member of a larger group of growth factors comprising of TGF-α, amphiregulin (AR), 
betacellulin (BTC), and heparin-binding EGF (HB-EGF) which all share several common 
structural and functional properties. All these growth factors are small proteins, and mediate 
their effects by interacting with the family of EGF receptors (EGFR) or Erb receptors. Despite 
EGF and TGF-α being able to bind to the similar EGFR with similar affinity, both proteins 
only share 40% of structural similarity. This suggests that conformation of the growth factor 
is far more important for receptor binding than actual individual amino acid sequences. The 
interaction between the ligand and binding site results in an intricate intracellular signalling 
network leading to changes in cellular behaviour. 
The epidermal growth factor receptor, also known as human EGF receptor (EGFR), is 
a glycoprotein composed of an extracellular ligand binding domain, a transmembrane region 
and an intracellular tyrosine kinase domain. The tyrosine kinase domain is flanked by a 
carboxyl-terminal tail with tyrosine autophosphorylation sites which serves as a docking site 
for various adaptor proteins or enzymes (Figure 1.2). The receptor is a member of the ErbB 
receptor family (ErbB1 [HER-1], ErbB2, ErbB3 and ErbB4) which are all encoded by the c–
erb proto-oncogene (Slamon et al. 1987). Activation of these receptors leads to initial 
dimerisation of two ErbB receptors, and subsequent autophosphorylation of the C-terminal 
tail by the tyrosine kinase domain (Figure 1.2). The specificity and potency of the 
intracellular signals are determined by the type of ligand, the composition of the 
heterodimeric receptor, the positive and negative effectors of the receptor, and the 
phosphotyrosine-binding proteins that associate with the tail of the receptor (Yarden and 
Sliwkowski 2001). Cell surface to nuclear signalling can occur via several pathways, but they 
are commonly mediated by the ERK MAPK pathway or the PI3K/Akt pathway. These signals 
translate into distinct transcriptional programmes within the nucleus, involving the proto-
oncogenes fos, jun and myc, and the zinc-finger containing transcription factors Sp1 and 
Egr1. The activated cell could respond by cell proliferation, migration, adhesion, 
differentiation and apoptosis, but the eventual outcome is dependent upon the cellular context, 
the specific activating ligand, and the morphology of the ErbB dimer (Pinkas-Kramarski et al. 
1996). 
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Figure 1.2 Structure of erbB family receptors and their cognate ligands 
The receptor consists of three domains: a ligand-binding extracellular domain, a transmembrane 
domain, and an intracellular domain containing a tyrosine kinase region. EGF, epidermal growth 
factor; EGFR, EGF receptor; HER, human epidermal receptor; HB-EGF, heparin-binding EGF; NRG, 
neuregulin; TGF-α, transforming growth factor-α. (adapted from (Gschwind et al. 2004)) 
 
EGFR and its cognate receptors have been implicated in pathogenesis and 
progression of CRC (Lockhart and Berlin 2005). Overexpression of EGF and EGFR have 
been demonstrated in approximately 70-75% of CRC, with expression levels higher in 
malignant zones than in surrounding benign mucosa, and particularly in advanced stages of 
disease (Lockhart and Berlin 2005). Experimental animal models have shown increased 
expression of TGF-α and increased EGFR phosphorylation following treatment with colon 
cancer-promoting agents (Coffey et al. 1992; Malecka-Panas et al. 1996). Furthermore, 
mouse model of FAP developed fewer colorectal polyps when crossbred with EGFR-deficient 
mice, or treated with EGFR tyrosine kinase inhibitors compared to controls (Roberts et al. 
2002). Studies using xenograft models also showed beneficial effects of potentiating 
conventional cytotoxic chemotherapy by the addition of anti-EGFR treatment (Petit et al. 
1997). All of this evidence provided the impetus towards development of the first novel anti-
EGFR human-mouse chimeric monoclonal antibody Cetuximab, and more recently 
Panitumumab (a fully humanised monoclonal antibody). The efficacy of cetuximab has been 
proven as third-line therapy for advanced CRC in the randomised BOND I trial, where 329 
patients who had treatment resistance to irinotecan-based regimen were randomised to receive 
either cetuximab alone or in combination with irinotecan (Cunningham et al. 2004). The 
combination treatment resulted in an increased response rate from 11 to 23% and an improved 
time to progression from 1.5 months to 4.5 months, but there was no significant improvement 
in overall survival. Due to the lack of a control group in the BOND I study, a larger phase III 
trial conducted by the National Cancer Institute of Canada Clinical Trials Group in 
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collaboration with the Australasian Gastro-Intestinal Trials Group recruited 572 patients who 
received pretreatment with irinotecan and oxaliplatin. Patients were randomised to best 
supportive care or cetuximab monotherapy. In comparison with best supportive care alone, 
cetuximab treatment was associated with a significant improvement in overall survival (6.1 
months in the cetuximab versus 4.6 in best supportive care group), and in progression-free 
survival (Jonker et al. 2007). In a larger multinational trial to assess the efficacy and safety 
(MABEL study) of cetuximab in a wider community, 1100 patients with EGFR-detectable 
and irinotecan refractory metastatic CRC were randomised to receive three different 
irinotecan regimens with cetuximab. The overall response rate to treatment was 20%, with a 
median time to progression of 3.3 months and median overall survival of 9.2 months. These 
results were comparable to the 8.6 months median overall survival in the BOND study.  
Cetuximab represents a useful and alternative therapy for advanced CRC, but the 
mediocre results reported in clinical trials are not indicative of a potent treatment, which 
theoretically inhibits tumour growth by suppressing cancer cell proliferation. Furthermore, its 
reported ability to inhibit tumour angiogenesis would have conferred a greater therapeutic 
effect by normalising tumour blood vessels and inducing apoptosis. Since development of 
EGFR antagonists for CRC relied heavily upon translational studies using non-CRC cell 
types, mainly on glioblastoma multiforme and squamous cell carcinoma models, it is possible 
that the pro-angiogenic response elicited following cytokine stimulation was specific to 
selected cell types. The outcome of direct EGFR stimulation in relation to angiogenesis 
specific to CRC still remains largely unknown. 
1.2.2 INTERLEUKIN-1β 
The pro-inflammatory IL-1 cytokine family comprises of three proteins. Although IL-
1α and IL-1β are derived from different genes, their functional and biological properties are 
similar upon activation of a shared common receptor. However, IL-1α is localised within the 
cytosol and cell membrane and mainly regulates the intracellular environment, whereas IL-1β 
which is secreted extracellularly requires interleukin-1β-converting enzyme (ICE) for 
conversion to its mature active form. The third member, IL-1 receptor antagonist (IL-1RA) 
binds competitively to IL-1 receptors without transmitting an activation signal, and thus 
represents a physiological inhibitor of IL-1 activity. IL-1 is a pleiotropic cytokine responsible 
for normal physiological roles such as mediating vascular permeability and fever during 
sepsis, to pathological roles in promoting autoimmune conditions such as rheumatoid arthritis, 
inflammatory bowel disease and malignancies. 
IL-1 is known to participate in pathogenesis and progression of malignancies 
involving skin (Lee et al. 1993; Krelin et al. 2007), breast, colon, lung, head and neck 
 27
MD (Res) Thesis Tak Loon Khong 
Chapter 1 
cancers, and melanomas (Chen et al. 1999; Gemma et al. 2001; Apte et al. 2006; Elaraj et al. 
2006). IL-1 promotes metastasis by stimulating malignant and stromal cells to secrete 
invasion-promoting factors, such as matrix metalloproteinases (MMP) (Stetler-Stevenson 
2001; Stetler-Stevenson and Yu 2001), adhesion molecules (Vidal-Vanaclocha et al. 2000) 
and angiogenic factors (such as VEGF and fibroblast growth factor (FGF)-2 and ELR-
positive CXC chemokines, i.e. IL-8 and MCP-1) (Dvorak 2002). Immunohistochemical and 
gene expression studies confirm that IL-1β is commonly overexpressed in CRC. IL-1β 
expression was demonstrated to be significantly higher in CRC tissue, and correlated with 
increased expression of several known inducers of angiogenesis such as cyclooxygenase 
(COX)-2, IL-6 and p65 (Maihofner et al. 2003). Gene expression analyses also confirmed that 
IL-1β was overexpressed in 50% of metastatic colonic adenocarcinomas, and it has also been 
demonstrated to be constitutively expressed in several CRC cell lines (Elaraj et al. 2006). 
1.3 ANGIOGENESIS 
Angiogenesis is the growth of new capillaries from existing blood vessels within the 
body. This process can occur via a sprouting or intussusceptive mechanism. The sprouting 
process is based on endothelial cell migration, proliferation and tube formation, whereas 
intussusceptive microvascular growth divides existing vessel lumens by formation and 
insertion of endothelial columns into the vessel lumen. The process of angiogenesis is 
normally quiescent in adult humans and only occurs during highly regulated processes of 
normal bodily function, for example in wound repair or female reproductive cycles due to an 
intricate balance between pro- and anti-angiogenic signals. Where there is loss of intrinsic 
control, pathological chronic inflammatory conditions and fibroproliferative disorders arise 
for example in ophthalmic, rheumatic diseases, and tumour angiogenesis. Cancers in 
particular exploit various control mechanisms which regulate angiogenesis with the aim of 
improving survival, increasing proliferation and growth, and enhancing tumour spread. In 
order to appreciate the mechanisms by which cancers transform these regulatory pathways to 
promote angiogenesis, we need to understand the regulatory systems underlying physiological 
angiogenesis. 
1.3.1 MECHANISMS UNDERLYING NORMAL PHYSIOLOGICAL ANGIOGENESIS 
Sprouting angiogenesis which is typically utilised by tumours to increase blood flow 
occurs in several well-characterised stages, with each stage requiring coordinated signals 
between various growth factors and receptors. The first step of angiogenic remodelling of 
mature vasculature requires disengagement of endothelial cells from surrounding supporting 
cells. This destabilisation process is driven by a progressive shift in angiopoietin (Ang) 
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expression from Ang1, which maintains vessels in a quiescent state, to Ang2 which 
encourages pericyte detachment by competitively inhibiting Tie2 receptor signalling 
(Maisonpierre et al. 1997). This detachment renders endothelial cells accessible to angiogenic 
stimuli, such as VEGF and FGF-2, causing endothelial cells to be activated with resultant 
release of proteases such as MMP, plasminogen activators (uPA and tPA) (Millauer et al. 
1993; Pepper 1997), and interstitial collagenase (Unemori et al. 1992). Endothelial cell 
basement membrane and extracellular matrix are then degraded and remodelled by these 
proteases (Moses 1997), and new matrix synthesized by stromal cells is then laid down. The 
new matrix, coupled with the proliferative (Gospodarowicz et al. 1987; Connolly et al. 1989; 
Gospodarowicz et al. 1989) and pro-migratory effects (Terranova et al. 1985; Dimmeler et al. 
2000) of soluble growth factors such as VEGF and FGF-2, foster migration of endothelial 
cells to create finger-like projections. Invasion and migration of endothelial cells through 
extracellular matrix (ECM) comprising of Type I collagen, vitronectin, fibronectin, and fibrin 
requires cell-matrix interactions, which are mediated by integrins such as αvβ3 (Cheresh 
1987). Integrin αvβ3 mediates endothelial cell attachment, spreading, and migration 
(Leavesley et al. 1993), and its importance for endothelial cell function is reflected by its 
transient expression on tips of sprouting endothelial cells, and on newly formed blood vessels 
in granulation tissue (Clark et al. 1996; Li et al. 2003). As the endothelial cells coalesce 
together to form tube-like structures, mesenchymal cells which proliferate and migrate along 
the abluminal surface of the endothelium under the influence of platelet derived growth 
factor-B (PDGF-B), mature to form pericytes and smooth muscle cells (Conway et al. 2001). 
Presence of an enveloping layer of smooth muscle cells inhibits further endothelial cell 
proliferation and migration, signalling the end of new blood vessel formation (Beck and 
D'Amore 1997). Finally, ECM is deposited around the new vessel under the control of TGF-β 
which is secreted by interactions between endothelial cells and the vascular smooth muscle 
cell-pericyte complex. This signals the final stages of vessel stabilisation and maturation 
(Beck and D'Amore 1997). 
1.3.2 ANGIOGENESIS IN PATHOLOGICAL CONDITIONS 
Angiogenesis is a tightly regulated process which is dictated by a balance between 
pro- and anti-angiogenic factors, therefore any pathological condition which could alter the 
fine balance would lead to aberrant angiogenesis. This is demonstrated in psoriasis, 
ophthalmic and rheumatic diseases where inflammation recruits inflammatory cells causing 
release of pro-angiogenic factors and proteases. The mechanism of tumour angiogenesis is 
thought to be somewhat different, where an ‘angiogenic switch’ shifts the balance to a more 
pro- rather than anti-angiogenic state during the early, pre-malignant stage (Folkman and 
Shing 1992; Bergers and Benjamin 2003). The signals that trigger the angiogenic switch 
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include metabolic stress, genetic mutations that activate certain oncogenes or inactivate 
tumour suppressor genes, and the presence of an immune or inflammatory response 
(Carmeliet and Jain 2000). For most of these causative factors, VEGF has been shown to be 
the common effector in inducing angiogenesis, especially in the presence of other angiogenic 
allies such as nitric oxide synthase (NOS), PDGF-B and Ang-2 (Carmeliet and Jain 2000). 
Cancers which were once attributed directly to abnormal oncogene or tumour suppressor 
functions, such as loss of p53 function (Ravi et al. 2000) and mutant ras oncogenes (Rak et al. 
2000), or overexpression of growth factor signalling, such as EGFR overactivation (Goldman 
et al. 1993) have all been shown to exert angiogenic effects through significant upregulation 
of VEGF. Hypoxia, a hallmark of most solid tumours, has also proven to be a potent and 
consistent inducer of VEGF expression by recruiting hypoxia inducible factor (HIF)-
dependent or HIF-independent mechanisms. Furthermore, hypoxia can enhance degradation 
of the ECM to release pro-angiogenic factors by activating the MMP cascade, by recruiting 
the urokinase-type plasminogen activator (uPA)/ plasmin axis (Curran and Murray 2000). 
Once the balance is tipped in favour of angiogenesis, the process of sprouting 
angiogenesis as previously described ensues. Unlike normal blood vessels, tumour vessels are 
structurally and functionally abnormal (Jain 1994). The excess endothelial cells and abnormal 
perivascular cells contribute to formation of tortuous, dilated and saccular blood vessels that 
are poorly organised and hyperpermeable (Baish and Jain 2000). With such deranged 
architecture and likely compression by surrounding cancer cells, the newly formed vessels 
can increase resistance to blood flow and impair blood supply. With increased oxygen 
demand by neoplastic and endothelial cells, along with poor oxygen delivery, the resultant 
hypoxia fulfils a positive feedback loop to encourage development of more dysfunctional 
vessels. Vascular hyperpermeability also results in interstitial hypertension, eliminating the 
pressure gradient which typically drives fluid and macromolecules from the intravascular to 
interstitial compartments. These pathophysiological characteristics compromise the delivery 
and effectiveness of conventional cytotoxic therapies, as well as molecular targeted therapies 
(Jain 1998). One of the main pursuits in research currently is to develop therapies to prune 
such immature and inefficient blood vessels by eliminating excess endothelial cells, with the 
hope of ‘normalising’ the resulting vasculature which would theoretically be more conducive 
to deliver nutrients and therapeutics to the target sites (Jain 2001). 
1.3.3 ANGIOGENESIS INHIBITION IN CANCER 
The overall 5 year survival rate for all patients diagnosed with CRC still remains 
poor, primarily a result of advanced stage of disease at time of presentation which afford 
minimal therapeutic options (Campbell et al. 2001). There is clear indication for breakthrough 
novel therapeutic agents which would slow or inhibit tumour growth, and ideally cause 
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tumour regression. A new class of therapeutic agents recently developed relies on the 
understanding that tumour growth is limited to 2-3mm3 in the absence of neo-vascularisation 
(Folkman 1971). Bevacizumab, a recombinant humanised IgG1 monoclonal antibody (Presta 
et al. 1997), was developed as a selective antagonist of VEGF-A. VEGF was selected as the 
target as it is upregulated in numerous solid malignancies including primary and metastatic 
colon cancer, and is a pivotal promoter of tumour angiogenesis (Ferrara et al. 2003). In 
addition to inhibiting outgrowth of new tumour vessels, bevacizumab also causes regression 
and normalisation of existing tumour vasculature, and limits recruitment of bone marrow 
derived progenitor cells (EPC) (Presta et al. 1997). Normalisation of tumour vessels is 
associated with decreased tumour perfusion, vascular volume, microvascular density, 
increased pericyte coverage of the vasculature and a significant decrease in interstitial fluid 
pressure. All of these changes underlie greater penetration of chemotherapy into the tumour 
resulting in further damage of the vasculature and subsequent tumour regression (Jain 2001; 
Willett et al. 2004; Koukourakis et al. 2007). With the resultant deprivation in oxygen and 
nutrient delivery subsequent to complete tumour vasculature regression, bevacizumab may 
provoke tumour cells to enter cell-death pathways (Yao et al. 2005). 
Bevacizumab is licensed in the European Union for the first-line treatment of patients 
with metastatic cancer of the colon or rectum, in combination with fluorouracil (5-FU) and 
folinic acid (leucovorin) with or without irinotecan. A combination of bevacizumab with 
standard chemotherapy regimes have been shown to significantly improve survival of patients 
with metastatic CRC (Kabbinavar et al. 2003). In a Phase III clinical trial of 813 patients with 
untreated metastatic disease, patients were randomised to receive irinotecan, 5-FU and 
leucovorin (IFL) alone, or in combination with bevacizumab at 5mg/kg every 2 weeks. The 
group that received additional bevacizumab had a longer median duration of survival (20.3 
versus 15.6 months), progression-free survival (10.6 versus 6.2 months) and an improved 
response rate to treatment (44.8% versus 34.8% respectively) (Hurwitz et al. 2004). The 
addition of bevacizumab to 5-FU and leucovorin also benefited patients with previously 
untreated metastatic CRC (Kabbinavar et al. 2005; Kabbinavar et al. 2005). Other Phase III 
trials using newer chemotherapeutic regimes such as 5-FU, leucovorin and oxaliplatin 
(FOLFOX)-4 have further confirmed improved median overall survival, progression survival 
time and higher response rates in patients receiving chemotherapy in combination with 
bevacizumab (Giantonio 2006; Giantonio et al. 2006). Bevacizumab has a good safety profile, 
and with the exception of hypertension, there was no significant difference in the incidence of 
adverse events. Other known adverse effects include gastrointestinal perforation (1.3%) 
(Hurwitz et al. 2004; Berry et al. 2006), arterial thromboembolic events, proteinuria and 
wound complications (Scappaticci et al. 2005). 
A new family of tyrosine kinase inhibitors (TKI) such as vatalanib is also proving 
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promising. Such agents block both angiogenesis and lymphangiogenesis by inhibiting 
downstream signalling of all three VEGF family receptor members, and also signals mediated 
by PDGF and FGF-2 (Wood et al. 2000). Despite possessing multiple mechanisms of action, 
TKI treatment failed to show overall significant clinical benefit, except for a sub-group of 
patients with elevated lactate dehydrogenase (LDH) (Hecht et al. 2005; Kohne et al. 2007). 
Clinical trials have highlighted several dilemmas: firstly, LDH is a non-specific tumour 
marker and its role in selecting patients for such treatments remains unclear (Major et al. 
2006), secondly, the once daily dosing may be inadequate to sustain a sufficiently high level 
of the drug to ensure complete inhibition of signalling through VEGFR (Jost et al. 2006) and 
finally, inhibition of other kinase associated signalling pathways may be the cause for the 
attenuated drug effect. 
Regulation of angiogenesis occurs at multiple levels, with the balance between pro- 
and anti-angiogenic mediators controlling pathways leading to extracellular matrix 
degradation, endothelial cell proliferation, and its subsequent migration. Thus, targets for anti-
angiogenic drugs currently in development include MMP inhibitors, cell proliferation and 
migration inhibitors, agents that inhibit endothelial cell-specific integrin signalling, and 
agents that are antagonists to other angiogenic promoters (Zakarija and Soff 2005). 
Additionally, since naturally occurring anti-angiogenic factors exist to oppose formation of 
new blood vessels, current work is ongoing to examine the direct effect these factors have on 
the cellular regulatory pathways of endothelial cells. The attraction of targeting genetically 
stable endothelial cells is the theoretical risk reduction of patients developing drug-induced 
resistance. Angiostatic agents which may have future therapeutic roles include (1) endostatin, 
the internal fragment of collagen type 18, (2) angiostatin, a cleavage fragment of 
plasminogen, (3) tumstatin, (4) platelet factor-4, a platelet derived chemokine, (5) 
thrombospondin-1 and (6) 16-kDa N-terminal fragment of prolactin (Tabruyn et al. 2007). 
There is emerging evidence that these agents have multiple complex intra- and extracellular 
effects, capable of inhibiting MMP and integrins therefore limiting endothelial cell migration. 
In addition, angiostatic treatments have been shown to arrest the endothelial cell cycle, 
thereby attenuating endothelial cell proliferation, and the anti-angiogenic effect is further 
enhanced by the activation of both extrinsic and intrinsic pathways to promote endothelial cell 
apoptosis. Our understanding of how these inhibitors work is still at its infancy, but these 
therapeutic approaches could potentially have larger implications for the treatment of other 
cancer cell types and non-cancer related diseases. 
The first generation of angiogenesis inhibitors have provided us with a glimpse of 
how management of advanced CRC will be revolutionised in the near future. The success 
story of bevacizumab is an indication that novel therapies can benefit patients with advanced 
CRC, and crucially provides direction and encouragement for the development of other 
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treatments which inhibit angiogenesis. As further knowledge is gained about angiogenesis, it 
is obvious that further understanding is required into the various signalling mediators which 
control the complex interactions between endothelial cells, inflammatory cells and the 
extracellular matrix. In order to understand the benefits conferred by anti-VEGF therapy, 
detailed understanding is required into VEGF and its signalling pathways. 
1.3.4 VASCULAR ENDOTHELIAL GROWTH FACTOR 
The VEGF-related gene family encodes for six secreted growth factors which control 
the process of angio- and lymphangiogenesis. These glycoproteins are known as VEGF-A, 
VEGF-B, VEGF-C, VEGF-D, VEGF-E and placental growth factor (PlGF)-1 and -2 (Ferrara 
et al. 2003). Alternative splicing of VEGF-A mRNA transcript results in four main isoforms 
with varying number of amino acids – VEGF-A121, VEGF-A165, VEGF-A189 and VEGF-A206 
(Tischer et al. 1991). VEGF-A121 is freely secreted, compared to the larger isoforms VEGF-
A189 and VEGF-A206 which are sequestered in the extracellular matrix. VEGF-A165, the 
predominant isoform, can exist either in the soluble or ECM bound forms (Keyt et al. 1996). 
The ECM-bound isoforms have to be released into the soluble form, and this is mediated 
either by plasmin cleavage at the C-terminus which generates a bioactive fragment (Park et al. 
1993), or extracellular matrix degradation by MMP-9 (Bergers et al. 2000). The various 
isoforms are distributed differently and expression patterns of certain isoforms are tissue-
specific, implying that they have unique roles in angiogenesis (Ferrara 1999). In vivo 
experiments have shown that VEGF-A controls many key events in physiologic and 
pathologic angiogenesis, and its expression has to be temporally and spatially well 
orchestrated (Shweiki et al. 1993). VEGF-A is essential for physiological development, as 
mice with homozygous or heterozygous deletions of the gene have lethal defects in 
vasculogenesis and cardiovascular development (Carmeliet et al. 1996). It is also associated 
with pathological conditions including arthritis, psoriasis, macular degeneration and diabetic 
retinopathy (Ferrara et al. 2003). However, VEGF-B does not seem to have a role in 
angiogenesis during development, as no defects were noted in the embryonic vasculature of 
mice with deletion of the gene (Carmeliet et al. 2001). In contrast, VEGF-C and VEGF-D 
play key roles in lymphangiogenesis during the embryonic developmental phase and later 
stages in life. Homozygous deletion of VEGF-C gene is embryonically lethal, and 
heterozygous deletion results in defective lymphatic development (Karkkainen et al. 2004). 
VEGF-E is similar to a viral protein produced by the parapoxvirus Orf and has been observed 
to exert a potent mitogenic effect on cells (Ogawa et al. 1998). Loss of PlGF is associated 
with impaired angiogenesis, plasma extravasation and collateral vessel growth, characteristics 
which are only manifested during adulthood (Carmeliet et al. 2001). 
VEGF ligands are required to interact with specific tyrosine kinase receptors for 
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transduction of cell-surface signals to affect endothelial cell activity. The first identified 
receptors were VEGF receptor 1 (VEGFR-1), also known as fms-like tyrosine kinase 1 (Flt-1) 
receptor (Shibuya et al. 1990), and VEGF receptor 2 (VEGFR-2), also known as KDR or Flk-
1 (murine homologue) receptor (Matthews et al. 1991). More recently, VEGFR-3 also 
referred to as fms-like tyrosine kinase 4 (Flt-4) has been identified and its primary function is 
in lymphangiogenesis (Kaipainen et al. 1995). All three receptors contain an intracellular 
tyrosine kinase domain which phosphorylates specific second messenger proteins to mediate 
downstream signalling. In addition, VEGFR-1 and VEGFR-2 share many structural 
homology, both notably composed of an extracellular domain resembling seven 
immunoglobulin (Ig)-like molecules, a transmembrane domain linking the Ig-like domain to 
the tyrosine kinase domain, and a kinase insert domain which is wedged in between the 
tyrosine kinase domain (Shibuya et al. 1990; Terman et al. 1991). 
The interaction between the VEGF ligand and receptor illustrate substrate specificity, 
therefore the different VEGF subtypes selectively bind to certain receptors (Figure 1.3). All 
VEGF-A isoforms bind to VEGFR-1 and VEGFR-2, but VEGF-B (Olofsson et al. 1998) and 
PlGF (Park et al. 1994) only interact with VEGFR-1. VEGFR-1 has been demonstrated to be 
critical for normal embryonic development (Fong et al. 1995), but its exact function still 
remains unclear. One of its proposed roles is an intermediary function in transphosphorylating 
VEGFR-2 when activated by PlGF in endothelial cells (Autiero et al. 2003). Furthermore, 
VEGF or PlGF binding could activate VEGFR cross talk by forming VEGFR-1/VEGFR-2 
heterodimers. The overall effect mediated by VEGFR-1 is more complex than just inhibitory 
or stimulatory, as its function may differ depending on stage of development, various 
physiological or pathological conditions and the cell type in which it is expressed. 
Figure 1.3  The VEGF family 
Binding specificities of the receptors are illustrated. Adapted from Hicklin and Ellis (Hicklin and Ellis 
2005) 
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VEGFR-2 is the dominant mediator of downstream effects when VEGF ligands bind 
to the receptor (Dvorak 2002). VEGFR-2 selectively binds VEGF-A, VEGF-C (Joukov et al. 
1996), VEGF-D (Achen et al. 1998) and VEGF-E (Shibuya 2003). VEGFR-2 signalling is 
obligatory for embryonic development as hetero- and homozygous gene deletions results in 
in-utero murine deaths, secondary to defects in blood island formation and vascular 
development (Shalaby et al. 1995). Receptor activation results in phosphorylation of G-
proteins and downstream signalling pathways, culminating in promotion of angiogenesis, 
increased microvascular permeability, endothelial cell proliferation (Veikkola et al. 2000), 
invasion, migration and survival (Abedi and Zachary 1997). The activation and signalling of 
VEGFR-2 may be positively or negatively influenced by co-expression and activation of 
VEGFR-1. 
VEGFR-3 is expressed throughout embryonic vasculature, and homozygous deletion 
in early stages of development has been shown to result in in-utero death (Dumont et al. 
1998). It has been implicated with lymphangiogenesis, as the receptor is only expressed by 
lymphatic endothelial cells in adults (Kaipainen et al. 1995), and the receptor demonstrates 
selectivity for the lymphatic associated VEGF subtypes. In addition to lymphangiogenesis, 
VEGFR-3 participates in cardiovascular development and remodelling of primary vascular 
networks during embryogenesis, and is able to modulate VEGFR-2 signalling. 
The neuropilin receptors, NRP-1 and NRP-2 also participate in VEGF signalling 
through direct interaction with the ligand, or acting as co-receptors for VEGFR-1 and 
VEGFR-2 to enhance VEGF ligand binding affinity (Soker et al. 1998). NRP-1 shows 
substrate specificity for VEGF165, VEGF-B and PlGF2 (Soker et al. 1996; Soker et al. 1998), 
whereas NRP-2 selectively binds to VEGF165, VEGF-C and PlGF2 (Karkkainen et al. 2001). 
The importance of NRP-1 was demonstrated by experiments where inhibition of VEGF165 and 
NRP-1 interactions resulted in decreased VEGF-VEGFR-2 binding with attenuation in 
endothelial cell proliferation. NRP-2 in contrast, has a predominant role in lymphogenesis, as 
homozygous mutants for the gene are characterised by absent or reduced numbers and size of 
lymphatic vessels (Yuan et al. 2002). 
From its time of discovery (Senger et al. 1983) as a vascular permeability factor, 
VEGF has been recognised as a promoter of endothelial cell survival, mitogenesis, migration, 
differentiation and recruiter of EPC from bone marrow (Asahara et al. 1997). The precise 
principal mechanisms of action which confer VEGF with such multifunctional roles still 
remain unclear. Its ability to increase permeability of vessels causes leakage of plasma 
proteins, particularly fibrinogen and coagulation factors (Senger et al. 1983). The deposited 
extravascular fibrin and interstitial oedema transforms the typical anti-angiogenic stroma of 
normal tissues into a pro-angiogenic environment (Dvorak 2002). One theory suggests that 
VEGF induces a transendothelial cell transport pathway which is assisted by specialised 
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vesicovascular organelles (Dvorak 2002). Others propose an increased number of endothelial 
fenestrations by increasing openings of gap junctions between cells (Zhang et al. 2002). 
VEGF also promotes endothelial cell survival (Ferrara et al. 2003) by activating the PI3K-Akt 
pathway to acquire resistance against apoptosis (Gerber et al. 1998; Thakker et al. 1999). 
Further evidence has linked upregulation of focal adhesion kinases (FAK) (Abedi and 
Zachary 1997; Zachary and Gliki 2001) and various anti-apoptotic proteins including bcl2, 
survivin and XIAP (Gerber et al. 1998; Gerber et al. 1998; Zachary 2001) by VEGF to 
maintain survival signals in endothelial cells. Furthermore, VEGF acts as a chemoattractant 
and poses as a ‘scent’ which attracts endothelial cells at sprouting tips of new vessels 
expressing VEGFR-2, thus forming a navigation system to direct appropriate growth of new 
vessels (Gerhardt et al. 2003). 
1.3.4.1 Regulation of VEGF expression 
Cancers commonly exploit the potent effects mediated by VEGF to tip the angiogenic 
balance towards the pro-angiogenic switch. To achieve this goal, cancers exploit various 
mechanisms involved in metabolic stress, oncogene or tumour suppressor gene function, and 
immune or inflammatory responses to culminate in overexpression of VEGF (Carmeliet and 
Jain 2000). In addition to relaying stimulatory signals to promote cell proliferation and 
division, oncogenes can affect angiogenesis by inducing expression of proangiogenic growth 
factors such as VEGF. The ras oncogene is an example as it is typically mutated in several 
types of solid cancers (Konishi et al. 2000; Ikeda et al. 2001; Zhang et al. 2001), and 
disruption of mutant K-ras in human CRC is associated with reduction in VEGF activity (Rak 
et al. 1995). The p53 tumour suppressor gene which is loss relatively early in carcinogenesis 
also has a pivotal role in VEGF regulation. p53 affects VEGF expression through direct 
interactions with the transcription factor Sp1 to prevent transcriptional activation of the 
VEGF promoter (Olofsson et al. 1998), or indirectly by affecting HIF-1α expression (Ravi et 
al. 2000). Furthermore, restoration of p53 function in colon (Bouvet et al. 1998) and 
endometrial (Fujisawa et al. 2003) cells with pre-existent p53 mutations resulted in decreased 
VEGF expression. 
Experiments with tumour cell lines have identified several growth factors and 
cytokines that can influence VEGF expression. EGFR and HER-2/neu (ErbB2) systems have 
been demonstrated to regulate VEGF expression in several types of cancers, including colon 
(Ciardiello et al. 2000), pancreatic (Bruns et al. 2000), gastric (Akagi et al. 2003) and breast 
cancers (Yang et al. 2002). The first study to reveal a pro-angiogenic role for EGF by 
inducing VEGF production was established using a glioblastoma multiforme model 
(Goldman et al. 1993). The increase in VEGF expression was attributed to EGFR-induced 
activation of VEGF gene transcription which was dependent on Ras/PI3K signalling (Maity et 
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al. 2000). Further analysis to account for the EGF-induced VEGF response revealed that the 
increased transcriptional activity was directly related to increased Sp1 binding to the VEGF 
promoter region, and also through an indirect effect through HIF-1α signalling (Pore et al. 
2006). HER2 is also capable of promoting VEGF expression through two pathways, by 
directly influencing VEGF transcriptional activity, but also through increased HIF-1α 
translation, both of which are PI3K/Akt dependent (Laughner et al. 2001). Analogously, 
selective EGFR inhibition of various cancer cell types including CRC cells with cetuximab or 
TKI produced dose dependent reduction in VEGF secretion (Ciardiello et al. 1996; Petit et al. 
1997; Inoue et al. 2000). In agreement with these findings, immunohistochemical analysis of 
tumour xenografts showed significant decrease in VEGF protein expression and microvessel 
counts (Ciardiello et al. 2000; Ciardiello et al. 2001). Other growth factors capable of 
inducing VEGF production include PDGF, which has been demonstrated to recruit VEGF-
producing tumour-associated fibroblasts for sustained stromal derived VEGF (Dong et al. 
2004). Prostaglandins which are metabolites of arachidonic acid through the action of COX 
enzymes have also been demonstrated to affect VEGF expression and control tumour 
angiogenesis (Gately 2000). As a result, COX-2 which is overexpressed in several solid 
tumours including CRC (Yao et al. 2003) has been associated with tumour progression and 
increased angiogenesis. 
IL-1β potentiates tumour growth and metastasis via pathways dependent on 
angiogenesis. IL-1β stimulation of CRC cells resulted in induction of VEGF mRNA 
expression (Akagi et al. 1999), but the upregulatory effect was abrogated by IL-1RA (Konishi 
et al. 2005). Expression of IL-1RA and IL-1β as a ratio showed an inverse correlation with 
VEGF protein levels, and this was reflected clinically by fewer patients having vessel 
involvement with a high IL-1RA/ IL-1β ratio (Konishi et al. 2005). IL-1β primarily acts to 
promote tumour growth indirectly by modifying and transforming the tumour landscape. 
Mouse Lewis lung carcinoma cells supplemented with IL-1β only showed significant increase 
in tumour growth rates when xenografted into a murine model, as opposed to no difference in 
in vitro assays. Immunohistochemical staining of these tumours showed increased CD31+ 
microvessel, VEGF and IL-8 in xenografts stimulated with IL-1β compared with wild-type 
controls and null transfected xenografts. 
The restrictions imposed by a hypoxic micro-environment can be overcome by 
construction of new vessels to increase blood flow to the tumour, and thus correct any 
imbalance between oxygen supply and demand. Hypoxia is a potent and well known inducer 
of VEGF expression and represents one of the most effective stimulus in promoting 
angiogenesis. I will therefore be discussing about hypoxia and its effects on angiogenesis in 
further detail in the section below. 
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1.4 TUMOUR HYPOXIA 
Hypoxia is a hallmark of most solid tumours and has been demonstrated in cancers of 
the cervix, breast, head and neck, colon and rectum, and melanoma (Wouters et al. 2002). 
Intra-tumoural hypoxia has been confirmed in CRC by oxygen electrode measurements, 
through immunohistochemical examination (IHC) of samples following exogenous infusion 
of imidazole-based markers, or through IHC identification of endogenous hypoxia markers 
such as carbonic anhydrase or hypoxia-inducible proteins (Goethals et al. 2006). Since 
malignant cells undergo proliferation at an exponential rate which is typically faster than the 
development of infiltrating new tumour vessels, oxygen consumption far outstrips supply 
resulting in development of hypoxia. Angiogenesis is critical for supporting tumour growth as 
tumours are restricted to 2-3mm3 in size without neo-vascularisation (Folkman and Shing 
1992). However, angiogenesis is an imperfect compensatory mechanism as the new vessels 
are inadequate and disproportionately distributed to meet demand, and they are structurally 
and functionally inept compared to those in normal tissues (Denekamp 1990; Konerding et al. 
1999). The new tumour vessels are intrinsically more permeable and leaky causing tissue 
fluid to accumulate, and the consequent rise in interstitial pressure impedes free diffusion of 
oxygen within the tumour microenvironment. Thus, despite the expansion in the tumour 
vascular network, solid tumours ironically continue to harbour hypoxic regions. 
Tumour hypoxia is a poor prognostic factor, and experimental and clinical evidence 
suggests that hypoxia (1) reduces sensitivity to conventional treatment modalities, (2) 
influences tumour growth and invasion, and (3) selects for more aggressive tumour 
phenotypes. Hypoxic cells are intrinsically more resistant to treatment, as the dose of ionising 
radiation required could be up to 3 times higher to achieve similar amount of cell killing in 
hypoxic than well-oxygenated cells (Gray et al. 1953). Treatments could be less effective due 
to reduction in oxygen-dependent free radical production, poor penetration of 
chemotherapeutic agents as a consequent of distorted and dysfunctional vasculature, or 
hypoxia-induced dormancy conferring protection against chemotherapy. Hypoxia is also a 
poor prognostic indicator because it enhances the ability of cancer cells to metastasise. Loss 
of E-cadherin expression, a landmark feature of epithelial-mesenchymal transition (EMT), is 
precipitated by hypoxia through transcriptional repression by the nuclear family Snail/Slug 
under the influence of HIF-1α and lysyl oxidase family of enzymes (LOX) (Esteban et al. 
2006). Furthermore, hypoxia increases microvessel density, increases secretion of MMPs and 
modulates cell adhesion molecules, to enhance tumour cell invasion and migration in chick 
embryo models implanted with human glioblastoma cells (Plasswilm et al. 2000). The 
hypoxic tumour micro-environment also poses a significant biological challenge to select 
cells with favourable phenotypes in a test of survival of the fittest. The development of 
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hypoxia-induced genetic mutations through point mutations, DNA double-strand breaks 
causing chromosomal aberrations, gene amplification and polyploidy can confer advantages 
to survive under such adverse circumstances. This striking feature has been demonstrated in 
the hypoxic selection of p53-negative embryonic fibroblast clones (Graeber et al. 1996), 
where surviving cells were more resistant to apoptosis through p53 mutation, and in turn were 
genomically more unstable with the loss of a potent tumour suppressor gene which 
maintained genomic integrity. 
Hypoxia is a potent and well recognised inducer of VEGF expression and it 
represents one of the most effective stimulus in promoting angiogenesis. By inhibiting 
hydroxylation of hypoxia-inducible factor (HIF) and preventing its natural degradation, 
hypoxia increases expression of angiogenic genes, most notably VEGF. Hypoxia enhances 
HIF binding to consensus hypoxia responsive elements (HRE)-encoded promoter regions to 
enhance transcription of selected angiogenic genes. Hypoxia alone can also initiate and 
sustain a pro-angiogenic response independent of HIF signalling. VEGF gene transcription 
has been shown to be upregulated by hypoxia through a PI3K/Rho/ROCK dependent 
pathway, with the final transduction step mediated by phosphorylated c-Myc to activate 
VEGF gene transcription (Mizukami et al. 2006). Cells derived from HIF-1α knock-out 
models also demonstrated the capacity to trigger angiogenic responses to hypoxia, albeit 
markedly attenuated, by inducing VEGF and IL-8 expression (Levy et al. 1996; Ryan et al. 
1998; Mizukami et al. 2004; Mizukami et al. 2005). Furthermore, hypoxia not only increases 
VEGF transcriptional rate, but it also exerts an independent effect on VEGF mRNA stability. 
This differential regulation was discovered during investigations into discrepancies between 
transcriptional rate and steady state of VEGF transcripts induced by hypoxia, as there was 
sustained and progressive increase in the pool of VEGF transcripts with time (Ikeda et al. 
1995). The hypoxia-mediated stabilisation of VEGF transcripts is thought to be dependent 
upon a hypoxia-induced trans-acting protein interacting with sequences in the VEGF 3’-UTR, 
to assist prolongation in the half-life of VEGF mRNA (Levy et al. 1996). In addition to 
effects on VEGF, hypoxia is capable of upregulating Ang-2 expression which is critical for 
initiating vessel sprouting. The increase in Ang-2 expression which is HIF-regulated displaces 
Ang-1 from Tie-2 receptors, leading to vessel destabilisation and overcoming the rate limiting 
step for angiogenesis (Maisonpierre et al. 1997). 
1.4.1 HYPOXIA INDUCIBLE FACTOR 
Cells must be able to respond rapidly to sudden changes in oxygen levels to maintain 
energy-dependent activities and survive in response to hypoxic stress. At the heart of this 
complex homeostatic regulatory system is Hypoxia Inducible Factor-1α (HIF-1α), a member 
of a family of three HIFs (HIF-1α, HIF-2α and HIF-3α), which controls an estimated 70 gene 
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products involved in regulating nutritional stress, angiogenesis, tumour metabolism, invasion 
and cell death (Semenza and Wang 1992; Semenza 2002). HIF is an oxygen dependent 
transcriptional activator and is crucial in mediating the adaptive responses to changes in tissue 
oxygenation (Semenza 1999). In vitro studies have shown that HIF is activated at a threshold 
level of 5% oxygen (40 mmHg), with a progressive increase in its activity as oxygen levels 
steadily decrease to 0.2-0.1% oxygen (1.6–0.8 mmHg) (Wang et al. 1995). HIF activation is a 
multi-step process involving HIF-α stabilisation, heterodimerisation, nuclear translocation 
and transcriptional activation which is dependent upon interactions with other partner 
proteins. In order to mediate responses to hypoxia, HIF is highly regulated at the post-
translational level by oxygen, through a series of hydroxylation and acetylation reactions that 
consequently affect its stability and interactions with HRE (Figure 1.4). Hydroxylation 
reactions are orchestrated by a class of 2-oxoglutarate-dependent and iron-dependent 
dioxygenases known as prolyl hydroxylase domain (PHD) 1, 2 and 3 proteins, and their 
activity is strictly dependent upon cellular oxygen pO2. PHDs hydroxylate the prolyl residues 
P402 and P564 in the oxygen-dependent degradation domain (ODDD) of the HIF-α region, 
allowing interactions with von Hippel-Lindau (vHL), the E3 ubiquitin ligase complex 
(Maxwell et al. 1999). Once HIF-α subunits have been ubiquitinated by vHL, this marks the 
protein for destruction by proteosomes. Under hypoxic conditions however, PHD enzymes 
are no longer active, and the stabilised HIF-α subunit dimerises with its partner HIF-β subunit 
(ARNT) via interactions between complimentary basic helix loop helix–Per-Arnt-Sim 
(bHLH-PAS) domains, and translocates into the nucleus to bind to cis-acting HRE sites in the 
promoters of hypoxia-responsive genes (Semenza et al. 1997). The second oxygen regulatory 
step is controlled by an asparaginyl hydroxylase referred to as factor inhibiting HIF-1 (FIH), 
which interferes with the ability of HIF to initiate transcription. Under normoxic conditions, 
hydroxylation of the asparagine residue N803 in the carboxyl-terminal transcriptional 
activation domain (C-TAD) of HIF abrogates interactions with the transcriptional co-
activators p300 and CREB-binding protein (CBP) (Mahon et al. 2001) (Figure 1.4). Finally, 
the third oxygen dependent regulatory component relies upon acetylation of lysine residue 
Lys-532 in the ODDD. This acetyl-CoA-dependent ARD1 acetyltransferase regulation of HIF 
enhances the interaction of vHL with the acetylated HIF-α promoting its ubiquitylation and 
degradation. The expression of ARD 1 decreases as the length of hypoxic exposure time 
increases therefore leading to stabilisation of HIF-α. 
HIF is highly effective in modifying global gene responses to hypoxia to facilitate 
cells to adapt and progress in a hostile environment. Currently, 70 genes have been 
discovered to be transcriptionally activated by HIF-1 and they can be classified into genes 
involved in angiogenesis, glucose transporters and glycolytic enzymes, survival factors and 
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invasion factors (Lee et al. 2004). The abundance of data generated from analysing global 
cellular responses to hypoxia by microarray technology have revealed that expression of HIF-
1 target genes is induced in a cell-type-specific manner. Expression of several HIF-1 target 
genes such as VEGF is induced by hypoxia in most cell types, but the heterogeneity in 
expression of other target genes could be accounted for by functional interaction of HIF-1 
with other transcription factors. Nevertheless, the ability of a single transcription factor to 
transactivate a myriad of hypoxic response genes has appropriately earned HIF the title of 
master regulator of oxygen. 
Figure 1.4 Regulation of gene transcriptional activity by HIF with oxygen tensions 
Under normal oxygen tensions (A), HIF-α activity is inhibited by (1) hydroxylation of proline residues 
402 and 564 by PHD2, ubiquitinated by the pVHL complex and degraded by proteasome and, (2) FIH 
hydroxylation of asparagine residue 803, abrogating formation of a transcription complex with 
p300/CBP. Under hypoxia (B), HIF-α is stabilized, forms a transcription complex with HIF-β and 
p300 and CBP, which translocates into the nucleus to initiate gene transcription by interacting with 
consensus HRE sites at promoter regions of genes. C/NTAD, C/N transactivation domain; PAS, per-
arnt-sim; bHLH, basic helix loop helix, PHD, prolyl hydroxylase; pVHL, Von Hippel-Lindau, FIH, 
factor inhibiting inhibitor, CBP, creb binding protein; HRE, hypoxia response element. 
 
1.4.2 HYPOXIA INDUCIBLE FACTOR IN COLORECTAL CANCER 
HIF plays critical roles in pathogenesis and progression of CRC, proven by four lines 
of evidence. Firstly, the association between HIF-1α overexpression and tumour 
vascularisation in CRC has been validated through immunohistochemistry and in vitro 
studies. CRC tissue samples consistently overexpressed HIF-1α protein levels and VEGF 
mRNA, and these were significantly correlated with tumour microvessel density, tumour and 
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lymphovascular invasion, and liver metastasis (Kuwai et al. 2003). Secondly, in addition to 
intratumoural hypoxia, genetic mutations in oncogenes for example K-Ras, and tumour 
suppressor genes (p53, VHL, PTEN) induce HIF-1 activity in CRC (Ravi et al. 2000; Kuwai 
et al. 2004; Giles et al. 2006; Greijer et al. 2008; Pencreach et al. 2009). Thirdly, in CRC 
xenograft models, overexpression of HIF activity had a positive effect on tumour growth and 
angiogenesis (Ravi et al. 2000; Dang et al. 2006). Finally, HIF-1 controls expression of 
multiple gene products that stimulate angiogenesis, glucose transporters, glycolytic enzymes 
and matrix proteases, all of which provide the molecular basis for tumour survival, growth 
and propagation. HIF is a potent inducer of angiogenesis, being capable of transactivating 
expression of several key genes known to exert angiogenic effects, for example VEGF and 
VEGFR-2, TGFβ3, nitric oxide synthase 2, haemoxygenase-1, plasminogen activator 
inhibitor-1 and endothelin-1 (Semenza 2001). To complement its role in inducing 
angiogenesis, HIF also promotes transformation of the ECM for sprouting and in-growth of 
new tumour vessels in CRC by upregulating production of ECM proteases, such as MMP-2, 
cathepsin D and urokinase plasminogen activator receptor (uPAR) (Krishnamachary et al. 
2003). HIF-1α has also been implicated in modifying the invasive potential of malignant 
CRC cells by altering expression of integrins on the surface of cancer cells and production of 
ECM proteins. Expression of genes encoding for vimentin and keratins 14, 18 and 19 were 
significantly upregulated in HIF-1α expressing cells and such effect was further accentuated 
with hypoxia (Krishnamachary et al. 2003). 
HIF-1α and HIF-2α share several common characteristics, such as possessing 48% 
overall amino acid homology, accumulating in the presence of hypoxia, forming heterodimers 
with HIF-1β and binding to HRE. Although HIF-1α and HIF-2α share many similarities, it is 
becoming evident that they both have different roles in physiological and pathological 
conditions particularly in relation to CRC. Differences in HIF-1α and HIF-2α expression 
relative to tumour stage have been noted, suggesting a possible progressive drift in hypoxic 
signalling from a preponderance of HIF-1α to HIF-2α with advancing stage. The 
predominance of HIF-2α has been postulated to underlie changes associated with increased 
tumour microvessel density, and expression of pro-angiogenic mediators such as COX-2, 
FGF-2 and thymidine phosphorylase during the later stages of CRC (Yoshimura et al. 2004). 
However, knockdown models suggest that HIF-1α has a more prominent role in modifying 
proliferation and migration of cells, but HIF-2α has more of a negative and inhibitory effect 
on CRC tumour growth and invasion (Imamura et al. 2009). Furthermore, 
immunohistochemical examination of rectal cancers confirmed that HIF-1α, and not HIF-2α, 
significantly correlated with advanced stage, vascular invasion and poorer outcome (Rasheed 
et al. 2009). In contrast, the HIF-2α pathway has a specific causal role in clear cell renal 
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carcinogenesis (Sowter et al. 2003). The divergent roles of HIF-1α and HIF-2α isoforms in 
CRC as elicited by these studies reflect differential regulation of intrinsic cell autonomous 
activities, which may also differ with varying cell types. Further work is therefore indicated 
into this field prior to conducting trials with emerging therapies which target HIF in a non-
selective manner. 
1.4.3 CYTOKINES AND HYPOXIA IN MODULATING CRC ANGIOGENESIS 
Activation of EGFR is known to have wide ranging effects particularly on cell cycle 
and survival, but a pro-angiogenic response has been elicited from various cancer cell types 
following exogenous stimulation with EGF and TGF-α. The pro-angiogenic function has 
been attributed to increased VEGF secretion following EGFR activation with EGF or TGF-α 
stimulation in a dose dependent manner. The mechanism underlying this angiogenic response 
requires direct activation of PI3K/Akt to promote VEGF transcriptional activity (Maity et al. 
2000). An indirect pathway involving HIF has also been described, where fibroblast cells 
expressing mutant EGFR induced expression of VEGF in a HIF-dependent manner. EGF has 
been demonstrated to increase HIF-1α expression by enhancing its translation to overcome 
intrinsic instability under normoxia (Laughner et al. 2001). The resultant increase in HIF-1α 
protein translation is accompanied by a significant induction in VEGF protein response, as the 
newly synthesised HIF are transcriptionally more active (Zhong et al. 2000). The co-existence 
of these two independent mechanisms were confirmed by Pore et al (Pore et al. 2006), where 
EGFR inhibitors downregulated VEGF transcription by direct inactivation of the transcription 
factor Sp1, or indirectly by decreasing translation of HIF-1 protein. 
The available evidence therefore confirms a pro-angiogenic response to EGFR 
activation which can be achieved through direct transcriptional activation of VEGF in a HIF-
independent manner, or indirectly by HIF-mediated transcription through interactions with 
VEGF HRE site. Despite the presented evidence, there still remains much ambiguity, and 
certainly much still remains to be explored. Firstly, most of the presented data to support the 
pro-angiogenic role of EGFR were derived from studies in non CRC cell types. It is known 
that studies using prostate cancer cells failed to demonstrate significant downregulation of 
VEGF, FGF-2 and IL-8 in treatment groups receiving EGFR antagonists (Karashima et al. 
2002; Kim et al. 2003), in marked contrast to findings from other studies using glioblastoma 
(Maity et al. 2000; Pore et al. 2006), squamous cancer (Petit et al. 1997; Hirata et al. 2002) 
and renal cancer cells (Kedar et al. 2002; Weber et al. 2003). Such variations reflect the 
possibility that observed responses may be specific to selected cell types. EGFR antagonists 
have been shown to exert antitumour and antiangiogenic activities in CRC xenograft studies 
(Ciardiello et al. 1996; Ciardiello et al. 2001). CRC cells treated with gefitinib exhibited a 
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dose- and time-dependent inhibition in VEGF expression (Ciardiello et al. 2001). Although 
gefitinib is often referred to as a "specific" or "selective" inhibitor of EGFR, it also inhibits 
activity of other intracellular transmembrane tyrosine-specific protein kinases at similar 
concentrations (Cohen et al. 2004). This may have therefore introduced confounding 
variables to the study, as the observed downregulation in VEGF expression may have been 
attributed to inhibition of other signalling pathways. There are still no studies to date 
confirming angiogenic responses with direct EGFR stimulation specific to CRC. Furthermore, 
validation of this angiogenic pathway with primary CRC cell cultures isolated from primary 
tissue would confer greater significance in translational value, as the study cell model would 
be more representative of CRC in vivo. 
Figure 1.5 Convergence model for Oxygen- and Growth Factor-regulated 
transduction pathways through HIF-1α protein expression. 
HIF-1α is induced by hypoxia (blue) in all cell types. In contrast, activation of the PI3K or MAPK 
pathway (green) has cell- and stimulus-specific effects on HIF-1α. See text for details and 
abbreviations. (adapted from (Semenza 2002)). 
 
HIF has long been acknowledged as the master regulator of tissue oxygenation, but 
more recently it has been discovered to mediate cytokine-and growth factor induced signals to 
promote an angiogenic response. This therefore creates an interesting convergence point, 
where both cytokine- and hypoxia-mediated angiogenic signals both meet to affect expression 
of a single target (Figure 1.5). With HIF’s pleiotropic role, it is fitting that critical intracellular 
signals utilise this potent transcriptional activator as a signal amplifier to affect multiple 
downstream processes. Despite proof that activated EGFR increases HIF-1α production 
(Zhong et al. 2000; Laughner et al. 2001; Pore et al. 2006), there is no evidence to date that 
could confirm such responses in CRC. More importantly, EGFR overactivation and hypoxia 
are hallmarks of CRC and typically co-exist within the similar tumour microenvironment. 
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Although regulation of HIF and VEGF by hypoxia in CRC is well recognised, the coexistence 
of EGFR overactivation and hypoxia within CRC in vivo may result in differential modulation 
in HIF and VEGF expression. As both EGFR and hypoxia are inducers of angiogenesis, an 
unproven synergistic relationship could potentially culminate in a downstream response 
which supersedes the angiogenic effect exerted by either of the stimuli in isolation. More 
importantly, if either stimulus exerts a more prominent influence over tumour 
microenvironmental angiogenesis, therapies aimed at inhibiting the weaker influence may 
prove fruitless. Further work is therefore required in this field to elucidate the contributory 
angiogenic effect of EGFR activation and hypoxia when acting in isolation, and to identify 
potential synergy when both stimuli are used in combination to stimulate CRC cells. 
Finally, the pro-angiogenic influence of EGFR activation and hypoxia were 
established based primarily on VEGF responses, but it is well recognised that the end-result 
of angiogenesis is a culmination of pro- versus anti-angiogenic effects. Although various 
studies have utilised PCR microarrays to genotype CRC to be compared to normal tissue, 
limited amount of data can be translated to identify a profile of genes which are specifically 
involved in EGFR or hypoxia induced angiogenic responses. There is a need for such gene 
profiles as it will identify key effectors involved in promoting tumour angiogenesis, and 
would prove invaluable in paving the way for development of novel therapies. 
1.5 OBJECTIVES 
1. To assess cellular responses induced by direct stimulation of EGFR, or by hypoxia or 
hypoxia-mimetics, in the specific context of CRC angiogenesis. 
2. To elucidate signalling pathways involved in mediating EGFR-induced angiogenesis. 
3. To establish an ex vivo primary CRC culture of heterogeneous cells from CRC tissue, 
for the purpose of EGFR and hypoxia stimulation studies. 
1.6 HYPOTHESIS 
EGFR activation and HIF-overexpression have independent and synergistic effects in 
modulating CRC angiogenesis by convergence upon HIF signalling. 
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2 MATERIALS AND METHODS 
2.1 COLORECTAL CELL LINES 
2.1.1 Colo 201 Cells 
The Colo 201 cell line (Figure 2.1A) used in this study was purchased from the 
American Type Culture Collection (ATCC, Rockville, MD, USA). It was derived from the 
same ascitic fluid of a human caucasian colonic Dukes’ stage D adenocarcinoma as the Colo 
205 cell line, but these cell lines differ in morphology. The Colo 201 cells are a suspension 
culture and they adopt a more bipolar, fibroblast-like structure and produce less 
carcinoembryonic antigen (CEA) than Colo 205. Tumourigenicity of the cells has been 
confirmed with animal experimentations, where subcutaneous inoculation of tumour cells into 
nude mice resulted in tumour development within 21 days (Semple et al. 1978). 
According to the manufacturer’s product leaflet, the product was frozen in July 2003 
but the number of passages prior to freezing was unknown. The ampoule which contained 
1mL of the product was expected to carry a cell concentration of 3.8x106 cells/mL with an 
expected cell viability of 67-72%. Upon arrival, the cells were thawed and grown according 
to the manufacturer’s instructions. 
2.1.1.1 Colo 201 Cell Culture 
The cells were grown in a culture medium of RPMI 1640 (PAA Laboratories GmbH, 
Pasching, Germany) containing 25mM HEPES, 2mM L-glutamine, 2g/L glucose and 2g/L 
sodium bicarbonate. The culture medium was completed by supplementing with 10% foetal 
calf serum (FCS; Biowest, Nuaille, France), 1mM sodium pyruvate (Sigma-Aldrich, St Louis, 
MO, USA), 1.1U/mL of streptomycin (100U/mL) and 1.1μg/mL penicillin (PAA 
Laboratories GmbH, Pasching, Germany). The cells were grown in 75cm2 flasks and 
incubated under humidified conditions with 5% CO2 at 37
oC.  
2.1.1.2 Sub-Culturing Procedure 
Although Colo 201 cells were suspension cultures, there were often some cells which 
were loosely adherent to the surface of the 75 cm2 flasks. These could be washed off by 
aspirating a small volume of the cell suspension with a pipette and gently irrigating the inner 
surface of the flask. Cells were passaged to maintain a cell concentration of 2x105 cells/mL, 
in accordance with the manufacturer’s recommendations. The concentration was determined 
by cell counts, and cells were passaged on average once a week to a sub-cultivation ratio of 
1:3. For cell counts, an equal volume of 0.4% Trypan blue solution (Sigma, St Louis, MO, 
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USA) was added to the cell suspension, and all viable cells within the 25 square grid of a 
haemocytometer were counted under microscopy. The concentration of cells was determined 
by: number of cells within the 25 square grid x 2x104 x dilution factor. 
Figure 2.1 CRC Cell Lines – Colo 201 and Caco-2 
Phase contrast microscopy of the Colo 201 (A) and Caco-2 (B) cells at 100x magnification. 
 
2.1.2 Caco-2 cells 
The Caco-2 cell line (Figure 2.1B) used in my study was purchased from the 
American Type Culture Collection (ATCC, Rockville, MD, USA). Caco-2 is an adherent cell 
line which expresses characteristics of enterocytic differentiation upon reaching confluence in 
in vitro cultures. It is well-known for its application as a cell-based functional assay to assess 
intestinal transport of drugs through a cell monolayer absorption model. It was isolated from a 
primary colonic tumour in a 72-year-old Caucasian male using the explant culture technique. 
Tumourigenicity of the cell line has been tested by subcutaneous inoculation into nude mice 
where moderate to well-differentiated adenocarcinoma, consistent with the colonic primary, 
(grade II) developed within 21 days of explantation. The cell line has been reported to express 
receptors for epidermal growth factor (EGF). 
2.1.2.1 Caco-2 Cell Culture 
Caco-2 cells were cultured in a base medium of Eagle's Minimum Essential Medium 
(EMEM) (Biowhittaker, Lonza, Switzerland) containing non essential amino acids (NEAA) 
and sodium pyruvate. The culture medium was completed by supplementing with 1mM 
Glutamine, 10% FCS (Biowest, Nuaille, France), and 1.1U/mL of streptomycin (100U/mL) 
and 1.1μg/mL penicillin (PAA Laboratories GmbH, Pasching), subsequently termed complete 
Caco-2 growth medium. The cells were grown in 75cm2 flasks and incubated under 
humidified conditions with 5% CO2 at 37
oC. Since Caco-2 cells undergo enterocytic 
differentiation upon reaching confluence, I decided to passage the cells at 80% confluence. 
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2.1.2.2 Sub-Culturing Caco-2 Cells 
Caco-2 cells have to be subjected to trypsinisation with 4mL of 0.25% Trypsin/EDTA 
to release the cells into suspension. The duration of trypsinisation varied between 2–4 minutes 
depending on the confluence of the cell culture. When the cells were brought into suspension, 
additional 20mL of complete culture medium with serum supplementation was added to 
neutralise the proteolytic activity of trypsin. On average an 80% confluent cell culture within 
a T75 flasks would yield 1.6x107 cells, therefore cells were passaged once every 5 days to a 
subcultivation ratio 1:3. 
2.2 EXPERIMENTAL SET-UP 
2.2.1 Investigation Of Colo 201 Under Normoxic Conditions (21% O2) 
The expression of HIF-1α, HIF-2α and VEGF by Colo 201 cells were analysed under 
normoxic conditions following EGF, TGF-α and IL-1β stimulation.  
Early experiments were performed on 2x106 Colo 201 cells suspended in 75cm2 
flasks, at a final concentration of 2x105 cells/mL with the appropriate concentration of 
stimulants. However, to improve efficiency and reliability in later experimental work, each 
experimental condition was performed in triplicate using 6 well (960mm2) trays, with each 
well seeded with 3.3x105 cells and cell concentration maintained at 2x105 cells/mL. The cell 
cultures were then allowed to settle for 48 hours prior to commencement of experiments. 
Results from my preliminary work suggested that serum supplementation could affect 
VEGF expression, and thus would affect reproducibility across separate experiments. Colo 
201 cells cultured in varying serum concentrations were subjected to hypoxia to determine the 
optimal serum concentration for the most reliable and consistent upregulation in VEGF 
protein response. Through these optimisation experiments, it was discovered that serum 
concentration should be decreased gradually from its standard 10% to 2% concentration for 
the purpose of experiments. Newly seeded cells were therefore established in complete 
culture medium for 48 hours, and on the evening prior to stimulation experiments, 
supernatants were extracted following a brief period of centrifugation and cells resuspended 
in 5% serum-supplemented medium. Cells were subsequently stimulated in 2% serum-
supplemented medium for the duration of the experiments to minimise the effects of serum. 
2.2.2 Cytokine Stimulation Studies 
Purified recombinant human EGF produced by Peprotech (Rocky Hill, NJ, USA) was 
used in the experiments. The 53 amino acid EGF protein which was produced using 
Eschericia Coli has a molecular mass of 6.2kDa. The activity of the product has been 
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validated in a proliferation assay with mouse fibroblast cell line Balb/3T3. The lyophilised 
product was reconstituted with water to a stock solution of 100μg/mL and diluted to the 
desired final working concentrations for cell stimulation experiments. 
TGF-α, an EGF-related polypeptide growth factor produced by monocytes, 
keratinocytes and various tumour cells, signals through the EGF receptors and stimulates the 
proliferation of epithelial cells. Recombinant human TGF-α produced by Peprotech (Rocky 
Hill, New Jersey, USA) using E. coli is a 50 amino acid polypeptide (5.5kDa) which shares 
approximately 40% sequence homology with EGF, including 6 conserved cysteine residues, 
which form 3 intramolecular disulfide bonds. The product was lyophilised prior to packaging 
and required reconstitution with deionised water to produce stock concentration of 20μg/mL. 
Purified recombinant human IL-1β produced by Biosource, Invitrogen (Carlsbad, 
California, USA) was used in the experiments. The protein which comprises of 154 amino 
acid residues with a molecular weight of 17.5 kDa is produced by Eschericia Coli and 
purified via sequential chromatography. The activity of the product has been validated in 
mice where a dose dependent proliferation of murine D10S helper T cells was observed in the 
absence of other mitogens. The lyophilised product was reconstituted with water to produce 
stock concentration of 10μg/mL. 
2.2.3 Investigation of Colo 201 Under Hypoxic Conditions 
The expression of HIF-1, HIF-2 and VEGF by Colo 201 cells were also analysed at 
the mRNA and protein level under hypoxic conditions. The experiments were performed 
either in 75cm2 flasks within a total volume of 10mL, or in 6 well trays within a total volume 
of 1.6mL as described earlier. 
The hypoxic environment of 1% oxygen, 5% carbon dioxide and 94% nitrogen was 
achieved by incubating cells in a Galaxy ‘R’ carbon dioxide incubator (Wolf, York, England) 
which was humidified at 37oC. A hypoxic environment of 1% oxygen concentration was 
chosen because published work using pimonidazole, an extrinsic hypoxic chemical marker 
known to bind tissues with oxygen tensions of 1kPa or 1%, have been proven to bind regions 
within CRC which were furthest away from tumour blood vessels (Goethals et al. 2006). 
Extra time was factored into the experimental time course to accommodate for the gradual 
decrease in oxygen levels within the incubator. 
Care was taken to minimise re-oxygenation of cells during the experiment and also 
during harvesting of cells, particularly for HIF-1α protein quantitation. Since the unstable 
HIF-1α protein has a half-life of 5 minutes, the time interval between transferring cells out of 
the incubator to time of cell lysis using a buffer enriched with protease inhibitors was kept to 
a minimum. The suspension of cells were centrifuged for a shorter time interval of 3 minutes 
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at 1200rpm and 4oC, and following the removal of 1mL of supernatant for the purpose of 
VEGF ELISA, the cell bead was lysed in a HIF-1 lysis buffer. Although mRNA levels are 
more stable and would not alter as quickly, the time interval between transferring samples out 
of the hypoxic environment to addition of lysis buffer was kept to a minimum.  
2.2.4 Investigation Of Caco-2 Cells Under Normoxic Conditions 
The expression of HIF-1α, HIF-2α and VEGF by Caco-2 cells were analysed 
following stimulation with purified recombinant human EGF (R&D Systems; Minneapolis, 
MN, USA). Each experimental condition was performed in triplicates on 6 well trays with an 
initial seeding cell population of 4.8x105 per well, equivalent to 25% confluence, in a total of 
2mL of complete Caco-2 growth medium. The cell cultures were then allowed to settle for 48 
hours prior to commencement of experiments. The cells were starved of serum overnight by 
exchanging for EMEM supplemented with 15nM sodium selenite, 1mM pyruvate, 1.7μM 
insulin, 69nM transferrin, 33μM ethanolamine (commercially available as S5666, Sigma-
Aldrich, St Louis, MO, USA), and 34mM linoleic acid, 33mM oleic acid and 15μM albumin 
(available as L9655, Sigma-Aldrich, St Louis, MO, USA). 
2.2.5 Investigation Of Caco-2 Cells With DMOG  
Preliminary studies investigating the effects of hypoxia on Caco-2 cells revealed their 
susceptibility to hypoxic stress, where sheets of previously adherent cells underwent 
detachment despite reintroduction of serum to the medium. Unlike Colo 201 cells, the 
viability of Caco-2 cells is affected by hypoxia and thus, dimethyloxalylglycine (DMOG), a 
cell-permeable oxalylglycine analogue, was used to simulate a hypoxic environment. Since 2-
oxoglutarate is an essential co-factor for PHD and FIH activity, competitive inhibition by 
DMOG prevents hydroxylation of HIFs, thus the resultant accumulation in HIFs activates the 
classical adaptive responses mimicking that of hypoxia. The expression of HIF-1α, HIF-2α 
and VEGF by Caco-2 cells were therefore analysed following stimulation with 1mM DMOG 
alone (Biomol, Plymouth Meeting, PA, USA) or in combination with EGF. 
2.3 ANALYSIS OF GENE EXPRESSION 
RNA was extracted from cells using the QIAamp RNA blood mini kit (QIAGEN, 
GmbH, Germany). The extraction process was followed by a DNAse reaction to ensure any 
DNA contaminant is removed from the RNA specimen. Subsequently a polymerase chain 
reaction (PCR) was performed on the specimen using the Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) primer, a house keeping gene present in all DNA to confirm the 
absence of any DNA contaminant. The specificity of primers in PCR makes them ideal 
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probes, but RNA cannot be used directly in PCR due to the inability of Taq polymerase 
enzyme to recognise RNA. The mRNA had to be reverse transcribed to produce 
complementary strands of DNA (cDNA), which was then annealed with specific HIF-1α, 
HIF-2α and VEGF primers and amplified by PCR to confirm their expression. A more 
detailed description of the individual processes will be discussed below. 
2.3.1 RNA extraction 
The QIAamp RNeasy mini kit (QIAGEN GmbH, Germany) is a purposely designed 
kit to ease RNA extraction from cells. The kit enriches RNAs larger than 200 nucleotides by 
binding onto specially designed spin columns. Smaller RNAs such as 5.8S RNA, 5S RNA 
and tRNA, which make up 15-20% of the total RNA and are of limited value in this study, 
were discarded. At the end of experiments, cell suspensions were centrifuged at 1200 rpm for 
10 minutes. Once supernatants were removed, cells were lysed with a specialised lysis 
solution from the kit supplemented with 0.01M β-Mercaptoethanol (βME), and dispersed by 
gentle pipetting. The lysate was subsequently processed according to manufacturer’s 
instructions for RNA separation, involving a series of purification steps using specialised 
buffers and centrifugation to bind RNA onto the membranes within the spin columns. The 
final separated RNA product was dissolved in 50μL of RNAse free water and stored at -80oC 
to minimise degradation. Any contaminating genomic DNA was subsequently degraded with 
DNAse enzyme within the Turbo DNAse kit (Ambion, Austin, USA). PCR for the ubiquitous 
gene Glyceraldehyde 3-phosphate dehydrogenase (GAPDH), also termed a housekeeping 
gene, was subsequently performed to confirm absence of any DNA within the specimens. 
2.3.2 cDNA synthesis 
As a first step towards examining expression of the genes of interest, complementary 
DNA (cDNA) was synthesised from RNA by reverse transcription. The amount of RNA used 
to determine gene expression was fixed at 500ng to limit variability between experiments, 
therefore RNA concentrations were measured by photospectrometry and calculated by 
Absorbency x dilution factor (1:10)x40. The volume of RNA equivalent to 500ng RNA was 
added to DEPC water and 1μL of OligoDT primer to achieve a total volume of 11μL. The 
sample was incubated at 70oC for 10 minutes to unravel any secondary structures within the 
RNA template, and then rapidly cooled for 5 minutes to prevent secondary structures from 
reforming. A reaction mix (Table 2.1) containing MMLV reverse transcriptase, RNase H 
Minus, Point Mutant (M-MLV RT (H-)) from Promega (Promega, Madison, USA) was 
subsequently added to the sample. The specimen was incubated at 21oC for 10 minutes to 
allow annealing between primer and RNA template, and then incubated for 1 hour at 42oC for 
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the extension phase. At the end of the reaction, the enzyme was inactivated by heating the 
specimen at 70oC for 15 minutes. 
Table 2.1  Composition of the RT-PCR reaction mix 
Constituents of the reaction mix for reverse transcription. 
Reagents Volume /μL 
DEPC water 1.5 
dNTP 1.0 
MMLV enzyme 0.5 
RNAsin 1.0 
Buffer 4.0 
Table 2.2 Properties of the primers used in gene expression experiments 
Primers produced are exon-exon spanning, based on complementary nucleotide sequences published on 
GenBank. Primers are generated using the programme Primer 3 and most appropriate sequence 
selected, based on product size (ideally less than 200bp for efficient amplification with quantitative 
PCR) and annealing temperature. The oligonucleotide sequences were manufactured by MWG Biotech 
(Ebersberg, Germany). 
Primer 
Annealing 
temp (oC) 
Primer sequence 
Gene product 
size 
GAPDH 60 
Fwd: 5’ – atgaggtccaccaccctgtt – 3’ 
Rev: 5’ – catggagaaggctggggctc – 3’ 
671bp 
ARP 60 
Fwd: 5’ – cgacctggaagtccaactac – 3’ 
Rev: 5’– atctgctgcatctgcttg– 3’ 
115bp 
HIF-1α 59.6 Fwd: 5’ – cacctctggacttgcctttc – 3’ 
Rev: 5’– ggctgcatctcgagactttt – 3’ 
194bp 
HIF-2α 60 Fwd: 5’ – ccttcaagacaaggtctgca – 3’ 
Rev: 5’ – ttcatccgtttccacatcaa – 3’ 
190bp 
Total VEGF 59.4 
Fwd: 5’ – cttgccttgctgctctacct – 3’ 
Rev: 5’ – ctgcatggtgatgttggact – 3’ 
183bp 
VEGF isoforms 
• VEGF121 
• VEGF145 
• VEGF165 
• VEGF189 
60 
Fwd: 5’ – cacgaagtggtgaagttcatgg – 3’ 
Rev: 5’ – ggaggctccttcctcctg – 3’ 
 
357bp 
429bp 
489bp 
561bp 
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2.3.3 Polymerase chain reaction (PCR) 
The cDNA copies generated following reverse transcription are relatively limited in 
numbers and would hinder meaningful interpretation into the expression of the specified 
genes of interest. To overcome this, PCR was used to exponentially amplify a short, well 
defined segment of a cDNA strand. This process utilises DNA polymerase enzyme and 
primers designed to specifically complement the beginning and end of the cDNA segment to 
be amplified. PCR therefore utilises cDNA as the template to replicate large quantities of 
cDNA copies, and the relative abundance in amplicons would correlate to the transcriptional 
activity of the specific gene of interest. The primers used in my study were designed to span 
across adjacent exons to minimise risk of amplifying any potential contaminating genomic 
DNA. The list of primers used are summarised in Table 2.2. 
Table 2.3 Composition of the PCR reaction mix 
Summary of reagents and their stock concentrations provided within the kit, and the volumes of 
individual reagents to be used to achieve final working concentrations for individual PCR reactions.  
Reagent Concentration Final concentration Amount /µL 
Purified water - - 19.15 
PCR buffer 10 x 1 x 2.5 
dNTP 10mM 200 µM 0.5 
Forward Primer 12.5 µM 0.25 µM 0.5 
Reverse Primer 12.5 µM 0.25 µM 0.5 
Magnesium chloride 50mM 1.5mM 0.75 
Taq polymerase 5 units/µL 0.5 units 0.1 
cDNA sample   1.0 
 
The PCR reaction required a mixture of purified water, deoxynucleotide triphosphates 
(dNTPs), forward and reverse primers, PCR buffer, polymerase enzyme and DNA template. 
The Taq polymerase enzyme used in the experiments was produced by Invitrogen (Carlsbad, 
California, USA) and was supplied in a kit, comprising of PCR buffer solutions for generating 
a suitable chemical environment. The quantities of individual reagents for each PCR reaction 
are listed in Table 2.3. The samples were heated and cooled cyclically for up to 36 cycles in a 
thermal cycler Biometra T3 machine (Biometra GmbH, Goettingen, Germany). The process 
denatured the cDNA templates and primers by heating up to 94oC for 30 seconds, then 
allowed annealing between primer and cDNA by cooling to the primer melting point for 30 
seconds, and copying of the cDNA by Taq polymerase enzyme at 72oC – a process termed 
DNA extension. A final extension step comprised of a 5-minute incubation period at 72oC 
ensured that any remaining single stranded cDNA was completely copied after the last cycle. 
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The expression of a particular gene of interest within the specimen is usually confirmed by 
comparisons with known standards. The positive control used was cDNA from human 
synovial fibroblast which has been established to express HIFs and VEGF by colleagues at 
my laboratory, and negative control used was water. 
2.3.4 Gel electrophoresis 
The amplified cDNA had to be separated in the order of size to aid its identification. 
This was performed by electrophoresis through 1% agarose gel to separate cDNA copies 
according to their mass and charge. A standard 1% agarose gel was prepared in Tris-Acetate-
EDTA (TAE) solution with SYBR® Green I nucleic acid gel stain (Invitrogen, Carlsbad, 
California, USA) in 1:10,000 dilution. The gel was casted on a tray with sample combs, and 
once solidified, 20μL of PCR specimen mixed with 5μL of glycerol-enriched loading buffer 
was loaded into the sample wells. A 1 kilo base DNA ladder was loaded into a peripheral well 
to help gauge the molecular weight of the various DNA fragments. An electrical current of 
180 volts was applied across the gel for 20 minutes and care was taken to prevent the DNA 
fragments from over running. The agarose gel was then placed on an ultraviolet 
transilluminator to visualise the fluorescent electrophoretic bands representing the various 
DNA fragments of interest. 
2.3.5 Quantitative PCR 
Gel electrophoresis enabled the direct visualisation of gene products following cDNA 
amplification by PCR. Both techniques were useful in confirming expression of specific 
genes of interest, but the main limitation was in its inability to quantify gene products. 
Quantitative PCR (Q-PCR) was therefore used in my study to overcome this problem, as the 
technique allowed expression of genes to be quantified by comparing expression levels 
between stimulated cells and unstimulated cells. The technique which was developed from 
PCR technology utilised cDNA as a starting template, and involved a series of heating and 
cooling steps to amplify cDNA with DNA polymerase. However, the main difference was the 
application of DNA-binding dyes into the PCR reaction which emitted fluorescence when 
provoked by an excitatory beam of light of a particular wavelength. SYBR Green I, example 
of a DNA-binding dye, was used in my experiments and it is known to have an excitation 
maxima of 494nm and fluorescence emission at 521nm. This principle known as fluorescence 
resonance energy transfer (FRET) formed the basis of a progressive rise in fluorescence 
emission during the course of the PCR reaction, as more SYBR Green was progressively 
incorporated into the increasing number and length of amplified targets. A graph constructed 
with data relating to change in fluorescence emission as a function of cycles typically 
produced an S-shaped curve. From this graph, an arbitrary threshold cycle value (Ct value) 
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correlating to the cycle number at which the fluorescence exceeded baseline was chosen. The 
Ct value decreased linearly with increasing starting target quantity, as the presence of 
increased templates at the beginning of the reaction would require fewer amplification cycles 
to achieve statistically significant higher fluorescence signal above background. The point 
defined as Ct should always occur during the exponential phase of amplification to discount 
rate-limiting effects caused by depletion in reaction components during the plateau phase, 
thus improving reliability between individual experiments. The amplification, detection and 
quantification steps as described above were carried out using the Rotor-Gene 6000 
centrifugal thermal cycler designed by Corbett Research (Mortlake, Sydney, Australia). 
SYBR Green I used in my experiments was present within a ready-to-use mixture as 
SYBR® Green JumpStart™ Taq ReadyMix™ (Sigma-Aldrich, St Louis, MO, USA), 
comprising of SYBR Green I, Taq DNA polymerase, 99% pure deoxynucleotides and 
reaction buffer. The other constituents to complete the reaction included forward and reverse 
components of the specific primer, and cDNA sample which was pre-diluted to a ratio of 1:5 
with purified water (Table 2.4). 
Table 2.4 Constituents of Q-PCR reaction 
Constituents of Q-PCR reaction and their respective volumes. 
Reagent Concentration/ μM Volume / μL 
SYBR® Green JumpStart™ 
Taq ReadyMix™ 2× 7.5 
Primer 
(Forward & Reverse) 6.25 0.6 
Purified water  0.9 
Template DNA 1:5 dilution with water 6.0 
 
The Rotorgene was programmed to perform 40 amplification cycles, each cycle 
comprising of 95oC for 10 seconds for DNA denaturation, followed by 60oC for 30 seconds 
for annealing, and finally the extension step at 72oC for 30 seconds.  
Gene expression was quantified by relative quantification or the comparative 2-∆∆Ct 
method. The technique involves comparing gene expression levels of treatment groups to a 
calibrator or control with a steady-state transcription of the gene. Direct comparisons between 
Ct values of treatment and control groups would provide an indicator of the relative gene 
expressions by reflecting on their quantity of gene product produced. However, these Ct 
values would have to be normalised to a housekeeping gene (HKG) which serves as an 
internal reference (Karge et al. 1998). The purpose of this is to adjust for the potential 
significant variability in starting cDNA concentrations between samples due to variability in 
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reverse transcriptional activity (Freeman et al. 1999). Acidic ribosomal phosphoprotein 
(ARP) was used as the HKG in my experiments because it is ubiquitously expressed, and 
crucially its expression remained constant with various stimuli. The target gene for both the 
treated and non-treated cells were normalised to ARP by the equation: 
∆Ct TARGET = Ct TARGET - Ct ARP 
The final equation to calculate the gene expression level within the treatment group 
relative to the control group is given by 2-∆∆Ct, where: 
∆∆Ct = ∆Ct TREATMENT - ∆Ct CONTROL 
The principle of relative quantification via 2-∆∆Ct method relies on the amplification 
efficiency of the target gene and HKG to be almost identical (Livak and Schmittgen 2001). 
The amplification efficiency of primer sets were validated relative to HKG by analysing 
changes in ∆Ct values with varying concentrations of input cDNA over a 100-fold dilution 
range. Assuming that primer efficiencies were similar, the expected ∆Ct values would be 
almost identical with varying input cDNA concentrations. Therefore, a correlation coefficient 
of <0.1 extrapolated from a logarithmic plot of cDNA concentration versus ∆Ct would be 
indicative of a primer with an equal amplification efficiency relative to the HKG. Such primer 
pairs would thus be suitable for our gene expression studies. However, where the correlation 
coefficient is >0.1, the primers were redesigned and revalidated again. 
2.3.6 PCR-based Angiogenesis Arrays 
Q-PCR has proven invaluable for analysing the effect of a stimulus on the expression 
of selected genes, but it is mainly limited to studying a handful of genes which are presumed 
to be the most relevant and important in a given biological system. EGF receptor (EGFR) 
signalling and hypoxia are known to exert angiogenic effects primarily by upregulating 
expression of the potent pro-angiogenic factor VEGF. However, the end-result of tumour 
angiogenesis is considerably more complex, with multiple interconnected intra- and 
extracellular regulatory processes which determine the balance between pro- and anti-
angiogenic signals. These regulatory signals identified to date could be subdivided into 
growth factors and accompanying receptors, cytokines, chemokines, transcription factors, 
adhesion molecules, proteases, matrix proteins. In order to elucidate the involvement of these 
alternate pathways in mediating EGFR and hypoxia-induced angiogenesis in CRC, a 
commercially available assay known as the Human Angiogenesis RT2 ProfilerTM PCR Array 
(SABiosciences, Frederick, MD, USA) was used to profile the expression of 84 key genes 
known to be involved in modulating the biological processes underlying angiogenesis (Table 
2.5). The array was developed from Q-PCR technology where cDNA was amplified within 
wells pre-coated with specifically designed primers to study the expression of various 
angiogenic genes within a 96-well plate format. 
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Table 2.5 Genes Included In Angiogenesis PCR Array 
The Human Angiogenesis RT² Profiler™ PCR Array profiles the expression of 84 key genes involved 
in modulating the biological processes of angiogenesis. The array includes growth factors and their 
receptors, chemokines and cytokines, matrix molecules (proteases and their inhibitors), adhesion 
molecules, as well as transcription factors. 
RefSeq Symbol Gene Name Description Function 
NM_005163 AKT1 PKB/PRKBA V-akt murine thymoma viral oncogene homolog 1 Transcription factor 
NM_001146 ANGPT1 AGP1/AGPT Angiopoietin 1 Vascular remodelling 
NM_001147 ANGPT2 AGPT2/ANG2 Angiopoietin 2 Vascular remodelling 
NM_014495 ANGPTL3 ANGPT5 Angiopoietin-like 3 Adhesion molecule 
NM_016109 ANGPTL4 ANGPTL2/ARP4 Angiopoietin-like 4 Cellular metabolism & 
vascular remodelling 
NM_001150 ANPEP CD13/LAP1 
Alanyl (membrane) 
aminopeptidase 
(aminopeptidase N, 
aminopeptidase M, microsomal 
aminopeptidase, CD13, p150) 
Extracellular matrix 
remodelling 
NM_001702 BAI1 BAI1 Brain-specific angiogenesis inhibitor 1 Adhesion molecule 
NM_002986 CCL11 SCYA11 Chemokine (C-C motif) ligand 11 Chemokine 
NM_002982 CCL2 GDCF-2/GDCF-2 HC11 
Chemokine (C-C motif) ligand 
2 Chemokine 
NM_001795 CDH5 7B4 Cadherin 5, type 2, VE-cadherin (vascular epithelium) Adhesion molecule 
NM_030582 COL18A1 KNO Collagen, type XVIII, alpha 1 Adhesion molecule 
NM_000091 COL4A3 TUMSTATIN Collagen, type IV, alpha 3 (Goodpasture antigen) Adhesion molecule 
NM_001511 CXCL1 GRO1/GROa 
Chemokine (C-X-C motif) 
ligand 1 (melanoma growth 
stimulating activity, alpha) 
Chemokine 
NM_001565 CXCL10 C7/IFI10 Chemokine (C-X-C motif) ligand 10 Chemokine 
NM_002090 CXCL3 CINC-2b/GRO3 Chemokine (C-X-C motif) ligand 3 Chemokine 
NM_002994 CXCL5 ENA-78/SCYB5 Chemokine (C-X-C motif) ligand 5 Chemokine 
NM_002993 CXCL6 CKA-3/GCP-2 
Chemokine (C-X-C motif) 
ligand 6 (granulocyte 
chemotactic protein 2) 
Chemokine 
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NM_002416 CXCL9 CMK/Humig Chemokine (C-X-C motif) ligand 9 Chemokine 
NM_001953 ECGF1 MNGIE/PDECGF Endothelial cell growth factor 1 (platelet-derived) Growth factor 
NM_001400 EDG1 CHEDG1/D1S3362 
Endothelial differentiation, 
sphingolipid G-protein-coupled 
receptor, 1 
Adhesion molecule 
NM_182685 EFNA1 B61/ECKLG Ephrin-A1 Growth factor 
NM_004952 EFNA3 EFL2/EPLG3 Ephrin-A3 Growth factor 
NM_004093 EFNB2 EPLG5/HTKL Ephrin-B2 Growth factor 
NM_001963 EGF URG Epidermal growth factor (beta-urogastrone) Growth factor 
NM_000118 ENG CD105/END Endoglin (Osler-Rendu-Weber syndrome 1) Adhesion molecule 
NM_004444 EPHB4 HTK/MYK1 EPH receptor B4 Growth factor 
receptor 
NM_001432 EREG ER Epiregulin Growth factor 
NM_000800 FGF1 AFGF/ECGF Fibroblast growth factor 1 (acidic) Growth factor 
NM_002006 FGF2 BFGF/FGFB Fibroblast growth factor 2 (basic) Growth factor 
NM_000142 FGFR3 ACH/CEK2 
Fibroblast growth factor receptor 
3 (achondroplasia, thanatophoric 
dwarfism) 
Growth factor 
receptor 
NM_004469 FIGF VEGF-D/VEGFD 
C-fos induced growth factor 
(vascular endothelial growth 
factor D) 
Growth factor 
NM_002019 FLT1 FLT/VEGFR1 
Fms-related tyrosine kinase 1 
(vascular endothelial growth 
factor/vascular permeability 
factor receptor) 
Growth factor 
receptor 
NM_021973 HAND2 DHAND2/Hed Heart and neural crest derivatives expressed 2 Transcription factor 
NM_000601 HGF F-TCF/HGFB Hepatocyte growth factor (hepapoietin A; scatter factor) Growth factor 
NM_001530 HIF1A HIF-1alpha/HIF1-ALPHA 
Hypoxia-inducible factor 1, alpha 
subunit (basic helix-loop-helix 
transcription factor) 
Transcription factor 
NM_006665 HPSE HPA/HPR1 Heparanase Transcription factor 
NM_002165 ID1 ID 
Inhibitor of DNA binding 1, 
dominant negative helix-loop-
helix protein 
Transcription factor 
NM_002167 ID3 HEIR-1 
Inhibitor of DNA binding 3, 
dominant negative helix-loop-
helix protein 
Transcription factor 
NM_024013 IFNA1 IFL/IFN Interferon, alpha 1 Cytokine 
NM_002176 IFNB1 IFB/IFF Interferon, beta 1, fibroblast Cytokine 
NM_000619 IFNG IFG/IFI Interferon, gamma Cytokine 
NM_000618 IGF1 IGFI Insulin-like growth factor 1 (somatomedin C) Growth factor 
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NM_000576 IL1B IL-1/IL1-BETA Interleukin 1, beta Cytokine 
NM_000600 IL6 BSF2/HGF Interleukin 6 (interferon, beta 2) Cytokine 
NM_000584 IL-8 3-10C/AMCF-I Interleukin 8 Adhesion molecule 
NM_002210 ITGAV CD51/MSK8 Integrin, alpha V (vitronectin receptor, alpha polypeptide, antigen CD51) Adhesion molecule 
NM_000212 ITGB3 CD61/GP3A Integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) Adhesion molecule 
NM_000214 JAG1 AGS/AHD Jagged 1 (Alagille syndrome) Cell differentiation 
NM_002253 KDR FLK1/VEGFR Kinase insert domain receptor (a type III receptor tyrosine kinase) 
Growth factor 
receptor 
NM_005560 LAMA5 KIAA1907 Laminin, alpha 5 Matrix 
NM_007015 LECT1 BRICD3/CHM-I Leukocyte cell derived chemotaxin 1 Chemokine 
NM_000230 LEP OB/OBS Leptin (obesity homolog, mouse) Cytokine 
NM_002391 MDK MK/NEGF2 Midkine (neurite growth-promoting factor 2) Growth factor 
NM_004530 MMP2 CLG4/CLG4A 
Matrix metallopeptidase 2 (gelatinase 
A, 72kDa gelatinase, 72kDa type IV 
collagenase) 
Matrix 
NM_004994 MMP9 CLG4B/GELB 
Matrix metallopeptidase 9 (gelatinase 
B, 92kDa gelatinase, 92kDa type IV 
collagenase) 
Matrix 
NM_004557 NOTCH4 INT3/NOTCH3 Notch homolog 4 (Drosophila) Transcription factor 
NM_003873 NRP1 DKFZp686A03134/DKFZp781F1414 Neuropilin 1 
Angiogenesis 
receptor 
NM_003872 NRP2 NP2/NPN2 Neuropilin 2 Angiogenesis 
receptor 
NM_002607 PDGFA PDGF-A/PDGF1 Platelet-derived growth factor alpha polypeptide Growth factor 
NM_000442 PECAM1 CD31/PECAM-1 Platelet/endothelial cell adhesion molecule (CD31 antigen) Adhesion molecule 
NM_002619 PF4 CXCL4/SCYB4 Platelet factor 4 (chemokine (C-X-C motif) ligand 4) Chemokine 
NM_002632 PGF PLGF/PlGF-2 
Placental growth factor, vascular 
endothelial growth factor-related 
protein 
Growth factor 
NM_002658 PLAU ATF/UPA Plasminogen activator, urokinase Matrix 
NM_000301 PLG DKFZp779M0222 Plasminogen Growth factor 
NM_020405 PLXDC1 TEM3/TEM7 Plexin domain containing 1 Angiogenesis 
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NM_021935 PROK2 BV8/MIT1 Prokineticin 2 Growth factor 
NM_000962 PTGS1 COX1/COX3 
Prostaglandin-endoperoxide 
synthase 1 (prostaglandin G/H 
synthase and cyclooxygenase) 
Transcription factor 
NM_002615 SERPINF1 EPC-1/PEDF 
Serpin peptidase inhibitor, clade 
F (alpha-2 antiplasmin, pigment 
epithelium derived factor), 
member 1 
Growth factor 
NM_021972 SPHK1 SPHK Sphingosine kinase 1 Transcription factor 
NM_015136 STAB1 CLEVER-1/FEEL-1 Stabilin 1 Endosome trafficking 
NM_000459 TEK CD202B/TIE-2 
TEK tyrosine kinase, endothelial 
(venous malformations, multiple 
cutaneous and mucosal) 
Growth factor 
receptor 
NM_003236 TGFA TFGA Transforming growth factor, alpha Growth factor 
NM_000660 TGFB1 CED/DPD1 
Transforming growth factor, 
beta 1 (Camurati-Engelmann 
disease) 
Growth factor 
NM_003238 TGFB2 TGF-beta2 Transforming growth factor, beta 2 Growth factor 
NM_004612 TGFBR1 ACVRLK4/ALK-5 
Transforming growth factor, 
beta receptor I (activin A 
receptor type II-like kinase, 
53kDa) 
Growth factor 
receptor 
NM_003246 THBS1 THBS/TSP Thrombospondin 1 Adhesion molecule 
NM_003247 THBS2 TSP2 Thrombospondin 2 Adhesion molecule 
NM_003254 TIMP1 CLGI/EPA TIMP metallopeptidase inhibitor 1 Matrix 
NM_003255 TIMP2 CSC-21K TIMP metallopeptidase inhibitor 2 Matrix 
NM_000362 TIMP3 HSMRK222/K222 
TIMP metallopeptidase inhibitor 
3 (Sorsby fundus dystrophy, 
pseudoinflammatory) 
Matrix 
NM_000594 TNF DIF/TNF-alpha Tumour necrosis factor (TNF superfamily, member 2) Cytokine 
NM_006291 TNFAIP2 B94 Tumour necrosis factor, alpha-induced protein 2 Cytokine 
NM_003376 VEGF VEGFA/VPF Vascular endothelial growth factor Growth factor 
NM_005429 VEGFC Flt4-L/VRP Vascular endothelial growth factor C Growth factor 
X03205 18SrRNA 18SRNA Human 18S ribosomal RNA Housekeeping 
NM_000194 HPRT1 HGPRT/HPRT Hypoxanthine phosphoribosyltransferase 1 Housekeeping 
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The initial step was to synthesise cDNA using a purposefully designed reverse-
transcription kit, the RT2 First Strand Kit (SABiosciences, Frederick, MD 21703, USA) 
according to the manufacturer’s instructions (SABiosciences 2008). The principle of the 
technique is similar to that as previously described, where the first step involved eradicating 
any contaminating genomic DNA with a reagent from the kit. Complementary DNA was then 
synthesised by reverse transcribing 500ng RNA within a cocktail of reagents consisting of 
reverse transcriptase enzyme, buffer solution and primer for 30 minutes at 42oC. RNA from 3 
representative experiments were reverse transcribed and equal quantities of the generated 
cDNA were pooled to create the test sample to be loaded onto the PCR array. The purpose of 
pooling samples from separate experiments was to minimise the impact of one erroneous 
experiment from potentially skewing the overall data. Furthermore, each experimental 
condition was tested in duplicate PCR arrays, and a mean Ct value was taken to calculate the 
relative expression for a given gene. The real-time PCR array employed a specially-
formulated SYBR Green fluorescent dye available as SABiosciences RT2 qPCR Master Mix. 
The pooled cDNA was diluted with water and SYBR Green as illustrated by Figure 2.2, and 
25μL of the reaction mix was carefully pipetted into each well of the plate with a multi-
channel pipette.  
Figure 2.2  Schematic representation of the stepwise procedures to obtain gene 
expression data using the RT2 Profiler Angiogenesis PCR Array 
 
The amplification, detection and quantification steps were carried out using the ABI 
PRISM 7700 Sequence Detector designed by Applied Biosystems (Foster City, CA, USA). 
The arrays were initially heated to 95oC for 10 minutes to activate the polymerase, and this 
was followed by 40 repeated cycles comprising of 15 seconds at 95oC for melting, 40 seconds 
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for annealing at 55oC and 20 seconds for extension at 78oC. Ct values were obtained using the 
pre-installed ABI PRISM® 7700 Sequence Detection System software by setting the 
threshold at the exponential phase of gene amplification. Relative expression of various genes 
were calculated by 2-∆∆Ct comparative method by entering the obtained Ct values into a 
spreadsheet designed by SABiosciences as illustrated by Table 2.6 (portion of table is 
illustrated as an example). 
Table 2.6 PCR array data – sample calculation 
Replicate Ct values from stimulated (test) and control samples were determined using Human 
Angiogenesis RT2 ProfilerTM PCR Array. Values for 2-ΔCt were calculated by normalising to a panel of 
housekeeping genes. Relative differences in expression of individual genes by stimulated cells (test) 
were determined by relating to unstimulated control samples by the 2-ΔΔCt method. 
Ct 2-ΔCt
Symbol 
Test Control Test Control 
Fold 
Difference 
Test versus 
Control 
ANGPTL4 30.63 30.67 36.63 36.99 1.8E-04 6.5E-06 27.69 
HIF1A 20.32 20.07 19.18 19.29 2.5E-01 3.6E-01 0.70 
VEGF 22.63 23.05 24.84 25.63 4.1E-02 5.7E-03 7.14 
18SrRNA 17.14 16.83 16.40 16.44 2.4E+00 2.6E+00 0.92 
HPRT1 22.12 21.97 20.93 21.27 7.1E-02 1.0E-01 0.71 
 
The angiogenesis array included 5 different HKG to normalise Ct values of studied 
genes to internal references with presumed steady-state levels of expression. The HKG Ct 
values were scrutinised to ensure their expression did not vary significantly with stimuli, and 
where there were significant variations in expression across experiments, the specific HKG 
were omitted from calculations. Two HKG, 18srRNA and HPRT1 (hypoxanthine 
phosphoribosyltransferase 1) are illustrated. 
Data derived from the PCR angiogenesis arrays had to be validated with an alternate 
method of detection, such as with Q-PCR, to confirm data quality and reproducibility. 
Furthermore, by pooling cDNA from 3 separate experiments, each of the contributory 
samples had to be validated independently to ensure the trends were consistent across 
experiments, and the overall result was accurately represented by the pooled sample. VEGF, 
HIF and angiopoietin-like 4 (ANGPTL-4) were selected for the validation process using Q-
PCR as their gene expressions were known to be significantly altered by stimulation, based on 
my experiments in Chapter 3 and also through the angiogenesis PCR array. Expressions of 
VEGF, HIF-1α and ANGPTL-4 within the pooled sample were therefore determined by Q-
PCR to validate the PCR arrays data. cDNA samples from the three separate experiments 
were also individually tested for VEGF, HIF-1α and ANGPTL-4 expressions, to exclude the 
possibility of significant variability in gene expression across experiments as a consequence 
of a sampling error. 
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2.4 ANALYSIS OF PROTEIN EXPRESSION 
The effects of EGFR and hypoxia on various biological activities in CRC cells may 
extend beyond transcriptional and into the field of post-transcriptional regulation to exert their 
angiogenic influences within the tumour microenvironment. Expression of HIF-1α and VEGF 
was therefore evaluated at the protein level in both Colo 201 and Caco-2 cells, as any 
significant biological effects exerted by EGFR and hypoxia on downstream cellular events 
would most likely be reflected by increased protein production. HIF-1α and VEGF protein 
were quantitated by Enzyme-linked Immunoassay (ELISA) and presented visually through 
Western Blotting.  
2.4.1 HIF-1α ELISA 
Cells were harvested and lysed in 50mM TRIS, 300mM NaCl, 3mM EDTA, 1mM 
MgCl2, 25mM NaF, 20mM β-glycerophosphate, 1% Triton-X, 10% glycerol and protease 
inhibitor cocktail P-8340 (Sigma, St Louis, MO, USA), containing 4-(2-
aminoethyl)benzenesulfonyl fluoride (AEBSF), pepstatin A, E-64, bestatin, leupeptin, and 
aprotinin. The HIF-1α Duoset IC which comprises of a mouse anti-human capture antibody 
and a biotinylated goat anti-human HIF-1α detection antibody (R&D Systems, Minneapolis, 
USA) was utilised for HIF-1α protein quantitation. The wells of a 96-well polystyrene 
microtitre plate (Corning, Lowell, MA 01851, USA) were coated with 100μL of HIF-1α 
capture antibody diluted to 4μg/mL in PBS solution, and left to incubate overnight at 4oC. 
Following three washes with 0.05% Tween in PBS, any unreacted sites in the wells were 
blocked with 300μL of 5% Bovine Serum Albumin, Fraction V (Sigma, St Louis, MO, USA) 
and left for 2 hours at room temperature. The plate was washed and 100μL of cell lysates 
were pipetted into individual wells, with triplicate wells performed for each experimental 
condition. A seven point standard curve was generated using 2-fold serial dilutions from the 
highest standard of 8000pg/mL. The ELISA was then left to incubate overnight at 4oC. 
Following a wash step, 100µL of biotinylated detection antibody at 400ng/mL concentration 
was added to each well and the plate was incubated for 2 hours at room temperature. The 
plate was washed and 100µL of diluted streptavidin-horseradish peroxidase (HRP) was added 
to bind the antigen-antibody complex. Addition of 100µL of substrate solution comprising of 
equal volumes of hydrogen peroxide and tetramethylbenzidine (R&D Systems, Minneapolis, 
USA) resulted in development of a turquoise-blue tinge in positive wells which typically fully 
developed after 20 minutes at room temperature. 50µL of sulphuric acid was then used to halt 
the chromogenic reaction, resulting in a change of colour from turquoise blue to bright 
yellow. Since the colour formed was proportional to the amount of antigen in the test solution, 
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the microplate reader which was set to read at a wavelength of 450nm determined the optical 
density of each well and subsequently calculated the HIF-1α protein concentrations based on 
the standard curve. This was calculated by the accompanying computer software Ascent 
Version 2.6 (Thermo Fisher Scientific, Waltham, MA 02454, USA). 
2.4.2 VEGF ELISA 
The VEGF ELISA protocol shared considerable similarities with the procedures for 
HIF-1α ELISA, except for concentrations of reagents and standards used. The ELISA plate 
was coated with 100µL of mouse anti-human capture antibody (R&D Systems, Minneapolis, 
USA) at 1µg/mL concentration in PBS, and left to incubate overnight at 4oC. Following a 
wash step, the plate was blocked with 250µL of 2% BSA for 2 hours. The plate was washed 
and 100µL of sample was pipetted into individual wells, with each experimental condition 
tested in triplicate. A seven point standard curve was generated using 3-fold serial dilutions 
from the highest standard of 10000pg/mL. The plate was left at 4oC overnight. The plate was 
washed and 100µL of biotinylated goat antibody specific for VEGF (R&D Systems, 
Minneapolis, USA) at 200ng/mL concentration was added to each well. The subsequent steps 
of enzyme conjugation and substrate catabolism for photometry measurement were identical 
to the HIF-1α protein ELISA procedures. 
2.4.3 Bicinchoninic Acid (BCA) Determination 
The amount of measured HIF-1α could vary significantly between experiments due 
to variations in amounts of protein within samples. Such variability could be introduced by 
minor differences in cell numbers between experiments, thus levels measured by ELISA have 
to be corrected to allow for fair comparisons. Total protein was quantified by the 
Bicinchoninic assay (BCA) (Pierce, Rockford, USA). Twenty-five µL of standard or 
unknown sample was loaded onto duplicate wells of a 96-well polystyrene plate. 200µL of 
the working reagent, comprising of a 50:1 mixture of BCA Reagent A:B were added to 
individual wells and the plate was covered and incubated at 37oC for 30 minutes. Absorbance 
measurement was performed at 540nm using a plate reader, and the protein concentrations 
within test samples were calculated by Ascent software (Version 2.6, Thermo Labsystems) 
using the 9 point standard curve as reference. 
2.5 ANALYSIS OF SIGNALLING BY WESTERN BLOTTING 
Western blotting was performed to investigate signalling pathways which were 
potentially activated following EGFR stimulation. This would allow for further in-depth 
analysis into the variations in biological responses elicited from Colo 201 and Caco-2 cells. 
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Cells were prepared and stimulated according to the protocol as previously described for cell 
stimulation, with the only difference in the shorter duration of stimulation. Cells were 
harvested and lysed with 100μL RIPA buffer (50mM Tris pH 7.4, 150mM NaCl, 1% Triton 
X, 0.1% SDS, 5mM MgCl2, 50mM NaF, 50mM DTT, 2mM orthovanadate, 5mg/ml sodium 
deoxycholate, 10mM sodium pyrophosphate, 25mM β-glycerophosphate, 2mM EDTA, 2mM 
PMSF and P-8340 (Sigma, St Louis, MO, USA) protease inhibitor) per well after 15, 30, 60 
and 120 minutes of stimulation. Following a brief period of sonification, 70μg (for EGFR 
signalling) or 30μg of cleared lysates were mixed with loading buffer and DTT to a total 
volume of 30μL, and boiled for 5 minutes at 95oC. The samples were then resolved on SDS-
polyacrylamide gels, where 3-8% Tris-Acetate NuPAGE® Novex (Invitrogen, Carlsbad, CA, 
USA) was used for EGFR signalling studies, and 4-12% Bis-Tris NuPAGE® Novex 
(Invitrogen, Carlsbad, CA, USA) was used for ERK, p38 and Akt signalling studies. 
Procedures and buffers used were according to manufacturer’s recommendations (Invitrogen 
2003). A current of 80V was initially applied across the gel and this was subsequently 
increased to 150V for 1 hour. The separated proteins were blotted onto polyvinylidene 
difluoride (PVDF) membranes by electroelution at 100V for 1½ hours in transfer buffer 
(10mM Tris base, 100mM glycine, 10% methanol, 0.005% SDS). Following 2 hours of 
blocking with 1% TBS (Merck), 5% fat free milk powder (Premier Brands, UK), 1% BSA 
(Sigma, St Louis, MO, USA) and 0.1% Tween (Sigma, St Louis, MO, USA), the PVDF 
membrane was washed once in TBS/ Tween 0.01% and incubated overnight in 1:1000 
dilution of primary antibodies in 15mL of 5% BSA, 0.1% Tween and 1:1000 sodium azide. 
Primary antibodies for anti-phospho EGFR (Tyr1068), anti-phospho EGFR (Tyr845), anti-
phospho p38 MAP Kinase (Thr180/Tyr182), anti-phospho p44/42 MAP Kinase 
(Thr202/Tyr204), anti-phospho-Akt (Ser-473), total EGFR, total p38 MAPK and total p44/42 
MAPK were rabbit anti-human antibodies from Cell Signaling Technology (Danvers, MA, 
USA). The PVDF membrane was washed for 4 times at 10 minutes each, and incubated with 
secondary anti-rabbit HRP-conjugated antibody (DakoCytomation, Glostrup, Denmark) at 
1:5000 concentration in blocking buffer. Following another thorough wash step, the blot was 
developed with ECL chemiluminescence detection kit (GE Healthcare Lifesciences, 
Piscataway, NJ, USA) and exposed to x-ray film. The protein band of interest was confirmed 
by comparing its known molecular weight with the protein ladder, and also through 
comparisons with the positive control. The degree of luminescence captured on photographic 
film was proportional to the amount of protein to be tested, but corrections were made for any 
inconsistencies in total protein loaded by stripping and re-probing for the corresponding total 
unphosphorylated form of the signalling molecule and α-tubulin. 
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2.6 HUVEC MIGRATION ASSAY 
Human umbilical vein endothelial cells (HUVEC) were co-cultured with pre-
stimulated Caco-2 cells in a double-chamber model, to assess the angiogenic potential of 
CRC cells. The principle of the study relied upon migration of endothelial cells towards a 
chemical gradient of angiogenic mediators produced by stimulated CRC cells, such that the 
total cell numbers migrated would correlate directly with the potency of the angiogenic 
response from the CRC cells. Caco-2 cells cultured within the lower chamber would release 
angiogenic mediators in response to stimuli, thus encouraging HUVEC cultured within 
specially designed cell inserts to migrate through the floor of the insert (composed of a porous 
membrane) by chemotaxis (Figure 2.3). Caco-2 cells were specifically selected for this study 
as their adherent nature would minimise contamination of the outer surface of the cell insert, 
avoiding the potential of a confounding variable. 
Caco-2 cells were cultured in a 24-well plate format at initial seeding density of 
1x105cells/cm2 in 500μL complete culture medium. Each experimental condition was 
performed in triplicates. The preparation of cells, and the subsequent stimulation process were 
identical to that previously described in my Caco-2 stimulation protocol, with the only 
exception of using 1% FCS supplemented EMEM as the base medium for Caco-2 
stimulations. HUVEC were kindly donated by two colleagues in my laboratory who have 
significant experience in successful isolation and culture of these cells. Work utilising 
HUVEC has been consented by patients and approved by the local ethical committee. 
HUVEC were trypsinised, centrifuged and resuspended in RPMI 1% FCS to achieve 1x106 
cells/mL concentration. 100μL of HUVEC suspension was introduced into 1% pre-gelatinised 
BD FalconTM Cell Culture Inserts with 8μm pores (Franklin Lakes, NJ, USA), and incubated 
for 1 hour to allow cells to settle. Following 24 hours of Caco-2 stimulations, the cell inserts 
were carefully placed above the Caco-2 cells, and the double chamber cell system was 
allowed to co-culture for 6 hours. Negative control wells contained base medium in the 
absence of cells, and positive control wells comprised of 10ng/mL VEGF. At the end of the 
migration experiment, unmigrated HUVEC were carefully removed from the inner surface of 
the cell inserts, and migrated cells located on the undersurface of the membrane was fixed in 
ice-cold 70% ethanol for 30 minutes. Cells were then permeabilised with 0.5% Triton X-100 
for 3 minutes to allow for nuclear staining with haematoxylin, which lasted for further 30 
minutes. The cell inserts were washed to remove excess haematoxylin, and migrated HUVEC 
were quantified by nuclear counts under phase contrast microscopy at 3 separate high power 
fields (100x magnification), designated as the 1, 5 and 9 o’clock positions on the undersurface 
of the cell insert membrane (Figure 2.3). 
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Figure 2.3  Diagrammatic representation of the HUVEC migration assay consisting 
of a double chamber co-culture model of Caco-2 cells and HUVEC. 
Caco-2 cells, adherent to the lower chamber, were stimulated with EGF/ DMOG/ EGF and DMOG for 
24 hours prior to the introduction of HUVEC, cultured independently within cell inserts. Both cell 
types were suspended in their respective base medium with 1% FCS. HUVEC were allowed to migrate 
over 6 hours in response to a chemical gradient of angiogenic mediators released by Caco-2 cells. 
Following removal of unmigrated cells from the inner surface of cell inserts, migrated cells on the 
undersurface of the cell insert membrane were fixed, permeabilised and stained. Under phase contrast 
microscopy, cell nuclei present at 3 separate high power fields (100x) on the membrane were counted 
and a mean was calculated. 
 
2.7 ESTABLISHMENT OF PRIMARY CRC CELL CULTURES 
The heterogeneous cell population representative of CRC tissue were isolated and 
cultured following surgical resection of the tumour to establish an ex-vivo cell culture model. 
All colorectal specimens were obtained from patients with diagnosis of adenocarcinoma 
involving the colon and rectum from Charing Cross Hospital, London. Histopathological 
diagnosis of tumour specimens were confirmed prior to surgery by examination of biopsies 
obtained during colonoscopy by the Histopathology Department at Charing Cross Hospital. 
The study was approved by the local ethics committee (reference 07/Q0407/6). Patients 
participating in the study had a written information leaflet and full consent was obtained prior 
to surgery. Specimens removed from patients were taken immediately to the histopathology 
department for examination prior to opening by the pathologist. Tissue samples measuring 
0.25 – 0.5cm3 in size were excised from the invading edge of the cancer and were placed 
directly in wash medium, comprising of 15mL RPMI 1640, 100μg/mL gentamicin, 2.5μg/mL 
amphotericin, 200U/mL penicillin and 200μg/mL streptomycin at 4oC. This aspect of my 
research, specifically the results obtained, is described in considerable detail in Chapter 5. 
Following multiple washings with wash medium to reduce microbial contamination, 
the tissue was finely minced with surgical blade and digested with 1mg/mL of Collagenase A 
(Roche, Mannheim, Germany) in RPMI at 37oC. This process lasted for approximately 1 
hour, during which the digestion solution became cloudy and viscous with strands of 
undigested mesenchymal fibrous tissue becoming more apparent in suspension. The viscous 
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digested mixture was separated into two fractions, with each diluted with Hanks’ Balanced 
Salt Solution (PAA, Pasching Austria) to a total volume of 50mL prior to filtration through 
sterile nylon gauze. The filtrate was centrifuged to recover various cellular components, 
comprising of cellular debris, single cells (mostly stromal elements and erythocytes), clumps 
of cells and epithelial tubules. The cellular constituents were resuspended in 7mL HBSS and 
carefully layered onto the liquid surface of 7mL of Histopaque®-1077 (Sigma-Aldrich, St 
Louis, MO, USA) for differential density gradient separation. The composite solution 
composed of two distinct layers was centrifuged at 400g for 30 minutes at room temperature. 
The separated fraction containing larger sized cellular components, which were typically 
visible at the Histopaque–cell suspension interface was carefully extracted, washed with 
Hanks’ medium and centrifuged at 200g to recover the constituent cells. 
The heterogeneous cell population was resuspended in complete culture media, and 
inspected under phase contrast microscopy to determine cell viability and total cell numbers. 
The cells were trialled on various culture media, including 10 and 20% serum supplemented 
RPMI medium, and two fully defined media in the form of MCDB-153 and selective stem 
cell promoting media (Table 2.7). Due to scarcity in published work on serum-free cultures of 
CRC cells, findings from studies using MCDB cell culture media to establish primary 
keratinocytes were translated to my work on CRC, as both cell types are of epithelial origins 
(Ham 1963; Ham 1965; Wille et al. 1984). A culture media developed specifically for the 
establishment of human neural stem and progenitor cells isolated from the CNS (Galli et al. 
2000; Westerlund et al. 2003) was also adapted for my studies (Ricci-Vitiani et al. 2007; Rich 
and Bao 2007; Vermeulen et al. 2008), with the ultimate goal of improving survival and 
proliferative capacity of the primary cultures by purposefully supporting clonal expansion of 
CRC progenitor or stem cells within cultures. 
Cultures were left to settle during the initial 48-hours of seeding to encourage cell 
attachment, and they were subsequently inspected under direct vision and phase contrast 
microscopy on alternate days for microbial contamination and growth of cell colonies. The 
first medium change was performed five days following initial seeding, and twice weekly 
subsequently. During the first few medium changes, any non-adherent material present in the 
extracted media were recovered by centrifugation, resuspended and replated in complete 
culture medium to support growth of potential future cell progenies. Cultures were 
discontinued if there were evidence of microbial contamination, or exhibited regression with 
minimal evidence of surviving cell colonies after several weeks of culture. 
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Table 2.7 Fully defined media: MCDB-153 and Stem Cell promoting medium 
Constituents of the fully defined media and their relative concentrations used for establishing primary 
CRC cultures. 
Reagent 
MCDB-153 
medium 
Stem Cell 
promoting medium 
Function 
Base medium MCDB-153 DMEM/F12 Basic supplements 
Bovine Serum Albumin - 0.12% or 1mg/mL 
Glucose - 50mM or 0.6% 
L-Glutamine - 2mM 
Cell metabolism 
Apotransferrin 62.5nM 1.3µM/ 100µg/mL 
Na selenite - 30nM 
Trace elements 
Hydrocortisone 0.69µM - 
Insulin 0.86µM 4.4µM 
Progesterone - 20nM 
Hormones 
B-27 supplement - x 1 
Bovine basic fibroblast 
growth factor 
- 1.1nM/ 20ng/mL 
Bovine pituitary extract 70µg/mL - 
Putrescine - 60µM 
Recombinant human EGF 3.2nM/ 20ng/mL 3.2nM/ 20ng/mL 
Recombinant human Stem 
Cell Factor 
- 10ng/mL 
Growth factors 
HEPES - 5mM 
L-N-acetylcysteine - 60µM 
NaHCO3 - 3mM 
2-Mercaptoethanol - 100µM 
Antioxidants/ 
Buffers 
Amphotericin B - 250ng/mL 
Gentamicin 40µg/mL 40µg/mL 
Penicillin/ Streptomycin 100u/100µg/mL 100u/100µg/mL 
Antimicrobials 
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2.8 STATISTICAL ANALYSES 
Statistical significance was evaluated with one way ANOVA with a Dunn’s post test 
to compare selected groups of data, and a 2-tailed Wilcoxon signed rank test was used to 
compare 2 groups of data. The two-way ANOVA with Bonferroni correction was used to 
compare selected groups of data with respect to time. The actual ΔCt values were used to 
determine the statistical significance of differences between groups. The relationship between 
VEGF protein expression by primary CRC and control tissues were evaluated by Spearman 
rank correlation test. The Friedman test with multiple comparisons was used to analyse the 
overall effect of EGF and hypoxia stimulation on VEGF expression compared to unstimulated 
controls. The significance level was set at 5% for each analysis. 
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3 GENE EXPRESSION STUDIES IN COLORECTAL CANCER 
CELL LINES 
3.1 INTRODUCTION 
Tumour vasculature has been recognised as a key target for novel adjunctive 
therapies in an attempt to improve treatment outcomes of cancers. The rationale for targeting 
tumour vessels stems from knowledge that tumour growth is limited to 2-3mm3 in the absence 
of neo-vascularisation, and highlights the importance of tumour angiogenesis in potentiating 
tumour growth and metastasis (Folkman and Shing 1992). Amongst the various growth 
factors regulating the development of new tumour blood vessels, VEGF is widely accepted as 
one of the most potent and crucial pro-angiogenic mediators (Ferrara et al. 2003). Several 
immunohistochemical studies have shown a direct correlation between VEGF expression and 
development of metastasis in CRC with increased microvessel density (MVD) (Brown et al. 
1993; Takahashi et al. 1995). A meta-analysis of 32 independent studies also demonstrated 
that high VEGF levels expressed by tumours significantly predicted poorer relapse-free 
survival (RFS) in patients, with a relative risk (RR) increase of 2.84 (p<0.001), and poorer 
overall survival (RR = 1.65; p<0.001). Therefore, the current evidence identifies VEGF as an 
important biological marker, having a significant impact on CRC survival and progression. 
The significance of the erb signalling network in CRC was highlighted by 
immunohistochemical studies, showing that 70-75% of colorectal malignancies overexpress 
EGFR. This was supported by work on other cell types where malignancies affecting the 
brain, breast, ovary and stomach which overexpressed EGF and its receptor carried an overall 
poorer prognosis (Salomon et al. 1995). The EGF family of receptors has classically been 
associated with cellular transformation and sustained proliferation of abnormal malignant 
cells, through its effects on cell cycle progression and cellular apoptosis (Chan et al. 1999). 
However, EGFR signalling has also been implicated in inducing tumour angiogenesis to 
support the continued growth, propagation and survival of cancers. Such an angiogenic effect 
was first demonstrated in a glioblastoma multiforme cell model, where secretion of bioactive 
VEGF was induced by introduction of exogenous EGF in a dose dependent manner (Goldman 
et al. 1993). A similar pro-angiogenic mechanism has not been confirmed in CRC cells. 
Ever since VEGF has been uncovered as a potent angiogenic stimulus, there have 
been several key developments in understanding the underlying regulatory mechanisms of 
this growth factor. Semenza et al discovered that VEGF expression was regulated by 
hypoxia-inducible factor (HIF), an intracellular oxygen-dependent transcriptional activator 
transcription factor which is crucial in mediating the adaptive responses to changes in tissue 
oxygenation (Semenza 1999). HIF is highly regulated at the post-translational level, and in 
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vitro studies have shown that HIF is activated at a threshold level of 5% oxygen (40 mmHg). 
It is highly effective in modifying global gene responses of cells to hypoxia, in order to 
facilitate adaptation of cells to a hostile environment. Of the 70 genes, VEGF has been 
identified as a target gene, possessing a hypoxia responsive element for HIF binding which 
allows transactivation of the gene under hypoxic conditions. A study by Kuwai et al (Kuwai 
et al. 2003) confirmed that HIF-1α protein was upregulated in three different CRC cell lines 
in response to hypoxia, with concomitant increase in VEGF mRNA expression. The same 
study also examined the expression of HIF-1α in 139 CRCs by immunohistochemistry, and 
showed that carcinomas which had high concentrations of HIF-1α also had significantly more 
VEGF expressed with higher MVD. 
Given that VEGF expression is tightly regulated by HIF-1α, other tumour related 
factors other than intratumoural hypoxia which could alter HIF-1α expression would 
inherently affect VEGF production. This would represent a HIF-1α dependent regulatory 
mechanism which is independent of oxygen tensions. Exploitation of such potent signalling 
machinery has been uncovered by several studies, where growth factors and cytokines have 
been shown to alter the expression of various angiogenic mediators. EGF, in addition to its 
direct effect on VEGF production, has been shown to increase translation of HIF-1α mRNA 
via a PI3K/Akt/FRAP-dependent pathway (Zhong et al. 2000). The role of activated PI3K is 
thought to alter both the efficiency of HIF-1α mRNA translation and stability of the HIF-1α 
protein. The ability of activated EGFR to affect VEGF expression by both HIF-1-dependent 
and HIF-1-independent mechanisms was elegantly demonstrated by a study using tyrosine 
kinase inhibitors. VEGF expression was significantly downregulated by the tyrosine kinase 
inhibitor gefitinib through inhibition of the PI3K/ Akt pathway. Inhibition of Akt 
phosphorylation had two direct effects, the first being a reduction in synthesis of HIF protein 
by affecting its translation, and secondly preventing phosphorylation of the transcription 
factor Sp1, thus inhibiting transactivation of the promoter sequence of VEGF (Pore et al. 
2006). However to date, there is no available data to support a similar EGFR-mediated 
mechanism in CRC cells. 
The focus of this chapter was to determine whether EGFR signalling exerts a pro-
angiogenic stimulus in CRC. This effect was evaluated by examining the expression of VEGF 
following direct EGFR stimulation in CRC cells, and compared to responses induced by 
hypoxia and hypoxia-mimetics such as DMOG which are known to upregulate VEGF 
expression and would therefore act as internal positive controls. Expressions of HIF-1α and 
HIF-2α will also be evaluated to identify the possibility of underlying EGFR-induced HIF-
dependent mechanisms to account for changes in VEGF expression. 
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3.2 OBJECTIVES 
The objective of this part of the study was to assess the angiogenic responses 
resulting from direct EGFR, hypoxia or DMOG stimulations in two CRC cell lines, each 
derived from different stages of disease. The measured angiogenic responses included 
evaluating expressions of the potent pro-angiogenic mediator VEGF, and the HIF 
transcriptional factors at the transcriptional and protein level. The purpose of this study was to 
examine a potential pro-angiogenic effect induced by EGFR activation through a HIF-
mediated mechanism to promote VEGF release in CRC. Furthermore, the CRC cells were 
also exposed to a combination of EGF and hypoxia or DMOG to explore a possible synergy 
between EGFR activation and HIF-overexpression. The synergistic relationship could 
culminate in a downstream response which would supersede the angiogenic effect exerted by 
either of the stimuli in isolation. 
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3.3 METHODS 
The CRC cell lines Colo 201 and Caco-2, as described in Chapter 2 Section 2.1, were 
used in my study to investigate the pro-angiogenic effects of EGFR stimulation in CRC. 
These cell lines were selected due to their differences in stage and grade of the malignant 
tissue from which the cells originated. Colo 201 cells are poorly differentiated and derived 
from tumour metastases (ascitic fluid) of a patient with advanced CRC. In contrast, Caco-2 
cells which are well to moderately differentiated were derived from a primary colonic tumour 
using explant culture technique. 
CRC cells, depleted of serum overnight, were directly stimulated with EGF, TGF-α 
or IL-1β for Colo 201 cells, whereas Caco-2 cells were stimulated with EGF only. Internal 
positive controls were represented by cells subjected to hypoxia (1% oxygen) in the case of 
Colo 201 cells, or the hypoxia mimetic DMOG (1mM) for Caco-2 cells. In order to explore 
the possible synergy between growth factors and HIF over-expression in mediating a pro-
angiogenic environment, Colo 201 cells were exposed to EGF, TGF-α or IL-1β in 
combination with hypoxia, and Caco-2 cells were stimulated with EGF in combination with 
DMOG. 
The cellular responses to EGF, TGF-α, IL-1β and hypoxic stimuli were determined 
by examining VEGF, HIF-1α and HIF-2α gene expressions. This was performed using 
quantitative PCR technique by 2-ΔΔCt method through the use of SYBR Green as the 
luminescent dye, and complementary primers produced by our laboratory. The genes of 
interests were normalised to ARP as the control gene, and relative fold-changes in 
expressions following stimulations were related to their matched unstimulated samples. The 
protein expressions of HIF-1α and VEGF were also determined by standard sandwich ELISA 
technique using antibodies which are commercially available. Supernatants were extracted 
from individual experiments to determine VEGF protein levels. Since stability of HIF 
proteins are dependent upon oxygen tensions, precautions were taken to minimise 
reoxygenation time following removal of cells from the hypoxic stimulus. Cells were 
immediately lysed with ice-cold lysis buffer containing a cocktail of protease inhibitors and 
time spent to mechanically dissociate cells with scrapers was kept to a minimum. In order to 
control for variations in cell numbers across experiments, the data on HIF protein expression 
from various experiments were expressed as per unit total protein. 
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3.4 RESULTS 
3.4.1 COLO 201 CELL LINE 
Initial experiments aimed to determine the expression of VEGF, HIF-1α and HIF-2α 
mRNA under normoxic condition. Figure 3.1 shows constitutive expression of VEGF, HIF-
1α and HIF-2α mRNA by the Colo 201 cell line. 
Figure 3.1 VEGF, HIF-1α and HIF-2α mRNA expression in Colo 201 cells. 
Positive control used was from human synovial fibroblasts (HSF) and negative control (-) was water. 
Molecular weight was determined by using 1kb ladder as reference: (A) VEGF isoforms - VEGF189 
(561bp) and VEGF165 (489 bp), (B) HIF-1α (194bp), and (C) HIF-2α (443bp) expression by Colo 201 
cells. 
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3.4.1.1 Analysis Of Colo 201 Responses To EGF Stimulation Alone And In 
Combination With Hypoxia: Effect On VEGF And HIFs. 
Goldman et al (Goldman et al. 1993) showed that direct stimulation of EGFR with 
exogenous EGF could induce secretion of VEGF in glioblastoma multiforme. Furthermore, 
Zhong et al (Zhong et al. 2000) demonstrated that EGF was capable of inducing expression of 
HIF-1α protein, HIF-1-dependent transcription activity and VEGF expression in prostate 
cancer cells. However, the pro-angiogenic effect of direct EGF stimulation in CRC remains 
unknown. Experiments were therefore performed on the CRC cell line Colo 201 to determine 
the influence EGF exerts on VEGF, HIF-1α and HIF-2α expression. 
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Figure 3.2 VEGF, HIF-1α and HIF-2α and mRNA expression in Colo 201 cells 
following EGF stimulation 
Colo 201 cells were stimulated with EGF for 6 and 24 hours. (A) VEGF, (B) HIF-1α and (C) HIF-2α 
mRNA expression were determined using SYBR Green with the 2-ΔΔCT method. Results shown 
represent the mean from 3 experiments and are normalised relative to unstimulated controls. 
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Contrary to findings from glioblastoma and prostate cancer cell models (Goldman et 
al. 1993; Zhong et al. 2000), direct EGFR stimulation of Colo 201 cells did not affect VEGF 
expression. Following 6 hours of stimulation at 10ng/mL EGF, the mean relative expression 
of VEGF was 0.90±0.31, and exposure to 100ng/mL EGF did not further affect VEGF 
transcriptional activity (Figure 3.2A). Furthermore, no change was detected in VEGF 
expression after 24 hours of stimulation with EGF. The mean relative expression of VEGF by 
Colo 201 cells following 10ng/mL stimulation was 0.93±0.24 (P > 0.05), and 1.29±0.28 (P > 
0.05) with 100ng/mL (Figure 3.2A). These results were confirmed by corresponding VEGF 
protein analyses. Results from one representative experiment to examine the effect of EGF on 
VEGF protein expression by Colo 201 cells demonstrated EGF had minimal effect on VEGF 
expression (Figure 3.3). Constitutive release of VEGF by the cells was 215pg/mL but 
stimulation of the cells with EGF at 10ng/mL for 24 hours resulted in a slight decrease of 
VEGF to 184pg/mL. Even with 100ng/mL EGF, VEGF expression remained largely 
unchanged yielding a small increase to 247pg/mL. Statistical analysis was not performed due 
to insufficient data. 
Figure 3.3 Effect of EGF stimulation on VEGF protein expression in Colo 201 cells 
Colo 201 cells were stimulated with EGF for 24 hours. VEGF protein expression was determined by 
sandwich ELISA technique and data shown are from a single experiment. Error bars are SD of 
triplicate determinations.  
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Transcription of HIF-1α and HIF-2α genes were also unaffected by exogenous EGF 
stimulation (Figure 3.2B and Figure 3.2C). Following 6 hours of EGF stimulation, Colo 201 
cells stimulated with 10 and 100ng/mL EGF demonstrated no change in HIF-1α mRNA 
levels relative to unstimulated controls (mean fold change of 1.08±0.41 (mean ± SD) and 
1.05±0.57 (P > 0.05) respectively). Similarly at 24 hours, there was no significant difference 
in HIF-1α expression with EGF stimulation, even with 100ng/mL EGF (mean change 
0.93±0.59). HIF-2α expression was downregulated following 6 hours of EGF stimulation 
(0.64±0.02 and 0.78±0.02 with 10 and 100ng/mL EGF stimulation respectively), but the 
change in gene expression was not statistically significant (Figure 3.2C). Even at 24 hours, 
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HIF-2α transcriptional activity remained unaltered in Colo 201 cells following EGF 
stimulation as illustrated by Figure 3.2C. 
To ensure that the absence in downstream responses as demonstrated by my earlier 
experiments was not related to differences in gene transcriptional activity with time, a time-
course experiment was performed. The data from this experiment confirmed that EGF 
stimulation alone did not affect expression of VEGF either at the mRNA or protein level 
(Figure 3.4 and Figure 3.5). However, Colo 201 cells stimulated with hypoxia demonstrated 
significant increase in VEGF mRNA expression. Figure 3.4 shows a time-dependent increase 
in expression of VEGF mRNA under hypoxia, achieving a maximal 10-fold increase in 
VEGF mRNA expression at 24 hours of stimulation. Although the existence of EGFR over-
expression and hypoxia within solid tumours have been confirmed in isolated studies, it is 
unknown whether the co-existence of the two factors within the same tumour environment 
could synergise each other’s effects to exert a potent combined stimulus to drive tumour 
angiogenesis. When Colo 201 cells stimulated with a combination of EGF and hypoxia were 
compared to cells stimulated with either EGF or hypoxia alone, there was no further 
significant increase in VEGF mRNA expression. VEGF protein expression also paralleled our 
mRNA data showing an obvious hypoxia-induced VEGF upregulation in a time-dependent 
manner. Maximal VEGF protein expression was observed at 24 hours of hypoxia stimulation 
(mean of 1130pg/mL for hypoxia versus 226pg/mL for controls). Combined EGF and 
hypoxia stimulation did not result in any further increase in VEGF protein expression, with 
the expression profile of cells subjected to combined stimulation matching that of cells 
stimulated with hypoxia alone (Figure 3.5). 
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Figure 3.4 VEGF mRNA in Colo 201 cells following stimulation with EGF or 
hypoxia alone and in combination 
Colo 201 cells were stimulated with 20ng/mL EGF and/or exposed to hypoxia (1% O2). VEGF mRNA 
expression was determined using SYBR Green with the 2-ΔΔCT method and results shown are 
representative of 2 experiments. Data are mean ± SD. Dashed line shows HIF-1α mRNA under 
normoxic conditions. Statistical significance was tested by two-way ANOVA with Bonferroni post hoc 
correction versus EGF *** p<0.001. 
2 4 6 8 10 24
0
2
4
6
8
10
12
EGF
Hypoxia
Hypoxia + EGF
***
Time (hours)
Ex
pr
es
si
on
ve
rs
us
 c
on
tr
ol
***
 
 
Figure 3.5 VEGF protein in Colo 201 cells following stimulation with EGF or 
hypoxia alone and in combination 
Colo 201 cells were stimulated with 20ng/mL EGF and/or exposed to hypoxia (1% O2). VEGF protein 
expression data are mean ± SD of a sample assayed in triplicate by ELISA and are representative of 2 
experiments. Statistical significance was tested by 2-way ANOVA with Bonferroni post hoc correction 
versus normoxia *** p<0.001 and versus EGF alone †††p<0.001. 
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A study was also conducted to examine the changes in HIF expression as a response 
to EGFR activation and hypoxia over a specified timecourse. The data presented in Figure 
3.6, Figure 3.7 and Figure 3.8 confirm no significant change in HIF-1α mRNA and protein, 
and HIF-2α mRNA expression with EGF stimulation over 24 hours (as seen in Figure 3.2). 
Hypoxia alone resulted in progressive downregulation of HIF-1α expression, with maximal 
0.66-fold difference achieved relative to controls at 24 hours. This pattern was also repeated 
by cells co-stimulated with EGF and hypoxia, where HIF-1α mRNA expression was 
downregulated by 0.63 relative to controls. Direct EGFR stimulation in Colo 201 also did not 
yield significant changes in HIF-1α expression at the protein level. The minimal constitutive 
levels of HIF-1α protein was unaffected by exogenous EGF stimulation, reflecting findings at 
the mRNA level (Figure 3.7). However under hypoxic conditions, Colo 201 cells significantly 
upregulated HIF-1α protein expression by approximately 20-fold, reaching a maximum of 
7.0±0.21 pg per μg of total protein after 6 hours of hypoxia. Co-stimulation of Colo 201 cells 
with hypoxia and EGF did not result in further increase in HIF-1α protein expression. 
Figure 3.6 HIF-1α mRNA in Colo 201 cells following stimulation with EGF or 
hypoxia alone and in combination 
Colo 201 cells were stimulated with 20ng/mL EGF and/or exposed to hypoxia (1% O2). HIF-1α 
mRNA expression was determined using SYBR Green with the 2-ΔΔCT method and results shown are 
representative of 2 experiments. Data are mean ± SD. Dashed line shows HIF-1α mRNA under 
normoxic conditions. 
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Figure 3.7 HIF-1α protein in Colo 201 cells following stimulation with EGF or 
hypoxia alone and in combination 
Colo 201 cells were stimulated with 20ng/mL EGF and/or exposed to hypoxia (1% O2). HIF-1α protein 
data are mean ± SD of a cell lysate sample assayed in triplicate by ELISA and results shown are 
representative of 2 experiments. Statistical significance was tested by 2-way ANOVA with Bonferroni 
post hoc correction versus control ***p<0.001 and versus EGF alone †††p < 0.001. 
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Figure 3.8 HIF-2α mRNA in Colo 201 cells following stimulation with EGF or 
hypoxia alone and in combination 
Colo 201 cells were stimulated with either 20ng/mL EGF and/or exposed to hypoxia (1% O2). HIF-2α 
mRNA expression was determined using SYBR Green with the 2-ΔΔCT and results shown are 
representative of 2 experiments. Data are mean ± SD. Dashed line shows HIF-1α mRNA under 
normoxic conditions. 
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Figure 3.8 confirms exogenous EGF stimulation did not significantly affect HIF-2α 
transcriptional activity, similar to data demonstrated by Figure 3.2C. Contrary to the 
suppressive effect hypoxia imposed on HIF-1α expression, hypoxia appeared to exert a 
stimulatory effect on HIF-2α mRNA. Figure 3.8 shows a steady, time-dependent increase in 
HIF-2α mRNA levels, reaching a maximal two-fold upregulation at 24 hours. A similar (but 
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not additive) effect was seen with cells stimulated with EGF and hypoxia (Figure 3.8). 
In summary, stimulation of Colo 201 cells with EGF in the presence or absence of 
hypoxia over a 24-hour time-course clearly demonstrated that EGF had no effect on VEGF, 
HIF-1α or HIF-2α expression. However, hypoxia had a significant pro-angiogenic effect on 
these cells by significantly upregulating VEGF expression probably through both HIF 
dependent and independent mechanisms. 
3.4.1.2 Analysis Of Colo 201 Responses To TGF-α Stimulation Alone And In 
Combination With Hypoxia: Effect On VEGF And HIFs. 
EGFR is known to bind several other ligands including TGF-α to initiate a series of 
intracellular cascades to transform cells towards sustained proliferation and survival. Since 
stimulation of EGFR with exogenous EGF failed to induce any detectable angiogenic 
responses from Colo-201 cells, TGF-α was used as an alternate ligand to exclude the 
possibility of cell-specific selectivity for binding with its reciprocal ligands. However, the 
responses elicited from Colo 201 cells following TGF-α stimulation in two separate 
experiments were similar to those following EGF stimulation. Stimulation of Colo-201 cells 
with TGF-α overall had no significant effect on the expression of VEGF, HIF-1α and HIF-
2α. VEGF expression remained largely unchanged despite stimulations with 10 and 
100ng/mL TGF-α at both short and long time points (Figure 3.9A). At 6 hours with 10ng/mL 
and 100ng/mL TGF-α, the mean relative VEGF expression was 1.04±0.09 and 1.18±0.39 
versus unstimulated, but this was statistically not significant (P > 0.05). The data from the two 
24 hour experiments with 10ng/mL and 100ng/mL TGF-α illustrate minimal change in VEGF 
expression - mean relative changes were 1.15±0.02, (P > 0.05) and 1.27±0.09 (P > 0.05) 
respectively (Figure 3.9A). 
Stimulation of Colo 201 cells with 10 and 100ng/mL TGF-α for 6 hours lead to 
statistically non-significant differences in HIF-1α expression of 0.9 and 1.75-fold change 
relative to unstimulated controls. When Colo 201 cells were subjected to longer stimulation 
period of 24 hours, there were still no differences in HIF-1α mRNA expression with both 
10ng/mL and 100ng/mL TGF-α (Figure 3.9B). Exogenous TGF-α stimulation of Colo-201 
cells also had minimal effect on HIF-2α gene transcriptional activity (Figure 3.9C). Mean 
relative fold changes of 0.83±0.08 and 1.47±0.12 were observed following 6 hours of 
stimulation with 10 and 100ng/mL TGF-α respectively, and none of these results were 
statistically significant. The 24 hour experiments also showed no significant change in HIF-
2α expression with 10ng/mL TGF-α, recording a mean relative fold change of 0.98±0.08 (P > 
0.05) and 1.40±0.11 relative fold change with 100ng/mL TGF-α. 
84 
MD (Res) Thesis Tak Loon Khong 
Chapter 3 
Figure 3.9 VEGF, HIF-1α and HIF-2α mRNA expression in Colo 201 following 
TGF-α stimulation 
Colo 201 cells were stimulated with TGF-α for 6 and 24 hours. (A) VEGF (B) HIF-1α and (C) HIF-2α 
mRNA expression were determined using SYBR Green with the 2-ΔΔCT method. Results shown 
represent the mean from 2 experiments and are normalised relative to controls. 
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Figure 3.10 HIF-1α protein in Colo 201 cells following EGFR stimulation with EGF 
or TGF-α or hypoxia for 24 hours 
Colo 201 cells were stimulated with 100ng/mL EGF or TGF-α  or exposed to hypoxia for 24 hours. 
HIF-1α protein expression was determined using ELISA and data are mean ± SEM of a sample 
assayed in triplicate by ELISA and are representative of 3 separate experiments. Statistical significance 
was tested by one-way ANOVA with Bonferroni post hoc correction versus control *** p<0.001. 
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To establish whether EGFR activation has an independent role in modulating the 
stability or production of the HIF-1α protein, HIF-1α protein expression was measured by 
ELISA following 24 and 48 hours of TGF-α or EGF stimulation. Neither EGF or TGF-α  
resulted in significant alteration in HIF-1α protein expression. At 24 hours, mean HIF-1α 
protein expression was 0.078 and 0.055 pg per μg protein following TGF-α and EGF 
stimulations respectively, versus 0.091pg per μg protein in the unstimulated control group. 
Colo 201 cells however demonstrated a significant response to hypoxia, where HIF-1α 
protein expression was increased by approximately 5-fold following hypoxia stimulation 
compared to unstimulated cells (Figure 3.10). Even with 48 hours of EGFR stimulation, there 
was still no significant change in HIF-1α protein expression. The measured mean HIF-1α 
protein levels were 0.044±0.004 and 0.070±0.024pg per μg total protein following TGF-α 
and EGF stimulations respectively (Figure 3.11), compared to 0.030±0.015pg HIF-1α per μg 
total protein in unstimulated controls. Hypoxia still remained the domineering regulatory 
factor of HIF-1α protein expression in Colo 201 cells, as HIF-1α level was approximately 40-
fold higher in hypoxia-stimulated compared to control cells. 
Western blotting for HIF-1α (Figure 3.12) following 24 hours of TGF-α stimulation 
confirmed my ELISA results, where additional TGF-α resulted in marginal change in the 
intensity of the HIF-1α band. However under hypoxia, there was a marked increase in HIF-
1α protein content as illustrated by an intense vivid band. When the cells were co-stimulated 
with TGF-α under hypoxia, the intensity of the band was reduced indicating that additional 
TGF-α stimulation may decrease expression of HIF-1α protein, but this immunoblot is 
representative of one experiment. 
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Figure 3.11 HIF-1α protein expression in Colo 201 cells following EGFR stimulation 
with EGF or TGF-α hypoxia for 48 hours 
Colo 201 cells were stimulated with 100ng/mL EGF or TGF-α for 48 hours. HIF-1α protein expression 
was determined using sandwich ELISA technique and data are mean ± SD of a sample assayed in 
triplicate by ELISA and are representative of 1 experiment. Statistical significance was tested by 1-way 
ANOVA with Bonferroni post hoc correction versus control *** p<0.001. 
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Figure 3.12 Western blot for HIF-1α protein in Colo 201 cells following TGF-α 
stimulation, hypoxia and a combination 
Colo 201 cells were stimulated with 100ng/mL TGF-α, hypoxia or a combination of TGF-α and 
hypoxia for 24 hours. Cell lysates were resolved on polyacrylamide gel, transferred onto PVDF 
membrane and incubated with mouse anti-human HIF-1α antibodies. Following incubation with 
biotinylated secondary anti-mouse antibody, HRP-conjugated chemiluminescence agent was applied 
onto the membrane and exposed to X-ray film for 24 hours. 
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3.4.1.3 Analysis Of Colo 201 Responses To IL-1β Stimulation Alone And In 
Combination With Hypoxia: Effect On VEGF And HIFs. 
Despite stimulating EGFR with increasing concentrations of EGF and TGF-α over 
prolonged periods of stimulation, there was no significant change in expression of VEGF, 
HIF-1α, or HIF-2α. Colo 201 cells were therefore stimulated with an EGFR-independent 
stimulus, with the pro-inflammatory cytokine IL-1β. These experiments were aimed at 
uncovering a research area which still remains unexplored, as it is still unknown whether IL-
1β has a pro-angiogenic effect on Colo 201 cells. Furthermore, it would be invaluable to 
evaluate the relative importance of EGFR-related angiogenic signals relative to angiogenic 
signals induced by a pro-inflammatory stimulus in CRC. 
Colo 201 cells demonstrated a positive response to exogenous IL-1β stimulation by 
upregulating VEGF mRNA expression, as illustrated by Figure 3.13A. However, although the 
trend supported an IL-1β stimulatory effect on VEGF expression, the overall changes were 
not statistically significant. Following 6 hours of 10 and 100ng/mL IL-1β,  VEGF expression 
was increased by mean of 1.75±1.02 (P > 0.05) and 1.48±0.58 fold relative to controls. At 24 
hours, although VEGF mRNA levels remained elevated following IL-1β stimulation, the 
differences were marginal, with cells treated with 10 and 100ng/mL IL-1β demonstrating 
mean fold changes of 1.79±1.02 and 1.95±1.42 relative to unstimulated controls. A time-
course experiment examining VEGF protein expression over 24 hours with IL-1β stimulation 
confirmed data from the gene expression studies. Figure 3.14 shows Colo 201 cells 
constitutively expressed VEGF protein, resulting in a linear rise in protein levels from 
80pg/mL to 667pg/mL over 24 hours. Stimulation with IL-1β alone did not alter VEGF 
expression between 2–10 hours, although a potential downregulatory response was 
demonstrated between 10–24 hours following stimulation. However, Colo 201 cells were 
highly responsive to hypoxia by steady and significant upregulation in VEGF protein 
expression over the studied timecourse. VEGF protein expression reached a peak of 
1200pg/mL with 24 hours of hypoxia, which was approximately two-fold higher compared to 
unstimulated controls. Additional IL-1β however did not further modulate the responses of 
Colo 201 cells to hypoxia, as VEGF expression for combined stimulation with hypoxia and 
IL-1β mirrored that of hypoxia alone. 
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Figure 3.13 VEGF, HIF-1α and HIF-2α and mRNA expression in Colo 201 following 
IL-1β stimulation 
Colo 201 cells were stimulated with IL-1β for 6 and 24 hours. (A) VEGF, (B) HIF-1α, (C) HIF-2α and 
mRNA expression were determined using SYBR Green with the 2-ΔΔCT method. Results shown 
represent the mean from 3 experiments and expression levels are normalised relative to controls. 
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Figure 3.14 VEGF protein expression in Colo 201 cells following stimulation with IL-
1β or hypoxia alone and in combination 
Colo 201 cells were stimulated with 10ng/mL IL-1β and/or exposed to hypoxia (1% O2). VEGF protein 
expression data are mean ± SD of a sample assayed in triplicate by sandwich ELISA and are 
representative of 2 experiments. Statistical significance was tested by two-way ANOVA with 
Bonferroni post hoc correction versus control *** p<0.001, and versus IL-1 alone ††† p<0.001. 
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Further analyses into alternate effects mediated by IL-1β confirmed HIF-1α mRNA 
and protein, and HIF-2α mRNA, were generally unaffected by exogenous IL-1β stimulation. 
Colo 201 cells demonstrated minimal response to 6 hours of stimulation with 10 and 
100ng/mL IL-1β as shown by Figure 3.13B and Figure 3.13C. However when cells were 
stimulated for 24 hours, the observed trend in HIF-1α expression was towards a modest rise 
in HIF-1α mRNA levels in stimulated samples compared to controls (Figure 3.13B). The 
mean fold difference in HIF-1α mRNA levels were 1.62±0.75 and 2.49±0.49 relative to 
unstimulated controls in cells stimulated with 10 and 100ng/mL respectively. However, 
neither of these observed differences in HIF-1α gene transcription were statistically 
significant (P > 0.05). There was also marginal but consistent increase in HIF-2α mRNA 
expression following 24 hours of IL-1β stimulation. Colo 201 cells exposed to 10 and 
100ng/mL of IL- 1β demonstrated 1.56±0.41 and 1.59±0.59 relative fold change in HIF-2α 
expression respectively (Figure 3.13C), but again none of these observed changes were 
statistically significant. 
Although the mRNA data showed no significant change in HIF-1α transcriptional 
activity following IL-1β stimulation, alternate downstream cellular activities such as 
translational and post-translational processes could potentially be affected thus modulating 
HIF-1α protein expression. HIF-1α protein levels were therefore determined by ELISA 
following 24 and 48 hours of IL-1β stimulation. Despite the apparent induction in HIF-1α 
mRNA expression by 100ng/mL IL-1β (Figure 3.13B), the corresponding protein expression 
remained largely unchanged and levels were comparable to unstimulated controls at 6, 24 and 
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48 hours of IL-1β stimulation (Figure 3.15). In contrast, Colo 201 cells demonstrated a 
significant response to hypoxia by upregulating HIF-1α protein expression by 6-fold relative 
to unstimulated controls. HIF-1α protein expression peaked at 1.1pg HIF-1α per μg total 
protein at 6 hours of hypoxia, and steadily fell over the subsequent 48 hours to approximately 
0.40pg HIF-1α per μg total protein. Additional stimulation with IL-1β however did not 
further modulate the hypoxic response in Colo 201 cells at all three measured timepoints 
(Figure 3.15). 
Figure 3.15 HIF-1α protein expression in Colo 201 cells following IL-1β stimulation 
alone or in combination with hypoxia 
Colo 201 cells were stimulated with 100ng/mL IL-1β. HIF-1α protein expression was determined 
using ELISA and data are mean ± SD of a sample assayed in triplicate by ELISA and are representative 
of 1 experiment. Statistical significance was tested by 2-way ANOVA with Bonferroni post hoc 
correction versus control *** p<0.001, and versus IL-1β alone †††p<0.001. 
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3.4.2 CACO-2 CELL LINE 
The experiments on Colo 201 did not reveal significant modifications in HIFs and 
VEGF expression in response to direct EGFR stimulation. The absence of such responses to 
EGFR stimulation could have been a cell-specific characteristic of Colo 201 cells, given that 
these poorly differentiated cells originated from metastatic ascites of a human in advanced 
stages of the disease. In order to confirm that the responses elicited from Colo 201 were not 
specific to that particular cell type, similar experiments were performed on Caco-2 cells. 
Initial experiments performed on Caco-2 aimed to determine the expression of VEGF, HIF-
1α, and HIF-2α under normoxic condition. Figure 3.16 shows constitutive expression of 
VEGF, HIF-1α and HIF-2α in the Caco-2 cell line.  
Figure 3.16 VEGF, HIF-1α and HIF-2α mRNA expression in Caco-2 cells 
Positive control used was from human synovial fibroblasts (HSF) and negative control (-) used was 
water. Molecular weight was determined by using 1kb ladder as reference: (A) VEGF 165 – 183bp (B) 
HIF-1α − 194bp, and (C) HIF-2α – 190bp. 
     
(A) (B) (C) 
3.4.2.1 Analysis Of Caco-2 Responses To EGF Stimulation Alone And In 
Combination With Hypoxia Mimetic, Dimethyloxalylglycine: Effect On 
VEGF And HIFs  
Since Goldman et al (Goldman et al. 1993) showed that direct stimulation of EGFR 
with exogenous EGF could induce secretion of VEGF in glioblastoma multiforme, the aim of 
this part of the study was to establish whether a similar response exists in Caco-2 cells. This 
response was however unlikely to be due to modifications in VEGF gene transcriptional 
activity in Caco-2, as VEGF mRNA expression remained generally unchanged following 
exogenous EGFR stimulation (Figure 3.17). In contrast, Caco-2 cells were highly responsive 
to DMOG-induced HIF overexpression by significantly upregulating VEGF mRNA and 
protein. Since 2-oxoglutarate is an essential co-factor for prolyl-hydroxylase activity, 
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competitive inhibition by DMOG prevented hydroxylation of HIFs, thus the resultant 
accumulation in HIFs activated the classical adaptive responses mimicking that of hypoxia. 
As illustrated by Figure 3.17, DMOG treatment resulted in a steady increase in VEGF gene 
expression to a maximal mean of 8.3-fold relative to controls at 6-hours following 
stimulation. This VEGF upregulation was sustained even at 24 hours following DMOG 
stimulation. Although stimulation of cells with EGF alone did not affect VEGF gene 
expression, VEGF mRNA expression was higher in Caco-2 cells stimulated with combined 
EGF and DMOG compared to DMOG alone. This trend was particularly well demonstrated 
between 2 and 6 hours of combined stimulation compared to DMOG alone, with maximal 
difference in VEGF responses achieved at 4 hours following stimulation (3.97 fold versus 
6.55 relative fold difference compared to controls respectively). Maximal upregulation of 
VEGF gene expression was detected at 6 hours with combined DMOG and EGF stimulation 
compared to controls, and this additive effect subsequently diminished from 6 hours onwards 
as illustrated by Figure 3.17. The additive effect of combined stimulations however was not 
statistically significant when compared to gene expression by cells stimulated with DMOG 
alone. 
Figure 3.17  VEGF mRNA following stimulation with EGF or hypoxia alone and in 
combination in Caco-2 cells 
Caco-2 cells were stimulated with 20ng/mL EGF and/or DMOG (1mM). VEGF mRNA expression was 
determined using SYBR Green with the 2-ΔΔCT method and results shown are representative of 3 
experiments. Data are mean ± SD. Dashed line shows VEGF mRNA under normoxic conditions. 
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Figure 3.18 VEGF protein in Caco-2 cells following stimulation with EGF or DMOG 
alone and in combination 
Caco-2 cells were stimulated with 20ng/mL EGF and/or exposed to hypoxia (1% O2). VEGF protein 
expression data are mean ± SD of a sample assayed in triplicate by ELISA and are representative of 2 
experiments. Statistical significance was tested by 1-way ANOVA with Bonferroni post hoc correction 
versus appropriate time-point control * p<0.05, ** p<0.01 and *** p<0.001. 
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One of the most significant findings of the study was revealed during my 
investigation into the expression of VEGF protein by Caco-2 cells following EGF stimulation. 
In contrast to mRNA data, EGF stimulation alone resulted in significant upregulation in 
VEGF protein expression which was comparable, and to a certain extent, better than the 
responses seen with the hypoxia-mimetic DMOG alone (Figure 3.18). At 6 hours following 
stimulation with EGF, there was a statistically significant 1.6 fold increase in VEGF protein 
expression compared to controls (mean VEGF protein levels of 725.4pg/mL versus 
454.8pg/mL respectively; p < 0.05). This significant upregulation was also seen at 24 hours, 
where mean VEGF protein expression was 1712pg/mL in EGF stimulated cells compared to 
1286pg/mL in unstimulated cells. This response was markedly different to the gene 
expression data as illustrated by Figure 3.17, where there was minimal change in VEGF gene 
expression relative to corresponding controls following EGF stimulation alone. 
Another difference highlighted by our VEGF protein data is the rather modest 
response of VEGF protein expression during the early phases of DMOG stimulation. The 
mean increase in VEGF protein levels in DMOG treated cells, although higher than controls 
at 6 hours, was statistically not significant (665.7pg/mL versus 454.8pg/mL respectively). 
This lack of statistical significance in VEGF protein levels was also observed in Caco-2 cells 
stimulated with combined DMOG and EGF. These findings are in marked contrast to VEGF 
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gene expression which showed mRNA levels reaching a peak, with mean of 8.4-fold increase 
in VEGF mRNA expression at 6 hours following DMOG stimulation. However, VEGF 
protein expression was significantly increased at 24 hours following stimulation with DMOG 
and this was further enhanced with combined EGF and DMOG stimulation. The response of 
Caco-2 cells to DMOG stimulation paralleled that of EGF stimulation, where there was a 
statistically significant 1.3 fold increase in VEGF protein expression relative to controls 
(1674pg/mL versus 1286pg/mL respectively). The combined stimulation of DMOG and EGF 
resulted in a further increase in VEGF protein expression to a mean of 1868pg/mL, 
representing a 1.5 fold increase compared to controls. However, when compared to DMOG 
alone, the further increase in VEGF following combined stimulation was not statistically 
significant as determined by one-way ANOVA with Bonferroni's Multiple Comparison Test. 
Since VEGF studies revealed several critical differences in intrinsic cell behaviour 
between Caco-2 and Colo 201 cells specific to EGFR stimulation, studies were performed to 
elucidate effects of EGFR activation on expression of HIFs. HIF-1α gene expression in Caco-
2 cells remained generally unchanged following 2 to 10 hours of EGF stimulation compared 
to unstimulated cells. Figure 3.19 which shows expression of HIF-1α relative to untreated 
control cells highlights a general inhibitory effect mediated by all three different treatments 
on HIF-1α transcription. EGF stimulation alone lead to 0.8-fold relative change in HIF-1α 
expression, whereas DMOG stimulated cells demonstrated consistent and progressive 
decrease in HIF-1α mRNA expression relative to controls over the 24 hour study period. The 
earliest sign of HIF-1α gene transcriptional inhibition by DMOG was apparent at 4 hours 
following stimulation, and such inhibitory effect was consistently maintained resulting in 
maximal 0.66-fold downregulation in HIF-1α expression at 24 hours. Addition of EGF 
abrogated the DMOG-mediated suppression of HIF-1α transcriptional activity during the 
earlier phases of treatment. However, the downregulatory effect of combined DMOG and 
EGF on HIF-1α gene expression was only apparent after 6 hours of stimulation, where 
triplicate experiments revealed a consistent relative reduction in HIF-1α gene expression of 
0.83 fold (0.83, 0.84, 0.81 fold change versus control) at 10 hours. Furthermore, the 
downregulation was consistently maintained, eventually resulting in 0.47-fold decrease in 
HIF-1α gene expression (0.54, 0.24 and 0.64 fold change relative to unstimulated controls) at 
24 hours following combined EGF and DMOG. 
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Figure 3.19 HIF-1α mRNA following stimulation with EGF or DMOG alone and in 
combination in Caco-2 cells 
Caco-2 cells were stimulated with 20ng/mL EGF and/or DMOG (1mM). HIF-1α mRNA expression 
was determined using SYBR Green with the 2-ΔΔCT method and results shown are representative of 3 
experiments. Data are mean ± SD. Dashed line shows HIF-1α mRNA under normoxic conditions. 
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Figure 3.20 HIF-1α protein in Caco-2 cells following stimulation with EGF or 
DMOG alone and in combination 
Caco-2 cells were stimulated with 20ng/mL EGF and/or DMOG (1mM). HIF-1α protein data are mean 
± SD of a cell lysate sample assayed in triplicate by ELISA and results shown are representative of 3 
experiments. 
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As previously demonstrated in my VEGF studies, EGFR stimulation may not 
necessarily rely upon modulating gene transcriptional mechanisms to mediate its effects, but 
rather exerts its primary effect through regulation of downstream cellular processes to affect 
expression of proteins. Therefore further studies were conducted into elucidating expression 
of intracellular HIF-1α protein to identify potential translational and post-translational 
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mechanisms which may be altered by EGFR stimulation. HIF-1α protein analysis 
demonstrated a consistent upregulation in HIF-1α protein expression following EGF 
stimulation. Although the detected increase in HIF-1α protein expression was relatively 
modest, the trend was preserved at each of the specified time intervals over a 24-hour period 
as illustrated by Figure 3.20. The stimulatory effect of EGF is further demonstrated by Figure 
3.21 where the focus is on comparing the relative change during maximal HIF-1α protein 
expression at 6 hours of stimulation. As mentioned previously, the differences in HIF-1α 
protein expression between control and EGF stimulated cells were subtle but consistent, and a 
paired t-test confirmed that the difference was significant (p<0.001).  
Caco-2 cells stimulated with DMOG demonstrated an average of 16.7-fold (over 24 
hours) higher HIF-1α protein levels compared to unstimulated controls. Figure 3.20 shows 
HIF-1α protein expression was significantly higher at 2 hours following DMOG stimulation, 
with progressive rise in intracellular HIF-1α over time, reaching a peak of 2.32pg/μg at 6 
hours following DMOG stimulation. This finding represents a maximal 21-relative fold 
increase in HIF-1α protein expression compared to corresponding unstimulated controls. 
Combined EGF and DMOG enhanced the upregulation in HIF-1α protein expression further, 
and the difference in HIF-1α levels was most prominent at its peak at 6 hours, and also during 
the early phase of its progressive fall within 10 hours following stimulation (Figure 3.20). At 
the peak of HIF-1α expression, DMOG and EGF stimulation resulted in maximal 24-fold 
upregulation in HIF-1α protein expression compared to unstimulated controls (0.11pg/μg 
versus 2.35pg/μg versus 2.63pg/μg; control versus DMOG alone versus DMOG and EGF 
respectively). This compares to 21-fold upregulation in HIF-1α protein expression following 
6 hours of DMOG stimulation alone. The enhanced stimulatory effect of EGF and DMOG 
lasted for 10 hours following stimulation, and the effect progressively diminished as HIF-1α 
protein levels gradually drifted towards normal levels. 
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Figure 3.21 Effect of EGF alone or with DMOG on HIF-1α protein in Caco-2 cells 
Caco-2 cells were stimulated for 6 hours with 20ng/mL EGF and/or DMOG (1mM). HIF-1α protein 
was assayed in triplicate by ELISA. Results are paired from 6-8 comparable experiments, and were 
assayed by paired-t-test: ***p<0.001 versus control and †††p < 0.001versus DMOG alone. 
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Figure 3.22 HIF-2α mRNA following stimulation with EGF or hypoxia alone and in 
combination in Caco-2 cells 
Caco-2 cells were stimulated with 20ng/mL EGF and/or DMOG (1mM). HIF-2α mRNA expression 
was determined using SYBR Green with the 2-ΔΔCT method and results shown are representative of 3 
experiments. Data are mean ± SD. Dashed line shows HIF-2α mRNA under normoxic conditions. 
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Although HIF-1α and HIF-2α share the homologous oxygen dependent regulatory 
mechanism, there is emerging evidence that HIF isoforms may be regulated differently by 
exogenous growth factors or cytokines to mediate varying and distinctive functional roles in 
mediating downstream responses. The results from the HIF-2α gene expression study clearly 
demonstrate a distinctive difference in HIF regulation following EGFR stimulation. HIF-2α 
gene expression showed an initial mean marginal increase of 1.4 fold relative to control at 2 
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hours (Figure 3.22), which was subsequently followed-on by a sustained downregulation in 
HIF-2α gene expression ranging between 0.57 to 0.70 fold relative to controls over the 
observed time intervals. This result is in marked contrast to our HIF-1α data showing 
minimal change in HIF-1α gene expression following EGF stimulation over the same 
observed time intervals. However, with DMOG stimulation alone, there was a 
downregulatory pattern observed in HIF-2α gene responses similar to that seen in HIF-1α 
gene expression. Stimulation of the Caco-2 cells with DMOG stimulation alone lead to a 
consistent time-dependent downregulation in HIF-2α mRNA expression ranging between 
0.87 to 0.53 relative to controls, with maximal downregulation reached at 10 hours post 
DMOG stimulation. The addition of EGF to DMOG in combination lead to a further and 
more consistent downregulation in HIF-2α gene expression compared to if either stimulant 
was used alone. This was particularly evident at the 6 and 10 hour timepoint, where 
combination of EGF and DMOG exerted the most prominent downregulatory effect (mean 
0.55 and 0.46-fold downregulation in HIF-2α expression relative to controls). This compares 
to a mean downregulation of 0.61 and 0.70 with EGF stimulation alone, and 0.74 and 0.54 
with DMOG stimulation alone at the 6- and 10-hour post stimulation time interval 
respectively. 
Figure 3.23 Caco-2 cell counts following 24 hours of EGF ± DMOG stimulation 
Caco-2 cells were stimulated with EGF and/or DMOG for 24 hours as previously described. 
Supernatants were extracted and 0.25% trypsin was used to detach the adherent Caco-2 cells. Full 
culture medium enriched with serum was added at completion of the detachment process to neutralise 
effects of trypsin. Following centrifugation of the cell suspension, cells were resuspended in 1mL 
Hank’s solution and counted on a haemocytometer. 
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Since EGF enhances cellular growth and proliferation of epithelial cells, this 
mitogenic effect may act as a confounding variable to account for the observed increased 
VEGF and HIF protein following EGF stimulation in Caco-2 cells. In order to exclude this 
possibility, cell counts were performed at the end of the stimulatory studies to determine total 
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number of Caco-2 cells for each experimental condition. Figure 3.23 confirms that cell counts 
were not significantly different between the different treatment groups. Cell numbers from the 
EGF alone and combined EGF and DMOG groups were comparable to unstimulated controls. 
Although there was a decrease in cell numbers noted following DMOG stimulation, this 
difference was not significant. 
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3.5 DISCUSSION 
Emphasis has recently been placed on developing novel agents which target critical 
biological systems that underlie the deregulated cellular proliferation which is native to 
cancers. The EGFR antagonist cetuximab was amongst the first of such targeted therapies to 
be developed, based on the considerable mitogenic effect EGFR signalling exerts in various 
solid tumours. In addition to its direct involvement in regulating cell cycle progression, 
hyperactivation of the EGFR pathway may also enhance tumour growth, survival and 
metastasis by modulating angiogenesis in the tumour environment. The evidence stems from 
studies performed on glioblastoma (Goldman et al. 1993; Maity et al. 2000) and squamous 
cell carcinoma (Hirata et al. 2002) where EGFR stimulation resulted in increased secretion of 
VEGF. By translating this discovery to CRC xenograft studies, EGFR inhibitors in the form 
of monoclonal antibodies or EGFR-selective tyrosine kinase inhibitor such as gefitinib has 
been shown to exert antitumour and antiangiogenic activities in CRC (Ciardiello et al. 1996; 
Ciardiello et al. 2001). The earliest report providing robust supporting data for a direct 
correlation between EGFR signalling and CRC angiogenesis was derived from a study by 
Ciardello, where CRC cells treated with gefitinib exhibited a dose- and time-dependent 
inhibition in VEGF expression (Ciardiello et al. 2001). However gefitinib, although often 
referred to as a "specific" or "selective" inhibitor of EGFR, also inhibits activity of other 
intracellular transmembrane tyrosine-specific protein kinases at similar concentrations (Cohen 
et al. 2004). This may have therefore introduced confounding variables to the study, as the 
observed downregulation in VEGF expression may have been attributed to inhibition of other 
signalling pathways. My study therefore subjected two CRC cell lines at different stages of 
differentiation to direct and selected stimulation of EGFR with EGF and TGF-α, with an aim 
to uncover a potential role for EGFR to promote angiogenesis in CRC. 
The angiogenic response of Colo 201 cells to EGFR stimulation was determined by 
measuring mRNA and protein levels of VEGF, since it is recognised as a potent 
proangiogenic growth factor which is central to the development of tumour vascularity by 
activating the proangiogenic switch. EGFR stimulation with either EGF or TGF-α failed to 
elicit significant alterations in VEGF transcriptional or translational activity, even with 
exposure to high concentrations of ligand for periods lasting up to 24 hours. VEGF protein 
levels remained unchanged even following 48 hours of EGF or TGF-α stimulation relative to 
controls, dismissing a possible delayed VEGF response as a consequence of post-translational 
modifications. The absence of an angiogenic response to exogenous EGF stimulation in Colo 
201 cells could be attributed to a masking effect imparted by added growth factors including 
EGF through supplementation of culture medium with bovine serum. An attempt was 
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therefore made to quantify EGF concentrations within 10% serum supplemented culture 
medium using a commercially available ELISA kit, but the test failed to identify quantifiable 
amounts of EGF within the culture media (results not shown). It is possible that serum 
products do not contain EGF above the lowest detection limit of the assay of 3.9pg/mL, but 
given that human EGF serum levels have been reported to range from 0.55 to 1.5ng/mL, this 
would be unlikely (Ibelgaufts 2007). The EGF ELISA may also have limitations in 
identifying bovine isoforms of EGF due to potential variations in epitopes expressed by 
different species. 
Parallel studies performed with Caco-2 cells uncovered several critical functions of 
activated EGFR in modulating cell behaviour, notably in its ability to upregulate VEGF 
protein expression in response to exogenous EGF stimulation. EGF stimulation alone resulted 
in significant upregulation in VEGF protein expression which was comparable, and to a 
certain extent, better than the responses seen with the hypoxia-mimetic DMOG. The 
consistent increase in VEGF protein production induced by EGF stimulation is a reflection of 
an EGFR-mediated activation of VEGF translational or post-translational activity, as VEGF 
mRNA remained unchanged. EGF has been shown to induce VEGF protein secretion in 
glioblastoma cells (Goldman et al. 1993) primarily through transcriptional regulation which is 
dependent upon an EGFR/Ras/PI3K signaling pathway to affect VEGF promoter activity 
(Maity et al. 2000). VEGF protein expression has also been shown to be regulated at the 
transcriptional level by EGFR through recruitment of activated Sp1 to bind and induce VEGF 
promoter activity in squamous cell carcinoma (Pore et al. 2006). Furthermore, VEGF gene 
transcription could also be indirectly modulated by EGFR signalling by increasing HIF-1α 
protein synthesis through an EGFR/PI3K/Akt/FRAP pathway (Laughner et al. 2001; Fukuda 
et al. 2002). However, none of these published data would account for the increased VEGF 
protein expressed by Caco-2 cells in response to direct EGFR stimulation as observed in my 
experiments. In a study to examine the relationship between overexpression of ras and VEGF 
expression in intestinal epithelial cells, Rak et al (Rak et al. 2000) also discovered that VEGF 
mRNA did not always correlate with VEGF protein levels. The discrepancy was due to a 
post-transcriptional effect imposed by reactive oxygen intermediates (Irani et al. 1997) to 
upregulate VEGF protein expression in response to overactivated ras signaling. There are 
therefore several possible post-transcriptional regulatory mechanisms which could alter 
VEGF gene translation, the first through function of internal ribosomal entry sites (Akiri et al. 
1998), or by modulating translational activity of the eIF-4E protein (Kevil et al. 1996). Since 
neither of these pathways has been investigated to determine their involvement in promoting 
VEGF translational activity in response to EGFR stimulation, this would present an 
interesting field to pursue in future work. 
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HIF has been linked to pro-angiogenic states in various disease processes including 
malignancies, rheumatoid arthritis and diabetic retinopathy. Since its inception as a core 
regulator of cell metabolism in order to adapt to hypoxic stress (Semenza 1999), HIF has also 
been discovered to function as a mediator for growth factors, such as insulin-like growth 
factor 2 (Feldser et al. 1999; Fukuda et al. 2002), EGF, TGF-α (Richard et al. 2000; Garcia 
2006), vascular hormones (Gorlach et al. 2001), and cytokine signalling, for example IL-1β, 
TNF-α (Hellwig-Burgel et al. 1999). EGFR has been shown in several studies to affect 
tumour angiogenesis by modulating HIF-1α expression (Zhong et al. 2000; Laughner et al. 
2001; Pore et al. 2006), but this relationship is not defined in CRC. My study showed a 
significant disparity in HIF expression between Colo 201 and Caco-2 cells following EGF 
stimulation. Unlike Colo 201 cells which failed to demonstrate any response to EGFR 
stimulation, Caco-2 cells demonstrated a consistent upregulation in HIF-1α protein 
expression with EGFR stimulation. Although the detected increase in HIF-1α protein 
expression was relatively modest, the trend was statistically significant at each of the 
specified time intervals over the studied 24-hour period. Gene transcription studies did not 
identify significant change in HIF-1α mRNA, therefore the regulation of HIF-1α expression 
by EGFR was primarily at the protein level through translational and post-translational 
modifications of the protein. Similar findings were reported in a study on breast cancer cells, 
where HER2 signalling specifically induced HIF-1α protein expression without affecting 
HIF-1α mRNA (Laughner et al. 2001). This induction process required activation of the 
PI3K/Akt/FRAP pathway to modulate the 5’ untranslated region (5’-UTR) of HIF-1α mRNA 
to increase rate of protein synthesis. This result was supported by inhibitory studies on 
squamous carcinoma cells, where translation of HIF-1α was dampened by EGFR-inhibition 
in a PI3K-dependent manner to decrease expression of HIF-1α protein (Pore et al. 2006). 
These studies clearly demonstrate EGFR is capable of regulating VEGF expression through 
an indirect pathway involving HIF-1α, but the absence of VEGF transcriptional activation in 
my Caco-2 experiments rejects an active role of HIF in modulating VEGF protein expression. 
Nevertheless HIF is capable of transactivating a myriad of genes, several of which are potent 
inducers of angiogenesis, therefore it is unlikely that HIF has an absolute redundant role in 
mediating downstream events following EGFR signalling in CRC. 
Hypoxic regions within cancers exist due to imbalance between oxygen consumption 
by metabolically active cells undergoing uncontrolled cellular division, and oxygen delivery 
via morphologically and functionally abnormal tumour blood vessels. Appreciation for 
tumour hypoxia is important because such tumours are more resistant to treatment, and the 
significant stress of hypoxia selects for more aggressive subpopulations of cancer clones 
which have a propensity to metastasise early. In my study, hypoxia and DMOG were the most 
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consistent stimuli to induce an angiogenic response from Colo 201 and Caco-2 cells. Colo 
201 cells demonstrated significant time-dependent upregulation in both VEGF mRNA and 
protein expression with hypoxia stimulation. The steady increase in VEGF expression over 
time could in part be attributed to induction of VEGF transcriptional activity by increased 
HIF-1α binding, as HIF-1α protein was concomitantly upregulated by hypoxia to achieve a 
maximal expression of 20-fold relative to controls. HIF-1α protein expression achieved its 
peak at 6 hours of hypoxia stimulation, and despite demonstrating a gradual fall in its 
expression over the subsequent 18 hours, VEGF continued to rise in a linear fashion. This 
implies the presence of an alternate HIF-independent mechanism by which VEGF expression 
is induced under hypoxia. An alternate hypoxia response mechanism which is independent of 
HIF was discovered through studies using HIF-1α knockout embryos, which demonstrated 
the ability to mount a significant, albeit reduced induction of VEGF in response to hypoxia 
(Levy et al. 1996). It has also been shown that the VEGF promoter can be induced by hypoxia 
when canonical HREs are mutated or deleted in human cancer cells (von Marschall et al. 
2001). A detailed study to elucidate the underlying mechanisms revealed two HIF-
independent pathways, the first implicates activated K-ras signalling, and the second involves 
induction of the PI3K/ Rho/ ROCK signalling pathways (Mizukami et al. 2006). 
Caco-2 cells were stimulated with the hypoxia mimetic DMOG, since exposure of 
these cells to hypoxia induced marked cell death. Caco-2 stimulated with DMOG also 
consistently upregulated both VEGF mRNA and protein in response to HIF overexpression. 
However, there was a marked difference in VEGF mRNA expression profiles between the 
two CRC cell lines. Rather than a linear and progressive increase in VEGF expression with 
time as demonstrated by Colo 201 cells, the rate at which VEGF mRNA increased during the 
initial phase was significantly more rapid in Caco-2 cells. Peak VEGF expression was 
achieved at 6 hours following DMOG stimulation in Caco-2 cells (opposed to 24 hours in 
Colo 201), and this was accompanied by a plateau phase in the subsequent 18 hours, during 
which VEGF mRNA expression remained approximately 7-fold higher relative to controls at 
a steady-state. This trend in VEGF expression directly correlated with the expression pattern 
of HIF-1α protein, therefore the evidence suggests that VEGF upregulation following DMOG 
stimulation is predominantly mediated by HIF. 
Since DMOG functions to selectively inhibit PHD and FIH activity, the observed VEGF 
response is a direct result of HIF-induced transcriptional activation of VEGF which is 
subsequently translated to protein. The application of a hypoxia-mimetic to selectively induce 
HIF overexpression in Caco-2 cells may account for the differences in VEGF mRNA 
expression profiles between the two CRC cell lines. Although VEGF expression profiles 
differed between the hypoxia-stimulated Colo 201 and DMOG-treated Caco-2 cells, the 
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profiles of HIF-1α protein expression for both cell types were however almost identical. Both 
cell lines achieved maximal HIF-1α protein expression at 6 hours following exposure to 
hypoxia or DMOG, and this was subsequently followed by a steady and progressive fall in 
HIF-1α protein levels. One possible explanation for this phenomenon lies with the 
accompanied decrease in HIF-1α transcription with prolonged hypoxic exposure as 
demonstrated by my results. It is possible that the progressive decrease in HIF-1α protein is 
due to effects on protein synthesis rather than protein stability which was the driver for the 
initial significant upregulation under hypoxia. Although the downstream effects mediated by 
the HIF-1α transcription complex have been well studied, the regulation of HIF-1α gene 
transcription by hypoxia is still relatively poorly understood. Although a study by Heidbreder 
et al reported that hypoxia did not affect mRNA levels of HIF-1α, HIF-1β and HIF-2α after 2 
hours of hypoxia (Heidbreder et al. 2003), results from our laboratory with rheumatoid 
synovial fibroblast also support a significant downregulatory effect of hypoxia on HIF-1α 
mRNA expression. The discovery of a naturally occurring antisense RNA complementary to 
the 3' UTR of HIF-1α mRNA known as aHIF could account for the observed decrease in HIF 
transcripts with hypoxia. The function of aHIFs has been postulated to regulate HIF-1α 
mRNA at the post-transcriptional level by increasing its instability via an exposition of AU 
rich elements in the HIF-1α mRNA 3′UTR. Its expression level is not constant and most 
likely dependent upon HIF-1α protein expression since the aHIF promoter sequence possesses 
putative HRE. Thus, aHIF could be implicated in the complex regulation of HIF-1 by 
reducing HIF-1α mRNA and in turn reduce its translation, a theory which would account for 
our observations in both CRC cell lines following prolonged hypoxia (Rossignol et al. 2002). 
An alternate direct negative regulatory mechanism has also been proposed where hypoxia 
limits accumulation of HIF-1α by inducing expression of human PHD2 and PHD3, thus 
accelerating degradation of excess HIF-1α on reoxygenation after long-term hypoxia 
(Marxsen et al. 2004). Results from my work and published literature therefore highlight the 
existence of negative feedback control mechanisms which ensure rapid adaptation of hypoxic 
cells to reoxygenation when blood flow is re-established. 
Although HIF-1α and HIF-2α are regulated by similar oxygen dependent 
mechanisms, the different isoforms appear to be differentially regulated and exhibit 
distinctive roles in modulating cellular responses. My study revealed significant differences in 
HIF-2α expression profiles between Colo 201 and Caco-2 cells with hypoxia and DMOG 
stimulations. Colo 201 cells demonstrated a progressive time-dependent increase in HIF-2α 
mRNA expression with a peak of 2-fold upregulation seen at 24 hours of hypoxia. This 
compares favourably to a study by Uchida et al (Uchida et al. 2004) showing a significant rise 
in HIF-2α mRNA of approximately 1.5 fold and 2 fold with hypoxia or cobalt chloride 
105 
MD (Res) Thesis Tak Loon Khong 
Chapter 3 
stimulation, an agent also known to be a hypoxia-mimetic. The upregulation in HIF-2α 
mRNA was attributed to changes occurring at the transcriptional level since mRNA stability 
was unaffected. These findings were also consistent with a study on squamous cell carcinoma 
confirming the capacity of HIF-2α protein to increase transcription of HIF-2α by enhancing 
its own promoter activity (Sato et al. 2002). In contrast, Caco-2 cells responded to HIF 
overexpression by downregulating HIF-2α gene expression over time, to achieve maximal 
inhibition of 0.5-fold relative to controls at 10 hours post DMOG stimulation. Since this 
pattern of HIF-2α gene regulation parallels that of HIF-1α, it is conceivable that aHIF could 
be involved in dampening HIF-2α mRNA levels. However this mechanism is less plausible as 
the 3'-UTR segment in HIF-2α is relatively shorter with absence of AU-rich elements, despite 
the high sequence homology in their open reading frames between HIF-2α and HIF-1α 
(Pesole et al. 2002). The 3'-UTR design could therefore prevent HIF-2α mRNA from being 
destabilised by aHIF. The variations in HIF-2α responses could also be a reflection of the 
different stimuli used in the individual cell types. The global stress imposed by hypoxia could 
activate other signalling processes independent of HIFs, which in turn could exert varying 
effects on HIF-2α gene transcriptional activity. Evaluation of HIF-2α protein levels as part of 
future work could provide useful insight into post-transcriptional processes affecting HIF-2α 
expression, and therefore provide a greater appreciation of its participation in mediating 
various downstream cellular processes in response to hypoxia. It is apparent that further 
studies are required to unravel the complex interwoven web of multiple regulatory pathways 
involved in mediating hypoxia signalling in CRC. 
Since hypoxia and EGF overexpression are typical features of CRC, the possibility of 
both stimuli co-existing to enhance their respective angiogenic effects within the tumour 
microenvironment still remains unknown. A study on glioblastoma cells revealed that 
hypoxia and EGF could interact to increase VEGF levels in an additive manner (Maity et al. 
2000). In my study, an additive effect was only demonstrated in Caco-2 cells, where 
combined EGF and DMOG resulted in overall increased levels of VEGF mRNA and protein, 
and HIF-1α protein. Although the additional increase in VEGF mRNA and protein expression 
following combined stimulation was not significant relative to EGF or DMOG stimulation 
alone, the consistent upregulation in HIF-1α protein with combined stimuli was statistically 
significant. Combined EGF and DMOG also lead to further suppression in HIF-1α and HIF-
2α transcriptional activity, but the observed differences were not significant compared to 
individual stimulus. In contrast, our study with Colo 201 cells failed to demonstrate any 
further additive effect of combined stimuli on hypoxia and EGFR-mediated responses. The 
expression profiles of HIF-1α, HIF-2α and VEGF for combined stimulation with EGF and 
hypoxia over a 24 hour period in Colo 201 were almost identical to cells treated with hypoxia 
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alone. The absence of HIF or VEGF responses to EGFR stimulation under normoxic and 
hypoxic conditions highlights a potential redundancy of EGFR signalling in Colo 201. 
Appreciation for the disparity in EGFR-induced responses between Caco-2 and Colo 201 
cells is crucial, especially in light of current clinical application of novel EGFR-inhibitory 
therapies in the treatment of CRC. Therefore, the aim of the next chapter of my study is to 
elucidate the differences in the underlying signalling pathways recruited by Colo 201 and 
Caco-2 cells to explain for the variations in cell responses to EGFR stimulation. 
Since angiogenic responses elicited from Colo 201 cells were totally independent of 
EGFR signalling, further experiments were conducted to explore the importance of EGFR-
related angiogenic signals relative to that induced by a pro-inflammatory stimulus. The 
involvement of inflammation and innate immunity in cancers is well recognised, as immune 
and inflammatory cells commonly feature in the tumour microenvironment to promote 
various inflammatory, angiogenic and proliferative processes. Inflammatory cytokines, 
particularly IL-1β and TNF-α have critical functions in orchestrating the complex cross-talk 
between various cell types to modulate the host response, to generate either an anti-tumour 
response by activating immune cells, or to promote a tumourigenic environment (Lin and 
Karin 2007). IL-1β, a pluripotent cytokine capable of a myriad of functions, has been shown 
to be overexpressed in CRC and is capable of promoting tumour growth and metastasis by 
inducing production of angiogenic factors (Lewis et al. 2006). In my studies, despite 
stimulating Colo 201 cells with varying concentrations of IL-1β, VEGF expression was not 
significantly affected. Although VEGF mRNA level appeared to be increased by maximal of 
2-fold, this was statistically non-significant. Furthermore VEGF protein levels were 
unchanged with IL-1β stimulation. This is in contrast to work by Konishi et al (Konishi et al. 
2005), where Caco-2 cells were able to upregulate VEGF expression following IL-1β 
stimulation. The possibility of a HIF-dependent mechanism to account for the increased 
VEGF expression remains unconfirmed in CRC, although IL-1β has been demonstrated to 
upregulate HIF-1α expression (El Awad et al. 2000) and enhance HIF-1α binding activity 
(Hellwig-Burgel et al. 1999) in non CRC cell types. Colo 201 cells were therefore stimulated 
with IL-1β to examine expression of HIF-1α and HIF-2α expression, but the cells 
demonstrated no significant difference in expression of HIFs following stimulation. The 
overall resistance of Colo 201 to respond to exogenous cytokine stimulation may be specific 
to this poorly differentiated metastatic cell line, as acquired mutations may have rendered 
them inert to extrinsic regulatory cues. It is also conceivable that Colo 201 cells may respond 
to exogenous cytokine or growth factor stimulation by upregulating other angiogenic 
mediators other than VEGF which still remains to be uncovered. Thus, the aim of the next 
chapter of my study was to identify a panel of known angiogenic genes, which may be 
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involved in mediating downstream signals to promote angiogenesis in CRC in response to 
cytokine stimulation. 
In summary, EGFR stimulation increased VEGF protein expression in Caco-2 cells, a 
moderately differentiated CRC cell line. VEGF transcription was unaffected, and the 
underlying mechanism was also independent of HIF signalling. In contrast Colo 201 cells, a 
poorly differentiated CRC cell line, failed to demonstrate any change in VEGF or HIF 
expression with EGFR and IL-1β stimulation. However, hypoxia or DMOG consistently and 
significantly upregulated both VEGF and HIF expressions in both Caco-2 and Colo 201 cells. 
HIF-1α protein which was significantly upregulated by both stimuli resulted in increased 
VEGF transcription, and this was eventually translated to increased VEGF protein. HIF-1α 
mRNA demonstrated time dependent downregulation in both cell types with hypoxia or 
DMOG stimulation, suggesting a post-translational stabilisation to account for significant 
upregulation in HIF-1α protein, and also a potential hypoxia mediated HIF-dependent 
negative feedback regulation on its gene activity. Furthermore, the variation in HIF-2α 
mRNA expression between Caco-2 and Colo 201 cells could be related to differences in 
stimuli used, but it could also reflect differential responses related to cell-specific behaviour. 
Addition of EGF to hypoxia or DMOG stimulations enhanced the responses previously 
elicited in Caco-2 cells only with DMOG stimulation, but these additional changes were 
largely not significant. The data therefore support a role for the application of EGFR 
antagonists in inhibiting CRC angiogenesis in selected patients in the clinical setting, 
although in relative terms, intratumoural hypoxia exerts an extremely potent and overriding 
effect in promoting CRC angiogenesis to drive tumours towards the angiogenic switch. The 
observed variations in EGFR-induced responses are clearly a reflection of differences in 
cellular biological mechanisms, and one of the leading causes is differential regulation of 
signalling transduction pathways. The next chapter will aim to identify differences in 
intracellular signalling pathways between Colo 201 and Caco-2 cells, and will examine the 
resultant variations in angiogenic gene responses from both cell types following EGFR and 
hypoxia or DMOG stimulations. 
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4 SIGNALLING AND FUNCTIONAL STUDIES IN 
COLORECTAL CANCER CELL LINES 
4.1 INTRODUCTION 
Human carcinomas frequently express high levels of receptors in the EGFR receptor 
family, including an estimated 65-70% of human CRC. Over-expression of one of the EGFR 
family of receptors, HER-2/neu, has been correlated with more advanced TNM staging 
(Lockhart and Berlin 2005), and independently related to poorer survival and postoperative 
recurrence in CRC (Park et al. 2007). The EGFR is composed of an extracellular binding 
domain, a transmembrane lipophilic segment, and an intracellular protein tyrosine kinase 
domain with a regulatory carboxyl terminal segment. Upon ligand binding, the EGFR 
becomes activated by dimerisation with a co-receptor and autophosphorylation of its protein 
tyrosine kinase domain. These events lead to recruitment and phosphorylation of several 
intracellular signalling pathways mediated by MAPK (Alroy and Yarden 1997), PI3K/Akt 
(Burgering and Coffer 1995; Liu et al. 1999), Src family kinases and Stat proteins. The 
intracellular signals regulate multiple biological processes including cell adhesion, cell 
locomotion, cell proliferation (Chan et al. 1999), differentiation, survival, apoptosis (Datta et 
al. 1997) and angiogenesis. 
My earlier studies (Chapter 3) examining the angiogenic response of CRC cells to 
direct stimulation of EGFR uncovered novel data, which to my knowledge have previously 
not been described. Two different CRC cell lines exhibited contrasting biological responses to 
direct EGF stimulation. Caco-2 cells, derived from a moderately differentiated primary CRC 
tumour, demonstrated an angiogenic response by upregulation of VEGF following direct EGF 
stimulation. This contrasted with Colo 201 cells, derived from advanced CRC cells from 
metastatic ascitic fluid, which failed to mimic any of the VEGF responses seen with Caco-2. 
This variation in response could be explained by a myriad of differences in cellular biological 
mechanisms. However given that demonstrable changes in cellular biology are commonly 
heralded by the smallest differences elicited at the beginning of a biological cascade, the aim 
of this part of the study was to examine the initial signalling transduction pathways in both 
cell types. The objective was to identify possible differences in intracellular signalling 
pathways to account for the underlying variation in angiogenic responses of both CRC cell 
types to direct EGFR stimulation. 
The process of angiogenesis is a tightly regulated process, with the eventual outcome 
determined by the prevailing influence of either the pro- or anti-angiogenic factors. There is 
currently still a lack of published data revealing the global changes in angiogenic genes with 
EGFR and/or hypoxia stimulation, but a limited degree of inference can be made using data 
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from earlier studies designed to evaluate the therapeutic benefits of inhibiting EGFR. 
Treatment of GEO CRC cell lines with anti-EGFR monoclonal antibody cetuximab resulted 
in a dose-dependent inhibition of TGF-α, VEGF and bFGF, and furthermore was associated 
with decreased microvessel density in xenografts (Ciardiello et al. 2000). My experiments as 
described in Chapter 3 have primarily focused on VEGF expression as an indicator of the 
angiogenic effect of direct EGFR stimulation, VEGF being a well-recognised potent effector 
in stimulating new blood vessel formation. However, in order to further explore the complex 
dynamics driving CRC angiogenesis in vivo, the study has to encompass interactions and 
expressions of a range of other cytokines, chemokines, growth factors, adhesion molecules, 
proteases, matrix proteins, and transcription factors known to affect tumour angiogenesis, and 
this formed the basis of the second part of this chapter. 
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4.2 OBJECTIVES 
The first objective of this part of my study was to elucidate and identify differences in 
the activation of intracellular signalling pathways following EGFR stimulation in the two 
CRC cell lines, Caco-2 and Colo 201. The phosphorylation status of EGFR following receptor 
stimulation was initially determined, and this was followed by investigations into the 
signalling messengers recruited by activated EGFR, such as extracellular signal-regulated 
protein kinases (ERK), p38, and PI3K/Akt. The purpose of this study was to identify 
variations in signal transduction pathways to explain for differences in angiogenic responses 
elicited by the two CRC cell lines following EGFR stimulation. 
The second objective was to identify a panel of pro- and anti-angiogenic genes which 
may be modulated by EGFR activation and/or hypoxia stimulation. A commercially available 
assay known as the Human Angiogenesis RT2 ProfilerTM PCR Array was used to identify 
novel genes involved in EGF- and hypoxia-mediated CRC angiogenesis. The benefit of such 
multiplexing technology is that it enables profiling of 84 key genes known to be involved in 
modulating the biological processes underlying angiogenesis. Gene expression profiles 
between Caco-2 and Colo 201 cells were determined, with the aim of elucidating how 
differences in intracellular signalling transduction mechanisms recruited by EGFR activation 
would affect angiogenic gene transcriptional activity. 
The angiogenic gene profile enables identification of a panel of genes which may 
promote CRC angiogenesis in tumours with dysfunctional EGFR signalling, or with a 
relatively hypoxic tumour microenvironment. However, the detected differences in gene 
expressions may not reflect their overall biological ability to stimulate angiogenesis within 
the in vivo CRC microenvironment. Several in vitro assays have been developed to enable 
functional assessments of the angiogenic potential of human cancers. A cell migration study 
was developed to assess the pro-angiogenic role of EGF stimulation in human A431 vulvar 
squamous carcinoma (Hirata et al. 2002). By utilising separate culture chambers to isolate 2 
different cell types, human umbilical vein endothelial cells (HUVEC) were observed to 
migrate from an inner chamber through a polycarbonate filter by chemotaxis in response to a 
chemical gradient of angiogenic factors produced in response to EGF stimulation of A431 
cells. However, no studies to date have specifically explored the biological significance of 
CRC cells pre-stimulated with EGF and/or DMOG have on angiogenesis. Thus the final aim 
of my study was to assess the physiological effects of EGF and/or DMOG stimulated Caco-2 
cells have on the migration of a co-culture of HUVEC, to determine the biological 
significance of the changes in expression of known angiogenic genes which were alluded to 
by the gene array following CRC cell stimulations. 
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4.3 METHODS 
In order to determine the activation status of EGFR and recruitment of downstream 
signalling pathways, Colo 201 and Caco-2 cells were stimulated with EGF for durations of 
15, 30, 60 and 120 minutes. Supernatants were discarded and remaining cells lysed with 
buffer containing a cocktail of protease-inactivating agents to stabilise the various signalling 
molecules in their phosphorylated state. The cell lysates were resolved on SDS-PAGE gels, 
transferred to PVDF membrane, and subsequently incubated with antibodies targeted for the 
particular signalling molecule of interest. Activation of the EGFR receptor was determined by 
immunoblotting for anti-phospho-EGFR Tyr-1068 and Tyr-945 residues. In order to identify 
activated downstream signalling pathways involved in EGFR-induced responses, 
immunoblotting was performed for phospho ERK 1/2 (Thr-202/Tyr-204), anti-phospho-p38 
MAPK (Thr-180/Tyr-182) and anti-phospho-Akt (Ser-473). Immunoblots of EGF-stimulated 
cells were compared to unstimulated cells (negative controls) at the corresponding time-
points, and whole cell lysate of EGF-treated A431 epithelial carcinoma cells was used as 
positive control. To ensure that the differences observed in the immunoblots were not a direct 
result of unequal loading, blots were stripped and reprobed for the total protein corresponding 
to the molecule of interest, and furthermore immunoblotting was performed for α-tubulin. 
For the purpose of the angiogenesis PCR array, the CRC cell lines were cultured and 
stimulated using similar procedures that were previously described in Chapter 3. Following a 
24 hour period of stimulation with EGF and/or DMOG for Caco-2 cells, and EGF and/or 
hypoxia for Colo 201 cells, experiments were promptly terminated by lysis of cells. 
Messenger RNA was extracted and purified from cell lysates using custom-made spin 
columns from a commercially available kit, and contaminating DNA was subsequently 
selectively degraded by DNAse. Complementary DNA was subsequently obtained following 
reverse transcription using the recommended cDNA synthesis kit from the manufacturer of 
the angiogenesis array, and success of transcription was verified by GAPDH PCR. In order to 
ensure that the differences in angiogenic gene expression following stimulations were truly 
representational of CRC cell behaviour, cDNA used for the array was pooled from 3 separate 
experiments to minimise the potential skewed effects inflicted by one erroneous experiment. 
In a further attempt to minimise sampling error, a sample of cDNA was used to verify the 
mRNA expressions of VEGF, ANGPTL4 and HIF-1α by independent real-time PCR, which 
have been demonstrated to be consistently up- or downregulated by hypoxia or DMOG in my 
experiments. The pooled cDNA samples were subsequently loaded onto the array which was 
pre-coated with primers of 84 key genes known to be involved in modulating the biological 
processes of angiogenesis (Table 2.5). The expression of individual genes were normalised to 
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a panel of control genes which were selected based on their steady nature of expression even 
with EGF, hypoxia or DMOG stimulations. The relative difference in gene expressions were 
subsequently determined by performing comparisons with unstimulated control samples using 
the 2-ΔΔCT method. All samples were run in duplicate, and a typical calculation is illustrated in 
Table 2.6. 
In order to demonstrate the ability of EGF- and/or DMOG-stimulated Caco-2 cells to 
affect angiogenesis, an in vitro functional migration assay based on co-culture of HUVEC and 
CRC cells was developed (Figure 2.3). The assay relied on the preparation of two separate 
cell cultures, with HUVEC cultured within a cell culture insert (representing the inner 
chamber), that is subsequently placed into an established CRC cell culture (representing the 
outer chamber of cells). As it is important to minimise the potential of CRC cells 
contaminating the inner chamber of endothelial cells and thus affect counts of migrated 
HUVEC, the Caco-2 cell line was selected for this study due to its adherent growth pattern in 
culture. Caco-2 cells were pre-stimulated for 24 hours with EGF and/or DMOG as previously 
described, and HUVEC was subsequently co-cultured with the Caco-2 cells for 6 hours in 3 
separate replicates for each experimental condition. At the end of the experiment, any residual 
non-migrated HUVEC was removed from the inner chamber with care taken to avoid 
disrupting any migrated cells at the undersurface of the inserts. Migrated HUVEC cells were 
fixed in ethanol and their nuclei stained with haematoxylin to aid in their identification during 
the cell counting process. Three separate cell counts were performed at consistent sites on 
each cell insert and a mean calculated for the migrated HUVEC per insert. The data from the 
3 replicate co-cultures were subsequently pooled and the mean ± SEM number of HUVEC 
migrated for each experimental condition was calculated. 
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4.4 RESULTS 
4.4.1 SIGNALLING STUDIES IN COLO 201 CELLS 
4.4.1.1 Expression of EGFR and phospho-EGFR in Colo 201 cells 
Colo 201 cells, which were serum depleted overnight, were stimulated with EGF 
20ng/mL or left unstimulated as controls. EGF-induced activation of EGFR was determined 
by Western Blotting for autophosphorylation of the intracellular signalling portion, with focus 
on the phosphorylation status of the EGFR Tyr-1068 and 945 residues.  
Figure 4.1 Colo 201: phosphorylation of EGFR following EGF activation 
Western blot analysis of EGF-induced EGFR autophosphorylation in Colo 201 cells following 
stimulation with 20ng/ml EGF for time intervals between 15 to 120 minutes. Total cell proteins were 
fractionated through 3-8% SDS-PAGE, transferred to PVDF membrane, and incubated with anti-
phospho-EGFR Tyr-1068 and Tyr-945 antibodies. Comparisons were made to the EGFR 
phosphorylation status of unstimulated cells (negative controls) at the corresponding time-points, and 
positive control was whole cell lysate of EGF-treated A431 cells. The blots were stripped and reblotted 
for total EGF-R and α-tubulin as loading controls. 
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The Western blots illustrated by Figure 4.1 show that EGFR was expressed by Colo 
201. Colo 201 cells had minimal background EGFR activity as proven by the observed weak 
or even undetectable anti-phospho-tyrosine bands in unstimulated cells (Figure 4.1). 
Furthermore, stimulation with EGF resulted in a significant increase in phosphorylation of 
Tyr-1068 and Tyr-945 residues which are located within the receptor’s signalling domain. 
The peak of receptor activation was seen 15-30 minutes following stimulation, and this 
response progressively declined over the course of 60-120 minutes. 
4.4.1.2 Expression of ERK 1/2 in Colo 201 cells  
EGFR activation can initiate signalling of several downstream kinase cascades, with 
ERK 1/2 having been identified as one of the key downstream protein kinases. The Western 
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blot illustrated by Figure 4.2 shows constitutive expression of phosphorylated ERK 1/2 in 
Colo 201 cells. Since EGFR in Colo 201 cells was not constitutively activated, the effects 
mediated by ERK signalling on downstream cellular processes were therefore independent of 
EGFR activity. 
Figure 4.2 Colo 201: constitutive activation of ERK1/2 pathway 
Western blot analysis of ERK 1/2 phosphorylation in Colo 201 cells following stimulation with 
20ng/ml EGF for time intervals between 15 to 120 minutes. Total cell proteins were fractionated 
through 4-12% SDS-PAGE, transferred to PVDF membrane, and incubated with anti-phospho-ERK 
1/2 Thr-202/Tyr-204. Comparisons were made to the ERK phosphorylation status of unstimulated cells 
(negative controls) at the corresponding time-points, and positive control was whole cell lysate of EGF-
treated A431 cells. The blots were stripped and reblotted for total ERK as loading control. 
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4.4.1.3 Expression of p38 MAPK in Colo 201 cells  
EGFR-induced cell responses have also been reported to be p38 MAPK dependent in 
several other cancer cell types (Wang et al. 2005; Xu and Shu 2007). Western blotting for p38 
MAPK was therefore performed to investigate its potential role in mediating downstream 
effects of EGFR activation in Colo 201. The p38 Western blot resembled that of ERK1/2 as 
there was also constitutive expression of phosphorylated p38 in Colo 201 cells (Figure 4.3). 
In contrast, phosphorylated p38 was not observed in EGF treated A431 cells. 
4.4.1.4 Expression of Akt in Colo 201 cells  
In addition to the MAPK pathways, PI3K/Akt is one of the major well-established 
mechanisms known to have a crucial role in effecting alterations in a broad range of cellular 
functions in response to extracellular signals. Western blotting was therefore performed to 
identify phosphorylated Akt as a surrogate marker for PI3K involvement in mediating 
intracellular signalling following EGF stimulation in Colo 201 cells. In contrast to the A431 
cells, phosphorylated Akt was undetectable in both the EGF-treated and unstimulated Colo 
201 cells (Figure 4.4). 
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Figure 4.3 Colo 201: constitutive activation of p38 MAPK pathway 
Western blot analysis of p38 MAPK phosphorylation in Colo 201 cells following stimulation with 
20ng/ml EGF for time intervals between 15 to 120 minutes. Total cell proteins were fractionated 
through 4-12% SDS-PAGE, transferred to PVDF membrane, and incubated with anti-phospho-p38 
MAPK Thr-180/Tyr-182. Comparisons were made to the p38 phosphorylation status of unstimulated 
cells (negative controls) at the corresponding time-points, and positive control was whole cell lysate of 
EGF-treated A431 cells. The blots were stripped and reblotted for total p38 MAPK as loading control. 
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Figure 4.4 Colo 201: absence of Akt pathway activation 
Western blot analysis of Akt phosphorylation in Colo 201 cells following stimulation with 20ng/ml 
EGF for time intervals between 15 to 120 minutes. Total cell proteins were fractionated through 4-12% 
SDS-PAGE, transferred to PVDF membrane, and incubated with anti-phospho-Akt Ser-473. 
Comparisons were made to the Akt phosphorylation status of unstimulated cells (negative controls) at 
the corresponding time-points, and positive control was whole cell lysate of EGF-treated A431 cells.  
 
4.4.2 SIGNALLING STUDIES IN CACO-2 CELLS 
The differences in angiogenic responses elicited from the two CRC cell lines, Caco-2 
and Colo 201, with EGF stimulation may be attributed to variations in the activation of 
intracellular signalling pathways. Western blotting was therefore performed on Caco-2 cell 
lysates following EGF stimulation to examine similar signalling pathways previously 
investigated in Colo 201 cells. By comparing signalling profiles from the two CRC cell lines, 
any identifiable differences in signal transduction could account for their innate cell-specific 
behaviours in response to extracellular EGFR stimulation. 
4.4.2.1 Expression of EGFR and phospho-EGFR in Caco-2 cells  
Caco-2 cells which were serum starved overnight were stimulated with EGF 
20ng/mL, or left unstimulated as controls. EGF-induced autophosphorylation of EGFR was 
determined by Western blotting as illustrated by Figure 4.5. Protein bands corresponding to 
EGFR and phospho-EGFR were observed. This confirmed native EGFR expression in Caco-2 
cells which were capable of activation, by autophosphorylation of their Tyr-1068 and Tyr-945 
EGF stimulation 20ng/mL Unstimulated +ve 
control
15 30 60 120 15 30Time(minutes) 60 120 EGF treated 
A431 cells 
Antiphospho-Akt (Ser 473) Western blot
60 kDa 
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residues which formed the intracellular signalling components of the receptor. The activity of 
the receptor also appeared to diminish with time as demonstrated by the decreasing intensity 
of the bands on the anti-phospho-Tyr-945 EGFR blot. 
Figure 4.5 Caco-2: phosphorylation of EGFR following EGF activation 
Western blot analysis of EGF-induced EGFR autophosphorylation in Caco-2 cells following 
stimulation with 20ng/ml EGF for time intervals between 15 to 120 minutes. Total cell proteins were 
fractionated through 3-8% SDS-PAGE, transferred to PVDF membrane, and incubated with anti-
phospho-EGFR Tyr-1068 and Tyr-945 antibody. Comparisons were made to the EGFR 
phosphorylation status of unstimulated cells (negative controls) at the corresponding time-points, and 
positive control was whole cell lysate of EGF-treated A431 cells. The blots were stripped and reblotted 
for total EGF-R and α-tubulin as loading controls. 
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4.4.2.2 Expression of ERK 1/2 in Caco-2 cells  
The MAPK signalling pathways were investigated as potential signal transducers 
involved in initiating various intracellular activities resulting from EGF-induced EGFR 
autophosphorylation. Western blotting as illustrated by Figure 4.6 confirms expression of 
ERK 1/2 and phospho-ERK 1/2 in Caco-2 cells. This is based on presence of similar bands in 
the positive control, and bands observed at the expected molecular weights of 44 and 42kDa. 
However, the most crucial finding from the immunoblot is the significantly higher expression 
of phosphorylated ERK 1/2 in EGF-stimulated versus control cells. This phosphorylated ERK 
status remained active beyond 2 hours following stimulation of EGFR. 
4.4.2.3 Expression of p38 MAPK in Caco-2 cells  
The alternate p38 MAPK pathway was also investigated as a prospective signalling 
pathway in relaying EGFR activity following EGF-induced receptor activation. Figure 4.7 
shows protein bands with molecular weight consistent with that of p38 and phosphorylated 
p38 MAPK in Caco-2 cells. Although the anti-phospho-p38 MAPK protein band was more 
intense at 15 minutes following EGF stimulation, this was probably due to unequal total 
protein loaded as confirmed by the more intense band being seen in the total p38 blot. 
Overall, the presence of anti-phospho-p38 MAPK protein bands in both stimulated and 
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unstimulated cells suggested a basal level of activated p38 MAPK pathway in the Caco-2 
cells, and this activity was unaffected by direct exogenous EGF stimulation. 
Figure 4.6 Caco-2: activation of ERK1/2 pathway 
Western blot analysis of ERK 1/2 phosphorylation in Caco-2 cells following stimulation with 20ng/ml 
EGF for time intervals between 15 to 120 minutes. Total cell proteins were fractionated through 4-12% 
SDS-PAGE and incubated with anti-phospho-ERK 1/2 Thr-202/Tyr-204. Comparisons were made to 
the ERK phosphorylation status of unstimulated cells (negative controls) at the corresponding time-
points, and positive control was whole cell lysate of EGF-treated A431 cells. The blots were reblotted 
for total ERK as loading control. 
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Figure 4.7 Caco-2: absence of p38 MAPK pathway activation 
Western blot analysis of p38 MAPK phosphorylation in Caco-2 cells following stimulation with 
20ng/ml EGF for time intervals between 15 to 120 minutes. Total cell proteins were fractionated 
through 4-12% SDS-PAGE, transferred to PVDF membrane, and incubated with anti-phospho-p38 
MAPK Thr-180/Tyr-182. Comparisons were made to the p38 phosphorylation status of unstimulated 
cells (negative controls) at the corresponding time-points, and positive control was whole cell lysate of 
EGF-treated A431 cells. The blots were stripped and reblotted for total p38 MAPK as loading control. 
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4.4.2.4 Expression of Akt in Caco-2 cells  
The relevance of PI3K/Akt signalling in mediating an EGF-induced VEGF 
upregulation in CRC is still largely unknown. Western blotting was therefore performed to 
determine the expression of phosphorylated Akt in Caco-2 cells. Figure 4.8 shows 
constitutive expression of activated Akt in Caco-2 cells and this activity was not further 
affected by direct exogenous EGF stimulation. 
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Figure 4.8 Caco-2: constitutive Akt pathway activation 
Western blot analysis of Akt phosphorylation in Caco-2 cells following stimulation with 20ng/ml EGF 
for time intervals between 15 to 120 minutes. Total cell proteins were fractionated through 4-12% 
SDS-PAGE, transferred to PVDF membrane, and incubated with anti-phospho-Akt Ser-473. 
Comparisons were made to the Akt phosphorylation status of unstimulated cells (negative controls) at 
the corresponding time-points, and positive control was whole cell lysate of EGF-treated A431 cells.  
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4.4.3 GENE PROFILING OF COLO 201 AND CACO-2 CELLS 
The cell signalling studies clearly show differences in signalling pathways recruited 
by Colo 201 and Caco-2 CRC cell lines. The most important difference noted was in ERK 1/2 
signalling, where Colo 201 cells exhibited constitutive activation of the pathway, as opposed 
to Caco-2 cells which demonstrated significantly increased ERK 1/2 activity only following 
EGF stimulation. The differences in signalling may account for the variation in cell specific 
behaviour following EGFR stimulation, and may explain for the differences in HIF-1α or 
VEGF expression as described in Chapter 3 between cell types. Although VEGF exerts a 
potent pro-angiogenic stimulus, the end-result of tumour angiogenesis is considerably more 
complex, with multiple interconnected intra- and extracellular regulatory processes which 
determine the balance between pro- and anti-angiogenic signals. These regulatory signals 
identified to date could be subdivided into growth factors and accompanying receptors, 
cytokines, chemokines, transcription factors, adhesion molecules, proteases, matrix proteins. 
In order to investigate the role of these alternate pathways, a commercially available assay 
known as the Human Angiogenesis RT2 ProfilerTM PCR Array was used to profile the 
expression of 84 key genes known to be involved in modulating the biological processes 
underlying angiogenesis. 
4.4.3.1 Validation 
In order to ensure that the differences identified by the angiogenesis array were truly 
representational of CRC cell behaviour with EGF, hypoxia or DMOG stimulations, the cDNA 
used for the array was pooled from 3 separate experiments to minimise the potential skewed 
effects inflicted by one erroneous experiment. In a further attempt to minimise sampling error, 
the mRNA expressions of VEGF, HIF and angiopoietin-like 4 (ANGPTL4) of the constituent 
cDNA samples were independently validated with real-time PCR. These genes were selected 
based on significant changes detected in their relative expression with stimulation as 
identified by the angiogenesis PCR array or through our earlier findings as highlighted in 
Chapter 3. There were differences in the absolute fold changes detected by both techniques, 
but the overall trends were preserved (Figure 4.9). Gene expressions for the pooled cDNA 
sample and its constituent cDNAs (cDNA 1-3) were also comparable when independently 
validated by real-time PCR. 
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Figure 4.9 Validation of angiogenesis PCR array in Colo 201 cells following EGF 
and hypoxia stimulation 
Data from pooled cDNA obtained using the PCR array were compared against results from quantitative 
real-time PCR for individual cDNA samples for three genes, ANGPTL4 (A), VEGF (B) and HIF-1α 
(C). 
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4.4.3.2 Angiogenesis PCR array data for Colo 201 cells 
Table 4.1 highlights 10 genes which were upregulated by at least 2.5-fold following 
stimulation with EGF or hypoxia or combination of the two stimuli. The results show that 
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none of the 84 angiogenic genes of interest demonstrated significant change in expression by 
Colo 201 cells compared to controls following EGF stimulation alone.  
Table 4.1 PCR Array Data for Colo 201 Cells: Upregulated Genes 
Angiogenic genes which were upregulated by at least 2.5-fold following stimulation with EGF, 
hypoxia or combination of the two stimuli. For description of gene symbols and function, see Table 
2.5. 
Fold Difference 
GENE 
EGF versus 
Control 
Hypoxia versus 
Control 
Hypoxia plus 
EGF versus 
Control 
ANGPTL4 0.96 27.69 31.86 
BAI1 0.95 5.51 2.68 
EFNA1 0.99 2.97 2.47 
EFNA3 0.88 3.04 2.93 
IL-8 1.32 2.85 2.41 
NRP2 1.12 2.41 2.54 
PECAM1 0.98 7.60 6.21 
PLXDC1 1.95 6.01 6.58 
PTGS1 1.09 4.84 7.01 
VEGF 1.81 7.14 5.16 
 
In contrast, the 10 angiogenic genes which were noted to be significantly upregulated 
were observed following stimulation with hypoxia. Amongst these genes is ANGPTL4, which 
demonstrated 28-fold upregulation following stimulation with hypoxia alone, and this was 
further increased following EGF and hypoxia, representing the highest upregulation detected 
amongst all other angiogenic genes studied. VEGF was upregulated 7-fold following 
stimulation with hypoxia as opposed to a 1.8-fold change with EGF stimulation alone. Also 
upregulated was PECAM-1 or CD31, a cell adhesion molecule, which was upregulated by 
7.6-fold under hypoxia but remained unchanged with EGF stimulation alone. Amongst the 
subset of angiogenic genes shown to be upregulated by hypoxia, the combination of EGF and 
hypoxia did not result in any further additive or synergistic effect. The only exception to this 
is PTGS1 or prostaglandin-endoperoxidase synthase 1, where combination of EGF and 
hypoxia resulted in 7-fold upregulation of the gene compared to hypoxia alone at 4.8-fold 
upregulation. Contrary to this, BAI1 or brain specific angiogenesis inhibitor 1 was 
upregulated by 5.5-fold following hypoxia stimulation alone, but was reduced to 2.7-fold 
upregulation with combination of hypoxia and EGF stimulation. Four of the 10 upregulated 
genes including EFNA1 and EFNA3, IL-8 and NRP2 achieved borderline significance at 
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between 2.5- to 3.0-fold upregulation and in addition, the upregulation was not further 
enhanced with combined EGF and hypoxia. 
Table 4.2 PCR Array Data for Colo 201 Cells: Downregulated Genes 
Angiogenic genes which were downregulated by at least 0.5-fold following stimulation with EGF, 
hypoxia or combination of the two stimuli. For description of gene symbols and function, see Table 
2.5. 
Fold Difference 
GENE 
EGF versus 
Control 
Hypoxia versus 
Control 
Hypoxia plus 
EGF versus 
Control 
ANGPT2 0.98 0.39 0.41 
CXCL10 0.72 0.68 0.49 
FLT1 0.78 0.38 0.43 
HIF1A 1.00 0.70 0.66 
PDGFA 1.28 0.46 0.55 
PF4 1.59 0.41 0.83 
PLG 1.85 0.46 0.70 
STAB1 0.49 0.79 0.63 
THBS1 1.17 0.45 0.51 
 
The PCR arrays also identified 9 genes which were downregulated by EGF and 
hypoxia stimulation in Colo 201 cells (Table 4.2). With the exception of STAB1 expression, 
which was downregulated by 0.5-fold compared to controls, EGF stimulation alone did not 
result in any significant downregulation of the 83 investigated genes. STAB1 was the only 
identified gene from the array which showed significant change in expression following EGF 
stimulation with 0.49-fold downregulation, and this effect was not seen with hypoxia. 
Combination of EGF and hypoxia was shown to reduce the downregulatory effect mediated 
by EGF alone to 0.63-fold. Five out of the ten genes (ANGPT2, FLT1, PDGFA, PF4, PLG 
and THBS1) were downregulated by more than 2-fold relative to their expression in 
unstimulated control cells. When Colo 201 was stimulated with combined EGF and hypoxia, 
the observed downregulation in PF4 and PLG gene expression with hypoxia alone was less 
pronounced with 0.41 to 0.83-fold and 0.46 to 0.70-fold downregulation respectively. The 
remaining genes, ANGPT2, FLT1, PDGFA and THBS1 did not however illustrate any further 
change in their expression when EGF was combined with hypoxia. CXCL10 was included in 
Table 4.2 because of the additive effect of downregulating the gene by combined hypoxia and 
EGF stimulation, which led to 0.49-fold relative expression compared to controls. This 
compared to 0.72- and 0.68-fold downregulation when Colo 201 cells were stimulated 
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respectively with either EGF or hypoxia. HIF-1α had been consistently downregulated in my 
real-time PCR studies following hypoxia stimulation, and this result was further supported by 
the data from the PCR arrays where there was 0.70-fold downregulation with hypoxia alone 
and 0.66-fold downregulation with combined hypoxia and EGF. 
Table 4.3 PCR Array Data for Colo 201 Cells: Unchanged Genes 
Angiogenic genes which remained unchanged following stimulation with EGF, hypoxia or 
combination of the two stimuli. For description of gene symbols and function, see Table 2.5. 
Fold Difference 
GENE 
EGF versus 
Control 
Hypoxia versus 
Control 
Hypoxia plus 
EGF versus 
Control 
AKT1 1.23 0.68 0.72 
ANGPT1 0.96 1.36 1.24 
ANGPTL3 0.82 1.46 1.06 
ANPEP 0.80 1.08 1.43 
CCL11 0.96 1.68 1.24 
CCL2 1.00 1.36 1.24 
CDH5 0.96 1.36 1.24 
COL18A1 1.39 1.34 1.72 
COL4A3 0.96 1.36 1.24 
CXCL1 1.30 0.80 0.77 
CXCL3 1.40 0.64 0.72 
CXCL5 0.94 1.33 1.70 
CXCL6 1.41 0.91 1.10 
CXCL9 0.96 1.36 1.24 
ECGF1 1.06 0.87 0.91 
EDG1 0.95 1.34 1.23 
EFNB2 1.14 0.75 0.75 
EGF 0.75 2.07 1.74 
ENG 1.35 1.26 1.69 
EPHB4 1.17 0.65 0.71 
EREG 1.20 0.99 0.84 
FGF1 1.48 1.71 1.46 
FGF2 0.96 1.36 1.24 
FGFR3 1.07 1.38 1.38 
FIGF 1.08 0.69 0.82 
HAND2 0.96 1.36 1.24 
HGF 0.96 1.36 1.24 
HPSE 1.19 0.57 0.64 
ID1 1.15 1.19 1.22 
ID3 1.55 2.12 1.24 
IFNA1 1.00 0.93 1.27 
IFNB1 0.82 1.00 0.83 
IFNG 0.96 1.36 1.24 
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IGF1 1.93 1.05 0.93 
IL1B 1.30 1.23 1.62 
IL6 1.15 1.40 1.24 
ITGAV 1.14 0.85 0.81 
ITGB3 0.96 1.36 1.24 
JAG1 1.53 1.44 1.46 
KDR 0.96 1.36 1.66 
LAMA5 1.37 1.97 2.26 
LECT1 1.21 1.99 1.84 
LEP 0.77 0.55 0.52 
MDK 1.01 0.81 0.83 
MMP2 0.96 1.36 1.27 
MMP9 1.29 1.15 0.76 
NOTCH4 0.96 1.36 1.24 
NRP1 1.28 1.48 1.47 
PLAU 1.53 0.63 0.77 
PROK2 0.96 1.36 1.24 
SERPINF1 0.87 0.70 0.51 
SPHK1 1.32 0.71 0.72 
TEK 0.96 1.36 1.24 
TGFA 1.10 1.74 1.77 
TGFB1 1.22 1.42 1.57 
TGFB2 0.79 0.81 1.51 
TGFBR1 1.01 1.05 0.99 
THBS2 2.07 1.13 1.13 
TIMP1 0.94 0.66 0.67 
TIMP2 0.93 0.59 0.60 
TIMP3 0.96 1.36 1.24 
TNF 1.29 1.34 2.30 
TNFAIP2 1.22 1.17 1.12 
VEGFC 0.84 1.18 1.08 
18SrRNA 0.98 0.92 1.04 
HPRT1 0.93 0.71 0.72 
 
Table 4.3 above shows the relative expression of the remaining angiogenic genes in 
Colo 201 cells which remained unchanged following stimulation with EGF alone, hypoxia 
alone and EGF in combination with hypoxia. 
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4.4.3.3 Angiogenesis PCR array data for Caco-2 cells 
The angiogenesis PCR array was also used to study the panel of genes known to 
modulate the biological processes underlying angiogenesis in Caco-2 cells. Overall, 32 genes 
associated with angiogenesis showed significant changes in their expression following 
stimulation with EGF, DMOG or combination of EGF and DMOG. 
A total of 13 of the 84 genes studied showed a significant upregulation of 2.5-fold or 
more in their expression following EGF and DMOG stimulation relative to unstimulated 
controls. As observed with the data from Colo 201 cells, none of the genes studied showed 
significant upregulation following EGF stimulation alone. However, DMOG stimulation 
alone did exert a greater influence on the Caco-2 cells by upregulating 8 genes, namely 
EFNA3, FLT1, IGF1, IL-8, PF4, TGFB1, THBS1 and VEGF, by more than 2.5-fold. THBS1 
was upregulated by 6.9-fold, representing the gene with the highest increase in expression 
following DMOG stimulation in Caco-2 cells. Of note is VEGF, known to be highly regulated 
by hypoxia, which was upregulated by 6.1-fold with DMOG. ANGPTL4, which was a highly 
regulated gene under hypoxia in Colo 201 cells (increase of 28-fold), was also upregulated in 
Caco-2 cells but the relative change in expression achieved borderline significance at 2.48-
fold increase. The data in Table 4.4 show 5 genes (THBS1, EFNA3, FLT1, IGF1 and PF4) 
which were specifically upregulated by DMOG alone, as combined stimulation of Caco-2 
cells with DMOG and EGF did not result in any further significant changes in their relative 
expressions. 
Combination of DMOG and EGF stimulation did result in 7 genes showing further 
increase in gene expression compared to DMOG and EGF acting alone. This additive effect 
was particularly pronounced in IL-8, ANGPTL4, EREG, ID1 and ID3 expression, and 
furthermore resulted in NOTCH4 and TGFB1 achieving significance of 2.5-fold upregulation. 
IL-8 demonstrated the largest change in gene expression with 12.1-fold increase in its 
expression following DMOG and EGF stimulation, compared to 4.4- and 0.59-fold change 
with DMOG or EGF stimulation acting alone respectively. The additive effect of combined 
stimuli was also seen with ANGPTL4, where there was almost a further 2-fold increase (4.72- 
versus 2.48-fold) in gene expression when Caco-2 cells were stimulated with a combination 
of DMOG and EGF versus DMOG alone. Significant upregulatory responses from ID1 & 3 
were also only seen with combined stimulation of DMOG and EGF. Expression of both genes 
were unchanged with EGF or DMOG stimulation in isolation, but their relative expressions 
were significantly upregulated by 2.6- and 4.4-fold respectively when Caco-2 cells were 
stimulated with combined EGF and DMOG. 
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Table 4.4 PCR Array Data for Caco-2 Cells: Upregulated Genes 
Angiogenic genes which were upregulated by at least 2.5-fold following stimulation with EGF, 
hypoxia or combination of the two stimuli. For description of gene symbols and function, see Table 
2.5. 
Fold Difference 
GENE 
EGF versus 
Control 
DMOG versus 
Control 
DMOG plus 
EGF versus 
Control 
ANGPTL4 1.05 2.48 4.72 
EFNA3 0.78 3.24 3.38 
EREG 0.94 1.19 2.73 
FLT1 0.90 2.62 1.38 
ID1 1.09 0.95 2.55 
ID3 1.02 1.39 4.35 
IGF1 2.06 2.66 1.69 
IL-8 0.59 4.44 12.08 
NOTCH4 0.60 2.11 2.97 
PF4 1.76 2.79 1.71 
TGFB1 1.14 2.64 3.29 
THBS1 2.13 6.89 7.41 
VEGF 0.79 6.08 5.54 
 
The angiogenesis array identified 19 out of the 84 angiogenic genes which were 
downregulated relative to controls following stimulation with EGF and DMOG. EGF 
stimulation alone exerted more of a downregulatory effect on the panel of angiogenic genes, 
with 6 genes showing a significant decrease in activity relative to controls. 
These downregulated genes included CXCL3 and 6, EGF, PLXDC1, STAB1, TGFA 
and TGFB2. The decreased expression of several of these genes, particularly the chemokines 
CXCL3 and 6, EGF, PLXDC1, TGFA and TGFB2 were effects mediated specifically by 
EGF. There was significant downregulation of EGF, PLXDC1 and TGFA by 0.40, 0.32 and 
0.43-fold respectively following exogenous EGF stimulation of Caco-2 cells, compared to 
minimal change in their relative gene expressions following DMOG and DMOG and EGF 
stimulations. In addition, the inhibitory effect exerted by EGF stimulation on ANGPTL3, 
THBS2 and TNFAIP2 gene expressions as shown in Table 4.5 were sustained even with 
combined stimulation with EGF and DMOG. DMOG stimulation alone however only resulted 
in 2 genes, CCL2 and CXCL6, to be significantly downregulated by 0.29- and 0.30-fold. 
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Table 4.5 PCR Array Data for Caco-2 Cells: Downregulated Genes 
Angiogenic genes which were downregulated by at least 0.5-fold following stimulation with EGF, 
hypoxia or combination of the two stimuli. For description of gene symbols and function, see Table 
2.5. 
Fold Difference 
GENE 
EGF versus 
Control 
DMOG versus 
Control 
DMOG plus 
EGF versus 
Control 
AKT1 0.78 0.66 0.45 
ANGPTL3 0.53 1.17 0.47 
CCL2 0.80 0.29 0.46 
CDH5 0.65 0.47 0.36 
COL18A1 0.56 0.75 0.33 
CXCL3 0.47 0.59 0.75 
CXCL6 0.29 0.30 0.69 
EGF 0.40 0.68 0.83 
ENG 0.69 0.94 0.29 
IL1B 0.57 0.56 0.16 
ITGB3 0.51 1.49 0.15 
LAMA5 0.62 0.92 0.44 
NRP2 0.60 0.73 0.33 
PLXDC1 0.32 1.55 0.71 
STAB1 0.24 0.64 0.08 
TGFA 0.43 0.98 1.61 
TGFB2 0.42 1.87 2.12 
THBS2 0.52 1.36 0.44 
TNFAIP2 0.50 1.32 0.35 
 
Amongst the 19 angiogenic genes downregulated by stimulation with either EGF or 
DMOG, combined stimulation affected their relative expressions in 3 different ways. These 
include normalising or restoring expression levels comparable to that of unstimulated 
controls, sustaining the downregulatory effect, or further enhancing the inhibitory effect of 
either stimulant alone. Six genes which include CXCL3, CXCL6, EGF, PLXDC1, TGFA and 
TGFβ2, all of which were significantly downregulated with EGF stimulation alone, had 
restoration of their respective gene expressions comparable to unstimulated following 
combined EGF and DMOG stimulation. This normalising effect of PLXDC1, TGFA and 
TGFβ2 gene expression occurred despite DMOG having minimal effect on their relative gene 
expressions. Similarly, expression of CXCL6 which was significantly downregulated by 
stimulation with either DMOG or EGF in isolation had normalisation of its gene expression 
with combined stimulation. A total of 13 genes underwent significant downregulation of their 
relative expressions following combined stimulation with EGF and DMOG. This combined 
stimulation demonstrated an additive effect in decreasing the expression of 10 genes, such 
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that the inhibitory effect is much larger compared to that mediated by either stimulant acting 
alone. The data for the identified ten genes are illustrated in Table 4.5, and these include 
AKT1, CDH5, COL18A1, ENG, IL1β, ITGB3, LAMA5, NRP2, STAB1 and TNFAIP2. The 
more pronounced of these downregulated genes were STAB1, IL1β, ENG and NRP2. 
Expression of STAB1 was decreased following EGF stimulation to 0.24-fold and with 
DMOG to 0.64-fold, but in combination, this resulted in further suppression to achieve 0.08-
fold expression relative to the unstimulated controls. Similarly EGF or DMOG stimulation 
resulted in a 0.57- and 0.56-fold relative expression in IL1β in Caco-2 cells but in 
combination, both agents further decreased IL1β gene expression to 0.15-fold compared to 
controls. Expression of ITGB3 was not significantly altered with either EGF or DMOG 
stimulation alone (0.51-fold and 1.49-fold change respectively), but combined stimulation 
resulted in a significant 0.15-fold change in expression compared to controls. Although the 
additional inhibitory effects on transcriptional activity for the other 7 genes were not of 
similar magnitude, the combination of EGF and DMOG nevertheless downregulated their 
respective gene expression to achieve significance. 
Table 4.6 PCR Array Data for Caco-2 Cells: Unchanged Genes 
Angiogenic genes which were unaffected by stimulation with EGF, hypoxia or combination of the two 
stimuli. For description of gene symbols and function, see Table 2.5. 
Fold Difference 
GENE 
EGF versus 
Control 
Hypoxia versus 
Control 
Hypoxia plus 
EGF versus 
Control 
ANGPT1 0.59 0.64 0.72 
ANGPT2 2.13 1.40 1.16 
ANPEP 0.66 1.54 0.59 
BAI1 0.62 1.03 2.03 
CCL11 0.89 0.68 2.12 
COL4A3 0.74 2.45 0.93 
CXCL1 0.66 1.64 1.19 
CXCL10 0.66 0.72 1.27 
CXCL5 1.22 0.68 2.12 
CXCL9 0.89 1.31 2.12 
ECGF1 0.83 1.74 0.46 
EDG1 1.13 0.67 1.17 
EFNA1 0.62 1.29 1.20 
EFNB2 0.65 1.09 0.72 
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Continued…. 
EPHB4 0.77 1.08 0.59 
FGF1 1.10 0.68 2.12 
FGF2 0.57 0.49 2.12 
FGFR3 0.71 1.72 0.83 
FIGF 1.41 0.95 1.71 
HAND2 0.89 0.68 2.12 
HGF 0.89 0.68 2.12 
HIF1A 0.85 1.04 1.16 
HPSE 0.92 1.07 0.77 
IFNA1 1.40 1.89 1.99 
IFNB1 0.89 0.68 2.12 
IFNG 0.89 0.68 2.12 
IL6 0.63 1.36 1.87 
ITGAV 1.02 0.78 1.69 
JAG1 0.64 1.51 0.61 
KDR 0.89 0.68 2.12 
LECT1 0.89 0.68 2.12 
LEP 1.69 0.85 2.12 
MDK 0.73 0.86 0.73 
MMP2 0.98 0.94 0.51 
MMP9 0.83 2.07 1.24 
NRP1 0.69 0.77 0.53 
PDGFA 0.65 0.76 0.47 
PECAM1 0.77 0.61 0.92 
PGF 0.70 1.19 0.59 
PLAU 0.71 1.28 1.02 
PLG 0.89 0.68 2.12 
PROK2 0.89 1.75 2.12 
PTGS1 0.48 1.28 0.77 
SERPINF1 0.62 1.86 0.97 
SPHK1 0.94 1.77 1.23 
TEK 0.89 2.00 2.12 
TGFBR1 0.95 1.55 0.85 
TIMP1 0.95 0.79 1.00 
TIMP2 0.68 0.95 0.72 
TIMP3 0.57 0.45 1.39 
TNF 0.89 0.68 2.12 
VEGFC 1.34 0.99 0.59 
18SrRNA 1.11 1.06 2.51 
HPRT1 0.04 0.93 1.89 
RPL13A 0.91 1.04 1.18 
 
Table 4.6 above shows the relative expression of the remaining angiogenic genes in 
Caco-2 cells which remained unchanged following stimulation with EGF alone, DMOG alone 
and EGF in combination with DMOG. 
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4.4.4 ASSESSMENT OF THE FUNCTIONAL RELEVANCE OF ANGIOGENIC GENE 
RESPONSES IN CRC BY HUVEC MIGRATION ASSAY 
The angiogenesis PCR arrays identified a panel of angiogenesis-related genes to be 
significantly altered in expression following EGF, hypoxia and DMOG stimulation of Caco-2. 
This data thus enables a unique profile to be created, outlining specific genes which may 
underlie promotion of CRC angiogenesis following EGF, hypoxia and DMOG stimulation. 
However, the end-effect mediated by these alterations in angiogenic gene expressions remain 
unknown, therefore migration assays using human umbilical vein endothelial cell (HUVEC) 
in a double-chamber model were performed to determine the functional relevance of these 
angiogenic gene responses. 
4.4.4.1 Effects of EGF and DMOG on migration of HUVEC 
Initial experiments were performed to study the effect of EGF, DMOG and the 
combination of both stimulants on HUVEC migration in the absence of Caco-2 CRC cells. 
The data in Figure 4.10 are representative of three separate experiments and show 
significantly increased HUVEC migration with VEGF and 10% FCS stimulation (7.7- and 
11.5-fold increase in HUVEC migration respectively compared to unstimulated controls). 
Direct stimulation of HUVEC with EGF, DMOG or combination of these stimuli however did 
not affect their migration. 
Figure 4.10 HUVEC migration following stimulation with EGF, DMOG and VEGF 
HUVEC were seeded into 8µm pore cell culture inserts at a total of 1x105 cells and stimulated with 
20ng/ml EGF, 1mM DMOG, combination of EGF and DMOG, and positive controls comprising of 
10ng/mL VEGF and 10% FCS for 6 hours. HUVEC migrated to the bottom of the insert were stained 
with haematoxylin and counted using phase-contrast microscopy. Data illustrated are mean number of 
cells per high powered field migrated through in 3 separate regions ± SD from 3 independent replicates 
for each condition. 
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4.4.4.2 Effects of co-cultivation of Caco-2 cells in the presence of EGF and/or 
DMOG on HUVEC migration 
To determine the biological significance of the angiogenic responses induced in CRC 
cells following EGF and DMOG stimulation, Caco-2 cells were pre-stimulated for 24 hours 
and then co-cultivated with HUVEC for 6 hours to examine the migration of HUVEC in a 
double chamber assay. Five separate experiments were performed with each of the conditions 
performed in triplicates. There were variations in the number of migrated HUVEC between 
experiments but the overall trend was preserved. Data is therefore presented as absolute 
numbers of migrated HUVEC in response to stimuli from a single representative experiment, 
and relative fold changes in migrated HUVEC were calculated to pool results from all five 
experiments. Figure 4.11 shows absolute cell counts from a HUVEC migration assay 
following a 6 hour period of co-culture with Caco-2 cells pre-stimulated with EGF and/or 
DMOG. 
Figure 4.11 HUVEC migration in response to activated Caco-2 cells  
HUVECs were seeded into 8µm pore cell culture inserts at a total of 1x105 cells and co-cultured for 6 
hours with Caco-2 cells pre-stimulated with 20ng/ml EGF, 1mM DMOG, or a combination of 20ng/mL 
EGF and 1mM DMOG. Negative control is EMEM only and positive control is VEGF 10ng/mL. Cells 
migrated to the lower surface of the insert were stained with haematoxylin and counted. Data illustrated 
are mean number of cells per high powered field migrated through in 3 separate regions of the insert ± 
SD and are from 3 independent replicates for each condition. 
EM
EM
VE
GF
EM
EM EG
F
DM
OG
 D
MO
G 
& 
EG
F
0
20
40
60
80
100
No cells Caco-2 cells
** *
***
*   p<0.05
**  p<0.01
*** p<0.001
versus EMEM
C
el
ls
 m
ig
ra
te
d 
pe
r 
H
PV
(1
00
 s
qu
ar
es
 o
f h
ae
m
oc
yt
om
et
er
)
 
Co-culturing HUVEC with unstimulated Caco-2 cells promoted migration of cells, 
where there was on average 6.6-fold more cells migrated. Importantly, the number of 
migrated HUVEC was significantly higher in co-cultures with Caco-2 cells pre-stimulated 
with EGF, DMOG and a combination of EGF and DMOG. There was consistent and 
significant increase in HUVEC migration with Caco-2 cells pre-stimulated with EGF, and 
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EGF in combination with DMOG. The data illustrated in Figure 4.11 show a mean of 65 
HUVEC migrated per HPV in co-cultures with Caco-2 cells pre-stimulated with EGF, 
compared to 33 migrated HUVEC in co-cultures with unstimulated cells. DMOG-stimulated 
Caco-2 cells also increased HUVEC migration compared to Caco-2 in EMEM alone, and 
although this represented a relative 1.74-fold increase, this difference was statistically 
significant. In this experiment, Caco-2 cells pre-stimulated with combined DMOG and EGF 
resulted in the highest number of migrated HUVEC, where there was a mean of 82 versus 33 
(2.5-fold higher) migrated HUVEC  
Figure 4.12 Fold difference in migrated HUVEC following co-culture with Caco-2 
cells pre-stimulated with EGF and/or DMOG 
Migrated HUVEC following co-culture with Caco-2 cells pre-stimulated with 20ng/ml EGF, 1mM 
DMOG, and combination of EGF and 1mM DMOG were normalised to unstimulated controls. Each 
data point represents the relative fold difference in migrated HUVEC in 5 different experiments with 
each experimental condition performed in triplicate.  
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Figure 4.12 illustrates the pooled data normalised to the respective unstimulated 
controls from individual experiments, allowing comparisons to be made across experiments. 
The data confirm the pro-migratory effect similar to that illustrated in Figure 4.11. Overall, 
EGF-stimulated Caco-2 cells (2.9-fold increase) had a comparable effect on HUVEC 
migration as that mediated by combined EGF- and DMOG-stimulated cells (2.8-fold 
increase). There was also a 2-fold increase in the number of migrated HUVEC relative to 
unstimulated controls in co-cultures with Caco-2 cells pre-stimulated with DMOG. 
Representative photographic images illustrating migrated HUVEC following 6 hours 
of co-culture with/out pre-stimulated Caco-2 cells are shown in Figure 4.13. 
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Figure 4.13 Photographs of migrated HUVEC in migration assay 
Photographic images illustrating migrated HUVEC on the outer surface of the cell inserts following 6 
hours of co-culture with Caco-2 cells pre-stimulated with 20ng/ml EGF, 1mM DMOG, and 
combination of EGF and DMOG. Caco-2 cells were omitted in negative control and 10ng/mL VEGF 
was used in the outer chamber as positive control. Migrated HUVEC were fixed, permeabilised and 
stained with haematoxylin. Each image was taken using a phase-contrast microscope at x100 
magnification. 
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4.4.4.3 Determination of VEGF protein in supernatants extracted from the 
outer chamber of HUVEC migration assay. 
Culture media was extracted from the outer chambers of the HUVEC migration 
assays from 3 separate experiments to determine the VEGF protein concentrations by ELISA. 
Figure 4.14 VEGF protein in supernatants extracted from the outer chamber of 
HUVEC migration assay 
Culture media was extracted from the outer chamber of the HUVEC migration assay following co-
culture of Caco-2 pre-stimulated with 20ng/ml EGF, 1mM DMOG, and combination of 20ng/mL EGF 
with 1mM DMOG with HUVEC cells. VEGF protein expression data are mean ± SD of a sample 
assayed in triplicate by ELISA and are representative of 3 experiments. Statistical significance was 
tested by 1-way ANOVA with Bonferroni post hoc correction versus No cells - control ** p<0.01 and 
*** p<0.001. 
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Figure 4.14 shows VEGF protein expressed within the culture media from one 
experiment. In the absence of Caco-2 cells in the migration assay, there was no VEGF 
detected. However, VEGF expression was significantly increased to a measured mean of 
501pg/mL by the presence of adherent Caco-2 cells within the outer chamber. VEGF 
expression was further elevated in co-cultures with Caco-2 cells pre-stimulated with EGF 
and/or DMOG, findings which parallel results reported in Chapter 3. EGF stimulation alone 
resulted in a significant 1.5-fold increase in VEGF expression relative to unstimulated Caco-2 
controls. Similarly, there was a significant 1.6-fold increase in VEGF expression within co-
cultures containing Caco-2 cells pre-stimulated with DMOG stimulation. Combined DMOG 
and EGF stimulation also marginally increased VEGF expression further to a 2-fold increase 
relative to unstimulated Caco-2 controls (997pg/mL versus 501pg/mL respectively). 
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4.5 DISCUSSION 
4.5.1 CELL SIGNALLING PATHWAYS 
The EGFR signalling pathway has evolved from a simple growth factor signalling 
pathway into an interactive, multilayered network, in which expression and activation of a 
multitude of components in various combinations permit context-specific biological responses 
to be elicited. Any activated downstream signalling cascades triggered by the receptor 
nevertheless requires an orderly stepwise activation of the receptor, firstly requiring receptor 
interaction with its ligand, then heterodimerisation of the receptor and finally 
autophosphorylation of various tyrosine kinase binding sites along the intracellular domain of 
the receptor. Since Colo 201 cells failed to demonstrate VEGF upregulation in response to 
direct EGF stimulation, it was crucial for my study to establish presence of EGFR and its 
activation status with stimulation. Studies to investigate EGFR by Western blotting 
established EGFR expression in both cell lines which demonstrated low or non-detectable 
baseline activity. However direct exogenous EGF stimulation resulted in significantly 
increased receptor activity in both cell types with maximal phosphorylation of the receptor 
detected between 15 to 30 minutes following stimulation. The specificity and potency of 
intracellular signalling pathways which are subsequently recruited are determined by the 
identity of the ligand, oligomer composition and specific structural determinants of the 
receptors, as these factors dictate autophosphorylation of selected receptor binding sites 
within the intracellular signalling domain to engage specific signalling proteins. The Ras- and 
Shc- activated MAPK pathway is an invariable target of all EGFR ligands, and the PI3K-
activated Akt pathways are downstream of most active EGFR dimers. Activation of such 
linear cascades translates in the cell into distinct transcriptional and translational programmes 
leading to modulation in cell division and migration, adhesion, differentiation, apoptosis and 
angiogenesis. 
With EGFR being over-expressed in approximately 70% of CRCs, the expected 
increase in intracellular signalling could alter cellular responses biased towards cellular 
transformation, cell proliferation and growth promotion and differentiation. One of the major 
signalling transduction cascades capable of mediating such global cellular responses is the 
ERK MAPK pathway. Aberrant ERK signalling pathways has been shown by 
immunohistochemistry studies to affect 50 – 83% of CRC, compared to normal colonic 
mucosal cells which typically show weak or negative expression of activated phosphorylated 
ERK. This evidence thus provides a link between development and progression of human 
CRCs and activation of the ERK MAPK signalling pathway (Cassano et al. 2002; Lee et al. 
2004; Corn et al. 2008). Since the MAPK cascade plays such a pivotal role in the mitogenic 
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signal transduction pathway, it is unsurprising that CRC cell lines with the capacity to 
undergo clonogenic expansion often possess constitutively activated MAPK activity. In a 
study by Hoshino et al (Hoshino et al. 1999) examining activation of MAPK in 138 human 
cancer cell lines, Colo 201 cell line was shown to constitutively over-express ERK MAPK 
and its overall activity was unaffected by stimulation with serum alone. These results support 
findings from my experimental work with Colo 201 which demonstrated a constitutively 
activated phosphorylated ERK pathway that was non-inducible even with direct stimulation 
with EGF. In marked contrast, Caco-2 cells expressed very low basal levels of phosphorylated 
ERK1/2, but upon stimulation with EGF, phosphorylation activity was significantly induced 
as shown by my immunoblotting studies. This finding was supported by two published 
studies (Nakata et al. 1998; Buzzi et al. 2009), one by Buzzi et al, in which the low basal 
activity of phosphorylated ERK was found to be significantly induced following stimulation 
with serum (Buzzi et al. 2009). The difference in ERK signalling elicited from the two cell 
lines may therefore underlie the divergence in response to EGFR activation in affecting 
VEGF expression, in a rather cell specific manner. 
Akt has been shown to have a pivotal role in cell cycle progression (Brennan et al. 
1997; Muise-Helmericks et al. 1998; Gille and Downward 1999), angiogenesis (Jiang et al. 
2000; Agarwal et al. 2005), inhibition of apoptosis (Franke et al. 1995; Downward 1998; 
Sabbatini and McCormick 1999), and cell growth (Verdu et al. 1999). Immunohistochemical 
analyses indicate over-expression of activated Akt frequently occur in human CRC (Phillips 
et al. 1998; Roy et al. 2002; Parsons et al. 2005), compared to normal colonic mucosa and 
hyperplastic polyps which express very low levels of Akt. Phosphorylated Akt has also been 
shown to be over-expressed in several CRC cell lines including HT29 (Roy et al. 2002), 
DLD-1 (Itoh et al. 2002) and Caco-2 (Laprise et al. 2002; Roy et al. 2002; Bockmann and 
Nebe 2003). In my study, Colo 201 and Caco-2 cells contrasted significantly in their relative 
dependence on Akt signalling. Activated Akt was not identified in Colo 201 even following 
EGF stimulation, but Caco-2 demonstrated constitutive activation of the Akt pathway with no 
further increase in transduction signalling following EGF stimulation. These findings 
therefore suggest that Akt signalling may be redundant in affecting downstream cellular 
activities in both cell types in relation to EGFR mediated signalling. 
The p38 MAPK has been implicated in inflammation, cell growth, cell differentiation 
and death, and cell cycle progression (Ono and Han 2000). Activation of the p38 pathway 
results in global changes in transcription and production of proteins involved in cell surface 
receptor expression, cytoskeletal structure, and programming towards cell survival and 
apoptosis. In immunohistochemical studies, phosphorylated p38 MAP kinase (pp38 MAPK) 
was found to be strongly expressed in CRC stroma, primarily by macrophages located within 
the stroma, but other cell types were also found to express pp38 MAPK (Hardwick et al. 
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2001). The precise role of p38 MAPK in CRC still remains unclear. Some of the evidence 
derived from inhibitory studies showed a dose-dependent suppression of proliferative activity 
in DLD-1 and SW480 CRC lines, with induction of cell apoptosis (Tsuchiya et al. 2008). In 
another similar study, blockade of p38α using small chemical inhibitors SB202190 or 
SB203580, or its genetic knock down using specific siRNAs, lead to cell cycle arrest and 
autophagic cell death (Comes et al. 2007). However, the role of p38 in mediating EGF-
induced cell responses in CRC still remains largely unknown. My investigation into the p38 
transduction pathway in Colo 201 cell line is novel and to my knowledge has not been 
previously reported. The immunoblot confirmed p38 MAPK was constitutively activated and 
phosphorylation was unaffected by additional EGFR stimulation in Colo 201 cells. Caco-2 
cells have previously been demonstrated to express low levels of activated p38 but the 
activity of the signalling pathway was inducible with serum stimulation (Buzzi et al. 2009). In 
my studies, pp38 was found to be constitutively activated in Caco-2 and their relative activity 
was unaffected by stimulation with EGF. The importance of the p38 MAPK transduction 
pathway in relation to CRC angiogenesis still remains unclear, thus future work could aim to 
examine changes in CRC cell behaviour with inhibition of the pathway with small inhibitory 
molecules, such as with SB 202190. 
4.5.2 PCR ANGIOGENESIS ARRAY DATA 
The goal of molecular analysis in cancer biology is to identify biological markers that 
have specific roles in promoting distinct behaviours of tumours to invade, survive and 
metastasise. Knowledge of these cancer-specific markers would therefore facilitate 
development of potential therapies aimed at neutralising these cancer promoting effects. 
Molecular studies have for a while been largely focused on individual candidate genes in a 
disease with significantly complex dysfunctional and transformed molecular processes 
underlying the pathological process. The advent of DNA microarray technology has allowed 
mRNA expression levels of thousands of genes to be measured simultaneously in a single 
assay, thus providing a molecular definition of a tumour sample to be characterised in order to 
compile a profile of the combinatory and complex genetic abnormalities of various cancers. 
Gene expression profiling-based studies of CRC have so far compared normal and tumour 
tissue samples or at different stages of disease (Alon et al. 1999; Backert et al. 1999; Hegde et 
al. 2001; Kitahara et al. 2001; Notterman et al. 2001; Agrawal et al. 2002; Birkenkamp-
Demtroder et al. 2002; Lin et al. 2002; Zou et al. 2002; Frederiksen et al. 2003; Tureci et al. 
2003; Williams et al. 2003; Sugiyama et al. 2005), but none has directly addressed the 
influence of EGF and hypoxia, features which are common within a CRC tumour 
microenvironment, on angiogenic gene responses. 
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Out of the 84 angiogenic genes, 24% were found to be significantly up- or 
downregulated in Colo 201 and 38% in Caco-2 cells following stimulation with EGF and 
hypoxia or DMOG. The gene profiles for CRC cells have highlighted 10 and 13 angiogenic 
genes which were significantly upregulated by more than 2.5-fold in Colo 201 and Caco-2 
cells respectively. The observed changes in gene expressions as demonstrated by Colo 201 
cells suggest an inherent resistance of the cell line to respond to EGFR stimulation, but are 
rather sensitive to hypoxia stimulation. This is confirmed by 0/84 angiogenic genes showing 
any significant change in gene expression following EGF stimulation alone, and furthermore, 
9 similar genes which were significantly upregulated by hypoxia did not illustrate any further 
increase in expression with combined hypoxia and EGF (Figure 4.15A). Only 1 gene 
(PTGS1/COX1) showed a greater change with EGF combined with hypoxia stimulation 
relative to hypoxia alone. In Caco-2 cells, 3 genes were found to be specifically upregulated 
by DMOG alone, 4 genes were upregulated by both DMOG and EGF, and 6 other genes 
showed further enhanced expression following combined DMOG and EGF stimulation 
relative to DMOG alone (Figure 4.15B). 
Figure 4.15 Diagrammatic representation of genes demonstrating significant 
upregulation in transcriptional activity following EGF, Hypoxia/DMOG, 
or combination of stimuli affecting (A) Colo 201 and (B) Caco-2 as 
identified by Angiogenesis Array  
Pale green circle represents EGF alone, blue circle represents hypoxia (for Colo 201) or DMOG (for 
Caco-2) and dark green circle represents combined stimulations. 
 
The angiogenic gene profiles identified 4 common genes which were significantly 
upregulated in both CRC cell lines, including angiopoietin-like 4 (ANGPTL4), ephrin 3 
(EFNA3), interleukin-8 (IL-8) and VEGF. These genes which were hypoxia-inducible in Colo 
201 cells, also demonstrated enhanced transcriptional activity with combined EGF and 
DMOG in Caco-2 cells. ANGPTL4 was a highly inducible hypoxia responsive gene with its 
relative expression significantly increased by 32-fold in Colo 201 cells and 4.7-fold in Caco-2 
cells with combined EGF and hypoxia/DMOG stimulations. ANGPTL4 is a member of seven 
molecules bearing structural similarities to angiopoietins by possessing the homologous 
coiled-coil domain forming the N-terminus, and fibrinogen-like domain forming the C-
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terminus of the protein. However, none of these proteins bind to either Tie-2 or Tie-1 
receptors, therefore they are still considered orphan ligands (Kim et al. 1999; Camenisch et 
al. 2002; Oike et al. 2004; Katoh and Katoh 2006). The functions of ANGPTL4 are to 
regulate lipid, glucose and energy metabolism (Kersten 2005; Oike et al. 2005) but its precise 
role in CRC still remains unknown. ANGPTL4 is known to be highly regulated by hypoxia, 
therefore implicating it as a potential pro-angiogenic gene (Le Jan et al. 2003). However the 
ability of ANGPTL4 to regulate angiogenesis appears to be rather complex, with the eventual 
pro- or anti-angiogenic outcome determined by cell-specific context, varying in accordance 
with expression of other angiogenic modulating factors (Ito et al. 2003; Le Jan et al. 2003; 
Oike et al. 2004; Galaup et al. 2006). It is therefore impossible to deduce the function of 
ANGPTL4 in the context of CRC angiogenesis based purely on gene transcriptional data. It is 
apparent that future studies should initially focus on elucidating the precise functions of the 
variant forms of the protein, combined with in vivo functional analyses. The expression of 
various ANGPTL4 isoforms by CRC should then be assessed under stimulated and 
unstimulated conditions to determine their function in CRC angiogenesis. 
Ephrin receptor tyrosine kinases (Eph) and their ligands, the ephrins, play key roles in 
embryological development by regulating cell migration and adhesion, thereby influencing 
cell lineage, morphogenesis and organogenesis. Recent findings suggest that Eph signalling is 
also important in adults, controlling the architecture and physiology of different tissues under 
normal and pathological conditions such as cancer. The intestinal epithelium relies upon Eph–
ephrin signalling to maintain normal tissue architecture in its various cell compartments, by 
facilitating ordered migration of epithelial cells along the crypt axis to continuously 
regenerate the epithelium. The expression of EphB2 and EphB3 in crypts is driven by Wnt 
signalling (Batlle et al. 2002), and since most colorectal tumours are initiated by mutational 
activation of the Wnt pathway, intestinal adenomas are characterised by high expression of 
crypt EphB2 and EphB3 receptors (Batlle et al. 2005). Eph–ephrin signalling is also 
implicated in angiogenesis, particularly during embryonic development of the blood vascular 
system to differentiate the boundary between venous and arterial vessels (Kuijper et al. 2007). 
In CRC, EFNA1 and EphA2 have been proven to be over-expressed in cancer compared to 
normal tissue (Kataoka et al. 2004). Furthermore, mutational analyses performed on CRC 
protein kinase complement of the human genome (kinome) have identified mutated EphA3 in 
CRC cell lines and primary tissues (Bardelli et al. 2003). In my angiogenic gene expression 
studies, EFNA3 was consistently upregulated in both Caco-2 and Colo 201 cells under 
DMOG or hypoxia stimulation respectively. EGF stimulation or combination of 
hypoxia/DMOG with EGF did not result in further additive effect on gene expression. In 
addition, expression of EFNA1 was increased in Colo 201 but not Caco-2 following hypoxia 
stimulation, with gene expression not altered by EGF or further upregulated with combined 
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EGF and hypoxia stimulation. These results, which to my knowledge have previously not 
been reported, implicate ephrin-ligands EFNA1 and EFNA3 involvement in CRC 
angiogenesis. Furthermore, the observed induction in their gene expressions by hypoxia and 
DMOG suggests they are HIF-dependent, thus implying potential crucial roles of ephrins in 
regulating tumour angiogenesis in response to tissue oxygenation. 
IL-8, a cytokine of the CXC chemokine family, has an important role in tumour 
progression and metastasis in a variety of human cancers, including CRC. The biological 
activity of IL-8 in tumours and the tumour microenvironment may contribute to tumour 
progression through its potential function in the regulation of angiogenesis, cancer cell growth 
and survival (Brew et al. 2000), tumour cell motion (Li et al. 2001), leukocyte infiltration and 
modification of immune responses. IL-8 over-expression has been demonstrated in tumour 
specimens of several human solid cancers including CRC (Ueda et al. 1994), predominantly 
focused within cancer cells surrounding necrotic areas of tumour lesions (Desbaillets et al. 
1999; Kunz et al. 1999; Shi et al. 1999). Haraguchi et al. showed that IL-8 levels in CRC 
tumour tissue and blood serum were significantly correlated with tumour microvessel density, 
with higher serum IL-8 levels detected in patients with more locally advanced cancers or with 
hepatic metastases (Haraguchi et al. 2002). The differential expression of IL-8 in determining 
metastatic potential of CRC cells has been demonstrated. Caco-2 cells which express low 
levels of IL-8 mRNA and protein, and its cognate receptors CXCR1 or CXCR2, had 
significantly decreased invasive and metastatic potential compared to 2 other cell lines, 
KM12C and KM12L4, which expressed significantly higher levels of IL-8 and cognate 
receptors (Li et al. 2001). In my gene array data, IL-8 was consistently upregulated in both 
Caco-2 and Colo 201 cells with DMOG and hypoxia stimulations respectively, but there was 
no effect with EGF stimulation alone. In comparison to Caco-2 responses, IL-8 induction was 
higher in Colo 201 cells in response to hypoxia stimulation, with an even greater additive 
effect with combination of EGF and hypoxia. The mechanisms for hypoxia and acidosis-
mediated up-regulation of IL-8 remain unclear. IL-8 mRNA shows rapid induction and 
decline to baseline levels upon reoxygenation, thus implying a transcriptional regulation and 
post-transcriptional mRNA stabilisation (Shi et al. 1999). Since the flanking regions of IL-8 
gene lack hypoxia responsive elements, HIF-1 seems unlikely to play a direct role in hypoxic 
regulation of IL-8 (Mukaida et al. 1994). 
Platelet endothelial cell adhesion molecule-1 (PECAM-1/CD31) is a member of the 
immunoglobulin gene superfamily. It is highly expressed at sites of endothelial cell-cell 
contact, on the surface of platelets and on haematopoietic cells at moderate levels (DeLisser et 
al. 1997; Newman 1997). PECAM-1 plays an important role during inflammatory responses 
by affecting leukocyte-endothelial transmigration (Muller 1995) and activation of integrins on 
leukocytes and T cells (Tanaka et al. 1992; Berman et al. 1996). The role of PECAM-1 in 
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tumour metastasis remains unclear due to conflicting reports on its function in mediating 
melanoma cell adhesion and transendothelial migration (Tang et al. 1993; Voura et al. 2000). 
Expression of PECAM-1 in CRC cell line (HCT-116) in vitro culture depended on degree of 
confluence, with level of expression being downregulated at confluence. Gene transcription 
activity of PECAM-1 following hypoxia stimulation has not been previously studied in CRC, 
but PECAM-1 gene transcription has been demonstrated to be induced in lungs of preterm 
baboons treated with intravenous FG-4095, an inhibitor of PHDs (Asikainen et al. 2006). In 
my studies, PECAM-1 expression was significantly induced by 7.6-fold following hypoxia 
stimulation compared to normoxic controls. PECAM-1 expression however was unaffected 
by EGF stimulation. This upregulatory effect however was confined to hypoxia treated Colo 
201 cells, but was not demonstrated by Caco-2 cells treated with DMOG. The disparity in cell 
responses could be cell-specific, but it could also be due to underlying regulatory mechanisms 
which may be independent of HIF, thus accounting for the lack of response with DMOG 
stimulation alone. Certainly the regulation of PECAM-1 still remains largely unexplored and 
would be a potential area for further studies. 
The thrombospondins (TSPs) are a family of five proteins involved in tissue 
remodelling which underlies various physiological processes such as embryonic development, 
wound healing, synaptogenesis, and pathological conditions like neoplasia. By interacting 
with the extracellular matrix and surrounding tissue, TSP-1 has been shown to exert an 
inhibitory effect on angiogenesis and tumour progression (Ren et al. 2006). The anti-
angiogenic effect of TSP-1 is mediated by its type 1 repeats (TSRs) through its interaction 
with endothelial cell membrane protein CD36, resulting in inhibition of migration and 
apoptosis (Dawson et al. 1997). In CRC, TSP-1 has been demonstrated to be mainly localised 
in fibroblasts of the tumour stroma on in-situ hybridisation. The result from 
immunohistochemical studies revealed that 55.3% of CRCs expressed high levels of TSP-1 
which correlated significantly with reduced vessel counts and increased TGF β1 expression, 
and furthermore TSP-1 expression was an independent prognostic factor (Miyanaga et al. 
2002). In addition, the balance of TSP-1 and its related molecule TSP-2 is also important 
because stromal angiogenesis is primarily controlled by TSP-2 as well as VEGF-189 
expression. TSP-2 expression has certainly been demonstrated to exert prognostic 
significance in CRC (Tokunaga et al. 1999). In my gene array study, TSP-1 was significantly 
upregulated by 6.9-fold with DMOG treatment alone in Caco-2 cells. On the contrary, 
hypoxia stimulation in Colo-201 cells resulted in a significant 0.45-fold downregulation in 
TSP-1, but there was no effect on TSP-2 expression. However, TSP-2 gene transcription was 
decreased by 0.4– to 0.5-fold relative to unstimulated controls in Caco-2 cells following EGF 
and combined EGF and DMOG stimulation. The observed effect of hypoxia or DMOG in 
downregulating expression of TSP-1 and TSP-2 in CRC cells would be an appropriate 
143 
MD (Res) Thesis Tak Loon Khong 
Chapter 4 
compensatory mechanism given their well-established inhibitory role in tumour angiogenesis. 
However, the significant upregulation in TSP-1 gene expression in Caco-2 cells stimulated 
with DMOG is rather unexpected and represents an interesting finding. Although TSPs have 
been universally classified as anti-angiogenic mediators, there is emerging evidence that TSP 
may also enhance tumour angiogenesis. The effect of TSP-1 appears to depend on the 
temporal phase of cancer progression, where high levels of TSP-1 expressed during the early 
dormant stage inhibits neovascularisation. At later stages however, the compensatory increase 
in pro-angiogenic factors overwhelms this checkpoint, thus resulting in an angiogenic 
phenotype which is accompanied by tumour growth and invasion (Roberts 1996; 
Sargiannidou et al. 2004). 
Cyclooxygenase enzymes play key roles in the biosynthesis of prostaglandins from 
arachidonic acid following its release from the plasma membrane by the action of 
phospholipase-A2. COX-1 or PTGS1 is constitutively expressed in a wide range of tissues 
including the colon, and is considered a housekeeping enzyme responsible for maintaining 
basal prostaglandin levels for tissue homeostasis. In contrast, most tissues do not normally 
express COX-2 constitutively. A large body of evidence now indicates that elevated levels of 
COX-2 are present in the majority of CRC carcinomas (Eberhart et al. 1994; Kargman et al. 
1995; Sano et al. 1995; Mariani et al. 2009). Aberrant expression of COX-2 plays crucial role 
in CRC development. The pro-tumourigenic effects of COX-2 in the colorectum are largely 
thought to be attributed to its ability to produce PGE2 (Rigas et al. 1993; Pugh and Thomas 
1994), which has pleiotropic effects on colorectal tumours including proliferation, survival, 
angiogenesis, migration and invasion (Sinicrope and Gill 2004). The angiogenic gene array 
used in my study identified a 4.8-fold and further 7-fold increase in COX-1 transcriptional 
activity following hypoxia and combined hypoxia and EGF stimulations respectively. The 
assay used did not include COX-2 as one of its candidate genes. Since COX-1 is thought to be 
constitutively expressed in most tissues and COX-2 particularly expressed in pathological 
conditions, majority of published work has primarily focused on uncovering the role of COX-
2 in CRC. Nevertheless a study by Tsujii et al highlighted the importance of both COX 
isoforms in CRC, as HUVEC transfected with COX-1 antisense oligonucleotide failed to 
form endothelial tubes in a co-culture with Caco-2 cells over-expressing COX-2, thus 
highlighting the importance of COX-1 in regulating endothelial cell biology (Tsujii et al. 
1998). However, the study did not examine the effect of COX-1 over-expression by CRC 
cells on endothelial tube formation, therefore the functional relevance of my findings from the 
angiogenic gene array still remains unknown.  
The inhibitor of DNA binding (Id) proteins are a family of transcription factors 
comprised of four related proteins which are implicated in the control of differentiation and 
cell cycle progression. The helix-loop-helix (HLH) structure of the transcription factor is 
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highly conserved and mediates dimerisation, whilst its N-terminal basic domain is responsible 
for DNA binding and gene activation (Kadesch 1993). Id proteins prevent transcription 
factors, primarily the basic HLH (or bHLH) transcription factors, from binding DNA by 
direct physical interaction (Benezra et al. 1990; Christy et al. 1991; Sun et al. 1991; 
Riechmann and Sablitzky 1995; Chen and Lim 1997; Yates et al. 1999). Id-1 has been 
reported as an oncogene that regulates cellular senescence, growth and survival in the 
development of tumours (Nickoloff et al. 2000; Wang et al. 2002). The abrogation of Id1-3 
functions, by antisense oligonucleotide blockade or by enforced expression of the bHLH 
protein, led to growth arrest in human CRC cell lines (Wilson et al. 2001). Id proteins appear 
to be crucial for angiogenesis as branching and sprouting of capillaries from the primary 
vascular plexus during murine development was severely disrupted in Id-1/Id-3 double 
knockout mice resulting in embryonic lethality (Jen et al. 1997). Through 
immunohistochemical analyses of CRC tissue obtained from surgical resection, Id-1 
expression was significantly increased in CRC compared to adjacent normal mucosa or 
adenoma. Furthermore increased expression of Id-1 was strongly correlated with advanced 
Dukes’ staging and presence of lymph node metastasis (Zhao et al. 2008). The role of EGF 
and hypoxia in regulating Id proteins in CRC still remains unknown. In my gene array 
studies, Id-1 and Id-3 were upregulated in Caco-2 cells, but such changes in gene expressions 
were only observed with combined DMOG and EGF stimulation. Neither DMOG nor EGF 
alone resulted in any change in Id-1 and Id-3 gene expressions in Caco-2 cells. This suggests 
a complex regulatory pathway which does not appear to be solely reliant upon HIF nor EGFR 
signalling. 
Tumour endothelial markers (TEM) were genes identified through serial analysis of 
gene expression (SAGE) to be significantly altered by at least 10-fold in expression in CRC-
derived endothelium compared to endothelium from normal tissue (St Croix et al. 2000). Nine 
novel TEMs were established from this study, with four of them (TEM1, TEM5, TEM7, and 
TEM8) appearing to reside on the cell-surface, thus making them ideal candidates to be 
involved in signalling pathways that regulate angiogenesis and as potential pharmacological 
targets (Nanda and St Croix 2004). However, all four genes are unrelated to each other. The 
expression pattern of TEMs is also elevated in liver metastases from CRC, primary sarcoma, 
and in primary cancers of the lung, pancreas, breast, and brain (St Croix et al. 2000). TEM7 
or plexin-domain containing 1 (PLXDC-1) is a type I transmembrane protein containing a 
signal peptide followed by a plexin-like domain, a nidogen-like domain and a single 
hydrophobic domain. The only other protein that seems to share significant homology to 
TEM7 is TEM7-related (TEM7R), another putative cell surface protein that also contains a 
nidogen-like domain. In situ hybridisation revealed that TEM7R, like TEM7, is abundantly 
expressed in the endothelium of malignant CRC, but is absent or rare in normal colonic 
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mucosa (Carson-Walter et al. 2001). TEM7 and TEM7R have been shown to be capable of 
binding with cortactin (Nanda et al. 2004), but no clear functional relevance has been 
elucidated. Although TEMs were initially thought to be specifically expressed only by 
endothelial cells, certain TEMs specifically TEM2 and TEM6 have been demonstrated in 
normal colonic mucosa. In addition, the mRNA expression levels of TEM7 and -7R were 
found to be higher in Dukes C compared to Dukes A tumours, but the difference noted was 
not statistically significant (Rmali et al. 2005). The regulation of TEM7 or PLXDC1 still 
remains largely unknown with no published data supporting the role of EGF and hypoxia on 
regulating gene expression in CRC cells. In my gene array study, TEM7 was shown to be 
upregulated by 6-fold by hypoxia relative to unstimulated controls in Colo 201 cells only. 
Stimulation with EGF alone did not affect gene expression, and furthermore, combination of 
EGF and hypoxia stimulation did not result in further upregulation in gene expression. Since a 
similar result was not observed in Caco-2 cells stimulated with DMOG, it is possible that 
TEM7 transcriptional activity is induced by hypoxia and independent of HIF-regulation. 
The gene profiles for CRC cells have identified 8 and 19 angiogenic genes which 
were significantly downregulated by at least 0.5-fold in Colo 201 and Caco-2 cells 
respectively. The only gene that was significantly affected by exogenous EGF stimulation in 
Colo 201 cells was stabilin (STAB1), with a 0.49-relative fold downregulation in expression. 
Furthermore, STAB1 expression was also significantly downregulated in Caco-2 cells 
following EGF stimulation, and combined EGF and DMOG lead to further suppression of its 
transcriptional activity. From this study, a common gene which is highly regulated by EGF in 
two different CRC cell lines has been identified, thus STAB1 appears to have a critical role in 
mediating angiogenesis in CRC cells. Apart from STAB1, 6 out of 7 genes that were 
significantly downregulated in Colo 201 were related to hypoxia exposure, with only 1 gene, 
CXCL10, achieving borderline significance following combined hypoxia and EGF 
stimulation (Figure 4.16A). These results support our earlier theory that angiogenic responses 
exhibited by Colo 201 cell line were almost entirely independent of EGFR activation, but 
Colo 201 remained highly responsive to hypoxia to mediate a pro-angiogenic environment. In 
Caco-2 cells however, the effect of EGFR activation on angiogenic gene responses was more 
pronounced. My study uncovered 5 genes specifically downregulated by EGF alone, 1 gene 
was downregulated by both EGF and DMOG, and 3 genes which were downregulated by 
EGF were not further affected with additional DMOG (Figure 4.16B). Furthermore, my study 
revealed enhanced downregulatory effect of combined EGF and DMOG in eight other 
angiogenic genes, clearly demonstrating an important functional additive relationship 
between the two separate stimuli to alter gene responses in Caco-2 cells (Figure 4.16B). 
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Figure 4.16 Diagrammatic representation of genes demonstrating significant 
downregulation in transcriptional activity following EGF, 
Hypoxia/DMOG, or combination of stimuli affecting (A) Colo 201 and 
(B) Caco-2 as identified by Angiogenesis Array  
Pale green circle represents EGF alone, blue circle represents hypoxia (for Colo 201) or DMOG (for 
Caco-2) and dark green circle represents combined stimulations. 
 
The multifunctional scavenger receptor stabilin-1 (STAB1) or CLEVER-1 is a type 1 
transmembrane protein with clusters of EGF-like and fasciclin domains (for cell/matrix 
interactions and homotypic adhesion, respectively), and one putative hyaluronan (HA)-
binding link domain. Extensive histological studies revealed that STAB1 is expressed by 
tissue macrophages and sinusoidal endothelial cells in healthy individuals, with its expression 
significantly induced during chronic inflammation and tumourigenesis. Functions of STAB1 
include clearance of a variety of proteins including advanced glycation end products, 
modified LDL and bacteria by receptor mediated endocytosis and recycling; and shuttling 
between the endosomal compartment and trans-Golgi network. There is an overall lack of 
evidence supporting expression of STAB1 in solid cancers, and certainly there are no studies 
to date examining the effect of EGF and hypoxia or DMOG on expression of STAB1 in CRC. 
In my angiogenesis array study, STAB1 was the only gene which was consistently 
downregulated in both Colo 201 and Caco-2 cells. Furthermore, transcriptional activity was 
significantly decreased by EGF stimulation alone in both cell types, with gene expression 
being further dampened in a synergistic manner by combined EGF and DMOG stimulation, 
particularly in Caco-2 cells. These dramatic changes in gene transcription following EGF and 
DMOG, or hypoxia stimulations demonstrated in two separate cell types clearly highlight the 
importance of STAB1 in mediating an important functional role in tumour angiogenesis. 
Since relatively little is known about STAB1 in CRC, it would represent an interesting and 
exciting subject to pursue in future work. 
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The gene expressions of the EGFR ligands, EGF and TGF-α, were found to be 
downregulated following EGFR activation in Caco-2 cells. The expressions of EGF and TGF-
α were decreased by 0.4- and 0.43-fold respectively relative to unstimulated controls. This 
result contravenes earlier published studies which showed exogenous stimulation of 
keratinocytes with EGF or TGF-α resulted in induction of TGF-α gene transcription (Coffey 
et al. 1987). TGF-α autoinduction was also demonstrated in CRC cells where a positive 
feedback mechanism was involved in increasing TGF-α mRNA levels, principally through 
enhanced transcriptional activity (Coffey et al. 1992). Furthermore, activated EGFR has been 
reported to stabilise TGF-α mRNA transcripts through a post-transcriptional modification 
process precipitating in increased steady-state levels of its transcripts (Coffey et al. 1992; 
Nicolini et al. 1996). In a study of the 5’-flanking promoter region of the TGF-α gene, a 
proximal element capable of conferring responses to EGF has also been identified (Raja et al. 
1991). These characteristics therefore strengthen the case for an autocrine feedback 
mechanism involving TGF-α/ EGFR signalling as a potential pathway through which cells 
could undergo malignant transformation (Sporn and Todaro 1980; Rosenthal et al. 1986; 
Coffey et al. 1987; Ziober et al. 1993). The absence of such a response as detected by the 
angiogenesis array in my study may highlight differences in cell specific responses. 
Furthermore, the observed upregulation in gene transcriptional activity as demonstrated in 
other studies occurred at 4 hours following EGFR stimulation, therefore future work could 
examine the effect of reducing the stimulatory period on EGF and TGF-α gene responses 
(Coffey et al. 1987). 
IL-1β is renowned as a potent pleiotropic cytokine involved in regulating 
inflammatory and immune responses, but it also enhances tumour invasion and metastasis by 
modulating angiogenesis in vivo (El-Omar et al. 2000; Voronov et al. 2003; Camargo et al. 
2006). IL-1β stimulated CRC cells have demonstrated consistent upregulation of VEGF-A 
and COX-2 (Akagi et al. 1999; Liu et al. 2003) in a HIF-1α-dependent manner involving NF-
κB inflammatory signalling pathway (Jung et al. 2003). Dysregulation in IL-1β expression in 
tumours is related to gene mutations that culminate in gain-of-function, but relatively little is 
known about the effects of EGF and hypoxia on IL-1β expression (Podolsky 2002; Elaraj et 
al. 2006). Although IL-1β mRNA expression was increased in human thymic epithelial (TE) 
cells following treatment with EGF or TGF (Le et al. 1991), my gene array study showed 
downregulation of IL-1β gene transcriptional activity following EGF stimulation alone in 
Caco-2 cells. The importance of hypoxia in regulating IL-1β expression in solid cancers still 
remains unknown, but human peripheral blood mononuclear cells demonstrated induction of 
IL-1β mRNA expression with hypoxia (Ghezzi et al. 1991; Naldini et al. 2001). However, my 
work with Caco-2 cells demonstrated downregulation of IL-1β expression with DMOG 
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stimulation. Such discrepancies could be a result of variations in activated intracellular 
mechanisms which may be independent of HIF signalling in response to the global stress of 
hypoxia. Furthermore, combination of EGF and DMOG stimulation in Caco-2 cells exerted a 
significant synergistic effect in further suppressing IL-1β gene transcriptional activity. These 
findings to my knowledge have not been previously reported in CRC cells and would warrant 
further investigation. In order to facilitate fair comparisons between studies, Caco-2 cells 
should ideally be subjected to hypoxic stimulation. However given their intolerance to 
prolonged hypoxia as proven in my study, Caco-2 cells could be exposed to hypoxia for 
shorter periods of time (up to 12 hours) to potentially limit hypoxia-induced cell death. 
Chemokine ligand 2 (CCL2), also known as monocyte chemoattractant 1 (MCP-1), is 
a low-molecular weight cytokine which recruits inflammatory cells in inflammatory 
conditions and cancers (Standiford et al. 1991; Sciacca et al. 1994). There is contrasting 
evidence as to the overall role MCP-1 plays in cancers, with reports of attenuated tumour 
metastatic potential by enhancement of monocyte infiltration (Huang et al. 1994; Shinohara et 
al. 2000), but also MCP-1 mediated induction of tumour neovascularisation promoting 
tumour metastasis (Saji et al. 2001; Robinson et al. 2002; Kuroda et al. 2005; Bailey et al. 
2007). MCP-1 expression is significantly increased in advanced stages of primary CRC 
tumours (Yoshidome et al. 2009), but a lower ratio of MCP-1 between CRC to normal tissue 
is associated with lymph node metastasis, higher staging and poorer survival (Watanabe et al. 
2008). Although MCP-1 expression levels are altered in other pathological states, relatively 
little is known about its regulation in CRC. MCP-1 expression was observed to be 
upregulated in primary human and mouse astrocyte cultures following exposure to hypoxia or 
cobalt chloride, and these effects have been attributed to HIF-binding sites on the promoter 
region of MCP-1 (Mojsilovic-Petrovic et al. 2007). In my gene array studies, Caco-2 cells 
stimulated with DMOG or with combined EGF however demonstrated consistent 
downregulation in MCP-1 expression. This result also supports published data from our group 
showing reduced MCP-1 release from synovial cells following hypoxic exposure (Sivakumar 
et al. 2008). Our data therefore suggest a HIF-dependent downregulatory effect on MCP-1 
expression which is consistent with published findings in other cell types exposed to hypoxia 
or hypoxic-mimetics (Negus et al. 1998; Safronova et al. 2003; Bosco et al. 2004; 
Hohensinner et al. 2006). This effect was recently ascribed to a transcriptional repressor role 
of NF-κB by its interaction with its co-repressor HDAC, a histone modifying enzyme 
(Safronova et al. 2009) under hypoxia. The uncovering of a complex regulatory mechanism, 
coupled with its dual pro- and anti-angiogenic effect through its influence on inflammatory 
and endothelial cell recruitment make interpretation of MCP-1 expression in isolation 
extremely difficult. It is becoming apparent that its eventual effect on tumour angiogenesis 
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would be highly variable and would be dependent upon temporal and tumour environmental 
context. 
CXCL6 is a low molecular weight cytokine belonging to the ELR+CXC chemokine 
family which is also known as granulocyte chemotactic protein 2 (GCP-2). CXCL6 acts as a 
chemoattractant (Proost et al. 1993) by interacting with its reciprocal chemokine receptors 
CXCR1 and CXCR2 (Wuyts et al. 1997) which are typically expressed by neutrophils and 
granulocytes. CXCL6 has been implicated in tumourigenesis and angiogenesis in several 
studies (Van Coillie et al. 2001), as its expression by endothelial cells primarily at the 
junctions of tumoural and normal tissue often represent sites of neovascularisation (Gijsbers 
et al. 2005). Although the pro-angiogenic effect of CXCL-6 is dependent upon MMP-9 
production by recruited neutrophils (Gijsbers et al. 2005), a recent study failed to show any 
clinicopathological significance in CXCL-6 expression in primary colorectal adenomas, 
carcinomas and corresponding metastatic liver lesions compared to control tissue (Rubie et al. 
2008). CXCL-6 expression has been demonstrated to be inducible by pro-inflammatory 
cytokines (Gijsbers et al. 2005; Zhu et al. 2006; Vandercappellen et al. 2007), but effects of 
EGF and HIF overexpression on CXCL-6 expression in CRC remain unexplored. CXCL-6 
was shown in my gene array studies to be significantly downregulated in Caco-2 cells 
following stimulation with EGF or DMOG in isolation. CXCL-6 has been demonstrated to be 
upregulated by hypoxia (Zhu et al. 2006) in squamous cell lung cancer cells, possibly through 
HIF-binding at the promoter region of CXCL-6, but this is still yet to be validated (Mine et al. 
2003; Zhu et al. 2006). However, microarray analysis of primary human monocytes has 
confirmed CXCL-6 as being one of the most highly repressed genes following hypoxic 
exposure (Bosco et al. 2006). It is apparent that the function of CXCL-6 still remains largely 
unknown, and further studies are required to elucidate its role in mediating angiogenesis in 
promoting carcinogenesis in CRC. 
Endoglin or CD105 is a transmembrane glycoprotein which primarily acts as an 
accessory protein in conjunction with the TGF-β receptor signalling complex. The interaction 
of endoglin with the TGF-β ligand/ receptor (TβR) complex modulates downstream responses 
to TGF-β signalling, such as controlling endothelial cell proliferation, migration and 
transcription of pro-angiogenic genes, or to induce a state of quiescence. Presence of endoglin 
selectively recruits ALK1 (Activin receptor-like kinase 1), as opposed to the inhibitory 
ALK5, in the formation of the heterotetrameric TβR complex. The TβR/ ALK1 receptor 
complex results in activation of Smad-2 signalling proteins and eventual transcription of 
several angiogenic genes such as eNOS, Id1, interleukin-1 receptor-like 1, and endoglin itself 
(Bertolino et al. 2005; Blanco et al. 2005). Endoglin is abundant in regions undergoing active 
angiogenesis, particularly within peritumoural and intratumoural blood vessels of several 
human solid malignancies including CRC. Immunohistochemical examination of resected 
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CRC specimens revealed a positive correlation of endoglin, CD31 counts and VEGF 
overexpression with angiolymphatic invasion and lymph node metastases. Endoglin 
expression was also significantly correlated with liver metastases and positive vascular 
pedicle lymph nodes. In endothelial cells, endoglin expression is induced by hypoxia through 
HIF-1 binding to a functional consensus HRE in the endoglin promoter (Sanchez-Elsner et al. 
2002). Despite the discovery of a putative HRE binding site, my data did not reveal 
significant alterations in endoglin expression in Caco-2 or Colo 201 cells following DMOG or 
hypoxia stimulation respectively. The data from my gene array however alludes to an EGF-
mediated downregulation of endoglin expression which has not been previously described, 
where stimulation of Caco-2 cells with EGF alone resulted in 0.7-fold downregulation, and in 
combination with DMOG resulted in further synergistic 0.29-fold downregulation in endoglin 
expression. 
Integrins are a family of heterodimeric transmembrane glycoproteins mediating 
bidirectional signalling across cellular plasma membrane to facilitate integration of the 
extracellular and intracellular environments (Hynes 1987). The integrin family consists of 
eight β and 18 α subunits that assemble as heterodimers to form 24 distinct integrins (Hynes 
2002). Integrins directly interact with the cytoskeleton (Zamir and Geiger 2001) and are 
therefore capable of regulating various aspects of cell behaviour, including survival, control 
of transcription, cell proliferation and motility, and cytoskeletal organisation (Hynes 2002). 
The integrins αvβ3 and αvβ5 which are particularly expressed in proliferating endothelial 
cells, and commonly found within tumour vasculature (Leavesley et al. 1993; Brooks et al. 
1994; Friedlander et al. 1995; Tonnesen et al. 2000), facilitate co-ordinated interactions 
between cells and extracellular matrix to promote angiogenesis (Brooks et al. 1994). Whereas 
integrin expression by endothelial cells associated within CRC has been demonstrated to 
enhance tumour angiogenesis (Vonlaufen et al. 2001), its expression by CRC cells 
predominantly enhances cellular proliferation and extracellular matrix invasion by activating 
and distributing proteases (Brooks et al. 1996; Deryugina et al. 2000; Karadag et al. 2005; 
Conti et al. 2008). Only one previous study performed using NIH3T3 cells confirmed ITGβ3 
expression was unaffected by transient stimulation with EGF. Such findings are in 
concordance with my data from the angiogenesis array. The study however showed that 
induction of ITGβ3 gene transcription required sustained activation of the ERK MAP kinase 
pathway (Woods et al. 2001). Despite this evidence, Colo 201 which have been characterised 
in our study to express constitutively activated ERK MAP kinase pathway did not exhibit any 
significant changes in ITGβ3 gene transcriptional activity even with additional EGF 
stimulation. Similarly, overexpression of HIFs through hypoxia or DMOG stimulation did not 
affect ITGβ3 transcriptional activity in both CRC cell types. The only comparable and 
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relevant data was derived from work on extravillous trophoblast cells, which mimicked 
endothelial cells in vitro. This study demonstrated HIF-1α dependent upregulation of ITGβ3 
and VEGF which encouraged tube formation in matrigel under hypoxic conditions 
(Fukushima et al. 2008). My gene array study identified significant 0.15-fold downregulation 
in ITGβ3 expression only with Caco-2 cells stimulated with combined EGF and DMOG 
stimulation. This finding which has not been previously described opposes the current 
accepted understanding that integrins facilitate a pro-angiogenic and tumourigenic 
environment. However this doctrine has been challenged in an animal study where tumour 
growth comprised of melanoma cells within ITGβ3-deficient mice were significantly 
enhanced through increased tumour angiogenesis by a compensatory mechanism involving 
upregulation in VEGFR-2 expression (Reynolds et al. 2002). 
In summary, a range of genes with the potential to regulate angiogenesis have been 
identified to be regulated by hypoxia/DMOG and/or EGF in Colo 201 and Caco-2 cells. The 
broader implications of these findings in the context of angiogenesis in CRC will be discussed 
in Chapter 6. In the next chapter, the development of ex-vivo CRC cell cultures from primary 
CRC tissue will be described, with an aim of establishing a more representative cell culture 
model which will be more comparable to that of in vivo cancers. The angiogenic responses 
from these novel cell cultures will be examined following EGF and hypoxia stimulations, and 
will be benchmarked against data obtained from my earlier work with the CRC cell lines. 
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5 STUDIES USING CELL CULTURES FROM TUMOUR 
TISSUE 
5.1 INTRODUCTION 
My study using two CRC cell lines as described in Chapter 3 and Chapter 4 identified 
cell-specific responses to EGF and hypoxia stimulation which were attributed to variations in 
cell signalling pathways. Cell-based models such as the Colo 201 and Caco-2 CRC cell lines 
have proven to be invaluable for furthering our understanding into tumour biology and 
elucidating potential targets for therapies. To date, cell culture models have found wide 
application in studies of cancer biology, as well as in the development and validation of new 
therapeutic approaches. The widespread application of cell culture models is a consequence of 
their relative ease of use, low labour, and minimal financial costs to maintain a cell system. 
The accuracy and depth of experimental studies could therefore be enhanced through the use 
of multiple cell lines. However, the most valuable feature of these cell systems is their 
clonogenic capability to consistently reproduce cell populations with identical properties. 
These reasonably stable cell systems with capacity for self-renewal represent the ideal 
opportunity for moderate throughput capabilities, and form the basis for valid and consistent 
comparisons to be drawn between experiments. Such properties therefore present the unique 
opportunity for mathematical determination of synergy, additivity and antagonism in studies 
where multiple combinations of drugs are involved. 
Although much can be gained from work with cell lines, there are also considerable 
limitations to using such cell models. The tumour microenvironment has a significant 
contributory role in supporting transformation, proliferation, survival and invasion of cancer 
cells. The absence of this stromal supportive framework in cell line cultures thus represents a 
significant downfall as an accurate representation of a cancer model. In addition, the absence 
of functional solid organs makes cell culture systems a poor representational model to study 
the effects of a pharmacologic drug, as the efficacy of the drug may rely on prior activation to 
achieve its active metabolite. Furthermore, potential variations in drug delivery and exposure 
are immeasurable in such cell systems. However, the most significant concern of using such 
immortalised cells is their discordance in behaviour relative to their tissue of origin in vivo, 
due to accumulation of multiple genetic mutations secondary to genomic instability. This is 
reflected by the study by Spremulli et al (Spremulli et al. 1983) where cell lines with different 
characteristics were established from two metastatic deposits from the same patient. Cell lines 
derived from metastatic sites normally comprise of a highly selected cell population possibly 
from a single cell origin (Kerbel 1984; Kerbel et al. 1984) and furthermore, cell lines derived 
from metastases are less differentiated than cells from the primary tumour (McBain et al. 
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1984). This is the paradox of cell lines, where the genomic mutations which endow the ability 
to grow indefinitely in vitro also transform them beyond their recognisable genotypic origins. 
In order to address the limitation posed by the genetic instability of CRC cell lines, an 
alternative would be to establish cancer cell cultures directly from patient tissue. The aim 
would be to establish cell cultures retaining differentiated features of colorectal epithelium 
displaying greater heterogeneity and differentiation. CRC cell cultures can be developed from 
ascitic effusions (such as the Colo 201 cells), metastatic tissues (regional lymph nodes and 
distant metastatic sites), and primary tumour. Establishing cell lines from ascitic effusions has 
proven to be more efficient than establishment from primary tumours, because cancer cells 
are rich, free floating and primed for in vitro growth. However, effusions usually contain 
mesothelial cells and lymphocytes which attach more readily to flasks and are capable of 
survival for more than one year. Since these mesothelial cells do not originate from the site of 
primary tumour, they are not representative of the supportive stromal framework of the 
primary cancer. The alternate methods of establishing cell cultures directly from tumour 
tissue include explantation techniques, or dissociation of cancer cells from primary tissue 
either by enzymatic digestion or mechanical spill-out technique. The procedure of 
disaggregating solid colorectal tumours to produce cell suspensions by enzymatic digestion, 
typically with collagenase, has previously been described (McBain et al. 1984; Giavazzi et al. 
1986; O'Brien et al. 2007; Oikonomou et al. 2007; Ricci-Vitiani et al. 2007). A similar 
technique has been successfully employed in our laboratory to culture cells from human 
atherosclerotic plaques and rheumatoid arthritic (RA) tissue to study pathways underlying 
their pro-inflammatory components (Elliott et al. 1993; Monaco et al. 2004). This novel ex 
vivo CRC culture model, using cells derived from human tissue would confer the advantage 
of a heterogeneous CRC cell population which would more accurately reflect in vivo 
conditions. 
The four main barriers to successful establishment of CRC cell cultures as described 
in previous studies include infection of cultures by microbes, contamination and overgrowth 
of fibroblasts, selective isolation of viable clusters of cancer cells from a milieu of dead and 
dying cells, and paucity of cell lines to grow and propagate (Franks 1976). Contamination 
with microbes is unavoidable given that primary CRC cells originate from cancer tissue 
within the large bowel which is known to be heavily colonised with a wide spectrum of gut 
flora. Therefore the objective is to reduce the microbial inoculum in the cultures by strict 
hygiene during processing of the tissues, use of a cocktail of antimicrobials and antifungals to 
suppress growth during washing of tissue samples, processing and early cultivation of the 
isolated cells (Giavazzi et al. 1986; Harris 1996; Oikonomou et al. 2007). Fibroblast 
overgrowth can be overcome by selective mechanical removal of contaminating fibroblasts 
following culture initiation, use of mechanical dissociation techniques rather than enzymatic 
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digestion for dispersion, differential trypsinisation on passaging cultures (Park et al. 2003), or 
the use of fully-defined media with avoidance of serum supplementation and low calcium 
(Boynton et al. 1977; Park et al. 1987; Munaron et al. 1995). 
One of the main challenges during the initial phases of CRC cell line culture is to 
encourage and promote continued cancer cell proliferation. This is reflected by the wide 
variation in reported success rates ranging from 10% to 45% (Leibovitz et al. 1976; McBain 
et al. 1984; Kirkland and Bailey 1986). Various techniques trialled to improve success rates 
include non-enzymatic dissociation of tumour tissue, delaying initial passage until a high cell 
density had been reached, seeding of cells at high density and continual removal of 
contaminating fibroblasts (Kirkland and Bailey 1986). The use of feeder cells primarily with 
mouse 3T3 cells (Paraskeva et al. 1984) and collagen-coated growth vessels have been 
advocated in studies (Park et al. 2003; Oikonomou et al. 2007; Ricci-Vitiani et al. 2007), but 
there is a lack of overall consensus as other studies have successfully established cell lines in 
their absence (McBain et al. 1984; Kirkland and Bailey 1986). Successful establishment of 
cell lines also appears to rely on maintenance of cell-cell contacts, thus several studies have 
recommended passaging with dispase which removes cells as clumps rather than as single 
cells. Normal colonocytes and early-stage adenomas have failed to survive following 
dissociation to single cells as colonocytes undergo apoptosis if cell-cell contacts are broken 
(Bedi et al. 1995). 
In addition to its fibroblast growth-suppressive effect, fully-defined culture media 
also confers significant advantage in sustaining proliferation of cells, as the media could be 
optimised for selective growth of human CRC cells. With increasing studies confirming the 
existence of cancer stem cells in initiating and sustaining infinite clonal expansion in cancers, 
it is conceivable that established cell lines are capable of continued replication through cancer 
stem cell renewal, and subsequent generation of future progenies. Fully defined culture media 
therefore offers an unprecedented advantage for culture of such cancer stem cells, as the 
constituents of the culture medium can be finely adjusted to allow control over growth and 
differentiation of the relative stages of CRC cells in culture (Park et al. 1987; Park et al. 2003; 
Ricci-Vitiani et al. 2007). In addition, fully defined culture media offers the great advantage 
of eliminating potential confounding effects imposed by unknown stimulants or inhibitors 
within serum-enriched media, thus facilitating the development of more robust and superior 
study designs. 
156 
MD (Res) Thesis Tak Loon Khong 
Chapter 5 
5.2 OBJECTIVE 
The objective of this part of my study was to establish a novel ex-vivo culture of 
heterogeneous cell population isolated from CRC tissue following surgical resection of the 
tumour. The cells would be cultured and propagated to provide sufficient cell numbers for 
EGF and hypoxia stimulation studies to be performed. As the cells used for the stimulation 
experiments are derived from primary CRC tissue, our investigation into the angiogenic 
responses of EGF and hypoxia on CRC would be more representative and relevant to the in 
vivo conditions. 
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5.3 METHODS 
5.3.1 ESTABLISHMENT OF CRC CULTURES 
All colorectal specimens were obtained from patients with diagnosis of 
adenocarcinoma involving the colon and rectum from Charing Cross Hospital, London. 
Histopathological diagnosis of tumour specimens were confirmed prior to surgery by 
examination of biopsies obtained during colonoscopy by the Histopathology Department at 
Charing Cross Hospital. The study was approved by the local ethics committee. Patients 
participating in the study had a written information leaflet and full consent was obtained prior 
to surgery. Specimens removed from patients were taken immediately to the histopathology 
department for examination prior to opening of the specimens by the pathologist. Tissue 
samples measuring 0.25 – 0.5cm3 in size were excised from the invading edge of the cancer 
and were placed directly in washing medium at 4oC. 
Following multiple washings with wash medium to reduce microbial contamination, 
the tissue was minced with surgical blade and then digested within 1 to 2 hours of removal 
from patients. Tumour specimens were digested with 1mg/mL of Collagenase A (Roche, 
Mannheim, Germany) at 37oC for approximately 1 hour, at which point the digestion solution 
became cloudy and viscous with strands of undigested mesenchymal fibrous tissue visible in 
suspension. The viscous digested mixture was separated into two fractions and diluted with 
Hanks’ medium prior to filtration through nylon gauze. After excluding undigested 
mesenchymal tissue by filtration, the filtrate was centrifuged to recover various cellular 
components released by the digestion process. The various cellular constituents comprising of 
cellular debris, single cells (mostly stromal elements and erythocytes), clumps of cells and 
epithelial tubules were further subjected to differential density gradient separation using 
polysaccharide solution. Fractions containing larger sized cellular components were extracted 
and washed with Hanks’ medium, followed by centrifugation to recover the constituent cells. 
The heterogeneous cell population was inspected by phase contrast microscopy and 
total cell counts were determined prior to seeding into tissue culture flasks. Various culture 
media were trialled to establish CRC cultures, including foetal calf serum (FCS) 
supplemented media and two fully defined media in the form of MCDB and selective stem 
cell promoting media. The cultures were left undisturbed during the initial 48-hours of 
seeding to encourage attachment, but cultures were subsequently examined under phase 
contrast microscopy every alternate day. The first medium change was performed five days 
following initial seeding and twice weekly subsequently. During the first few medium 
changes, the extracted medium was centrifuged to recover any non-adherent material which 
were resuspended and replated in fresh growth medium. Cultures were discontinued if there 
158 
MD (Res) Thesis Tak Loon Khong 
Chapter 5 
was microbial contamination or regression of cultures with minimal evidence of surviving 
adherent cell colonies.  
5.3.2 STIMULATION OF CRC CELLS WITH EGF AND HYPOXIA 
During the later phases of this study, cells isolated from primary CRC tissue 
following the digestion process were directly subjected to stimulation experiments, rather 
than their original intended use for initiating cell cultures. The behaviour of CRC cells to 
stimulation was also compared to cells isolated from normal non-diseased tissue obtained 
from the same resection specimen in selected patients. The mixed population of cells isolated 
from both cancer and control samples were suspended in RPMI supplemented with 20% FCS 
and allowed to settle for a period of at least 6 hours after tissue digestion. The isolated cells 
were then directly stimulated with 20ng/mL EGF and/or hypoxia at 1% oxygen. Cells were 
examined under phase contrast microscopy before and after stimulation experiments, and 
representative photographs were taken. The supernatants were extracted at 6 and 24 hours 
following stimulation and VEGF protein expression was determined by ELISA. There were 
considerable variations in the total number of cells yielded by different tumour and control 
samples, but replicate experiments were performed where permitted by sufficient cell 
numbers. The VEGF protein expression data was compiled from individual experiments and 
plotted on a scatter plot, and where replicates were performed, a mean was taken for each 
experimental condition. 
5.3.3 STATISTICAL ANALYSIS 
The relationship between VEGF protein expression by CRC and control tissues were 
evaluated by Spearman rank correlation test. Two-way ANOVA test was applied to compare 
the expression of VEGF following 6 and 24 hours of EGF and hypoxia stimulation versus 
unstimulated controls. The Friedman test with multiple comparisons was used to analyse the 
overall effect of EGF and hypoxia stimulation on VEGF expression compared to unstimulated 
controls. Results were considered statistically significant if P values were 0.5 or less. 
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5.4 RESULTS 
Attempts were made to isolate and culture CRC cells from 9 consecutive surgical 
resection specimens (Table 5.1). All 9 attempts failed to generate cell lines which could have 
been used as an experimental cell culture model. The main problems encountered were low 
isolated yield of CRC cells, microbial infection of cultures and failure of cells to propagate. 
Table 5.1 Characteristics of CRC specimens from which cultures were attempted 
Table summarises the clinical characteristics of patients from which primary tissue was obtained. 
Demographics includes patients’ age, sex, site, stage and differentiation of tumour, and use of pre-
operative chemo- or radiotherapy treatment. SCRT – short course radiotherapy. 
Clinical characteristics 
Histological 
stage Patient ID Age Gender Site of cancer TNM Dukes 
Differentiation Pre-op therapy 
31070701 87 M Desc colon T4N0 B Moderate None 
06080701 86 M Asc colon T3N0 B Moderate None 
13090701 84 M Caecum T2N0 A Moderate None 
14090701 85 M Sigmoid T4N1 C1 Mucinous None 
17090701 63 M Desc colon T2N0 A Moderate None 
24090701 57 F Rectum T3N0 B Moderate SCRT 
26110701 59 F Rectum T1N1 C1 Moderate None 
03010801 81 F Caecum T4N0 B Poor None 
14030801 82 M Asc colon T3N0 B Moderate None 
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Following tissue digestion, undigested tissue was separated from the disaggregated 
heterogeneous cell population by filtration, and the cell concentration and total cell numbers 
present in the filtrate were determined. The total cell yield within the filtrate varied 
considerably from 1.4x105 to 1.6x107 cells. Cells at time of seeding were comprised of 
heterogeneous population of single cells or clumps of cells adopting a multitude of 
morphology. Figure 5.1 shows that a number of erythrocytes were present following digestion 
of the primary tissue, and this was reduced by performing a cell separation based on selective 
sedimentation of erythrocytes using mixtures of polysaccharide solution (Histopaque-1077) 
by generating a density gradient. 
Figure 5.1 Phase-contrast microscopy of the mixed cell populations isolated 
following CRC tissue digestion with collagenase 
Photographs showing heterogeneous population of cells isolated from CRC tissue existing as single 
cells or clusters of cells adopting a multitude of morphology. At x200 magnification, cell clusters 
appeared to be mainly comprised of larger sized cells. A number of erythrocytes (smaller and 
doughnut-shaped) were also present within the culture. 
 
x 40 x 200
One of the challenges of culturing primary CRC cells was to maintain a sterile culture 
as the tissue of origin of these cells were naturally colonised by commensal intestinal bacteria. 
Despite using high doses of antibacterial and antifungal agents, 3 out of the 9 initial attempts 
in establishing primary cultures resulted in bacterial overgrowth. The infected cultures had a 
cloudy and turbid appearance and furthermore, inspection under microscopy revealed 
numerous small cells floating freely in suspension undergoing active replication and budding 
as illustrated by Figure 5.2. These cells exhibited an extremely high rate of turnover as they 
were observed to have multiplied by 1685-fold within 4 days from their first passage (from 
seeding number of 3.75 x 105 to 6.32 x 108 cells). In addition, there were also large clumps of 
freely suspended cells, commonly attached to short length fibrils which resembled the 
remains of undigested collagen fibrils. These large clumps of cells were typically non-viable 
cells as they stained intensely with Trypan blue. There was absence of morphologically larger 
sized cells consistent with epithelial cells and there were no identifiable adherent cells. 
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Figure 5.2 Phase-contrast microscopy representing an infected culture of cells 
derived from CRC tissue 
Microscopic appearances of an infected, cloudy and turbid culture characterised by predominance of a 
homogenous population of numerous small cells floating freely in suspension which demonstrate 
extremely high mitotic rates. 
 
5.4.1 ESTABLISHING PRIMARY CELL CULTURES WITH SERUM SUPPLEMENTED 
GROWTH MEDIA 
The objective for establishing a de novo cell culture was to achieve a representative 
cell culture model with minimal reliance on serum, in order to limit confounding effects from 
serum supplementation in my experiments. However, this had to be balanced with the 
inherent difficulty and unpredictability of establishing sustainable primary CRC cultures with 
the ability for continued survival, growth and self-renewal. Serum supplementation is 
commonly used in cell cultures to simplify the complex requirements of cultured cells by 
providing a broad spectrum of macromolecules, carrier proteins, lipoid substances and trace 
elements, attachment and spreading factors, low molecular weight nutrients, and hormones 
and growth factors (Gstraunthaler 2003). Therefore, two attempts were made at culturing 
primary CRC cells from primary tissue (Table 5.1) using a reduced concentration of 5% 
serum as opposed to the conventional 10% serum supplementation to the cell culture media. 
Both attempts resulted in adherence of cells onto the flask within Day 2 of seeding, but 
unfortunately the isolated cells failed to sustain their proliferation and eventually underwent 
apoptosis by Day 11 and Day 15 in respective patients. 
On Day 2 following isolation of CRC cells, phase-contrast microscopy (Figure 5.3) 
showed presence of several colonies comprised of adherent cells with scattering of single 
cells and cellular debris or tissue remnants freely suspended in the culture. Figure 5.3B shows 
varying cellular densities within individual colonies, with each colony generally comprised of 
small and rounded cells. 
x 100 x 200
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Figure 5.3 Phase-contrast microscopy of heterogeneous cell population at Day 2 
post isolation from primary CRC tissue (5% FCS-containing medium)
Adherent cells forming colonies were observed in cultures at Day 2 of seeding. At x100 magnification, 
the colonies appeared to be formed by varying number of cells coalescing together, thus resulting in 
different cell densities found within individual colonies. Non adherent solitary cells, cell debris and 
undigested mesenchymal remnants were also seen freely suspended in the culture. 
 
A x 40 x 100 B 
Figure 5.4 Phase-contrast microscopy of heterogeneous cell population at Day 4 
post isolation from primary CRC tissue (5% FCS-containing medium) 
Heterogeneous cell population composed of solitary cells or cells forming aggregates, which were 
either freely floating in suspension or adherent to the culture vessel as illustrated by Figure 5.4A. 
Figure 5.4B illustrates outgrowth of cells emanating from the adherent cell clusters, with enlargement 
of individual colonies at Day 4. The proliferating polygonal-shaped cells were closely packed and grew 
as an adherent monolayer, with edges of colonies consisting of elongated cells forming a flattened, 
well-defined border. 
 
x 40 x 100
x 100
A B 
C
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The phase-contrast images at Day 4 (Figure 5.4) following isolation of cells from 
primary CRC tissue showed a mixed cell population, similar to that seen immediately post-
digestion with collagenase. The cells existed either as single cells or in clumps, and were 
either freely floating in suspension or adherent to the bottom of the flask. Between Day 2 and 
4, there was increased outgrowth in the colonies of adherent cells with cells observed to 
migrate out (Figure 5.4B). The adherent cells grew as a monolayer, adopting a closely packed 
polygonal morphology, with some colonies composed of elongated cells along the edge of the 
epithelial sheet (Figure 5.4C). 
At Day 10, the CRC culture exhibited an overall increase in number of adherent cell 
colonies, and each colony appeared larger in size as illustrated by (Figure 5.5 and Figure 5.6). 
The individual colonies were distributed sparsely throughout the T75 flasks and there was 
considerable variation in their relative size and morphology between individual colonies. As 
the medium was changed on Day 5 by removal of the old supernatants, there was generally 
less cell debris and single cells floating freely in suspension. The supernatants which were 
removed were reseeded into new T75 flasks with fresh medium, but these unattached cells 
and epithelium failed to develop into further proliferating or sustained cultures. 
Figure 5.5 Phase-contrast microscopy at 40x magnification of cells at Day 10 
following isolation from CRC tissue (5% FCS-containing medium) 
There was an overall increase in number of adherent cell colonies and size of individual colonies. 
Significant variation was noted in relative size and morphology between the different colonies. Highly 
dense clusters of poorly organised cells were identified at the centre of the adherent monolayer of 
epithelial-like cells (A & B). This dense core of cells was typically surrounded by outgrowth of a 
variant cell type, which was neatly organized in monolayer and adopted a polygonal structure. 
 
x 40 x 40A B
Figure 5.6A shows a colony of cells adopting a halo-like appearance as the central 
dense core appeared to comprise of a cluster of disorganised cells arranged in multiple layers, 
and a periphery composed of cells which were less tightly condensed. These clusters of 
haphazardly arranged cells were observed to either exist in isolation, but more commonly 
they were located at the centre of most adherent cell populations showing signs of outgrowth 
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(Figure 5.5). This is illustrated by Figure 5.6A and Figure 5.6E, both of which are 
photographic images of the same cell colony at different magnifications. Both images 
demonstrate highly dense clusters of disorganised cells surrounded by an outgrowth of a more 
organised monolayer of polygonal shaped cells. A similar appearance was also noted in 
several of the other cell colonies as illustrated by Figure 5.6C and Figure 5.6D. Outgrowth of 
this monolayer of organised adherent cells from its central dense cluster appeared similar to 
those observed in Day 4. The cells located in the periphery of the cell cluster adopted a 
closely packed polygonal morphology, with some colonies composed of elongated cells along 
the edge of the epithelial sheet (Figure 5.5B, Figure 5.6C and Figure 5.6D). In the smaller 
colonies, these monolayer adherent cells were more clearly visible and they had large nuclei. 
They demonstrated varying morphology, ranging from rounded cuboidal cells to elongated 
spindle-like cells, thus giving these cell clusters a cobble-stoned appearance (Figure 5.6E to 
H). Although most of the larger adherent cell colonies were composed of a composite of the 
two different cell populations with distinctly contrasting morphology, some of the smaller cell 
colonies were composed solely of the polygonal cell type as illustrated by Figure 5.6E to G. 
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Figure 5.6 Phase-contrast microscopy at 100x magnification of cells at Day 10 
following isolation from CRC tissue (5% FCS-containing medium) 
Highly dense clusters of poorly organised cells (Figure 5.6A) were typically at the centre of adherent 
monolayer colonies of epithelial-like cells (Figure 5.6C-E). Cells located at the periphery of clusters 
possessed large nuclei, and appeared rounded and cuboidal or elongated with spindle-like morphology, 
producing colonies with cobble-stoned appearances (Figure 5.6E to H). Several colonies had flattened, 
elongated cells forming the edge of the epithelial sheet (Figure 5.6C & D). Smaller cell colonies were 
noted to be composed solely of the polygonal cell type (Figure 5.6G and Figure 5.6H), with absence of 
the disorganised and condensed subpopulation of cells. 
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Although the cell colonies at Day 14 of culture appeared larger in size compared to at 
Day 10, there were however early signs of involution with an overall decrease in total number 
of adherent cell colonies. As a result, the individual colonies were distributed even more 
sparsely throughout the T75 flasks, and as noted before there was considerable variation in 
their relative size and morphology between individual colonies. Some of the remaining 
adherent cell colonies continued to adopt the composite structure composed of a dense 
hypercellular core surrounded by a rim of more translucent cells (Figure 5.8A-C) as 
previously described, but there was emergence of new smaller colonies adopting a smooth-
surfaced spheroid structure (Figure 5.7B and Figure 5.7C). In addition the expansion in size 
of the colonies allowed architecture and several fine structures to be identified, notably the 
presence of transparent vacuoles which were particularly located at the periphery of the cell 
colonies. 
Figure 5.7 Phase-contrast microscopy at 40x magnification of cells on Day 14 
following isolation from CRC tissue (5% FCS-containing medium) 
Cell colonies showed further increase in size, but there was also an overall decrease in total number of 
adherent cell colonies. Fluffy dense aggregates of cellular material were seen projecting from the centre 
of cell colonies (Figure 5.7A), coinciding with the novel appearances of dense and disorganised multi-
cellular clusters floating freely in suspension (Figure 5.7D). These aggregates in suspension were 
disorganised and cell densities varied significantly within individual aggregates. There was emergence 
of new smaller colonies adopting a smooth-surfaced spheroid structure (Figure 5.7B and Figure 5.7C). 
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Figure 5.8 Phase-contrast microscopy at 100x magnification of cells at Day 14 
following isolation from CRC tissue (5% FCS-containing medium) 
Adherent cell colonies demonstrated two apparent subpopulations of cells forming a composite 
structure, composed of a dense hypercellular core surrounded by a rim of more translucent cells (Figure 
5.8A-C). Figure 5.8D shows free-floating cell clusters composed of compacted cells arranged unevenly 
to form aggregates with varying cell densities. Fluffy dense aggregates of cellular material are seen 
projecting from the centre of cell colonies as previously noted (E-G). Figure 5.8F shows the smaller 
smooth-surfaced spheroid colonies at higher magnification. 
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However, the most striking difference in the cultures noted between Day 10 and 14 
was the novel appearance of dense clusters of cellular material floating freely in suspension as 
illustrated by Figure 5.7D. These multi-cellular clusters in suspension were disorganised with 
cells arranged in varying densities within individual aggregates (Figure 5.8D), features which 
resembled the previously described dense inner core of adherent cell colonies. The 
appearance of this freely suspended dense cellular material also coincided with another 
unique feature noted at Day 14 of culture, notably the presence of fluffy dense aggregate of 
cellular material projecting from the centre of cell colonies. This can be better appreciated by 
photographs of two separate colonies at low magnification (Figure 5.7A and Figure 5.7B) and 
their corresponding images at higher magnification (Figure 5.8E and Figure 5.8F). This cell 
separation process occurred over days, with various colonies within a T75 flask noted to be at 
various phases of extruding cellular material from their respective cell colonies. The size of 
the expelled material was also noted to progressively increase with time (Figure 5.9). The 
projected cellular material typically originated from the centre of cell colonies, thus its 
location and microscopic appearance was highly suggestive of extrusion of the dense central 
core comprised of disorganised cells. This process subsequently resulted in the polygonal 
cells located at the periphery of the adherent cell colonies to be left as remnants. 
Figure 5.9 Phase-contrast microscopy of a cell colony at 16 days following isolation 
from CRC tissue (5% FCS-containing medium) 
Microscopic appearances were consistent with a cell separation process, where the pre-existent dense 
central core was extruded from adherent cell colonies. This process initially left the subpopulation of 
polygonal cells sited at the periphery of colonies to remain solitarily, but there was gradual progressive 
loss of these cells over the subsequent days. 
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From Day 14 onwards, there was progressive loss of adherent cell colonies which 
was typically preceded by the extrusion of dense cellular material from their core. As a result, 
cell cultures isolated from CRC using RPMI medium supplemented with 5% FCS failed to 
progress into sustainable long term cultures. 
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The practice of serum supplementation in culturing cells simplified the process of 
fulfilling the complex requirements of cultured cells. However, the disadvantage is that cells 
are cultured with a supplement of undefined components at unknown concentrations. Since 
various differentiated cell types have adapted to perform specific and specialised 
physiological roles, it is possible that the supplementary requirements to sustain cellular 
proliferation and survival may vary considerably between cell types. It is therefore 
conceivable that the initial failure to establish a sustainable cell culture from primary CRC 
tissue may be due to inadequate supplementation with growth and survival factors using 5% 
FCS. The next attempt at culturing CRC cells therefore used a higher concentration of 20% 
FCS. 
Figure 5.10 Phase-contrast microscopy of cells at Day 4 following isolation from 
CRC tissue (20% FCS-containing medium) 
Heterogeneous cell population composed of solitary cells or cells forming aggregates, which were 
either freely floating in suspension or adherent to the culture vessel. Adherent monolayer of cells 
possessed large nuclei, and appeared polygonal or elongated with spindle-like morphology (Figure 
5.10C and Figure 5.10D). Figure 5.10B shows the unique architectural feature of transparent vacuoles 
present within cells forming the adherent cell colony (Figure 5.10B). 
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Following digestion of primary CRC tissue (Table 5.1), the isolated cell and tissue 
remnants were cultured in RPMI supplemented with 20% FCS, penicillin/streptomycin and 
amphotericin. At Day 4 following cell isolation there was marked heterogeneity in the cell 
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culture, appearances which were similar to my earlier attempts at primary CRC cultures. The 
cells existed either as single cells or adherent in clumps, and could be further subdivided into 
those freely suspended in culture or adherent to the T75 flask. Amongst the variety of cells 
was a subpopulation of adherent cells clumped together form colonies as illustrated by Figure 
5.10. Many of the hallmarks of these adherent cell colonies paralleled those which were 
encountered in my earlier cultures, mainly their diffuse distribution throughout the T75 flask, 
and the characteristic tightly-packed monolayer of polygonal shaped cells with large visible 
nuclei. These features are depicted by the phase contrast photography of a cell colony taken at 
different magnifications (Figure 5.10C and Figure 5.10D). Furthermore, certain architectural 
features of the cells could be identified at Day 4, primarily the presence of transparent 
vacuoles present within cells forming the adherent cell colony (Figure 5.10B). 
Figure 5.11 Phase-contrast microscopy of cells at Day 6 following isolation from 
CRC tissue (20% FCS-containing medium) 
There was an overall increase in number of adherent cell colonies and size of individual colonies. 
Significant variation was noted in relative size and morphology between the different colonies. Figure 
5.11C and Figure 5.11D show adherent cell colonies to be a composite of 2 subpopulations of 
phenotypically varying cells, with the centre formed by a dense core of cells, and a periphery formed 
by polygonal and spindle-shaped cells arranged neatly in monolayer. 
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At Day 6, there was an overall increase in total number of adherent cells which were 
distributed diffusely throughout the T75 flask, with some cells coalescing to form colonies 
and some existing as solitary cells (Figure 5.11A and Figure 5.11B). The appearances of 
several of the larger adherent cell colonies resembled previously cultured cell colonies using 
5% FCS (Figure 5.8A). The obvious features common to both cultures of varying serum 
concentrations was the appearance of adherent cell colonies composed of two separate cell 
aggregates with different morphology within individual colonies. Figure 5.11C and Figure 
5.11D are photographs of the same cell colony at different magnifications illustrating a 
central dense core of cells surrounded by a periphery of cells arranged in monolayer. These 
peripheral cells appeared to adopt a more rounded and cuboidal appearance towards the outer 
edge of the cell colony, and cells closer towards the central hypercellular core appeared 
typically more fusiform. Due to the high density of cellular material within the central core, 
the higher structures within the cells could not be identified. However, the evenly distributed 
peripheral cells which were arranged in monolayer appeared to have large and clearly visible 
nuclei with possibility of forming vacuole-like structures. 
Although several solitary adherent cells remained in culture at Day 11, the noticeable 
difference was the increase in size of the aggregated cell colonies between Day 6 and Day 11 
which was primarily due to increased cell numbers of individual colonies (Figure 5.12A-C). 
Unlike cultures with 5% FCS, the dense hypercellular core was less prominent within 
individual cell colonies at Day 11 of culture. However, adherent colonies were formed by the 
distinctive polygonal shaped, large nucleated cells with the characteristic morphologically 
flattened cells outlining the periphery of colonies. There were also vacuole-like structures 
found mainly between cells which ranged considerably in size between colonies (Figure 
5.12D and Figure 5.12E). 
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Figure 5.12 Phase-contrast microscopy of cells at Day 11 following isolation from 
primary CRC tissue (20% FCS-containing medium) 
Microscopy of the cultures at Day 11 showed increase in size of the adherent cell colonies compared to 
Day 6, mostly a result of increased cell numbers of individual colonies. Colonies were formed mainly 
by the distinctive polygonal shaped, large nucleated cells with flattened cells outlining the periphery of 
colonies (Figure 5.12A-C). Cell colonies also illustrated vacuole-like structures which ranged 
considerably in size and these were located between cells (Figure 5.12D and Figure 5.12E). 
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Figure 5.13 Phase-contrast microscopy of cells at Day 18 following isolation from 
CRC tissue (20% FCS-containing medium) 
At Day 18, cultures showed a general decrease in number and size of adherent cell colonies, with an 
associated increase in freely suspended cellular material and debris within culture media (Figure 5.13A 
& Figure 5.13C). Cells began to detach resulting in discontinuity of colonies (Figure 5.13B), and 
remnants of previously existing adherent cell colonies (Figure 5.13E) were noted. Vacuolated 
structures of various sizes were located between cells, and in several colonies represented the most 
prominent feature (Figure 5.13D). Figure 5.13F shows outgrowth of a new cell type, appearing 
elongated and fusiform-shaped with prominent long cytoplasmic projections and visible oval nuclei. 
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At Day 18 of culture, there was no further increase in size of the cell colonies but 
rather, there was a general decline in the total number of adherent cell colonies compared to 
Day 11 (Figure 5.13A and Figure 5.13C). This was also associated with increased cellular 
material and debris freely suspended in the supernatants of the cultures (Figure 5.13A), but 
the general condition of the medium remained unchanged and did not exhibit increased 
turbidity. Several cell colonies appeared to have lost cell-to-cell cohesion, thus leaving 
smaller satellites of aggregated cells or single cells detached from the larger body of cells as 
demonstrated by Figure 5.13B. Furthermore, this was associated with the lost of the flattened 
rim of peripheral cells typically found at the edge of the cell colonies. The main body of the 
cell colonies was mainly composed of vacuolated structures of wide-ranging sizes, and such 
structures overshadowed the presence of any epithelial-like cells which were previously 
noted. Figure 5.13D also shows cellular remnants of a previously existing adherent cell 
colony. This was verified by the presence of residual heterogeneous cellular material 
comprised of disorganised, tightly packed cellular material resembling that of the central core, 
and also several remaining cells containing vacuolated structures. Furthermore, there was the 
earliest outgrowth of a new cell type as illustrated by Figure 5.13F, comprising of elongated 
and fusiform-shaped cells which possess long cytoplasmic projections and visible oval nuclei. 
Despite early establishment of adherent cell colonies during the initial 2 weeks, the 
cultures failed to subsequently progress. Twenty-eight days following isolation of cells from 
primary CRC tissue, there was significant reduction in total number of adherent cells with 
remaining colonies showing either an overall shrinkage or no further increase in size (Figure 
5.14A & Figure 5.14B) compared to earlier phases of culture. Nevertheless, the colonies 
maintained structural characteristics which were previously noted as cells continued to form 
tightly organised colonies organised in monolayer (Figure 5.14C and Figure 5.14D), and 
prominent vacuolated structures were identified within these conglomerate of cells (Figure 
5.14E and Figure 5.14F). There was also further outgrowth of fusiform-shaped cells which 
were initially noted on Day 18, and the appearances of these morphologically different cells 
as illustrated by Figure 5.14G are consistent with that of fibroblasts. 
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Figure 5.14 Phase-contrast microscopy of cells on Day 28 following isolation from 
primary CRC tissue (20% FCS-containing medium) 
Cultures reveal an overall shrinkage in size and reduction in total number of adherent cell colonies at 
Day 28 (Figure 5.14A and Figure 5.14B). Colonies maintained previously described structural 
characteristics in the form of well-organised polygonal cells in monolayer (Figure 5.14C and Figure 
5.14D), and prominent vacuolated structures located between aggregates of cells (Figure 5.14E and 
Figure 5.14F). The new fusiform-shaped cells as previously noted demonstrated further outgrowth 
(Figure 5.14G). 
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5.4.2 ESTABLISHING PRIMARY CELL CULTURES USING PRE-DEFINED MEDIA 
Serum is widely used in cell cultures as it provides a balanced supplementation 
composed of a multitude of essential components, crucial for the continued survival and 
growth of cells in a single simple to use formulation. Despite using serum in my preliminary 
attempts at culturing cells from primary CRC tissue, the early established cell colonies failed 
to exhibit continued cell growth, proliferation and survival to yield self-sustaining CRC 
cultures. Further attempts were subsequently made with different culture media which 
eliminated use of animal sera as supplementation, but rather relied on a fully defined cell 
culturing system. The first of such defined medium to be employed was the MCDB medium 
which was adapted from work to grow human epithelial skin keratinocytes. 
Figure 5.15 Phase-contrast microscopy of cells in MCDB medium at 24 hours 
following isolation from primary CRC tissue 
Adherent cell colonies with spheroid-liked morphology were formed by disorganised cells, arranged 
tightly in the centre of aggregates and a periphery formed by more diffusely arranged cells (Figure 
5.15A and Figure 5.15B). Colonies were demonstrated to grow as an adherent monolayer composed of 
polygonal shaped cells arranged in a cobblestone pattern, similar to those cultured with serum (Figure 
5.15B-D). 
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Within 24 hours of initiating culture, there were noticeable adherent cell colonies 
distributed throughout the T75 flasks. Several of the colonies adopted a spheroid-like 
structure composed of tightly condensed cells as illustrated by Figure 5.15A and Figure 
5.15B. The morphology of these colonies resembled those previously noted in serum enriched 
cultures, notably the appearance of dense clusters of disorganised cells with peripheries 
composed of fewer cells giving them the halo-like appearance. Figure 5.15C and Figure 
5.15D illustrate two separate colonies showing early outgrowths of an adherent monolayer of 
polygonal shaped cells arranged to adopt a cobblestone pattern, appearances which also 
parallel that as observed in Figure 5.6. 
Figure 5.16 Phase-contrast microscopy of cell culture in MCDB medium on Day 4 
following isolation from primary CRC 
At Day 4, cultures exhibited modest outgrowth of cell colonies comprising of rounded cuboidal, or 
flattened fusiform-shaped cells. Cells forming adherent colonies were generally more diffusely 
arranged with larger intercellular spaces compared to serum supplemented media (Figure 5.16B and 
Figure 5.16C). Figure 5.16D shows a typical colony composed of neatly arranged polygonal cells 
containing large nuclei, with small aggregates of compact cells scattered at the periphery. These dense 
peripheral aggregates possess morphological features consistent with the spheroidal clusters as 
previously noted. 
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The individual adherent cell colonies demonstrated modest increase in size after 4 
days of culture. Spheroids composed of tightly compact cells were once again noted, and 
these were typically associated with early outgrowths of a monolayer of adherent cells which 
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adopted either rounded cuboidal, or flattened fusiform appearances (Figure 5.16A and Figure 
5.16B). In general, adherent cell colonies that formed with MCDB medium were more 
diffusely arranged with larger intercellular spaces, compared to colonies which formed under 
serum supplemented growth media (Figure 5.16B and Figure 5.16C). Furthermore, there was 
absence of an outer lining of flattened cells surrounding the more established colonies, unlike 
those which formed with serum enriched growth media. Figure 5.16D depicts a colony under 
higher magnification, clearly showing the finely arranged polygonal cells with relatively large 
nuclei. Furthermore, the presence of a small bunch of compact cells found at the periphery of 
the colony resembled the remains of a spheroidal cluster of densely packed cells. 
Figure 5.17 Phase-contrast microscopy of cell culture in MCDB medium on Day 10 
following isolation from primary CRC 
Cultures began to show signs of involution with colonies shrinking in size as a result of reduction in  
total number of adherent cells (Figure 5.17A and Figure 5.17B). This was accompanied by free-floating 
dense aggregates of cellular material as illustrated by Figure 5.17B and Figure 5.17C. These free 
floating aggregates coincided with the previously described cell separation process, where fluffy dense 
cellular material projected from various cell colonies (Figure 5.17C and Figure 5.17D).  
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Despite achieving early establishment and outgrowth of adherent cell colonies during 
initial phases of culture, the colonies subsequently failed to progress. This was proven by 
diminishing numbers and size of individual cell colonies by Day 10. The remaining colonies 
were therefore sparsely scattered throughout the T75 flask and individual colonies were 
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composed of several residual cells that remained adherent (Figure 5.17A and Figure 5.17B). 
This was also accompanied by the first appearance of dense aggregates of cellular material 
floating freely in suspension as illustrated by Figure 5.17B and Figure 5.17C. Similar 
compact aggregates were previously noted in serum enriched cultures (Figure 5.8D), and their 
presence seemed to herald an impending failing culture. These free floating dense cellular 
aggregates also coincided with fluffy, dense cellular material projecting from various cell 
colonies. This could be better appreciated by photographs of an individual colony at low and 
higher magnification (Figure 5.17C and Figure 5.17D) demonstrating this cellular extrusion 
process. The process subsequently left the polygonal cells located at the periphery of the 
adherent cell colonies as remnants, with the inevitable progressive contraction of the residual 
colonies. 
The ultimate objective of this part of the project was to create sustainable cultures 
which are representative of the CRC primary tissue of origin. The cultures would ideally 
possess self replicating and renewing capabilities in order to generate clones of genotypically 
and phenotypically identical progenies. These desired properties are conferred by a special 
subgroup of stem or precursor cells, found within selected tissue types in vivo that permit 
continual regeneration and replacement of terminally differentiated cells. These stem cells, 
plus the precursor cell compartment, would therefore make up the bulk of cells in a 
proliferating culture. Since the major obstacle encountered to date was failure of CRC 
cultures to propagate by clonal expansion, it was therefore reasonable that the next attempts 
would be to focus on supporting the stem or precursor cells using specialised culture media. 
Cells cultured using the specially formulated stem cell promoting medium appeared 
significantly different compared to previous cultures using serum supplementation and 
MCDB media. At Day 4 following enzymatic digestion of CRC tissue (Table 5.1), there was 
marked heterogeneity in the morphology of various cells in culture, with majority of cells 
coalescing to form clusters of various sizes. The moderate to larger-sized clusters were 
composed of condensed but poorly organised cell aggregates appearing like bunches of 
grapes (Figure 5.18A and Figure 5.18B). These larger-sized and dense cell aggregates tended 
to be freely suspended in medium (Figure 5.18B) compared to the smaller aggregates which 
tended to form small adherent colonies (Figure 5.18C). These adherent cell colonies also 
abandoned the neatly arranged cobblestoned pattern as previously noted, rather preferring to 
adopt a more disorganised multilayer arrangement composed of variably shaped cells (Figure 
5.18D). Furthermore, there was absence of any discernible fine structures within cell colonies, 
such as cell nuclei or vacuolated structures. 
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Figure 5.18 Phase-contrast microscopy of cells at Day 4 cultured in Stem Cell 
Promoting Media post isolation from primary CRC tissue 
Cultured cells in stem cell promoting media displayed marked heterogeneity in morphology, with 
majority coalescing to form poorly organised cell aggregates of various sizes and densities. Cell 
colonies grew either in suspension or adherent to culture vessel (Figure 5.18A and Figure 5.18B), with 
larger sized colonies tending towards remaining in suspension. Adherent cell colonies were mainly 
formed by poorly organised polymorphic cells which grew over each other to form a multilayer 
arrangement (Figure 5.18C and Figure 5.18D). 
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Figure 5.19 Phase-contrast microscopy of cells at Day 14 cultured in Stem Cell 
Promoting Media post isolation from primary CRC tissue 
Cultures showed majority of cell aggregates were free-floating in suspension with an overall decrease 
in number of adherent cells. No significant outgrowth of cells was observed from any aggregates. 
Furthermore, constituent cells of the floating aggregates did not appear to coalesce to form compact 
spherical-shaped cell clusters which are typical of stem or progenitor cell colonies (Figure 5.19B and 
Figure 5.19C). 
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At Day 14 of culture, majority of the cell aggregates remained free floating in 
suspension with a concomitant decrease in the overall number of adherent cells (Figure 
5.19A) which were previously seen on Day 4 of culture. Although these cell aggregates in 
suspension were composed of densely packed cells, thus sharing some homology to the 
previously described spheroids, the arrangement of these clusters were relatively disorganised 
and majority failed to coalesce to form a typical condensed spherical ball of progenitor cells 
(Figure 5.19). Furthermore, there was absence of outgrowth of adherent polygonal cells 
originating from these cell aggregates as previously observed in serum supplemented and 
MCDB cultures. 
The appearances of the cultures from Day 14 onwards did not show any significant 
growth in the floating cellular aggregates, or any evidence of the constituent cells condensing 
to form compact and organised spherical-shaped cell clusters. There was also absence of 
outgrowth of any new populations of cells from these floating aggregates, therefore cultures 
were terminated. 
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5.4.3 STIMULATION EXPERIMENTS WITH PRIMARY CRC CELL ISOLATES 
My attempts at establishing representative CRC cultures unfortunately did not 
produce any sustainable cultures which would have been invaluable in complementing our 
experimental studies with CRC cell lines. The challenges which I encountered paralleled 
those previously reported by others, and highlight the multitude of technical difficulties and 
substantial amounts of effort and time required to eventually achieve sustainable primary 
cultures. Due to time limitations imposed by the project, it was eventually decided that our 
main focus should be on investigating the effects of EGF and hypoxia on the collection of 
cells obtained from primary CRC tissue following digestion. This therefore negated further 
requirements for establishing primary CRC cell cultures. I subsequently decided that cells 
obtained following digestion should be subjected to stimulation rather than aiming for 
propagation and establishment of cell lines. The isolated cells were allowed to settle for at 
least 6 hours, and subsequently subjected to EGF and/or hypoxia stimulation. Table 5.2 
illustrates the clinical characteristics of the CRC tissue specimens from which cells isolated 
from primary tissue were treated in this way. 
Fifteen cancer tissue samples and eight respective control samples as outlined in 
Table 5.2 were therefore processed according to the tissue digestion protocol as described. 
Following a ‘resting’ period of at least 6 hours to allow cells to settle, the heterogeneous 
population of cells were subjected to EGF and hypoxia stimulation. Two of the fifteen 
cultures (Samples 14040801 and 27040801) were infected before they could be used for 
stimulation experiments and therefore had to be discarded. These cultures exhibited opaque 
yellow supernatants, no signs of cell adherence and tiny speckles of rounded black spots most 
likely to represent bacterial contamination. Furthermore, 3 cancer samples (Sample IDs 
07040801, 24040801 and 12050801) which were processed according to protocol did not 
yield sufficient cell numbers to produce meaningful data following stimulatory experiments. 
The cell yields from cancer samples 07040801 and 12050801 were indeterminate as there 
were no discernible cells noted during cell counts. Sample 24040801 yielded a total of 
140,000 cells, but this was insufficient for our experimental setup to investigate the responses 
of CRC to hypoxia as there was no detectable VEGF protein using ELISA. Overall, there was 
considerable variation in the total number of cells obtained per cancer tissue sample, ranging 
from 1.4 x 105 to 1.28 x 107 cells. This was similar in control tissue samples where the total 
number of cells in the isolates ranged between 2.2 x 105 and 1.8x106 cells. In experiments 
where paired tumour and control tissues were both available, it was noted that cell yields 
obtained were generally lower in control tissues. This reflected the more robust nature of 
normal colonic architecture, as opposed to tumour tissues which were more friable and more 
easily disaggregated. 
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Table 5.2 Characteristics of CRC specimens from which mixed cell population 
were isolated from primary tissue and subjected to EGF ± hypoxia 
stimulation. 
Table summarises the clinical characteristics of patients from which primary tissue was obtained. 
Demographics include patients’ age, sex, site, stage and differentiation of tumour, and use of pre-
operative chemo- or radiotherapy treatment. *patients with matched non-tumour and cancer samples. 
Clinical characteristics 
Histological stage 
Patient ID Age Gender Site of cancer TNM-
stage 
Duke’s Differentiation 
Pre-op 
therapy 
07040801 64 F Rectum T2 N1 C1 Moderate None 
11040801 54 M Caecum T1 N0 A 
Moderate 
mucinous Chemo 
14040801 82 M Rectum T1 N0 A Moderate None 
15040801 68 M Sigmoid T3 N0 B Moderate None 
24040801 80 M 
Hepatic 
flexure T4b N2 C2 Moderate None 
25040801 79 F Caecum T3 N0 B Moderate None 
28040801 58 M Sigmoid T3 N1 C1 Moderate None 
12050801* 87 F Sigmoid T4 N2 C1 
Poor 
Mucinous 
None 
21050801* 66 F Rectum T3 N2 C1 
Poor 
Mucinous 
None 
28050801* 54 M Rectum Villous adenoma 
High grade 
dysplasia None 
30050801* 76 F Sigmoid T3 N0 B Moderate None 
10060801* 68 F Rectum T2 N0 A Moderate SCRT 
13060801 76 M 
Transverse 
colon T1 N1 C1 Moderate None 
13060802* 62 M Sigmoid T3 N0 B Moderate None 
16060801* 66 F Rectum T3 N0 B Moderate SCRT 
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Figure 5.20 Phase-contrast microscopy of isolated cells from primary CRC tissue 
28040801 before and after stimulation with EGF and hypoxia 
Figure 5.20A & Figure 5.20B depict the same culture composed of mixed population of cells isolated 
from primary CRC tissue (28040801) prior to experiments at low and higher magnifications. 
Microscopic images were taken of the cells at 24 hours following exposure to their respective 
experimental conditions: Unstimulated controls (Figure 5.20C), EGF alone (Figure 5.20D) and 
Hypoxia alone (Figure 5.20E). Distinct difference was noted at 24 hours where preceding free floating 
cells became adherent to the bottom of the culture wells, adopting a more polygonal, flattened 
morphology as illustrated by Figure 5.20C and Figure 5.20D. A higher proportion of cells subjected to 
hypoxia remained in suspension compared to cultures under normoxic conditions (Figure 5.20E). 
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Figure 5.20 illustrates an example of the heterogeneous cell population isolated from 
CRC tissue immediately before and after the cultures were stimulated for 24 hours with EGF 
and/or hypoxia. The cultures were composed of a variety of cells, existing primarily in 
suspension as single cells or in clusters. The various individual cells adopted wide-ranging 
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morphology, from small doughnut-like rings which represented erythrocytes, to larger and 
more prominent rounded cells which were typically members of larger cell clusters. A distinct 
difference was typically noted at the end of experiments, where the preceding free floating 
cells were eventually found adherent to the bottom of the culture well, adopting a more 
polygonal flattened appearance as illustrated by Figure 5.20C and Figure 5.20D. These cells 
could also appear fusiform-shaped and tended to coalesce together to form monolayer of 
colonies. There was marked resemblance in appearance of these cells with those previously 
encountered during my attempts at establishing CRC cultures. In this particular experiment, a 
larger proportion of cells demonstrated adherence to the wells under normoxic conditions 
with or without EGF stimulation compared to cells subjected to hypoxia. Cells stimulated 
with hypoxia tended to form floating aggregates of tightly condensed cells as shown by 
Figure 5.20E. 
In order for data to be comparable across various experiments using different tissue 
samples, VEGF protein data had to be standardised and adjusted for cell numbers and 
expressed as pg/mL per 10,000 cells. The adjusted VEGF protein data showed a wide 
variation in the total amount of VEGF expressed by the mixed cell populations from different 
primary CRC tissues even under unstimulated conditions. The range was between 
undetectable levels to a maximum expression of 197.1pg/mL VEGF per 10,000 cells. There 
was similarly a significant variation in VEGF protein expressed amongst control tissues, with 
3 out of the 7 samples having none detectable levels, to the highest expression of 289.2pg/mL 
VEGF per 10,000 cells in one sample. Although I obtained matched cancer and control 
tissues from seven donors, there was a trend supporting a direct correlation in VEGF levels 
expressed by cells from these two different tissues. This was particularly apparent in two 
specific donors identified as 21050801 and 28050801, where cancer tissues found to express 
higher baseline VEGF protein levels (197.1 and 15.8 pg/mL per 10,000 cells) also had 
matching control tissues expressing high levels of VEGF protein (289.9 and 34.7 pg/mL per 
10,000 cells). This correlation was confirmed by linear regression modelling as illustrated by 
Figure 5.21, confirming a linear correlation in VEGF expression by both cancer and control 
tissues with r2 of 0.843. The only exception to this correlation was from donor 13060802 
where cells derived from control tissue had 17.5-fold (125.8 versus 7.2pg/mL per 10,000 
cells) higher baseline expression of VEGF protein in control versus cancer tissue. This linear 
correlation was still preserved when outlying values from samples 21050801 and 13060802 
were excluded from the model. 
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Figure 5.21 Linear regression analysis of VEGF data from cancer and control tissue 
VEGF production by cells isolated from matched control and cancer tissue samples varied substantially 
between different patients. However, there was a direct correlation between VEGF expressed by cancer 
and control tissue obtained from the same patient (correlation coefficient of r2 = 0.8431). Correlation 
was still preserved when the two outlying data points were excluded from calculations. 
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Preliminary experiments were performed to determine the effect of exposing the 
isolated cells to two different timepoints of 6 and 24 hours of hypoxia on the expression of 
VEGF. Figure 5.22 illustrates upregulation in VEGF expression by 2.1-fold and 2.4-fold 
following hypoxia stimulation at 6 and 24 hours respectively. EGF stimulation alone did not 
result in any significant upregulation in VEGF expression at either timepoints. Furthermore, 
EGF in combination with hypoxia also resulted in no further additive effect on the release of 
VEGF. 
Based on the results from the 6 and 24-hour timepoint experiment, it was decided that 
VEGF responses from the CRC heterogeneous mixed cell population would be determined 
after 24 hours of EGF and/or hypoxia. As previously described, the isolated cells expressed 
varying baseline levels of VEGF ranging from 0 to 197.1, with mean of 29.2pg/mL VEGF per 
10,000 cells. However, cells expressing higher baseline levels of VEGF maintained the trend 
towards sustaining higher levels of VEGF release following stimulation as clearly 
demonstrated by data in Figure 5.23. The graph which summarises VEGF protein expression 
by the isolated cells showed significant upregulation of VEGF expression by an average of 
1.5-fold (43.7 versus 29.2pg/mL VEGF per 10,000 cells) following stimulation with hypoxia 
alone. 
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Figure 5.22 VEGF protein expression at 6 and 24 hours following EGF±hypoxia 
stimulation of cells isolated from primary CRC tissue sample 28040801 
Cells isolated from CRC tissue obtained from one patient were stimulated with 20ng/mL EGF and/or 
exposed to hypoxia (1% O2) for 6 and 24 hours. VEGF protein expression data are mean ± SD of two 
separate samples from a single experiment, each sample assayed in triplicate by ELISA. Statistical 
significance was tested by 2-way ANOVA with Bonferroni post hoc correction versus unstimulated 
control *** p<0.001. 
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Figure 5.23 Scatter plot showing VEGF expression following stimulation of cells 
isolated from CRC tissue following 24 hours of stimulation with EGF± 
Hypoxia 
Cells isolated from CRC tissues obtained from eight patients were stimulated with 20ng/mL EGF 
and/or exposed to hypoxia (1% O2) for 24 hours. Where possible, replicate experiments (of up to three) 
were performed for individual experimental conditions depending on cell yields following tissue 
digestion. Sample replicates were analysed in triplicate by ELISA, and the mean VEGF protein 
expression for each tissue sample was determined. The mean ± SEM of the pooled VEGF protein 
expression is shown by the scatter plot. Statistical significance was tested by 1-way ANOVA with 
Friedman post hoc correction versus unstimulated control * p < 0.05 and *** p<0.001. 
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Combined stimulation with hypoxia and EGF resulted in further marginal increase in 
VEGF expression to a mean of 55.5pg/mL VEGF per 10,000 cells compared to hypoxia 
alone, representing a significant 1.9-fold upregulation compared to unstimulated cells. The 
results overall demonstrate lack of VEGF responses to EGF stimulation, as the mean 
expression of 27.8pg/mL VEGF per 10,000 cells was almost identical to VEGF expressed by 
unstimulated controls. Several outlying data points at the upper end of the range were omitted 
to examine the effects these may have on the overall results. Even on omitting samples 
21050801 and 28050801 which yielded the two highest VEGF readouts, the overall trend as 
previously described was still preserved. These experiments therefore highlight the potency of 
hypoxia in upregulating VEGF expression in cells isolated from primary CRC tissue, as 
opposed to the absence of responses to EGF stimulation alone. 
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5.5 DISCUSSION 
CRC cell lines have been invaluable in facilitating studies exploring the biology of 
the disease, and for development and testing of novel therapeutic approaches. For in vitro 
studies to have translational value in clinical practice, cell lines must be representative of the 
disease. Since several of these cell lines have been in culture for many years and are often at 
very high passage levels, few retain the morphological and functional characteristics of CRC 
epithelium (Pinto et al. 1983; Dharmsathaphorn et al. 1984). Thus, there is need for new cell 
lines that have retained differentiated characteristics and are composed of heterogeneous cells 
which are typical constituents of CRC tissue in vivo (Whitehead et al. 1992; Whitehead and 
Watson 1994). Furthermore, majority of these cell lines have previously been established with 
serum enriched media. This poses a serious drawback as presence of undefined components, 
many of which have growth-modulating properties, would create difficulties in the 
interpretation of growth factor experiments (Moorghen et al. 1996). 
Achieving a successful CRC culture from primary tissue has proven challenging. The 
reported success rates for establishing successful primary CRC cell cultures ranged widely 
from 0% to 45% (Leibovitz et al. 1976; Whitehead 1976; McBain et al. 1984), possibly 
reflecting the wide variations in techniques employed to isolate and culture primary CRC 
cells. Due to time limitations, I attempted to establish primary cultures from tissue samples 
obtained from nine patients with histologically proven CRC prior to surgery, but all attempts 
failed to yield self-sustaining and propagating cultures sufficient for further experimental 
purposes. The challenges which I faced paralleled those that have been described by others, 
and these are (1) microbial contamination, (2) failure of cells to attach, (3) lack of continued 
proliferation (4) senescence of early cell colonies and progressive involution of cultures, (5) 
outgrowth of contaminating mesenchymal cells, primarily fibroblasts (Leibovitz et al. 1976; 
Whitehead 1976; McBain et al. 1984; Paraskeva et al. 1984; Kirkland and Bailey 1986). 
One of the significant obstacles encountered during the early phases of culture is 
microbial contamination. Despite washing the tumour specimens 3 times with wash medium 
containing high concentrations of broad-spectrum antibiotics and antifungals, 3 out of the 
nine attempted cultures, and 2 out of the 15 cultures for stimulatory experiments failed due to 
microbial contamination. This finding paralleled contaminated rates reported by Leibovitz et 
al where 31% in a total of 163 attempted cultures were infected with saprophytic fungi 
(Leibovitz et al. 1976). Kirkland et al also reported comparable findings where 24% of 
cultures had microbial contamination, mainly due to bacteria (Kirkland and Bailey 1986). The 
authors noted that extensive washing of tumour tissue reduced the number of cultures lost by 
reducing the microbial load. However, even by performing 8 wash steps with high doses of 
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antibiotics of penicillin (2U/mL), streptomycin (2µg/mL), gentamicin (50µg/mL), and 
mycostatin (50U/mL) prior to enzymatically digesting the tissue samples, Paraskeva et al 
reported 21% of cultures lost through microbial contamination (Paraskeva et al. 1984). Due to 
the natural presence of mixed commensal flora lining the human lower gastrointestinal tract, 
it is inevitable that the CRC tissues obtained are heavily colonised with bacteria and fungi. In 
addition, the trend towards decreasing use of bowel preparation prior to large bowel surgery 
could potentially increase the probability of contamination by introducing larger inocula of 
gut commensals into the cultures. It is therefore a logical precautionary measure to wash the 
tumour samples thoroughly to decrease microbial load, and to use the most appropriate 
combination of antibiotics and antifungals ideally targeted at particular organisms. This 
would therefore ideally involve antibiotic sensitivities to be predetermined for the multitude 
number of bacterial species forming the commensal flora. However, this would be impractical 
as bacterial cultures would have to be obtained from specific tumour sites prior to surgery, 
which in most cases would be inaccessible. A compromise would be to use an empirical 
antibiotic regime with broad-spectrum of action, thus all experimental work with primary 
tissues were washed and cultured in the same regime as that described by Paraskeva. 
(Paraskeva et al. 1984). 
The crux of achieving a successful culture relies upon the isolation of viable clusters 
of cancer cells from a milieu of dead and dying cells, which are subsequently encouraged to 
adapt and propagate in an in vitro environment. The first step towards isolating cancer cells 
requires constituent cells to be released from the glandular structures of the tumour. The two 
main techniques employed are enzymatic digestion, primarily dependent on collagenase, and 
mechanical dissociation using a mechanical spill-out method. Cell yields are largely 
determined by the mass of the original tissue sample obtained prior to processing. Since the 
mass of tumour samples obtained for my research were generally limited, as to avoid any 
potential interference the project would have on the routine histological examination of the 
colorectal tumour specimen, my attempts at establishing CRC cultures employed collagenase. 
Enzymatic digestion is particularly useful in increasing cell yields from the separation process 
as there is generally a more complete and homogeneous proteolysis of the enveloping 
mesenchymal stromal tissue, leading to increased numbers of cells released. Collagenase was 
therefore used in my studies in order to maximise cell yields obtained from relatively small 
tumour samples by inducing maximal dissociation of the mesenchymal tissue. However, 
opponents to enzymatic separation argue that the non-specific nature of proteolysis could 
result in poor recovery of viable cells due to increased trauma to the isolated cells (Park et al. 
2003). Furthermore, successful establishment of cell lines has been shown to rely on 
maintaining cell-cell contacts, thus severance of these intercellular links could increase the 
severity of selective pressure imposed (Harris 1996) and effectively decrease viability of 
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cells. McBain et al also noticed increased success when using cell aggregates to seed primary 
cultures, as it was postulated that the preservation of stromal cells, extracellular matrix and 
retained intercellular junctions may simulate the natural tissue milieu (McBain et al. 1984). 
The mechanical spill-out method is also thought to minimise stromal cell contamination as 
stromal cells are not as easily detached from the tissue matrix by mechanical means (Park et 
al. 2003). 
Following release of various cellular components from the primary tissue, a 
separation process is required to isolate the desired epithelial components in the form of 
epithelial tubules, single cells or clumps of cells, from the unwanted mesenchymal stromal 
elements and erythrocytes. In my study, larger fragments of undigested mesenchymal stromal 
tissue were initially separated by filtration through nylon gauze, and the filtrate was 
subsequently collected for cell culturing. Interestingly, a paper by Paraskeva et al reported 
repeated failures in initiating epithelial cultures from the filtrate comprised mainly of single 
cells, but they discovered that the epithelial tubules and large clumps of cells collecting on the 
gauze resulted in successful epithelial cultures (Paraskeva et al. 1984). However, it was 
unclear whether the authors attempted to separate the large fragments of undigested stromal 
tissue from the detached organoids. Hague et al described an isolation process where released 
epithelial organoids were cleaned repeatedly by pipetting and allowing for gravity 
sedimentation (Harris 1996). This technique relied upon diffuse mesenchymal tissue tending 
towards remaining afloat, whereas heavier and denser epithelial organoids would settle out. 
The inevitable presence of erythrocytes within primary CRC cultures were also not discussed 
in published studies, and the implication of such contamination on long term CRC cultures 
remains unclear. In order to reduce the potential effect these contaminating erythrocytes 
would impose on my cultures, a cell separation technique using a polysaccharide solution to 
generate a density gradient was performed. This separation technique proved effective in 
minimising erythrocyte contamination of cultures. Samples of supernatants extracted at 
multiple levels were examined under microscopy during preliminary studies, and CRC cells 
were predominantly found at the supernatant-polysaccharide solution interface. In contrast, 
erythrocytes were mainly sedimented at the bottom of the centrifuge tube. 
Cell lines which have been established in other studies report considerable variations 
between cultures from different specimens as well as from an individual specimen (McBain et 
al. 1984). The established cell lines have been largely subdivided into two phenotypic 
extremes relating to their ability to demonstrate early cellular adherence, either as anchorage 
preferent (thus adhering onto the plastic of culture flasks), or anchorage indifferent. In 
literature reporting successful established cultures, majority of these demonstrated anchorage 
preference with adherent colonies typically forming within 24-48 hours of seeding (McBain 
et al. 1984; Harris 1996). However, the time interval between initiation of primary culture to 
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observing adherence of cell colonies can be extremely variable, with periods of up to 6 weeks 
reported (Harris 1996). According to published literature, achieving attachment of cell 
colonies is one of the first indicators of a potential successful culture (Kirkland and Bailey 
1986). Outgrowth of epithelial cells was typically seen to migrate out only once the central 
organoid structures have attached. Therefore studies which have successfully established 
primary cultures have described using culture vessels pre-coated with various matrix proteins, 
such as collagen, laminin, fibronectin or combinations of these attachment factors to 
encourage cell anchorage. In my efforts to establish a primary cell culture, isolated CRC cells 
were trialled in culture flasks pre-coated with human fibronectin or gelatin. Contrary to the 
findings by others, pre-coating the culture flasks did not have a significant effect on my 
overall success in culturing CRC cells. 
Figure 5.24 Phase-contrast photograph of a primary culture from a colorectal 
tumour. 
Central dense organoid structure has attached and cells are migrating out to give a sheet of epithelium, 
with their characteristic cuboidal and pavement-like shapes. (Adapted from (Harris 1996)) 
 
X 150
The early phases of CRC cell culture was typically composed of a mixed population 
of constituent cells, demonstrating marked heterogeneity in cell size and morphology, and 
also anchorage preference. Cultures composed predominantly of adherent cells had colonies 
generally composed of two morphologically differing cell populations. Microscopic 
appearances show a core of densely packed cells at the centre of colonies (organoid), which is 
surrounded by a monolayer of adherent cells proliferating and migrating out from the central 
core. These appearances are very similar to the cell cultures which were successfully 
established into cell lines by Paraskeva et al, (Paraskeva et al. 1984), Oh et al (Oh et al. 1999) 
and Kirkland et al (Kirkland and Bailey 1986). In these studies, the most commonly reported 
cellular architecture was the epithelioid morphology, which was characterised by cells 
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growing as compact monolayer, and adopting a pavement-like appearance with varying 
degrees of attachment to the plastic. Majority of the cancer cells were polygonal or fusiform 
in shape, and had round-to-oval large pale nuclei carrying distinct single-to-double nucleoli. 
Elongated and flattened cells were sometimes observed along the edge of the epithelial sheet. 
In contrast, other cultures have also been established where cells predominantly grew as 
amorphous solid floating aggregates consisting of round cells, similar to the cell line known 
as SNU-769A as described by Oh et al (Oh et al. 1999). Other cell lines have maintained their 
colonies as two separate fractions, one existing as an adherent culture, and the other as 
floating aggregates. Cells cultured in growth medium supplemented with 20% serum and 
MCDB medium also formed smooth-surfaced spheroidal colonies which resembled cell 
aggregates previously described by McBain et al (McBain et al. 1984). The smooth-surfaced 
spheroid formed of highly condensed cells appeared to be caused by close apposition of 
plasma membranes. These aggregates which have been further characterised by McBain et al 
appear to have attenuated lumens circumscribed by microvilli and junctional complexes 
(McBain et al. 1984). Data regarding growth rates of various successful cultures published in 
literature showed considerable variation between tissue samples, with one study quoting a 
range between 26-110 hours for cell doubling time (McBain et al. 1984) and another study 
quoting generation times of 30-288 hours (Leibovitz et al. 1976). Indeed it has been reported 
that clusters of cancer cells could appear to lie dormant for variable periods ranging from 2 
weeks to about 6 months before obvious growth was noted (Leibovitz et al. 1976). Since 
many studies have attributed their success to deferment of initial passage until high cellular 
density had been established, the time elapsed until first passage could vary considerably 
from three weeks to eight months (Kirkland and Bailey 1986), and even up to one year 
(Leibovitz et al. 1976). Such characteristics as exhibited by CRC cell cultures during the early 
phases of culture may alter with time under in vitro culture conditions. Growth rates have 
been shown to accelerate after a period of culture (McBain et al. 1984), and the initial 
morphology could also change, such that cultures which were previously strongly adherent to 
plastic could become detached rounded cells and floating in medium (Kirkland and Bailey 
1986). 
In my attempts at CRC cell cultures with serum supplemented growth medium, cell 
colonies which were established within 24-72 hours showed signs of sustained proliferation 
and outgrowth following organoid attachment within the first 10 days of initiating culture. 
Despite these encouraging developments during the early stages of culture, the outgrowing 
cells from the established cell colonies were unable to sustain their proliferation and survival. 
The earliest indicator and most accurate predictor of an impending failing culture was typified 
by the extrusion of the central organoid from the cell colony, in a process that appeared to be 
a cell separation process. Following a detailed search for references in order to elucidate this 
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phenomenon further, I was unable to identify any published literature describing a similar 
phenomenon in CRC cell culture. The similar process was observed in cultures using the fully 
defined MCDB medium, but interestingly onset of cell extrusion occurred much earlier. 
Cultures initiated with MCDB started showing evidence of involution by day 10 of culture as 
opposed to day 28 for 20% serum-supplemented cultures, supporting the concept that 
relatively high levels of FCS provided the best support for establishing primary culture, serial 
passage and in vitro differentiation of carcinoma epithelium (Harris 1996). Despite using 20% 
serum-supplemented growth media, none of my attempted cultures underwent significant 
proliferation to achieve cell densities necessitating first passage. It is therefore a logical 
conclusion that the culture media was deficient of unknown substrates vital for sustained 
growth and survival of CRC cells cultured in vitro. 
In order to address the potential deficiencies of culture media as the only source of 
nutrients, trace elements and growth factors for propagation and survival of primary cultures, 
several strategies have been developed to optimise their growth in vitro. One such strategy is 
the use of feeder cells. Feeder cell layers provide an intact and functional extracellular matrix 
and matrix-associated factors to enhance intercellular adhesion and attachment. In addition, 
they are useful for secreting known and unknown cytokines into the conditioned medium to 
support in vitro survival and growth of some fastidious cells with specific requirements. As a 
result, CRC cell growth was noted to be significantly improved in the presence of Swiss 3T3 
feeders than in their absence (Brattain et al. 1982; Brattain et al. 1983; Paraskeva et al. 1984). 
However, using feeder cells does introduce potential problems, primarily the potential for 
feeder cells to overgrow and contaminate the more slowly growing human tumour cells if 
their growth were inadequately inactivated. Eliminating the dependency of CRC cells from 
feeder cells could be challenging and various methods have been trialled to isolate and wean 
cells from the feeder layer (Brattain et al. 1983). Furthermore there is a risk of 3T3 feeder 
cells inhibiting anchorage-dependent organoids from attaching to the flask, and spreading of 
outgrowing epithelial cells if the feeder cells are at too high a density. Due to the technical 
difficulties of employing feeder cells and time limitations imposed by my project, no attempts 
were made to establish CRC cultures with feeder cells. 
The unique ability of the colorectal epithelium to regenerate is due to the constant 
proliferative activity found mainly at the base of the colonic intestinal crypts by a special 
subgroup of stem or precursor cells. During asymmetric division, stem cells undergo self-
renewal and simultaneously generate a population of transit cells that migrate up the crypt, 
proliferate, and begin differentiating to form goblet, columnar, and other cells (Potten and 
Loeffler 1990; Brittan and Wright 2004). Because the stem cell population is long-lived, it 
continues to perform these tasks over the lifetime of an individual. This process ensures 
continual regeneration and replacement of the functional epithelium as the terminally 
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differentiated cells senesce, die, and are shed (Boman and Huang 2008). Established cell 
cultures are characterised by their ability to self replicate and renew, in order to generate 
clones of genotypically and phenotypically identical progenies. It would therefore reason that 
these stem cells, plus the precursor cell compartment, would make up the bulk of cells in a 
proliferating culture. Since the longevity of the stem cell compartment is what will ultimately 
determine the lifespan of the culture, attempts were made to focus on supporting the stem or 
precursor cells using specialised culture media in order to overcome failure of CRC cultures. 
CRC stem cells have been described and characterised in several studies (Ricci-Vitiani et al. 
2007; Rich and Bao 2007; Vermeulen et al. 2008) as expressing the CD133+ marker, which is 
common to normal primitive cells of the neural, haematopoietic, epithelial and endothelial 
lineages (Yin et al. 1997; Uchida et al. 2000). Following enzymatic disassociation of cancer 
tissues, CD133+ expressing colonic cells were successfully cultivated and expanded 
exponentially as sphere-like cellular aggregates in serum-free conditions, whilst maintaining 
their primitive undifferentiated phenotype for periods of more than a year. The reported 
success rates of achieving such cultures ranged between 33%-45% (Ricci-Vitiani et al. 2007; 
Rich and Bao 2007), which is comparable to earlier studies with serum supplemented media. 
Due to time limitations of my project, only 2 attempts were made to culture CRC cells using a 
sphere-promoting growth medium, but unfortunately both attempts failed to generate a 
proliferating and self-sustaining culture of CRC stem cell spheres. These cultures exhibited 
moderate to larger-sized aggregates of cells which were composed of condensed but poorly 
organised cell aggregates, appearing like bunches of grapes floating freely in suspension 
(Figure 5.18A and Figure 5.18B). Cell aggregates were relatively poorly organised and 
majority failed to coalesce to form the characteristic condensed sphere-like aggregates (Figure 
5.25) even at Day 14 of culture. However, several of the published studies only reported 
obtaining colon spheres which exhibited exponential cellular proliferation rates after 4 weeks 
following initiation of cultures (Ricci-Vitiani et al. 2007; Rich and Bao 2007). Furthermore 
the challenge of isolating CD133+ CRC stem cells is its relative rarity, with CD133+ cells 
making up between 0.3 – 3% of total cells within primary CRC tumour samples in all patient 
ranges (Ricci-Vitiani et al. 2007; Rich and Bao 2007). 
Despite these challenges, isolating and propagating colon cancer spheres have 
significant advantages over conventional serum-dependent techniques when establishing 
primary CRC cell cultures. Unlike tumour cells which have high probability of acquiring 
genomic mutations after prolonged expansion, colon cancer spheres have the innate ability to 
undergo unlimited expansion of a tumourigenic colon cancer cell population, whilst retaining 
characteristics of the primary tumour of origin. These spherical aggregates of stem cells have 
been shown to have the potential to differentiate into clusters of representative polygonal 
colon cancer cells expressing molecular markers expressed by CRC epithelium, and 
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proliferate and survive for up to 2 weeks in culture. Spheroid cultures have been shown to 
differentiate into large, polygonal colon cells starting from week 1 on exposure to serum 
supplemented culture media containing calcium, and in the presence of extracellular matrix, 
and growth factor withdrawal (Rich and Bao 2007). These properties thus confer colon cancer 
spheres as the superior cell model for more accurate and representative studies to be 
performed during the preclinical phases. 
Figure 5.25 A typical colon cancer sphere 
Tumourigenic CD133+ colon cancer spheres can be expanded in vitro as undifferentiated spheres in 
serum-free medium following tissue disassociation. (Adapted from (Ricci-Vitiani et al. 2007)) 
 
The second part of this study aimed to examine the effect of EGF and/ or hypoxia 
stimulation on VEGF expression by the heterogeneous cells isolated from primary CRC 
tissue. The purpose of this study was to compare the VEGF responses from a representative 
mixed cell population isolated directly from primary CRC tissue to the responses observed in 
my cell line studies. The relationship between tumour angiogenesis and clinical outcome in 
CRC has been widely studied, and the current consensus supports intratumoural microvessel 
density and VEGF as being inversely related to survival in CRC. In my study, the background 
expression of VEGF from the mixed cell populations derived from primary CRC tissues from 
different patients differed significantly, ranging from undetectable levels to a maximum 
expression of 197.1pg/mL VEGF per 10,000 cells. There was similarly a significant variation 
in VEGF protein expressed amongst the control tissue, with 3 out of 8 samples having no 
detectable levels, compared to the highest expression of 289.2pg/mL VEGF per 10,000 cells 
in one sample. Comparisons of the baseline VEGF expression of matched control and cancer 
tissue samples from identical patients showed that in most cases, where there was high 
background expression of VEGF by cancers, there was accompanying elevated background 
levels of VEGF expressed by the matched control samples. This finding could be explained 
by a study conducted by Kuniyasu et al where mucosa adjacent to colon cancer were 
discovered to undergo hyperplastic changes in response to the neighbouring tumour, probably 
through an autocrine-paracrine mechanism involving EGFR and its ligands (Kuniyasu et al. 
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2000). The adjacent hyperplastic tissues were found to express significantly higher levels of 
pro-angiogenic molecules such as VEGF, FGF and IL-8, compared to distant sites of at least 
10 cm from the edge of the neoplasm where the mucosa was morphologically normal. The 
elevated levels of pro-angiogenic molecules were correlated with increased vascular density 
at the junction between the tumour and the mucosa (Kuniyasu et al. 2000). Control samples 
for my study were taken from the resected specimen where the mucosa appeared 
macroscopically normal, and although sampling was performed away from the tumour edge, 
the exact distance was not routinely measured. This finding may therefore account for the 
observed correlation in VEGF expression by both cancer and control samples, especially if 
control samples were taken from regions of the specimen that have undergone hyperplastic 
changes. 
VEGF expression was significantly upregulated by hypoxia by an average of 1.5-fold 
and 1.9-fold in combination with EGF following stimulation of the isolated cells from CRC 
tissues. The cells overall failed to exhibit a significant VEGF response following EGF 
stimulation alone. These findings parallel the results from my Colo 201 cell line experiments 
where hypoxia exerted a potent effect on promoting a pro-angiogenic response. In several 
primary cell isolates where background VEGF levels were undetectable in unstimulated 
control samples, hypoxia stimulation alone significantly increased VEGF levels to detectable 
levels. Similarly cells which previously expressed higher baseline levels of VEGF maintained 
this trend towards sustaining even higher levels of VEGF release following hypoxia 
stimulation. These findings from the stimulation experiments, to my knowledge, have not 
previously been described in any published studies. It is possible that the rise in VEGF 
protein could be directly caused by cells undergoing cell death due to the extreme selective 
pressure exerted by hypoxia on the isolated cells. However, microscopic appearances of the 
cells following hypoxia stimulation are not supportive of a culture undergoing apoptosis, but 
future experiments would have to include a cell viability assay to confirm the survival status 
of cells. 
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6 GENERAL DISCUSSION 
CRC has a significant impact on global health, with over 1 million new diagnoses 
made, and over 500,000 dying from the condition each year (Parkin et al. 2005). CRC is the 
third most common cancer worldwide, and in the European Union alone, the lifetime 
estimated risk of developing the disease is 6%. The incidence of CRC is predicted to 
progressively rise with increasing average life expectancy, and will represent one of the 
leading causes of deaths beyond 2030 (WHO 2008). CRC is curable by surgical resection 
with minimal morbidity and mortality, but only a small proportion of patients presenting 
during the earlier stages of disease are suitable candidates for surgery. For the vast majority of 
patients who present with locoregional spread and distant metastasis, recurrence of disease is 
significant with attempted curative resection alone (Rao et al. 1981; Pilipshen et al. 1984; 
Søreide and Wiig 2001). Radio- and chemotherapy have contributed significantly to the 
management of patients with CRC by reducing recurrence following resection. In addition, 
chemoradiotherapy is useful for downstaging locoregional or distant involvement of tumours 
to allow surgical resection, and is also a vital tool for palliation. Despite combined approaches 
of adjuvant chemo- and radiotherapy with surgery, the overall prognosis of patients diagnosed 
at advanced stages with widespread dissemination still remains poor. 
To improve our treatment outcomes for CRC, it is apparent that further understanding 
is required into the pathogenesis and pathophysiology of the condition. The aim would be to 
identify critical biological systems which could be modified to promote treatment success. 
Significant advances in tumour biology have identified several key factors which tumours 
commonly exploit, one of which is angiogenesis. The process of growing new capillaries 
from existing blood vessels is one of the key contributory factors which promote tumour 
survival, proliferation and growth, and capacity to spread. Certainly it has been noted that 
tumour growth is merely limited to 2-3mm3 in the absence of neo-vascularisation (Folkman 
1971; Folkman et al. 1971). The process of angiogenesis is normally quiescent in adult 
humans, but cancers particularly exploit various control mechanisms underlying the delicate 
balance between pro- and anti-angiogenic mediators to activate the angiogenic switch. 
Activation of the angiogenic switch relates to unopposed actions of overexpressed pro-
angiogenic mediators to stimulate sprouting of new tumour vessels. VEGF, a potent inducer 
of angiogenesis, is typically overexpressed during the angiogenic switch as it has 
multifunctional roles in promoting endothelial cell survival, mitogenesis, migration, 
differentiation and recruitment of EPC from bone marrow (Asahara et al. 1997). Implicating 
VEGF as a major inducer of angiogenesis in CRC represented a significant milestone in 
tumour biology, and this discovery was subsequently translated to clinical practice. VEGF 
antagonists have most recently been developed and trialled, revealing some promising results. 
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Bevacizumab, a recombinant humanised IgG1 monoclonal antibody (Presta et al. 1997), was 
the first selective antagonist of VEGF-A and its efficacy has been proven in a Phase III 
clinical trial. Patients who received a combination of bevacizumab and standard 
chemotherapy had significant improvement in survival and progression-free survival with 
improved response rates to therapy (Kabbinavar et al. 2003; Hurwitz et al. 2004). 
As alluded to earlier, angiogenesis is tightly regulated by complex, multilevel 
signalling with interactions between a plethora of activators and inhibitory mediators. 
Similarly, close knit interactions between various regulatory signals must be in place to exert 
control over the expression of individual angiogenic mediators. Regulation of VEGF is 
complex, where its expression could be altered by activities of oncogenes and tumour 
suppressor genes, growth factor and inflammatory cytokine signals, and hypoxia to name a 
few. Growth factor signalling, particularly involving EGFR and its cognate receptors, has 
been implicated in pathogenesis and progression of CRC (Lockhart and Berlin 2005). 
Overexpression of EGF and EGFR have been demonstrated in approximately 70-75% of 
CRC, with expression levels higher in malignant zones than in surrounding benign mucosa 
particularly during advanced stages of disease (Lockhart and Berlin 2005). Available 
evidence implicates a pro-angiogenic role for EGFR activation which can be achieved 
through direct transcriptional activation of VEGF (Goldman et al. 1993). An alternate and 
more indirect regulatory pathway has also been identified, involving activation of HIF-1α 
(Maity et al. 2000) which subsequently interacts with the HRE cis-regulatory element to 
increase VEGF gene expression (Zhong et al. 2000; Laughner et al. 2001; Pore et al. 2006). 
The majority of these studies were based on non-CRC cells, with the exception of studies by 
Ciardello et al who examined the effect of EGFR antagonists on CRC angiogenesis 
(Ciardiello et al. 1996; Ciardiello et al. 2001). By employing gefitinib treatment, CRC cells 
demonstrated a dose- and time-dependent decrease in VEGF expression (Ciardiello et al. 
2001), but such findings may be confounded by gefitinib’s ability to inhibit activity of other 
intracellular transmembrane tyrosine kinases at similar concentrations (Cohen et al. 2004). 
Therefore, my study setup was to determine the angiogenic responses induced by direct 
stimulation of EGFR relevant to CRC. 
My studies confirmed EGFR stimulation promotes a pro-angiogenic response 
potentially through induction of VEGF and several other angiogenic genes which previously 
have not been described to modulate CRC angiogenesis. EGF stimulation alone resulted in 
significant upregulation in VEGF protein expression which was comparable to, and to a 
certain extent better than, the responses seen with the hypoxia-mimetic DMOG in Caco-2 
cells. With VEGF mRNA expression unchanged following EGFR activation, the consistent 
rise in VEGF protein is a reflection of an increase in VEGF translational or post-translational 
activity. In previous studies, the observed increase in VEGF protein expression was primarily 
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through transcriptional regulation under the direction of EGFR/Ras/PI3K signalling to affect 
VEGF promoter activity (Maity et al. 2000). VEGF protein expression has also been shown 
to be regulated at the transcriptional level by EGFR, through recruitment of activated Sp1 in a 
PI3K dependent manner to bind and induce VEGF promoter activity (Pore et al. 2006). 
Furthermore, VEGF gene transcription could also be indirectly modulated by EGFR 
signalling by increasing HIF-1α protein synthesis through an EGFR/PI3K/Akt/FRAP 
pathway (Laughner et al. 2001; Fukuda et al. 2002). In the absence of altered VEGF mRNA 
expression, the observed change in HIF-1α expression following EGFR activation in Caco-2 
cells is unlikely to account for the increased VEGF protein levels. In a study to examine the 
relationship between overexpression of ras and VEGF expression in intestinal epithelial cells, 
Rak et al (Rak et al. 2000) also discovered that VEGF mRNA and its protein levels did not 
always correlate. The discrepancy was due to a post-translational effect imposed by reactive 
oxygen intermediates to upregulate VEGF protein synthesis in response to overactivated ras 
signalling (Irani et al. 1997). The modulation in VEGF protein expression following EGFR 
stimulation could therefore possibly be a result of translational modification of transcripts, 
through enhanced translational activity through internal ribosomal entry sites (IRES) (Akiri et 
al. 1998), or by enhancing the activity of the eIF4F translational initiation complex (Kevil et 
al. 1996). 
HIF plays critical roles in pathogenesis and progression of CRC, proven by IHC and 
in vitro studies showing a direct correlation between HIF-1α overexpression and tumour 
vascularisation. CRC tissue samples were demonstrated to overexpress HIF-1α protein and 
VEGF mRNA consistently, and these were significantly correlated with tumour microvessel 
density, lymphovascular invasion, and liver metastasis (Kuwai et al. 2003). EGFR activation 
has been shown to affect HIF-1α expression through a PI3K/Akt dependent induction in HIF-
1α translation (Zhong et al. 2000; Laughner et al. 2001; Pore et al. 2006), but this 
relationship has not been defined in CRC. My data confirmed that EGFR activation is capable 
of inducing HIF-1α protein production under normoxia and DMOG treatment in Caco-2 cells. 
Although the upregulation in HIF-1α was modest, the trend was significantly preserved over 
the study period. Since HIF-1α gene transcriptional activity was unaffected by EGFR 
stimulation, the observed increase in HIF-1α protein was most likely attributed to 
translational or post-translational modifications. Similar findings were reported in a study on 
breast cancer cells, where HER2 signalling specifically induced HIF-1α protein expression 
without affecting HIF-1α mRNA (Laughner et al. 2001). This induction process required 
activation of the PI3K/Akt/FRAP pathway to modulate the 5’ untranslated region (UTR) of 
HIF-1α mRNA to increase rate of protein synthesis. Such findings were further supported by 
inhibitory studies on squamous carcinoma cells, where translation of HIF-1α was dampened 
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by EGFR-inhibition in a PI3K-dependent manner (Pore et al. 2006). Based on my results, the 
observed increase in HIF-1α protein in Caco-2 cells was unlikely to be dependent upon 
phospho-Akt signalling as it was constitutively active in this cell type, and furthermore, its 
activation status remained unchanged following additional EGF stimulation. 
Upon ligand binding, activated EGFR dimerises with a co-receptor and 
autophosphorylation of the protein tyrosine kinase domain occurs. Several intracellular 
signalling pathways are subsequently recruited and phosphorylated, including the MAPK 
(Alroy and Yarden 1997), PI3K/Akt (Burgering and Coffer 1995; Liu et al. 1999), Src family 
kinases and Stat proteins. Since these pathways relay cell surface to nuclear signals, variations 
in recruited pathways could explain for differences in biological behaviour exemplified by 
individual cell types. My study into cell signalling revealed the unique involvement of p42/44 
ERK MAPK in mediating the critical signals underlying EGFR induced angiogenesis in CRC. 
Examination of phospho-Akt and p38 excluded their participation in transducing EGFR 
induced downstream signals. The importance of ERK MAPK signalling was further 
reinforced by differences in its expression between Colo 201 and Caco-2 cells. Colo 201 cells 
were shown to possess an intrinsic constitutively activated ERK pathway, despite having 
functional EGFR which was inducible by EGF stimulation. In concordance with my data 
highlighting the critical function of ERK in regulating VEGF expression, Colo 201 cells were 
resistant to exogenous EGFR stimulation, but maintained their intrinsic ability to express 
VEGF constitutively, independent of EGFR signalling. Determining global angiogenic gene 
responses with PCR arrays also provided useful data for validating and confirming these 
findings. The derived gene profile allowed patterns in gene expression to emerge, providing 
invaluable insight into how selected differences in regulatory patterns could confer cells with 
unique characteristics defined as cell specific behaviour. The gene profile for Colo 201 cells 
reiterated the vital role ERK MAPK fulfilled in mediating EGFR-induced cell-signals to 
modulate downstream biological processes. In concordance with my earlier findings, Colo 
201 cells demonstrated a similar lacklustre effect with minimal difference noted in overall 
transcriptional activity of known angiogenic genes, with the exception of 3 genes tested on 
the PCR array. This was in marked contrast to Caco-2 cells with functional ERK MAPK 
signalling pathway, demonstrating upregulation of 6 genes and downregulation of 17 
angiogenic genes following EGFR stimulation. The gene transcription data therefore 
reinforced the ineffectiveness of exogenous EGFR stimulation in CRC cells expressing 
constitutively activated MAPK pathway, and further supports the redundancy of EGFR-
targeted therapy in patients with mutated MAPK signalling. Further studies using inhibitors of 
the MAPK pathway should be performed, to confirm its overwhelming role in transducing 
EGFR signals to mediate downstream angiogenic responses. 
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Despite having addressed several key issues relating to the role of EGFR in 
promoting angiogenesis in CRC, several further questions remain unresolved. Firstly, the 
cause for the constitutive activation of ERK in Colo 201 cells remains unknown. Given that 
activation of ERK MAPK signalling cascade is dependent upon phosphorylation of an orderly 
sequence of signalling mediators, the potential candidates constitutively activated must be 
upstream of ERK, and these include Ras, Raf and Mek in descending order. There is 
considerable clinical relevance to elucidating their relative activation status, as EGFR 
antagonists would be rendered ineffective if any of these signalling components downstream 
of EGFR were constitutively active. The findings from my cell signalling study can be 
translated to clinical practice, because these data highlight the positive impact molecular 
testing could have on selecting CRC patients most suited for EGFR-based therapies. Indeed 
there has been recent interest in determining K-Ras status rather than EGFR expression in the 
clinical setting, as the latest studies have demonstrated that CRC patients with wild-type K-
Ras demonstrated superior responses to EGFR-targeted therapies compared with patients with 
mutant K-Ras (Lievre et al. 2006; Khambata-Ford et al. 2007; Amado et al. 2008; Lievre et 
al. 2008). In a study investigating response rates of patients with metastatic CRC who were 
screened for K-Ras, B-Raf, and PI3K mutations as well as EGFR copy number prior to 
cetuximab treatment, none of the patients who responded to treatment had K-Ras mutations, 
compared to 68.4% of the non-responders expressing the mutant form. In addition, survival 
was significantly extended in patients with wild-type K-ras compared with those expressing 
mutant K-Ras (Lievre et al. 2006). A meta-analysis examining outcomes of patients with 
metastatic CRC with mutated K-ras and who were irinotecan-refractory, failed to demonstrate 
any response with additional cetuximab, with median progression free survival and overall 
survival being worse for this subgroup compared to those with wild-type K-ras (Di Fiore et 
al. 2008). Indeed proponents for pre-treatment testing have suggested a multiparameter 
marker test comprised of K-Ras mutation status and expression levels of a small number of 
genes (i.e., those encoding the EGFR ligands epiregulin and amphiregulin) to help predict 
response to EGFR-targeted treatment (Baker 2008). If validated, this type of multigene 
expression profiling may enable clinicians to select patients who would preferentially benefit 
from receiving EGFR-targeted therapies. 
From my studies, ERK MAPK was identified as the critical signalling messenger in 
relaying EGFR-induced signals in CRC cells. The second question which still remains 
unresolved is the underlying mechanism to account for increased VEGF and HIF translation 
associated with EGF stimulation in Caco-2 cells. It is known that one of the effects of MAPK 
activation is to alter the translation of mRNA to proteins through two potential mechanisms. 
The first involves MAPK-induced phosphorylation of 40S ribosomal protein S6 kinase, which 
mainly regulates translation of mRNAs containing polypyrimidine tracts at their 5' end (5'-
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terminal oligopyrimidine [5'TOP] mRNAs) by phosphorylating ribosomal protein S6 
(Jefferies et al. 1994; Pende et al. 2004; Hershey 2007). Given that both VEGF and HIF 
transcripts are translated in a cap-dependent as opposed to 5’TOP-dependent manner, MAPK 
could still regulate their protein expressions through an alternate regulatory control pathway 
involving the cap-binding protein eIF4E (Waskiewicz et al. 1999; Pyronnet 2000). This 
regulatory mechanism exerts a potent control over protein translation as interactions between 
mRNA and eIF4E typically represents the rate-limiting step in initiating translation (Hershey 
2007). eIF4E is a 25kDa phosphoprotein that binds 7-methlguanosine-containing cap of 
mRNA to initiate the first steps of cap-dependent mRNA recruitment. This translational 
regulator forms the eIF4F complex by interacting with eIF4G and eIF4A, in order to unwind 
the 5’-UTR to present the message to 40S ribosomal subunit for scanning of the translation 
start site (Sonenberg 1994). Phosphorylated ERK has been shown to phosphorylate 
downstream Mnk-1 which interacts with the adaptor protein eIF4G to enhance 
phosphorylation of eIF4E, consequently resulting in enhanced translational activity 
(Waskiewicz et al. 1999; Pyronnet 2000). Since VEGF transcripts possess long 5’-UTR of 
approximately 1040 bases which adopts a complex secondary structure, these morphological 
characteristics render VEGF a weakly translated transcript and a potential target for 
translational regulation through the eIF4E regulatory mechanism (De Benedetti et al. 1994; 
Kevil et al. 1995; Kevil et al. 1996). Furthermore HIF-1α mRNA translation has also been 
demonstrated to be regulated in a cap-dependent manner (Hui et al. 2006), but involvement of 
EGFR and MAPK in modulating this process remains unexplored. It is therefore conceivable 
that ERK MAPK signalling could represent the common pathway utilised by CRC cells to 
relay messages from activated EGFR to the cytoplasmic compartment, to enhance synthesis 
of VEGF and HIF-1α proteins. A recent study has shown that the Mnk/eIF4E kinase pathway 
can be activated by interferon (IFN) stimulation, resulting in mRNA translation for IFN 
stimulated genes and generation of IFN-inducible anti-proliferative responses (Joshi et al. 
2009). The prospect of this potential underlying mechanism to account for modulation of 
angiogenesis in CRC still remains unknown and would be of great interest to explore, given 
the translational value of novel eIF4E targeted therapies which are currently in development 
for cancer therapies. 
Tumour hypoxia is important because it is a poor prognostic factor. Hypoxia alters 
treatment sensitivity of tumours, rate of tumour growth and invasion, and alters the 
environmental niche to select for phenotypically aggressive cells. Furthermore, hypoxia is a 
potent and well known inducer of VEGF expression, and it represents one of the most 
effective stimuli in promoting angiogenesis. Despite formation of new tumour vasculature in 
response to hypoxia, these new vessels are inadequate and disproportionately distributed, and 
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furthermore are structurally and functionally inept compared to those in normal tissues 
(Denekamp 1990; Konerding et al. 1999). Thus hypoxia still persists despite the expansion in 
the tumour vascular network. The existence of hypoxia within CRCs have been confirmed by 
oxygen electrode measurements, IHC examination of samples stained with imidazole-based 
markers known to bind to regions of low oxygen tensions, or through IHC identification of 
endogenous hypoxia markers such as HIFs (Goethals et al. 2006). Hypoxia has been 
demonstrated to upregulate expression of HIF, an oxygen dependent transcriptional activator 
which is crucial in mediating various adaptive responses to changes in tissue oxygenation 
(Semenza 1999). The ability of HIFs to ‘sense’ intracellular oxygen tensions is related to a 
series of oxygen-dependent hydroxylation and acetylation reactions which determine its 
stability and ultimately its expression. Under hypoxic conditions, the oxygen-dependent 
modifications of HIF are inhibited, thus the stabilised HIF-α binds to HIF-β to translocate 
into the nucleus, where in the presence of co-activators initiate transcription of hypoxia-
responsive genes. Approximately seventy genes are known to be regulated by HIF, amongst 
which is VEGF, and they all have important functions in regulating nutritional stress, 
angiogenesis, tumour metabolism, invasion and cell death (Semenza and Wang 1992; 
Semenza 2002). The importance of appreciating the existence of hypoxia in CRC was clearly 
demonstrated by three separate pieces of evidence from my study. Firstly, hypoxia and 
DMOG stimulation resulted in significant upregulation in HIF-1α protein expression in Colo 
201 and Caco-2 cells through post-translational stabilisation. The accumulation in HIF-1α 
resulted in induction of VEGF transcriptional activity through increased HIF-1α binding, and 
consequently led to significant increase in VEGF protein expression. These findings reinforce 
the importance of hypoxia and HIF overexpression in CRC, as hypoxic stress imposed a 
potent stimulus to elicit a consistent and significant VEGF response in both Colo 201 and 
Caco-2 cells. Data from my gene array studies, which represent the second piece of evidence, 
further demonstrated that hypoxia and DMOG consistently and significantly induced 
angiogenic responses in both cell types. In marked contrast to the meagre responses elicited 
from Colo 201 cells with EGFR stimulation, 16 angiogenic genes were identified to be 
significantly altered following hypoxia stimulation in Colo 201 cells, and 23 genes in Caco-2 
cells with DMOG. The third piece of evidence was derived from my studies on primary CRC 
cells which demonstrated significant upregulation in VEGF expression following hypoxia 
stimulation. In agreement with my previous findings, cells treated with EGF alone failed to 
produce a detectable angiogenic response. Furthermore, the hypoxia-induced VEGF 
expression was unaffected by additional EGF stimulation, therefore further supporting a 
potential redundancy of EGFR signalling in primary CRC cells, as opposed to the critical role 
hypoxia plays in promoting CRC angiogenesis. 
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Given that VEGF responses are related to its induction by HIF, expression profiles 
for both mediators should almost be identical. This theory is applicable in Caco-2 cells where 
there was a correlation in expression profiles for both HIF-1α and VEGF expressions, 
confirming that DMOG-induced VEGF upregulation was primarily a result of increased HIF 
binding, with consequent stimulation of VEGF transcriptional and subsequent translational 
activity. On the contrary, Colo 201 cells demonstrated a progressive time-dependent rise in 
VEGF mRNA and protein levels, well beyond the point at which HIF-1α expression achieved 
its maximal. This implies the presence of an alternate HIF-independent mechanism by which 
VEGF expression is induced under hypoxia. Hypoxia alone has been demonstrated to initiate 
and sustain a pro-angiogenic response independent of HIF signalling, by directly modulating 
VEGF gene transcription through a PI3K/Rho/ROCK dependent pathway (Mizukami et al. 
2006). Furthermore, hypoxia not only increases VEGF transcriptional rate, but it also exerts 
an independent effect on VEGF mRNA stability (Ikeda et al. 1995). A possible trans-acting 
protein which is hypoxia inducible and capable of interacting with VEGF 3’-UTR sequences 
has also been proposed to assist prolongation of its half-life (Levy et al. 1996). These added 
effects conferred specifically by hypoxia, and which are independent of HIF, could possibly 
account for the differences in VEGF expression profiles for Colo 201 and Caco-2 cells. 
Although VEGF expression profiles differed between hypoxia-stimulated Colo 201 
and DMOG-treated Caco-2 cells, the profiles for HIF-1α protein and mRNA expression for 
both cell types were however almost identical. Both CRC cell lines demonstrated increased 
HIF-1α protein expression with hypoxia or DMOG, achieving peak levels at 6 hours 
following stimulation which subsequently decreased steadily over time. In contrast, HIF-1α 
gene expression demonstrated a steady progressive fall over the same study period. Such 
observed discrepancy could be accounted for by a naturally occurring antisense RNA known 
as aHIF which is complementary to the 3’-UTR of HIF-1α mRNA. The function of aHIFs has 
been postulated to regulate HIF-1α mRNA at the post-transcriptional level by increasing its 
instability. Its expression level is not constant and most likely dependent upon HIF-1α protein 
expression, since the aHIF promoter sequence possesses putative HRE sites. Thus, aHIF 
could be implicated in the complex regulation of HIF-1 by reducing HIF-1α mRNA and in 
turn decreasing its translation, a theory which would account for my observations in both 
CRC cell lines following prolonged hypoxia or DMOG treatment (Rossignol et al. 2002). An 
alternate direct negative regulatory mechanism has also been proposed where hypoxia limits 
accumulation of HIF-1α by inducing expression of human PHD2 and PHD3, thus 
accelerating degradation of excess HIF-1α on reoxygenation after long-term hypoxia 
(Marxsen et al. 2004). Results from my work therefore highlight the potential, but 
unconfirmed existence of a negative feedback control mechanism at the post-transcriptional 
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level, which facilitates rapid adaptation of hypoxic cells to reoxygenation when blood flow is 
re-established. 
However, even with the negative feedback imposed by aHIF, HIF-1α protein levels 
remained significantly elevated over a substantial period of hypoxia or DMOG stimulation. 
This finding refutes the accepted principle that cells subjected to significant stress classically 
shutdown total protein synthesis to conserve their valuable resources and energy 
consumption. Translation initiation of HIF-1α transcripts by the eIF4F complex was 
discussed earlier, but this mechanism alone is incapable of accounting for the significant 
upregulation in HIF-α protein. This is because hypoxia has a profound inhibition on initiation 
of transcriptional activity by restricting the amount of freely available eIF4E to bind to 
5’capped ends of mRNA (Tinton and Buc-Calderon 1999). Such limitations however could be 
overcome by the presence of an alternate translational regulatory mechanism. HIF, together 
with several other hypoxia-related mediators, possesses an internal ribosome entry site (IRES) 
found in the 5’-UTR of their genes, thus permitting their continued translation even under 
hypoxic stress. Interestingly, a number of cellular mRNAs which code for pro-angiogenic 
factors such as FGF (Vagner et al. 1995) and VEGF (Stein et al. 1998) also contain a region 
coding for the IRES, thus production of proteins crucial for cell survival is sustained during 
periods of stress. 
Although HIF-1α and HIF-2α are regulated by similar oxygen dependent 
mechanisms, the different isoforms appear to be differentially regulated and exhibit 
distinctive roles in modulating cellular responses. My study revealed significant differences in 
HIF-2α expression profiles between Colo 201 and Caco-2 cells with hypoxia and DMOG 
stimulations. Colo 201 cells demonstrated a progressive time-dependent increase in HIF-2α 
mRNA expression with peak expression achieved at 24 hours of hypoxia. This compares 
favourably to a study by Uchida et al (Uchida et al. 2004) showing a significant rise in HIF-
2α mRNA of approximately 1.5 fold and 2 fold with hypoxia or cobalt chloride stimulation 
(where cobalt chloride is thought to act as a hypoxia mimetic by inhibiting PHD, a 
mechanism similar to that of DMOG). In contrast, Caco-2 cells responded to HIF 
overexpression by downregulating HIF-2α gene expression over time following DMOG 
stimulation. The variations in HIF-2α responses could be a result of different stimuli used in 
the individual cell types. The global stress imposed by hypoxia could also activate other 
signalling processes independent of HIFs, which in turn could exert varying effects on HIF-
2α gene transcriptional activity. Evaluation of HIF-2α protein levels as part of future work 
could provide useful insight into post-transcriptional processes affecting HIF-2α expression, 
and therefore provide a greater appreciation of its participation in mediating various 
downstream cellular processes in response to hypoxia. Furthermore, with no current 
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consensus on the relative roles of HIF-1α and HIF-2α in CRC, future work using knock-
down models of CRC cells would be of great interest to determine their relative roles in 
promoting angiogenesis. This would also complement further work which is required to 
address the relevance of a supposed drift from predominance of HIF-1α to HIF-2α mediated 
angiogenesis, as CRCs progress into the advanced stages of disease. 
The process of angiogenesis is a tightly regulated process, with the eventual outcome 
determined by the prevailing influence of either the pro- or anti-angiogenic factors. The field 
of study was therefore broadened by the use of angiogenesis PCR arrays, to allow expression 
of a panel of known angiogenic genes to be profiled, and to facilitate further studies into 
global effects imposed by EGF and HIF overexpression on CRC angiogenesis. Although gene 
expression profiling has previously been reported on CRC with microarray technology, the 
data available have so far compared normal and tumour tissue samples, or compared tumours 
at varying stages of disease (Alon et al. 1999; Backert et al. 1999; Hegde et al. 2001; 
Kitahara et al. 2001; Notterman et al. 2001; Agrawal et al. 2002; Birkenkamp-Demtroder et 
al. 2002; Lin et al. 2002; Zou et al. 2002; Frederiksen et al. 2003; Tureci et al. 2003; 
Williams et al. 2003; Sugiyama et al. 2005). The PCR angiogenesis arrays identified a total of 
19 and 27 genes which were significantly up- or downregulated following EGF, hypoxia or 
DMOG stimulation in isolation, or as combined stimulations. Amongst the 46 identified 
genes, 5 common genes demonstrated significant changes in their expressions with EGFR and 
HIF overactivation in both CRC cell lines. Four of these genes demonstrated significant 
upregulation in expression, particularly following hypoxia or DMOG stimulation alone or in 
combination with EGF. Amongst the panel of upregulated genes, VEGF (Ellis et al. 2000; 
Khong et al. 2007) and IL-8 (Haraguchi et al. 2002; Mizukami et al. 2005), both of which are 
known inducers of angiogenesis in CRC, were demonstrated to be significantly upregulated in 
Colo 201 and Caco-2 cells following hypoxia and DMOG stimulations. However, the study 
also identified two novel genes ANGPTL4 and EFNA3 which were significantly upregulated 
following hypoxia or DMOG stimulations, and the importance of these genes in regulating 
angiogenesis specific to CRC still remain largely unknown. 
ANGPTL4 is a family member of 7 molecules bearing structural homology to 
angiopoietins, and they are known to lack reciprocal binding receptors (Oike et al. 2004; 
Katoh and Katoh 2006). The main function of ANGPTL4 is to regulate lipid, glucose and 
energy metabolism (Kersten 2005; Oike et al. 2005), but its involvement in regulating 
angiogenesis appears to be rather complex, with both pro- and antiangiogenic effects having 
been reported for the mediator. Studies so far have concluded that the eventual angiogenic 
outcome varies in accordance with cell-specific contexts, and expression of other angiogenic 
modulating factors (Ito et al. 2003; Le Jan et al. 2003; Oike et al. 2004; Galaup et al. 2006). 
209 
MD (Res) Thesis Tak Loon Khong 
Chapter 6 
Although ANGPTL4 is known to be highly regulated by hypoxia (Le Jan et al. 2003), its 
precise role in CRC remains unknown. Given that my angiogenesis gene array demonstrated 
significant increase of more than 4- and 20–fold upregulation in ANGPTL4 expression in 
Colo 201 and Caco-2 cells respectively, this is unlikely to be a redundant response and would 
most likely exert a significant biological effect. Unfortunately, it is not possible to predict the 
end-effects of ANGPTL4 overexpression in the context of CRC angiogenesis based solely on 
gene transcriptional data, therefore future work should be focused on elucidating the precise 
function which could be mediated by ANGPTL4 in CRC. The expression of various 
ANGPTL4 isoforms by CRC should then be assessed under stimulated and unstimulated 
conditions to determine their relative roles in CRC angiogenesis.  
Ephrins (EFNA) play critical roles in embryonic development by regulating cell 
migration and adhesion, influencing cell lineage, morphogenesis, organogenesis and 
development of the embryonic vascular system. Recent studies suggest that EFNA signalling 
is also important in adult life, particularly in controlling the architecture and physiology of 
tissues under normal and pathological conditions. The role of EFNA signalling in tumour 
angiogenesis is controversial, as opposing functions have been suggested for several members 
of this family depending on the experimental model. However, the role of EFNA in CRC 
angiogenesis remains largely unexplored. Currently, EFNA1 which has been demonstrated to 
be overexpressed by tumour endothelial cells (Ogawa et al. 2000; Kataoka et al. 2004) is 
thought to promote tumour angiogenesis (Brantley-Sieders et al. 2005; Brantley-Sieders et al. 
2006). A correlation between EFNA3 and cancer has only been validated in lung cancer 
(Hafner et al. 2004), but data confirming presence of mutant EFNA3 receptor (EphA3) in 
CRC cell lines and primary tissues provide a weak, but tangible link to the importance of 
EFNA3-EphA3 signalling in CRC (Bardelli et al. 2003). EFNA, primarily EFNA1 and its 
reciprocal receptor EphA2 is thought to promote angiogenesis through VEGF induction and 
potentiation of its effects (Cheng et al. 2002). However, this mechanism has not been 
specifically validated in CRC. The data from my gene array studies confirms hypoxic 
induction of EFNA 1 and EFNA3 expressions in CRC, and to my knowledge represents novel 
data that have not been previously reported. 
Stabilin-1 (STAB1) was the only common gene which was significantly 
downregulated in both CRC cell lines following stimulation with EGF, and particularly 
following combined EGF and DMOG stimulation. STAB1 is a multifunctional scavenger 
receptor expressed by sinusoidal endothelial cells in human spleen and liver (Politz et al. 
2002) to clear a variety of metabolic by-products through receptor mediated endocytosis. 
STAB1 is thought to modulate angiogenesis by interacting with SPARC (also known as 
osteonectin), a soluble extracellular glycoprotein which regulates angiogenesis by affecting 
ECM organisation, binding of growth factors, and induction of anti-adhesive states in 
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different cell types (Bradshaw and Sage 2001; Murphy-Ullrich 2001). The interaction results 
in internalisation, endocytosis and subsequent degradation of SPARC (Murphy-Ullrich 2001; 
Kzhyshkowska et al. 2006) although this mechanism still remains to be confirmed. 
Expression of STAB1 is significantly increased during chronic inflammation, tumourigenesis 
and angiogenesis (Goerdt et al. 1993; Salmi et al. 2004) and downregulated by hypoxia in 
primary human monocytes (Bosco et al. 2006). There is an overall lack of evidence 
supporting expression of STAB1 in solid cancers, and certainly there are no studies to date 
examining the effects of EGF and hypoxia or DMOG on expression of STAB1 in CRC. In my 
angiogenesis array study, STAB1 was the only gene which was consistently downregulated 
by EGF in both Colo 201 and Caco-2 cells, and demonstrated further repression when 
stimulated in combination with DMOG. These dramatic changes in gene transcription 
following EGF and DMOG or hypoxia stimulations by two separate cell types clearly 
highlight the importance of STAB1 in mediating a potential functional role in tumour 
angiogenesis. My study which uncovered a potential role for STAB1 in regulating CRC 
angiogenesis to my knowledge is novel, and would represent an interesting and exciting 
subject to pursue in future work. 
EGFR overactivation and hypoxia are hallmarks of CRC and would thus co-exist 
within the similar tumour microenvironment. My study also aimed to address a potential 
synergistic relationship between hypoxia and EGFR stimulation, to culminate in a 
downstream response which supersedes the angiogenic effect exerted by either of the stimulus 
in isolation. Existence of such synergistic relationship that imposes a significant functional 
relevance was unfounded in my studies. The first piece of supporting evidence originated 
from Chapter 3, showing a small and statistically non-significant further rise in VEGF protein 
expression by Caco-2 cells stimulated with combined EGF and DMOG, compared to 
individual treatments in isolation. Secondly, although it is difficult to quantitatively define a 
synergistic effect when interpreting gene expression data, the gene array only revealed 5/84 
genes which were further up- or downregulated by 2.5-fold in relative expression following 
combined EGF and DMOG stimulation, compared to individual treatments alone. Finally and 
most importantly, the HUVEC migration assay showed similar numbers of endothelial cells 
migrated in response to Caco-2 cells following pre-stimulation with EGF and DMOG in 
combination or as isolated agents. The lack of difference in migrated endothelial cell numbers 
must reflect upon a comparable angiogenic effect, which had been created by Caco-2 cells in 
response to pre-stimulation with EGF and DMOG either in combination or in isolation. Since 
the overall angiogenic effect created by combined stimuli was comparable to that of EGF or 
DMOG in isolation, these findings disprove a synergistic benefit of overexpressing both 
EGFR and hypoxia pathways on CRC angiogenesis. The results therefore highlight the 
importance of considering the contributory effect of each stimulus in promoting angiogenesis, 
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as targeted therapies such as EGFR antagonists alone may not confer sufficient therapeutic 
benefit due to the overriding effect imposed by hypoxia. The available data therefore supports 
the role of combined therapies to ideally target multiple angiogenic mediators to overcome 
potential treatment resistance, as alternate pathways emerge to exert an overriding effect and 
resume control over angiogenesis. 
The angiogenesis PCR array has provided an invaluable insight into the involvement 
of a panel of known angiogenic genes which are particularly important in potentiating EGF- 
and hypoxia-induced angiogenesis relevant to CRC. However, predicting the possibility of 
new vessel growth based on relative changes across multiple genes, some of whose precise 
functions are yet to be defined, would certainly represent a challenging and virtually 
impossible task. To overcome this shortfall, a functional HUVEC migration assay was 
performed to facilitate qualitative and quantitative evaluation of the angiogenic potential of 
EGF, hypoxia and DMOG stimulated CRC cells. The potential induction of a pro-angiogenic 
microenvironment fostered by stimulated CRC cells were modelled in a co-culture of Caco-2 
and HUVEC cells, utilising a dual chamber cell culture system or modified Boyden chamber 
(Glaser et al. 1980; Seppa et al. 1983). HUVECs seeded into a separate cell culture insert 
were observed for chemotaxis in response to alterations in the balance of angiogenic 
mediators induced by CRC cells following EGF and/or DMOG stimulation. Although 
evidence suggests ErbB ligands can exert a direct influence on endothelial cell types 
expressing ErbB receptors, such as EGFR present in microvascular endothelial cells (MVEC) 
(Baker et al. 2002) and HUVEC (Sini et al. 2005), the expression and function of such 
receptors in this cell type is still debated (De Luca et al. 2008). My preliminary studies which 
specifically examined the effect of direct EGF stimulation on migration of HUVECs did not 
support a stimulatory role for EGF in enhancing HUVEC migration compared to controls, a 
finding similar to that reported by Hirata et al (Hirata et al. 2002). Stimulation of HUVEC 
with DMOG also did not enhance migration, but as expected, VEGF represented a potent 
chemotactic stimulus enhancing HUVEC migration by 7.7-fold. The sheer presence of 
unstimulated Caco-2 within the co-culture resulted in increased numbers of migrated 
HUVEC, illustrating the capacity of Caco-2 cells to generate a natural chemotactic gradient to 
encourage endothelial cell migration. Stimulation of Caco-2 cells with EGF significantly 
modulated the culture environment to encourage HUVEC transmigration and chemotaxis 
towards Caco-2 cells. This result parallels findings reported by Hirata et al, where a similar 
co-culture system using A431 epidermal cancer cells resulted in a significant increase in 
HUVEC migration. This effect was specific to EGFR induction as the response was abrogated 
following treatment with an EGFR tyrosine kinase antagonist (Hirata et al. 2002). My results 
also confirmed a similar pro-migratory effect generated by DMOG stimulated Caco-2 cells, 
and similar effects were seen in cells stimulated with combined EGF and DMOG. Since 
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number of migrated cells is a reflection upon the potency of the angiogenic stimulus, the 
identical numbers of migrated cells in all three treatment groups rejects the hypothesis that 
EGFR overactivation synergises with HIF overexpression to generate a significantly potent 
angiogenic effect. These findings from the HUVEC migratory study, to my knowledge, have 
not been previously demonstrated and further work using EGFR antagonists, HIF knockdown 
and other functional models should be pursued to reaffirm the functional relevance of EGFR 
and HIF activation in promoting CRC angiogenesis. Since VEGF exerts a potent and 
prominent influence in promoting endothelial cell chemotaxis, VEGF protein expressed 
within the co-culture supernatants were measured. VEGF expression directly correlated with 
my HUVEC migration data, where VEGF protein levels were significantly increased in co-
cultures of Caco-2 cells pre-treated with EGF and/or DMOG. However, to confirm that the 
observed chemotaxis is an effect specifically mediated by VEGF, the experiment should be 
repeated with a VEGF-antagonist such as bevacizumab in future studies. Furthermore to 
broaden our understanding of the observed pro-migratory effect, future work could utilise 
angiogenesis antibody arrays which allows profiling expression at the protein level to detect 
multiple angiogenesis-specific cytokines. The proposed study would hope to identify critical 
angiogenic mediators which would account for the enhanced HUVEC migration as observed 
in my co-culture studies. 
Colo 201 and Caco-2 cell lines have clearly proven invaluable in my studies by 
uncovering several key biological processes which underlie angiogenesis within CRC cells. 
They have provided a glimpse of how these mechanisms may translate to CRC angiogenesis 
in vivo, and represent useful cell models for the testing and development of future therapies. 
The most valuable feature of cell lines is their clonogenic characteristic with their propensity 
to consistently reproduce cell populations with identical properties. These reasonably stable 
cell systems with capacity to self-renewal represent the ideal opportunity for moderate 
throughput capabilities, and form the basis for valid and consistent comparisons to be drawn 
between experiments. However, the greatest limitation of using such immortalised cells is 
their discordance in behaviour relative to their tissue of origin in vivo, due to accumulation of 
multiple genetic mutations secondary to genomic instability. This is the paradox of cell lines, 
where the genomic mutations which endow the ability to grow indefinitely in vitro also 
transform them beyond their recognisable genotypic origins. In order to address the limitation 
posed by the genetic instability of CRC cell lines, I attempted to establish an alternate cell 
culture system which involved culturing cells directly from patient tissue. The superiority of 
these primary isolates would be their relative similarities to the primary CRC tissue of origin, 
as they would retain certain differentiated features of colorectal epithelium. Despite multiple 
attempts, achieving a successful CRC culture from primary tissue proved challenging. This 
has been recognised by other studies reporting success rates ranging widely from 0% to 45% 
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(Leibovitz et al. 1976; Whitehead 1976; McBain et al. 1984), possibly reflecting the wide 
variations in techniques employed to isolate and culture primary CRC cells. Due to time 
limitations, I attempted to establish primary cultures from tissue samples obtained from nine 
patients with histologically proven CRC prior to surgery, but all attempts failed to yield self-
sustaining and propagating cultures sufficient for further experimental purposes. The 
challenges which I faced paralleled those that have been described by others, and these 
include (1) microbial contamination, (2) failure of cells to attach, (3) lack of continued 
proliferation (4) senescence of early cell colonies and progressive involution of cultures, (5) 
outgrowth of contaminating mesenchymal cells, primarily fibroblasts (Leibovitz et al. 1976; 
Whitehead 1976; McBain et al. 1984; Paraskeva et al. 1984; Kirkland and Bailey 1986). 
However, the potential rewards of working with primary cell cultures are considerable, given 
that the heterogeneous cell population would bear greater resemblance to the tissue of origin, 
and thus experimental findings would be more meaningful when translated to CRC in vivo. I 
therefore modified several of my techniques to overcome the challenges as stated above, and 
several of these modifications have proven useful. Microbial contamination of cultures, to a 
certain degree, will be inevitable due to the natural presence of mixed commensal flora lining 
the human lower gastrointestinal tract. In agreement with other published studies, tumour 
tissues should be extensively washed up to 8 wash steps with high doses of antibiotics 
comprising of penicillin, streptomycin and gentamicin, and fungicides such as mycostatin 
prior to enzymatically digesting the tissue samples to reduce microbial load (Paraskeva et al. 
1984). The second proposed modification which could be attempted in future work would be 
to use the larger fragments of enzymatically undigested mesenchymal stromal tissue, which 
were typically separated by filtration through nylon gauze, as starting material for cultures. 
This proposed modification is based on a paper by Paraskeva et al (Paraskeva et al. 1984) 
reporting repeated failures in initiating epithelial cultures from the filtrate comprised mainly 
of single cells, until they discovered that the epithelial tubules and large clumps of cells 
collecting on the gauze resulted in epithelial cultures when placed into culture. The most 
prominent challenges of establishing CRC cultures were undoubtedly to sustain continued 
proliferation, preventing senescence of early cell colonies and progressive involution of 
cultures. The key to solving this dilemma lies in supporting growth and proliferation of 
progenitor stem cells, which confer normal tissue and cell cultures the longevity, self-renewal 
and regeneration capabilities (Potten and Loeffler 1990; Brittan and Wright 2004; Boman and 
Huang 2008). Although cancer stem cell theory was conceptualised almost 12 years ago, it 
was only until recently that CRC stem cells were confirmed. This was primarily attributed to 
recent successes in isolating and culturing such cells using specialised culture media, initially 
developed for supporting growth of neural stem cells (Galli et al. 2000; Westerlund et al. 
2003). The constituents of this medium are fully defined, and basis for the composition are to 
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provide basic substrates for cell metabolism, anabolic hormones and growth factors to 
promote growth, antioxidants and trace elements to provide optimal conditions for enzymatic 
function, and low concentrations of calcium to prevent differentiation (Hennings et al. 1980; 
Black and Smith 1989). Due to time limitations of my project, only 2 attempts were made to 
culture CRC cells using the sphere-promoting growth medium. Unfortunately both attempts 
failed to generate proliferating and self-sustaining cultures of CRC stem cell spheres. Future 
efforts in establishing primary CRC cultures should be focused primarily on supporting 
growth of undifferentiated CRC stem cells, as their capacity towards self renewal could 
provide a consistent source of CRC cells (Todaro et al. 2007). 
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6.1 FUTURE WORK 
The study has revealed a void in our understanding into the relative roles HIF-1α and 
HIF-2α fulfil in promoting angiogenesis in CRC. Future work could focus on optimising 
knockdown of HIF-1α and HIF-2α in Colo 201 and Caco-2 at the level of mRNA and 
protein. Stable HIF knockdown of CRC cell models with small interfering (si) RNA would 
form the basis for determining the differential regulation in expression of hypoxia responsive 
genes at mRNA and protein levels. The effect of selective HIF knockdown on cell survival 
should also be evaluated by FACS analysis for apoptosis (annexin V/propidium iodide); and 
also through cell death and cell proliferation assays. Finally, the functional relevance of HIF 
isoform knockdowns should be determined by performing HUVEC migration assays. These 
findings would complement my studies using hypoxia and DMOG in Colo 201 and Caco-2 
cells, which uncovered changes in HIF protein, and identified a range of hypoxia/DMOG-
induced genes, without clarifying roles mediated by individual HIF isoforms. HIF-1α is the 
most extensively studied HIF-α isoform and its role in cancer is relatively well understood. 
HIF-2α on the other hand is much less characterised (Fukuda et al. 2002; Krishnamachary et 
al. 2003; Jubb et al. 2004; Dang et al. 2006; Giles et al. 2006). The two isoforms act in a 
similar manner by targeting HRE, however crucially several studies have suggested they 
activate transcription of different genes and hence have different functions, which could be of 
significance in CRC (Wang et al. 2005). The first studies to show that HIF-1α and HIF-2α 
have opposing effects in regards to tumour growth were carried out on renal carcinoma 
(Bertout et al. 2008). HIF-1α is thought to regulate genes involved in metabolism, regulating 
glycolysis and glucose uptake, as well as angiogenesis. Conversely HIF-2α has been reported 
to regulate genes, which is involved specifically in renal tumourigenesis and regulation of 
genes with special functions. It has also been shown that the relative contributions of the HIF-
α subunits to tumour growth versus suppression are likely to be tissue-specific (Bertout et al. 
2008). In endothelial and breast cancer cells HIF-1α mediates cell responses to hypoxia, 
where as in renal carcinoma cells HIF-2α is the more important hypoxia regulator (Sowter et 
al. 2003). In a study with another CRC cell line, SW480, HIF 1α promoted growth of SW480 
cells and HIF 2α restrained growth (Imamura et al. 2009). It would therefore be of relevance 
to determine the role of HIF isoforms in CRC. 
Furthermore, my work uncovered the role of EGFR stimulation in increasing HIF-1α 
and VEGF protein expression in CRC cells with functional ERK MAPK signalling. Absence 
of significant responses at HIF-1α and VEGF gene expression suggests that the effects 
mediated by EGFR activation could potentially be dependent upon regulating protein 
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translational activity. My data also revealed the importance of ERK MAPK signalling in 
mediating this response, but further work is required to confirm the critical role of MAPK by 
abrogating its function, for example using the specific p42/44 mitogen-activated protein 
(MAP) kinase cascade inhibitor, PD98059. Furthermore, the effects of EGFR activation on 
expression of the translation initiator eIF4E should be determined at both gene and protein 
levels, as this factor typically represents the rate-limiting step in translating 5’capped 
dependent mRNA. The possible role of activated ERK MAPK signalling on activating eIF4E 
should also be confirmed by performing phospho-eIF4E Western Blots following treatment 
with PD98059. 
As ANGPTL4, EFNA and STAB were common genes identified to be significantly 
altered in both Colo 201 and Caco-2 cells following hypoxia and DMOG stimulation, it is 
possible that all three genes are regulated by HIF. The role of HIF in regulating expression of 
these genes should be confirmed through the HIF knockdown models as described earlier. 
Their functional roles in promoting angiogenesis in CRC should be evaluated by transfecting 
CRC cells with overexpressing vectors of the corresponding genes, and using these cells in 
HUVEC migration, matrigel assays and if possible using in vivo xenograft models. 
The HUVEC migration assay demonstrated that co-cultures with pre-stimulated 
Caco-2 cells with EGF and DMOG resulted in enhanced HUVEC migration. Although VEGF 
protein was demonstrated to be correspondingly upregulated in co-cultures with increased 
HUVEC migration, the specific involvement of VEGF in inducing this pro-migratory effect 
should be confirmed by using the VEGF antagonist bevacizumab. Furthermore, to broaden 
our understanding of the observed pro-migratory effect, future work could utilise 
angiogenesis antibody arrays which allows profiling expression at the protein level to detect 
multiple angiogenesis-specific cytokines within cell supernatants. The proposed study would 
hope to identify critical angiogenic mediators which would account for the enhanced HUVEC 
migration as observed in my co-culture studies. 
Finally, in order to enhance the translational value of our data derived from cell lines 
to in vivo CRC, parallel studies should be performed to compare the gene signatures of EGF- 
and hypoxia-treated primary tumour-derived CRC cells. Primary CRC cells should therefore 
be stimulated with EGF and hypoxia, and the extracted mRNA is subjected to profiling by the 
angiogenesis PCR arrays. 
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6.2 CONCLUSION 
The physical, psychological and financial impact of CRC is significant, particularly 
when majority of malignancies of up to 55% of cases present at advanced stages with 
established lymph node involvement or distant metastases. Currently, the only curative 
treatment for the condition is by surgery, but only a small proportion of patients presenting 
during the earlier stages of disease are suitable candidates for surgery. For a large proportion 
of patients presenting with advanced malignancies, most are only amenable for chemo- and/or 
radiotherapy with hope of achieving downstaging of tumours for potential curative resection. 
Recent breakthrough discoveries in tumour biology have been translated to developments in 
several new and exciting therapeutic agents, with proven efficacy in selected patients with 
advanced CRC. Such success has reaffirmed the importance of identifying and understanding 
aberrant biological systems which underlie CRC pathogenesis, survival and progression. One 
of the critical systems which support survival and progression in cancers is angiogenesis, thus 
cancers typically exploit various regulatory mechanisms underlying tumour angiogenesis to 
gain significant survival advantage. 
EGFR overactivation is a hallmark of CRC, and it has previously been demonstrated 
to modulate angiogenesis in non-CRC cell types. My study confirmed that EGFR activation 
does stimulate an angiogenic response, but only in the presence of a functional ERK MAPK 
pathway. CRC cells with dysfunctional ERK signalling failed to demonstrate significant 
angiogenic responses, thus highlighting the critical role of ERK signalling in mediating 
downstream responses induced by EGFR activation. My results may in part explain for the 
poor treatment response observed in a subset of patients with mutated K-Ras (a signalling 
molecule which is upstream to ERK) receiving EGFR targeted therapies. My data also 
supported the most recent recommendations from clinical studies, that patients should 
undergo multiparameter testing to assess mutation status of selected markers in order to select 
patients who would benefit most from EGFR therapy. 
Hypoxia is a well recognised feature of solid tumours, and is a reflection of multiple 
pathological factors which contribute towards the imbalance between oxygen demand and 
supply. Hypoxia is known as a potent angiogenic stimulus, as it is capable of activating a host 
of angiogenic genes mediated through HIF, the master regulator of oxygen. My study 
reaffirmed the importance of tumour hypoxia, as it consistently and significantly affected 
activities of multiple genes in both CRC cell types. The study also rejected the hypothesis that 
hypoxia and EGFR overactivation could synergise their respective angiogenic effects by 
converging upon HIF. Analysis of gene and protein expression data, together with results 
from a functional model, confirmed that EGFR and HIF overactivation imposed significant 
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effects on CRC angiogenesis by functioning independently. As a result, targeting EGFR alone 
as a monotherapy in CRC may result in greater likelihood of treatment failure, due to the 
overriding and unopposed effect of hypoxia. 
In summary, my study into the role of EGFR activation and hypoxia on CRC 
angiogenesis uncovered several novel findings, which to my knowledge have not previously 
been reported in literature. Firstly, direct EGFR stimulation promoted an angiogenic response 
in CRC by modulating expression of several well established angiogenic mediators such as 
VEGF, and other relatively unknown mediators such as stabilin, angiopoietin-like 4 and 
ephrins. The second novel finding of the study uncovered the critical role of functional ERK 
MAPK signalling in mediating angiogenic responses to direct EGFR activation in CRC. This 
was proven by studies performed on Colo 201 CRC cells expressing aberrant ERK signalling, 
which failed to demonstrate significant difference in global angiogenic gene activity 
following EGFR stimulation. In contrast, hypoxia or hypoxia-mimetics which are well-
recognised potent regulators of angiogenesis exerted an overriding effect through consistent 
and significant induction of multiple angiogenic mediators in CRC cells. This observation 
was further reaffirmed using my novel heterogeneous CRC cell cultures derived from primary 
patient tissue, which demonstrated significant VEGF induction following stimulation with 
hypoxia, but not with EGF. Since these cultures were composed of mixed cell types derived 
directly from patient tumours, the results from this novel study model would be more accurate 
and representative of the behaviour demonstrated by CRC tissue in vivo. Finally, my study 
also rejected the possibility of synergy between EGFR overactivation and hypoxia in 
promoting CRC angiogenesis. Although the study uncovered consistent upregulation of HIF 
following direct EGFR stimulation in isolation, combination of hypoxia and EGFR 
stimulation did not synergise to further enhance HIF or VEGF expression. This discovery 
represented the fourth novel finding of the study, thus rejecting the hypothesis that both 
EGFR overactivation and hypoxia could converge upon HIF to further enhance CRC 
angiogenesis. 
Clearly, further research is required to elucidate the exact mechanisms by which 
CRCs with overactive EGFR develop resistance to EGFR-targeted therapies. However, my 
presented work has highlighted the importance of a mutation affecting a single critical 
signalling pathway in altering global cell behaviour, and conferring the transformed 
malignant cells with significant resistance to extrinsic control. My study has also served to 
emphasise the critical role of hypoxia in stimulating a pro-angiogenic response in CRC, and 
the importance of addressing this prominent feature present within most solid tumours in 
order to achieve a successful curative response with novel therapies. 
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